No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, d3flqA_, 1.0000, 0.00, 1.000, 345, 345, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((S)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN
2, d1r3cA_, 0.9943, 0.55, 0.997, 349, 345, THE STRUCTURE OF P38ALPHA C162S MUTANT
3, d2zazA_, 0.9936, 0.65, 1.000, 345, 345, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH 4-ANILINO QUINOLINE INHIBITOR
4, p5xyyA_, 0.9916, 0.75, 1.000, 350, 345, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
5, d1ouyA_, 0.9915, 0.76, 1.000, 350, 345, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROPYRIDO- PYRIMIDINE INHIBITOR
6, d3fmjA_, 0.9902, 0.46, 0.997, 344, 343, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 4-(5-METHYL-3-PHENYL- ISOXAZOL-4-YL)-PYRIMIDIN-2-YLAMINE
7, d2zb0A_, 0.9902, 0.80, 1.000, 349, 345, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
8, d3flzA_, 0.9901, 0.48, 1.000, 347, 343, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 8-METHYL-6-PHENOXY-2- (TETRAHYDRO-PYRAN-4-YLAMINO)-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
9, d1wbwA_, 0.9900, 0.82, 1.000, 351, 345, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
10, d3flyA_, 0.9899, 0.49, 1.000, 347, 343, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-ISOPROPYLAMINO-8-METHYL-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
11, d3fmlA_, 0.9892, 0.32, 1.000, 342, 342, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6224
12, d3fmhA_, 0.9890, 0.53, 1.000, 347, 343, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((R)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
13, d1bl6A_, 0.9890, 0.81, 1.000, 351, 345, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB216995
14, d1w84A_, 0.9886, 0.85, 1.000, 351, 345, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
15, d1bmkA_, 0.9882, 0.83, 0.994, 351, 345, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB218655
16, d1m7qA_, 0.9881, 0.80, 1.000, 348, 344, CRYSTAL STRUCTURE OF P38 MAP KINASE IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
17, d1w7hA_, 0.9880, 0.79, 1.000, 351, 345, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
18, d1bl7A_, 0.9878, 0.84, 1.000, 351, 345, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB220025
19, d1oukA_, 0.9875, 0.83, 1.000, 348, 344, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR
20, d3s3iA_, 0.9872, 0.83, 1.000, 349, 345, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
21, d1wboA_, 0.9862, 0.91, 1.000, 351, 345, FRAGMENT BASED P38 INHIBITORS
22, d1wbvA_, 0.9860, 1.05, 1.000, 351, 345, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
23, d5etcA_, 0.9859, 0.94, 1.000, 355, 345, STRUCTURE OF INACTIVE MAPK14 WITH ORDERED ACTIVATION LOOP
24, d3flsA_, 0.9857, 0.71, 0.997, 343, 343, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((R)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
25, d1p38A_, 0.9856, 0.90, 0.994, 351, 345, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTOMS RESOLUTION
26, d3flwA_, 0.9852, 0.42, 1.000, 345, 341, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH PAMAPIMOD
27, d3fknA_, 0.9848, 0.59, 1.000, 346, 342, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO7125
28, d1di9A_, 0.9844, 0.93, 1.000, 348, 344, THE STRUCTURE OF P38 MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH 4-[3-METHYLSULFANYLANILINO]-67- DIMETHOXYQUINAZOLINE
29, d3fmkA_, 0.9842, 0.61, 1.000, 346, 342, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((S)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
30, d5mz3A_, 0.9840, 1.10, 0.997, 350, 345, P38 ALPHA MUTANT C162S IN COMPLEX WITH CMPD2 [N-(4-METHYL-3-(4455- TETRAMETHYL-132-DIOXABOROLAN-2-YL)PHENYL)-3-(TRIFLUOROMETHYL) BENZAMIDE]
31, d3rinA_, 0.9840, 0.91, 1.000, 349, 345, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
32, d1zzlA_, 0.9836, 0.96, 1.000, 351, 345, CRYSTAL STRUCTURE OF P38 WITH TRIAZOLOPYRIDINE
33, d1oveA_, 0.9836, 0.95, 0.994, 349, 345, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROQUINOLINONE
34, d1wbtA_, 0.9835, 1.12, 1.000, 351, 345, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
35, d1w83A_, 0.9835, 1.13, 1.000, 351, 345, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
36, d3mptA_, 0.9832, 0.84, 1.000, 347, 343, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A PYRROLE-2- CARBOXAMIDE INHIBITOR
37, d3hrbA_, 0.9832, 0.85, 1.000, 344, 344, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
38, d3fmnA_, 0.9832, 0.51, 1.000, 341, 341, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO2530
39, d1wbnA_, 0.9832, 1.13, 1.000, 351, 345, FRAGMENT BASED P38 INHIBITORS
40, d1oz1A_, 0.9832, 0.33, 1.000, 344, 340, P38 MITOGEN-ACTIVATED KINASE IN COMPLEX WITH 4-AZAINDOLE INHIBITOR
41, d3gfeA_, 0.9829, 1.03, 1.000, 352, 345, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR
42, d2yixA_, 0.9829, 1.00, 1.000, 351, 345, TRIAZOLOPYRIDINE INHIBITORS OF P38
43, d3d7zA_, 0.9827, 0.93, 1.000, 348, 344, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
44, d3fmmA_, 0.9825, 0.69, 1.000, 346, 342, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6226
45, d3kq7A_, 0.9820, 1.11, 1.000, 348, 344, STRUCTURE OF HUMAN P38ALPHA WITH N-[4-METHYL-3-(6-{[2-(1- METHYLPYRROLIDIN-2-YL)ETHYL]AMINO}PYRIDINE-3-AMIDO)PHENYL]- 2-(MORPHOLIN-4-YL)PYRIDINE-4-CARBOXAMIDE
46, d3nnwA_, 0.9815, 1.14, 1.000, 349, 345, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP802
47, d1wbsA_, 0.9812, 1.17, 1.000, 351, 345, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
48, d1a9uA_, 0.9812, 1.07, 1.000, 351, 345, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB203580
49, d2zb1A_, 0.9809, 0.91, 1.000, 345, 343, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
50, d3nnuA_, 0.9808, 1.09, 1.000, 348, 344, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP1376
51, d3dt1A2, 0.9797, 1.10, 1.000, 352, 345, P38 COMPLEXED WITH A QUINAZOLINE INHIBITOR
52, d2gfsA_, 0.9795, 0.55, 1.000, 344, 340, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3201195
53, d3nnvA_, 0.9794, 1.08, 1.000, 348, 344, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP437
54, d3d83A_, 0.9794, 1.05, 1.000, 347, 343, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
55, d1w82A_, 0.9791, 1.16, 1.000, 351, 345, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
56, d3mw1A_, 0.9789, 0.80, 1.000, 342, 342, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
57, d3e92A_, 0.9785, 0.99, 0.997, 348, 343, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
58, d3gc7A_, 0.9784, 1.05, 0.997, 349, 345, THE STRUCTURE OF P38ALPHA IN COMPLEX WITH A DIHYDROQUINAZOLINONE
59, d3u8wA_, 0.9782, 1.18, 1.000, 349, 345, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A TRIAZOLOPYRIDAZINONE INHIBITOR
60, d1yqjA2, 0.9779, 1.18, 1.000, 351, 345, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH A SELECTIVE PYRIDAZINE INHIBITOR
61, d3fsfA_, 0.9775, 0.64, 0.997, 340, 340, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 3-(26- DICHLORO-PHENYL)-7-[4-(2-DIETHYLAMINO-ETHOXY)-PHENYLAMINO]- 1-METHYL-34-DIHYDRO-1H-PYRIMIDO[45-D]PYRIMIDIN-2-ONE
62, d3iphA_, 0.9768, 0.82, 1.000, 345, 341, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH A BIPHENYLAMIDE INHIBITOR
63, d3e93A_, 0.9763, 0.94, 0.994, 346, 341, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
64, d3fklA_, 0.9759, 0.71, 0.997, 344, 340, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO9552
65, d3itzA1, 0.9758, 1.20, 1.000, 353, 345, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDAZINE INHIBITOR
66, d5etiA1, 0.9737, 1.28, 0.997, 352, 345, STRUCTURE OF DEAD KINASE MAPK14
67, d3fkoA_, 0.9735, 0.70, 0.994, 343, 339, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3668
68, d3fskA_, 0.9734, 0.55, 1.000, 342, 338, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6257
69, d2i0hA_, 0.9731, 1.18, 0.997, 349, 345, THE STRUCTURE OF P38ALPHA IN COMPLEX WITH AN ARYLPYRIDAZINONE
70, d3flnC_, 0.9728, 0.61, 0.994, 343, 338, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH R1487
71, p5xyxA_, 0.9709, 0.37, 1.000, 337, 336, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
72, d5uojA_, 0.9679, 0.82, 0.991, 343, 338, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTROMS RESOLUTION
73, d1r39A_, 0.9671, 1.16, 1.000, 345, 341, THE STRUCTURE OF P38ALPHA
74, d3fi4A_, 0.9646, 0.58, 0.997, 339, 335, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO4499
75, d3fl4A_, 0.9643, 0.60, 1.000, 339, 335, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO5634
76, d1wfcA_, 0.9633, 0.85, 1.000, 340, 336, STRUCTURE OF APO UNPHOSPHORYLATED P38 MITOGEN ACTIVATED PROTEIN KINASE P38 (P38 MAP KINASE) THE MAMMALIAN HOMOLOGUE OF THE YEAST HOG1 PROTEIN
77, d1lezA_, 0.9613, 1.20, 0.991, 343, 338, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS ACTIVATOR MKK3B
78, d3ha8A_, 0.9605, 1.03, 1.000, 342, 338, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/COMPOUND 14B
79, d3ds6D_, 0.9543, 1.70, 1.000, 349, 345, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
80, d2lgcA1, 0.9539, 1.80, 1.000, 353, 345, JOINT NMR AND X-RAY REFINEMENT REVEALS THE STRUCTURE OF A NOVEL DIBENZO[AD]CYCLOHEPTENONE INHIBITOR/P38 MAP KINASE COMPLEX IN SOLUTION
81, d1lewA_, 0.9539, 1.11, 0.994, 341, 335, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS NUCLEAR SUBSTRATE MEF2A
82, d5larA_, 0.9532, 1.60, 0.971, 350, 341, CRYSTAL STRUCTURE OF P38 ALPHA MAPK14 IN COMPLEX WITH VPC00628
83, p3lhjA_, 0.9522, 1.19, 1.000, 341, 337, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR.
84, d4ka3A_, 0.9499, 1.11, 0.991, 340, 334, STRUCTURE OF MAP KINASE IN COMPLEX WITH A DOCKING PEPTIDE
85, d2onlB1, 0.9496, 1.19, 0.997, 339, 335, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
86, d3p4kA_, 0.9495, 1.06, 0.988, 338, 333, THE THIRD CONFORMATION OF P38A MAP KINASE OBSERVED IN PHOSPHORYLATED P38A AND IN SOLUTION
87, d2okrA_, 0.9488, 1.21, 1.000, 339, 335, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
88, d3ds6C_, 0.9479, 1.74, 0.997, 349, 345, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
89, d4eh2A_, 0.9467, 1.02, 1.000, 337, 333, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F1 AND RL87
90, d2onlA1, 0.9465, 1.20, 1.000, 338, 334, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
91, p4looA_, 0.9460, 1.72, 0.974, 349, 342, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (MONOCLINIC CRYSTAL FORM)
92, d4eh3A_, 0.9452, 1.28, 0.994, 339, 334, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F2 AND RL87
93, d4ewqA_, 0.9449, 1.67, 0.965, 346, 340, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A PYRIDAZINE BASED INHIBITOR
94, d3ds6A_, 0.9449, 1.49, 0.994, 343, 339, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
95, d4f9yA_, 0.9442, 1.15, 0.997, 339, 334, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
96, d3fc1X_, 0.9440, 0.95, 1.000, 330, 330, CRYSTAL STRUCTURE OF P38 KINASE BOUND TO PYRIMIDO-PYRIDAZINONE INHIBITOR
97, d4kinB_, 0.9436, 1.34, 0.988, 341, 337, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
98, d3py3A1, 0.9434, 1.60, 0.982, 352, 337, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38ALPHA MAP KINASE
99, d3ds6B_, 0.9426, 1.59, 0.991, 343, 339, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
100, d4eh8A_, 0.9425, 1.06, 0.997, 336, 332, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F7 AND RL87
101, d4eh7A_, 0.9417, 1.17, 0.997, 337, 333, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F6 AND RL87
102, d3hv3A_, 0.9417, 1.16, 0.988, 335, 333, HUMAN P38 MAP KINASE IN COMPLEX WITH RL49
103, d4eh6A_, 0.9413, 1.03, 1.000, 335, 331, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F5 AND RL87
104, d3hegA_, 0.9410, 1.35, 0.991, 333, 333, P38 IN COMPLEX WITH SORAFENIB
105, d3bx5A_, 0.9408, 1.35, 1.000, 338, 334, P38 ALPHA MAP KINASE COMPLEXED WITH BMS-640994
106, d2okrD_, 0.9408, 1.20, 1.000, 339, 332, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
107, d3nwwA_, 0.9406, 1.34, 0.991, 339, 334, P38 ALPHA KINASE COMPLEXED WITH A 2-AMINOTHIAZOL-5-YL-PYRIMIDINE BASED INHIBITOR
108, d4f9wA_, 0.9405, 1.08, 1.000, 336, 332, HUMAN P38ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
109, d3gcqA_, 0.9404, 1.20, 0.988, 337, 333, HUMAN P38 MAP KINASE IN COMPLEX WITH RL45
110, d4zthA_, 0.9401, 1.30, 0.994, 339, 334, STRUCTURE OF HUMAN P38AMAPK-ARYLPYRIDAZINYLPYRIDINE FRAGMENT COMPLEX USED IN INHIBITOR DISCOVERY
111, d4dljA_, 0.9398, 0.95, 1.000, 336, 330, HUMAN P38 MAP KINASE IN COMPLEX WITH RL163
112, d2ghmA_, 0.9398, 1.15, 0.982, 336, 332, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-895449
113, d3rocA_, 0.9393, 1.19, 1.000, 337, 333, CRYSTAL STRUCTURE OF HUMAN P38 ALPHA COMPLEXED WITH A PYRIMIDINONE COMPOUND
114, d3qudA_, 0.9390, 1.57, 1.000, 345, 335, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO-BENZOPHENONE
115, d1yw2A_, 0.9389, 1.48, 0.985, 341, 335, MUTATED MUS MUSCULUS P38 KINASE (MP38)
116, d4fa2A_, 0.9386, 1.31, 0.994, 339, 334, HUMAN P38 ALPHA MITOGEN-ACTIVATED KINASE IN COMPLEX WITH SB239063
117, d3hllA_, 0.9385, 1.23, 1.000, 337, 333, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH PH-797804
118, d3c5uA_, 0.9385, 1.34, 0.994, 338, 334, P38 ALPHA MAP KINASE COMPLEXED WITH A BENZOTHIAZOLE BASED INHIBITOR
119, d2balA_, 0.9385, 1.24, 0.997, 337, 332, P38ALPHA MAP KINASE BOUND TO PYRAZOLOAMINE
120, d3hv4A_, 0.9383, 1.51, 0.991, 339, 335, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
121, d3newA_, 0.9382, 1.01, 0.991, 334, 330, P38-ALPHA COMPLEXED WITH COMPOUND 10
122, d3gcuA_, 0.9382, 1.53, 0.991, 339, 335, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
123, d4r3cA_, 0.9379, 1.09, 1.000, 335, 331, CRYSTAL STRUCTURE OF P38 ALPHA MAP KINASE IN COMPLEX WITH A NOVEL ISOFORM SELECTIVE DRUG CANDIDATE
124, d4eh4A_, 0.9379, 1.31, 0.994, 337, 332, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F3 AND RL87
125, d3kf7A_, 0.9379, 1.22, 1.000, 337, 333, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A TRIAZOLOPYRIMIDINE COMPOUND
126, d3hv5A_, 0.9377, 1.55, 0.991, 339, 335, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
127, d3hl7A_, 0.9376, 1.16, 0.994, 336, 332, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH SD-0006
128, d4kiqB_, 0.9372, 1.28, 0.991, 338, 334, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
129, d1ywrA_, 0.9372, 1.39, 0.991, 338, 334, CRYSTAL STRUCTURE ANALYSIS OF INACTIVE P38 KINASE DOMAIN IN COMPLEX WITH A MONOCYCLIC PYRAZOLONE INHIBITOR
130, d3hv6A_, 0.9371, 1.15, 0.991, 331, 331, HUMAN P38 MAP KINASE IN COMPLEX WITH RL39
131, d4aa4A_, 0.9369, 1.68, 0.985, 347, 335, P38ALPHA MAP KINASE BOUND TO CMPD 22
132, d5o8uA_, 0.9368, 1.21, 0.997, 331, 331, COVALENT INHIBITOR 4B BOUND TO THE LIPID POCKET OF P38ALPHA MUTANT S252C
133, d4kinA_, 0.9366, 1.36, 0.985, 338, 334, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
134, d3mh0A_, 0.9366, 1.24, 0.994, 332, 332, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
135, d3o8tA_, 0.9365, 1.17, 0.994, 332, 331, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG-MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
136, d3objA_, 0.9363, 1.26, 0.991, 332, 332, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MUTANTS IN RESPONSE TO INHIBITOR BINDING
137, d3hp2A_, 0.9363, 1.29, 0.997, 341, 333, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIDINONE COMPOUND
138, d3l8sA_, 0.9361, 1.22, 0.988, 334, 332, HUMAN P38 MAP KINASE IN COMPLEX WITH CP-547632
139, d4dliA_, 0.9357, 1.15, 0.991, 334, 330, HUMAN P38 MAP KINASE IN COMPLEX WITH RL87
140, d4a9yA_, 0.9357, 1.03, 0.997, 334, 329, P38ALPHA MAP KINASE BOUND TO CMPD 8
141, d2bakA_, 0.9357, 1.03, 0.997, 334, 329, P38ALPHA MAP KINASE BOUND TO MPAQ
142, d3oc1A_, 0.9356, 1.14, 0.997, 330, 330, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
143, d3hucA_, 0.9356, 1.36, 0.997, 337, 333, HUMAN P38 MAP KINASE IN COMPLEX WITH RL40
144, d2pkjA_, 0.9356, 1.26, 0.994, 332, 332,  
145, d3lfeA_, 0.9355, 1.22, 0.985, 334, 332, HUMAN P38 MAP KINASE IN COMPLEX WITH RL116
146, d3hv5B_, 0.9354, 1.53, 0.991, 339, 335, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
147, d3bv2A_, 0.9349, 1.17, 0.997, 337, 330, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 30
148, d3lfcA_, 0.9345, 1.26, 0.985, 334, 332, HUMAN P38 MAP KINASE IN COMPLEX WITH RL99
149, d3lfaA_, 0.9345, 1.10, 0.997, 333, 330, HUMAN P38 MAP KINASE IN COMPLEX WITH DASATINIB
150, d5n66A_, 0.9343, 1.15, 0.997, 332, 330, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9J
151, d3p79A_, 0.9343, 1.23, 0.991, 332, 331, P38 INHIBITOR-BOUND
152, d3zyaA1, 0.9341, 1.35, 0.991, 341, 333, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO- DIBENZOSUBERONE
153, d3queA_, 0.9341, 1.55, 0.991, 343, 334, HUMAN P38 MAP KINASE IN COMPLEX WITH SKEPINONE-L
154, d4kiqC_, 0.9340, 1.34, 0.991, 338, 334, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
155, d4ehvA_, 0.9340, 1.33, 0.997, 337, 332, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F10 AND RL87
156, d3pg3A_, 0.9338, 1.27, 0.982, 337, 332, HUMAN P38 MAP KINASE IN COMPLEX WITH RL182
157, d3p78A_, 0.9337, 1.24, 0.991, 332, 331, P38 INHIBITOR-BOUND
158, d4kipB_, 0.9335, 1.36, 0.991, 338, 334, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
159, d3bv3A_, 0.9333, 1.44, 0.997, 338, 333, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 2
160, d5n65A_, 0.9331, 1.06, 1.000, 333, 329, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9H
161, d3hv4B_, 0.9330, 1.51, 0.991, 338, 334, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
162, d3iw7A_, 0.9329, 1.47, 0.985, 335, 333, HUMAN P38 MAP KINASE IN COMPLEX WITH AN IMIDAZO-PYRIDINE
163, d3iw6A_, 0.9328, 1.52, 0.985, 337, 334, HUMAN P38 MAP KINASE IN COMPLEX WITH A BENZYLPIPERAZIN- PYRROL
164, d2rg5A_, 0.9327, 1.45, 0.997, 333, 333, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11B
165, d3p7bA_, 0.9323, 1.27, 0.991, 332, 331, P38 INHIBITOR-BOUND
166, d3uvpA_, 0.9321, 1.43, 1.000, 334, 333, HUMAN P38 MAP KINASE IN COMPLEX WITH A BENZAMIDE SUBSTITUTED BENZOSUBERONE
167, d2ptoA_, 0.9321, 1.17, 0.997, 330, 330,  
168, d3iw8A_, 0.9320, 1.30, 0.982, 334, 332, STRUCTURE OF INACTIVE HUMAN P38 MAP KINASE IN COMPLEX WITH A THIAZOLE-UREA
169, d2ghlA_, 0.9319, 1.26, 0.991, 334, 330, MUTANT MUS MUSCULUS P38 KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-874743
170, d3mh2A_, 0.9318, 1.18, 0.997, 330, 330, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
171, d3k3jA_, 0.9318, 0.96, 0.997, 329, 327, P38ALPHA BOUND TO NOVEL DFG-OUT COMPOUND PF-00416121
172, d3hp5A_, 0.9316, 1.16, 1.000, 330, 330, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIMIDOPYRIDAZINONE COMPOUND
173, d3lfbA_, 0.9313, 1.32, 0.985, 333, 332, HUMAN P38 MAP KINASE IN COMPLEX WITH RL98
174, d3mvlB_, 0.9312, 1.46, 1.000, 339, 334, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
175, d4aa5A_, 0.9311, 1.72, 0.982, 340, 334, P38ALPHA MAP KINASE BOUND TO CMPD 33
176, d3mh3A_, 0.9311, 1.33, 0.994, 334, 331, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
177, d2ptjA_, 0.9311, 1.32, 0.994, 334, 331,  
178, d2puuA_, 0.9309, 1.29, 0.985, 330, 330, CRYSTAL STRUCTURE OF P38 COMPLEX WITH 1-(5-TERT-BUTYL-2-P- TOLYL-2H-PYRAZOL-3-YL)-3-[4-(6-MORPHOLIN-4-YLMETHYL- PYRIDIN-3-YL)NAPHTHALEN-1-YL]UREA
179, d4kinC_, 0.9308, 1.65, 0.997, 338, 336, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
180, d4kipA_, 0.9307, 1.36, 0.994, 337, 333, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
181, d3zs5A1, 0.9307, 1.40, 0.997, 339, 332, STRUCTURAL BASIS FOR KINASE SELECTIVITY OF THREE CLINICAL P38ALPHA INHIBITORS
182, d3ocgA_, 0.9307, 1.36, 1.000, 336, 332, P38 ALPHA KINASE COMPLEXED WITH A 5-AMINO-PYRAZOLE BASED INHIBITOR
183, d2gtnA_, 0.9307, 1.61, 0.985, 337, 333, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-951717
184, d3mh1A_, 0.9306, 1.40, 0.994, 337, 332, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
185, d2pv8A_, 0.9306, 1.40, 0.994, 337, 332,  
186, d3gcuB_, 0.9305, 1.49, 0.994, 337, 333, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
187, d1zyjA_, 0.9304, 1.29, 1.000, 331, 331, HUMAN P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1A
188, d3gcsA_, 0.9303, 1.21, 0.988, 331, 330, HUMAN P38 MAP KINASE IN COMPLEX WITH SORAFENIB
189, d3k3iA_, 0.9302, 1.08, 0.997, 332, 328, P38ALPHA BOUND TO NOVEL DGF-OUT COMPOUND PF-00215955
190, d3tg1A_, 0.9301, 1.21, 0.994, 334, 330, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH A MAPK DOCKING PARTNER
191, d3mvlA_, 0.9301, 1.51, 0.997, 339, 334, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
192, d3p5kA_, 0.9299, 1.32, 0.991, 332, 331, P38 INHIBITOR-BOUND
193, d3iw5A_, 0.9296, 1.54, 0.979, 336, 333, HUMAN P38 MAP KINASE IN COMPLEX WITH AN INDOLE DERIVATIVE
194, d4aacA_, 0.9293, 1.75, 0.985, 350, 334, P38ALPHA MAP KINASE BOUND TO CMPD 29
195, d3obgA_, 0.9293, 1.40, 0.994, 332, 332, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MUTANTS IN RESPONSE TO INHIBITOR BINDING
196, d2rg6A_, 0.9293, 1.56, 1.000, 335, 335, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11J
197, d4eh5A_, 0.9292, 0.82, 1.000, 329, 325, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F4 AND RL87
198, d4e5aX_, 0.9291, 0.97, 0.991, 332, 326, THE W197A MUTANT OF P38A MAP KINASE
199, d3zsgA_, 0.9290, 1.43, 0.997, 337, 332, X-RAY STRUCTURE OF P38ALPHA BOUND TO TAK-715
200, d2ozaB_, 0.9290, 1.58, 0.979, 340, 335, STRUCTURE OF P38ALPHA COMPLEX
201, d4kiqA_, 0.9289, 1.47, 0.994, 338, 334, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
202, p4lopB_, 0.9286, 2.41, 0.994, 350, 345, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
203, d2qd9A_, 0.9286, 1.12, 0.997, 330, 328, P38 ALPHA MAP KINASE INHIBITOR BASED ON HETEROBICYCLIC SCAFFOLDS
204, d3hubA_, 0.9285, 1.30, 0.988, 335, 331, HUMAN P38 MAP KINASE IN COMPLEX WITH SCIOS-469
205, d3mpaA_, 0.9284, 1.26, 0.994, 331, 330, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
206, d4kinD_, 0.9283, 1.71, 0.994, 339, 336, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
207, d3hv7A_, 0.9283, 1.22, 0.994, 330, 329, HUMAN P38 MAP KINASE IN COMPLEX WITH RL38
208, d5n64A_, 0.9282, 0.96, 0.997, 329, 326, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9G
209, d1kv1A_, 0.9282, 1.05, 0.997, 331, 327, P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1
210, d4eh9A_, 0.9281, 1.41, 0.994, 334, 330, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F11 AND RL87
211, d2pv5A_, 0.9279, 1.22, 0.997, 329, 329,  
212, d3o8pA_, 0.9278, 1.40, 0.994, 336, 331, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
213, d3ctqA_, 0.9274, 1.57, 0.985, 336, 332, STRUCTURE OF MAP KINASE P38 IN COMPLEX WITH A 1-O-TOLYL-12 3-TRIAZOLE-4-CARBOXAMIDE
214, d3mgyA_, 0.9272, 1.24, 1.000, 329, 329, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
215, d3gcvA_, 0.9271, 1.66, 0.985, 338, 334, HUMAN P38 MAP KINASE IN COMPLEX WITH RL62
216, d5n67A_, 0.9269, 0.90, 1.000, 327, 325, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9L
217, d4e6cA_, 0.9268, 1.08, 1.000, 330, 327, P38A-PERIFOSINE COMPLEX
218, d3p7cA_, 0.9268, 1.39, 0.991, 332, 331, P38 INHIBITOR-BOUND
219, d3nnxA_, 0.9268, 1.49, 0.985, 336, 332, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38 ALPHA IN COMPLEX WITH DP802
220, d4kiqD_, 0.9261, 1.49, 0.991, 338, 334, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
221, d3uvqA_, 0.9260, 1.20, 1.000, 333, 328, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOSUBERONE DERIVATIVE
222, d2gtmA_, 0.9258, 1.66, 0.985, 341, 332, MUTATED MOUSE P38 MAP KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-892579
223, d1zz2A_, 0.9253, 1.65, 0.997, 337, 333, TWO CLASSES OF P38ALPHA MAP KINASE INHIBITORS HAVING A COMMON DIPHENYLETHER CORE BUT EXHIBITING DIVERGENT BINDING MODES
224, d5n68A_, 0.9252, 1.04, 0.997, 328, 326, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9M
225, d4l8mA_, 0.9251, 1.48, 0.994, 339, 331, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOXEPINONE
226, p4lopD_, 0.9250, 2.17, 0.939, 351, 342, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
227, d5n63A_, 0.9249, 0.99, 0.997, 325, 324, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9C
228, p5etaB_, 0.9248, 1.35, 0.997, 335, 330, STRUCTURE OF MAPK14 WITH BOUND THE KIM DOMAIN OF THE TOXOPLASMA PROTEIN GRA24
229, d3p7aA_, 0.9245, 1.60, 0.991, 332, 331, P38 INHIBITOR-BOUND
230, d3o8uA_, 0.9243, 1.42, 0.994, 332, 331, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
231, d5o8vA_, 0.9242, 0.99, 0.997, 328, 325, COVALENT INHIBITOR 4A BOUND TO THE LIPID POCKET OF P38ALPHA MUTANT S251C
232, d3hvcA_, 0.9240, 1.04, 1.000, 327, 326, CRYSTAL STRUCTURE OF HUMAN P38ALPHA MAP KINASE
233, d2p5aA_, 0.9240, 1.04, 1.000, 327, 326,  
234, d2fslX_, 0.9239, 1.16, 0.991, 332, 327, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327S) ACTIVATING MUTANT FORM-A
235, p3lfdA_, 0.9238, 1.34, 0.985, 331, 330, HUMAN P38 MAP KINASE IN COMPLEX WITH RL113
236, d2ewaA_, 0.9238, 0.92, 0.997, 330, 324, DUAL BINDING MODE OF PYRIDINYLIMIDAZOLE TO MAP KINASE P38
237, p4loqB_, 0.9237, 2.35, 0.965, 351, 342, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
238, d4geoA_, 0.9236, 1.40, 0.985, 326, 326, P38A MAP KINASE DEF-POCKET PENTA MUTANT (M194A L195A H228A I229A Y258A)
239, p4lopA_, 0.9232, 2.16, 0.944, 351, 342, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
240, d4tyhB_, 0.9231, 1.43, 0.976, 335, 330, TERNARY COMPLEX OF P38 AND MK2 WITH A P38 INHIBITOR
241, d3zshA_, 0.9231, 1.16, 0.997, 331, 327, X-RAY STRUCTURE OF P38ALPHA BOUND TO SCIO-469
242, d3gcpA_, 0.9230, 1.47, 0.985, 337, 331, HUMAN P38 MAP KINASE IN COMPLEX WITH SB203580
243, d3gi3A_, 0.9229, 1.54, 0.994, 330, 330, CRYSTAL STRUCTURE OF A N-PHENYL-N -NAPHTHYLUREA ANALOG IN COMPLEX WITH P38 MAP KINASE
244, d5mtxA_, 0.9224, 1.36, 0.997, 331, 329, DIBENZOOXEPINONE INHIBITOR 12B IN COMPLEX WITH P38 MAPK
245, p4loqD_, 0.9220, 2.49, 0.965, 351, 344, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
246, d3hecA_, 0.9219, 1.49, 0.997, 329, 329, P38 IN COMPLEX WITH IMATINIB
247, d3mvmA_, 0.9209, 1.70, 1.000, 335, 335, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
248, p4loqA_, 0.9202, 2.52, 0.994, 352, 345, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
249, d4aa0A_, 0.9202, 1.08, 0.997, 328, 324, P38ALPHA MAP KINASE BOUND TO CMPD 2
250, p4lopC_, 0.9200, 2.07, 0.985, 341, 335, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
251, d2fsmX_, 0.9199, 1.19, 0.991, 326, 326, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327S) ACTIVATING MUTANT FORM-B
252, d2npqA_, 0.9195, 1.12, 0.994, 326, 325, A NOVEL LIPID BINDING SITE IN THE P38 ALPHA MAP KINASE
253, d1ianA_, 0.9188, 1.04, 0.997, 328, 324, HUMAN P38 MAP KINASE INHIBITOR COMPLEX
254, d4e8aA_, 0.9186, 1.09, 0.997, 327, 324, THE CRYSTAL STRUCTURE OF P38A MAP KINASE IN COMPLEX WITH PIA24
255, d5mtyA_, 0.9184, 1.38, 1.000, 328, 328, DIBENZOSUBERONE INHIBITOR 8E IN COMPLEX WITH P38 MAPK
256, d4e6aA_, 0.9181, 1.09, 1.000, 324, 324, P38A-PIA23 COMPLEX
257, d3lffA_, 0.9168, 1.62, 0.988, 335, 331, HUMAN P38 MAP KINASE IN COMPLEX WITH RL166
258, d4e5bA_, 0.9167, 1.05, 0.997, 324, 323, STRUCTURE OF P38A MAP KINASE WITHOUT BOG
259, d3cg2A_, 0.9167, 1.31, 0.997, 327, 327,  
260, d2fsoX_, 0.9163, 1.05, 0.997, 325, 323, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A) ACTIVATING MUTANT
261, p5o90A_, 0.9161, 1.23, 0.985, 330, 325, CRYSTAL STRUCTURE OF A P38ALPHA T185G MUTANT IN COMPLEX WITH TAB1 PEPTIDE.
262, d2yisA_, 0.9157, 1.21, 0.994, 325, 324, TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE.
263, d3oefX_, 0.9156, 1.73, 0.985, 334, 329, CRYSTAL STRUCTURE OF Y323F INACTIVE MUTANT OF P38ALPHA MAP KINASE
264, d3mvmB_, 0.9153, 1.76, 0.997, 332, 332, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
265, d2fstX_, 0.9151, 1.17, 0.994, 324, 324, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327L) ACTIVATING MUTANT
266, d3l8xA_, 0.9133, 1.30, 0.997, 326, 326, P38 ALPHA KINASE COMPLEXED WITH A PYRAZOLO-PYRIMIDINE BASED INHIBITOR
267, d2yiwA_, 0.9131, 1.27, 0.994, 325, 324, TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE
268, d2baqA_, 0.9128, 1.58, 0.988, 329, 325, P38ALPHA BOUND TO RO3201195
269, d5ml5A_, 0.9120, 1.40, 0.994, 326, 324, HUMAN P38ALPHA MAPK IN COMPLEX WITH IMIDAZOLYL PYRIDINE INHIBITOR 11B
270, d5tcoA_, 0.9117, 1.50, 0.994, 327, 327, HUMAN P38 MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 1
271, d3gc8B_, 0.9117, 2.35, 0.728, 346, 338, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
272, d1kv2A_, 0.9097, 1.07, 0.997, 325, 321, HUMAN P38 MAP KINASE IN COMPLEX WITH BIRB 796
273, d3uvrA_, 0.9095, 1.53, 0.988, 331, 327, HUMAN P38 MAP KINASE IN COMPLEX WITH KM064
274, d3s4qA_, 0.9093, 1.39, 0.982, 326, 326, P38 ALPHA KINASE COMPLEXED WITH A PYRAZOLO-TRIAZINE BASED INHIBITOR
275, p4loqC_, 0.9079, 2.15, 0.982, 337, 332, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
276, d3gc9B_, 0.9069, 1.84, 0.716, 339, 331, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
277, d3gc8A_, 0.9061, 2.30, 0.704, 347, 338, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
278, d4ynoA_, 0.9054, 1.85, 0.595, 342, 333, CRYSTAL STRUCTURE OF MAPK13 AT INACTIVE FORM
279, d3od6X_, 0.9025, 2.25, 0.923, 344, 336, CRYSTAL STRUCTURE OF P38ALPHA Y323T ACTIVE MUTANT
280, d3zsiA_, 0.9021, 1.47, 0.988, 326, 322, X-RAY STRUCTURE OF P38ALPHA BOUND TO VX-745
281, d3npcA_, 0.9014, 1.98, 0.503, 357, 330, CRYSTAL STRUCTURE OF JNK2 COMPLEXED WITH BIRB796
282, d2bajA2, 0.9010, 1.78, 0.960, 334, 327, P38ALPHA BOUND TO PYRAZOLOUREA
283, p4h3bA_, 0.8996, 1.94, 0.491, 351, 330, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH SAB PEPTIDE
284, d5ekoA_, 0.8994, 1.91, 0.596, 341, 332, CRYSTAL STRUCTURE OF MAPK13 COMPLEX WITH INHIBITOR
285, p4h3bC_, 0.8994, 1.94, 0.491, 351, 330, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH SAB PEPTIDE
286, d4h36A_, 0.8982, 1.98, 0.491, 353, 330, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH ATF2 PEPTIDE
287, d4eyjA_, 0.8981, 1.79, 0.596, 338, 329, MAPK13 COMPLEX WITH INHIBITOR
288, d3npcB_, 0.8974, 2.13, 0.515, 356, 330, CRYSTAL STRUCTURE OF JNK2 COMPLEXED WITH BIRB796
289, d3odzX_, 0.8970, 2.04, 0.946, 335, 333, CRYSTAL STRUCTURE OF P38ALPHA Y323R ACTIVE MUTANT
290, d4eymA_, 0.8961, 1.91, 0.598, 340, 331, MAPK13 COMPLEX WITH INHIBITOR
291, d3gp0A1, 0.8958, 2.02, 0.729, 332, 329, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 11 (P38 BETA) IN COMPLEX WITH NILOTINIB
292, p3zu7A_, 0.8940, 1.87, 0.480, 344, 327, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE MAP KINASE ERK2
293, d4ic8B_, 0.8935, 1.96, 0.442, 336, 330, CRYSTAL STRUCTURE OF THE APO ERK5 KINASE DOMAIN
294, d5eknA_, 0.8934, 1.77, 0.596, 336, 327, CRYSTAL STRUCTURE OF MAPK13 COMPLEX WITH INHIBITOR
295, d3gc9A_, 0.8924, 1.94, 0.726, 335, 328, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
296, p4h39A_, 0.8911, 1.83, 0.483, 340, 325, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH JIP1 PEPTIDE
297, p5nzzE_, 0.8910, 2.32, 0.961, 343, 334, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
298, p5nzzG_, 0.8897, 2.31, 0.988, 342, 334, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
299, d3coiA1, 0.8873, 2.14, 0.589, 342, 331, CRYSTAL STRUCTURE OF P38DELTA KINASE
300, p5nzzF_, 0.8850, 2.32, 0.967, 341, 332, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
301, d5tbeA_, 0.8847, 1.99, 0.970, 332, 328, HUMAN P38ALPHA MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 2
302, d3ptgA_, 0.8810, 1.87, 0.492, 340, 325, DESIGN AND SYNTHESIS OF A NOVEL ORALLY EFFICACIOUS TRI-SUBSTITUTED THIOPHENE BASED JNK INHIBITOR
303, p3zuvC_, 0.8783, 2.46, 0.483, 357, 329, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
304, d3qyiA_, 0.8777, 2.39, 0.479, 346, 330,  
305, d4ic8A_, 0.8772, 1.97, 0.451, 325, 324, CRYSTAL STRUCTURE OF THE APO ERK5 KINASE DOMAIN
306, d4o2zA1, 0.8765, 2.63, 0.375, 357, 333, CRYSTAL STRUCTURE OF MPK3 FROM LEISHMANIA DONOVANI LDBPK_100540 IN THE PRESENCE OF NVP-BBT594
307, d4mygA_, 0.8737, 2.12, 0.613, 335, 323, MAPK13 ACTIVE FORM
308, d3erkA_, 0.8734, 2.52, 0.471, 350, 329, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/SB220025
309, p3vugA_, 0.8730, 2.62, 0.489, 356, 333, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
310, p3vuiA_, 0.8722, 2.53, 0.480, 355, 331, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
311, d4i5hA_, 0.8721, 2.28, 0.483, 335, 325, CRYSTAL STRUCTURE OF A DOUBLE MUTANT RAT ERK2 COMPLEXED WITH A TYPE II QUINAZOLINE INHIBITOR
312, p5lenB_, 0.8717, 2.19, 0.472, 346, 326, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_D12_10_47 IN COMPLEX WITH JNK1A1 AND JIP1 PEPTIDE
313, p6f5eB_, 0.8716, 2.19, 0.472, 346, 326, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_D12_10_47 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
314, p3vuhA_, 0.8715, 2.55, 0.480, 355, 331, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M3 IN MAP KINASE JNK1
315, p3vukA_, 0.8713, 2.51, 0.489, 355, 331, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M5 IN MAP KINASE JNK1
316, d4iz5B_, 0.8711, 2.27, 0.463, 347, 328, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
317, d4iz5C_, 0.8710, 2.28, 0.463, 347, 328, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
318, d4iz5A_, 0.8709, 2.28, 0.466, 347, 328, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
319, p3zuvA_, 0.8709, 2.60, 0.480, 357, 329, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
320, d2erkA_, 0.8709, 2.49, 0.482, 351, 328, PHOSPHORYLATED MAP KINASE ERK2
321, d4iz5D_, 0.8706, 2.28, 0.463, 347, 328, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
322, d4mygB_, 0.8704, 2.18, 0.598, 335, 323, MAPK13 ACTIVE FORM
323, d4izaA_, 0.8700, 2.38, 0.476, 346, 328, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
324, p5nzzH_, 0.8699, 2.46, 0.979, 335, 329, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
325, d1wzyA_, 0.8699, 2.46, 0.459, 350, 329, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A PYRAZOLOPYRIDAZINE DERIVATIVE
326, d4ic7A_, 0.8691, 2.65, 0.451, 355, 328, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
327, d4b99A_, 0.8691, 2.44, 0.452, 335, 325, CRYSTAL STRUCTURE OF MAPK7 (ERK5) WITH INHIBITOR
328, p3vudA_, 0.8671, 2.48, 0.491, 355, 330, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
329, p5lw1H_, 0.8665, 2.55, 0.473, 355, 332, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
330, d2fysA_, 0.8657, 2.54, 0.476, 348, 330, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
331, d4ic7D_, 0.8653, 2.64, 0.456, 353, 327, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
332, d4qp4A_, 0.8652, 2.42, 0.486, 337, 327, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
333, d4qp8B_, 0.8640, 2.43, 0.480, 337, 327, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
334, p5lw1B_, 0.8639, 2.59, 0.473, 355, 332, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
335, p2gmxA_, 0.8638, 2.77, 0.470, 357, 332, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
336, d4iz7A_, 0.8637, 2.47, 0.477, 344, 327, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
337, d1erkA_, 0.8637, 2.63, 0.471, 357, 329, STRUCTURE OF SIGNAL-REGULATED KINASE
338, p5lw1E_, 0.8636, 2.68, 0.471, 355, 333, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
339, d4awiA_, 0.8636, 2.63, 0.473, 352, 332, HUMAN JNK1ALPHA KINASE WITH 4-PHENYL-7-AZAINDOLE IKK2 INHIBITOR.
340, p2no3A_, 0.8636, 2.56, 0.470, 357, 330, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
341, d2gphA_, 0.8631, 2.58, 0.477, 345, 329, DOCKING MOTIF INTERACTIONS IN THE MAP KINASE ERK2
342, d4iz7C_, 0.8626, 2.32, 0.475, 340, 326, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
343, d4qp7A_, 0.8624, 2.47, 0.483, 337, 327, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
344, d4qp4B_, 0.8624, 2.41, 0.482, 335, 326, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
345, p5v61A_, 0.8623, 2.48, 0.485, 348, 326, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP2
346, d1golA_, 0.8617, 2.68, 0.465, 357, 329, COORDINATES OF RAT MAP KINASE ERK2 WITH AN ARGININE MUTATION AT POSITION 52
347, p2h96A_, 0.8610, 2.74, 0.464, 358, 332, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
348, d1ukiA_, 0.8602, 1.98, 0.511, 328, 317, STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125
349, d5byyA_, 0.8598, 2.51, 0.461, 338, 323, ERK5 IN COMPLEX WITH SMALL MOLECULE
350, d4qp8A_, 0.8596, 2.45, 0.482, 335, 326, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
351, p3v3vA_, 0.8593, 2.58, 0.486, 351, 329, STRUCTURAL AND FUNCTIONAL ANALYSIS OF QUERCETAGETIN A NATURAL JNK1 INHIBITOR
352, d4qp7B_, 0.8586, 2.45, 0.482, 335, 326, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
353, d3c9wA2, 0.8586, 2.35, 0.485, 335, 324, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
354, d4qp9A_, 0.8584, 2.36, 0.477, 335, 325, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-PROPYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
355, d5nhvA_, 0.8582, 2.53, 0.469, 345, 326, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
356, d3c9wB2, 0.8581, 2.36, 0.478, 335, 324, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
357, p5v62A_, 0.8579, 2.51, 0.485, 349, 326, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP3
358, d4erkA_, 0.8579, 2.74, 0.465, 350, 329, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/OLOMOUCINE
359, p3o17A_, 0.8576, 2.72, 0.471, 357, 331, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
360, d3o2mA_, 0.8575, 2.56, 0.479, 358, 330, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
361, d4xrjA_, 0.8572, 2.59, 0.471, 344, 325, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
362, p6g97A_, 0.8570, 2.62, 0.469, 344, 326, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
363, p4fmqA_, 0.8570, 2.71, 0.474, 350, 331, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
364, d3v6sB_, 0.8569, 2.33, 0.485, 340, 324, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
365, p6g93A_, 0.8564, 2.43, 0.464, 343, 323, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
366, d2fysB_, 0.8561, 2.48, 0.480, 338, 325, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
367, d5nhhA_, 0.8560, 2.64, 0.471, 348, 327, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
368, d4zsjA_, 0.8560, 2.70, 0.457, 344, 324, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
369, p3vumA_, 0.8560, 2.52, 0.480, 347, 327, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M7 IN MAP KINASE JNK1
370, d4s2zA_, 0.8553, 2.67, 0.465, 346, 327, ERK2 INTRINSICALLY ACTIVE MUTANT R65S
371, d5hd7A_, 0.8550, 2.66, 0.468, 347, 327, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT MUTANT SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
372, p3vulA_, 0.8550, 2.39, 0.489, 344, 325, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
373, d5umoA_, 0.8548, 2.68, 0.471, 347, 327, STRUCTURE OF EXTRACELLULAR SIGNAL-REGULATED KINASE
374, d4qtbA_, 0.8547, 2.71, 0.463, 351, 328, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
375, d4zsgA_, 0.8545, 2.87, 0.457, 347, 326, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
376, d4nifB_, 0.8545, 2.75, 0.474, 349, 331, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
377, d3v6rB_, 0.8544, 2.69, 0.477, 346, 327, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
378, d4xneA_, 0.8539, 2.63, 0.471, 344, 325, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
379, d4nifE_, 0.8539, 2.73, 0.471, 348, 331, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
380, p2xs0A_, 0.8537, 2.56, 0.482, 346, 328, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
381, p2gmxB_, 0.8529, 2.75, 0.468, 357, 331, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
382, d4gvaA_, 0.8525, 2.59, 0.469, 345, 324, ADP-BOUND FORM OF THE ERK2 KINASE
383, d4zzmA_, 0.8524, 2.56, 0.469, 344, 324, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
384, d4qtdA_, 0.8522, 2.89, 0.461, 355, 334, STRUCTURE OF HUMAN JNK1 IN COMPLEX WITH SCH772984 AND THE AMPPNP- HYDROLYSED TRIPHOSPHATE REVEALING THE SECOND TYPE-I BINDING MODE
385, d3v6sA_, 0.8521, 2.53, 0.472, 349, 326, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
386, d1ukhA_, 0.8519, 1.68, 0.503, 321, 310, STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125
387, d4fv7A_, 0.8517, 2.57, 0.471, 342, 323, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E94
388, p2h96B_, 0.8516, 2.66, 0.467, 357, 330, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
389, d5v60A_, 0.8515, 2.60, 0.485, 347, 326, PHOSPHO-ERK2 BOUND TO AMP-PCP
390, d5nhlA_, 0.8514, 2.62, 0.469, 345, 326, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
391, d3o2mB_, 0.8514, 2.67, 0.473, 358, 330, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
392, p2g01A_, 0.8513, 2.66, 0.468, 355, 329, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
393, p4h3qA_, 0.8511, 2.82, 0.470, 352, 332, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
394, d4qtbB_, 0.8508, 2.75, 0.460, 348, 328, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
395, p2no3B_, 0.8508, 2.78, 0.467, 357, 330, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
396, p6g9aA_, 0.8506, 2.62, 0.469, 341, 322, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
397, d4gt3A_, 0.8505, 2.69, 0.469, 347, 326, ATP-BOUND FORM OF THE ERK2 KINASE
398, d4fuxA_, 0.8505, 2.57, 0.467, 342, 323, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E75
399, d5nhjA_, 0.8502, 2.72, 0.471, 345, 327, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
400, p6g9jA_, 0.8501, 2.81, 0.471, 347, 327, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
401, p5ax3A_, 0.8501, 2.47, 0.480, 329, 321, CRYSTAL STRUCTURE OF ERK2 COMPLEXED WITH ALLOSTERIC AND ATP- COMPETITIVE INHIBITORS.
402, p6g9dA_, 0.8497, 2.75, 0.466, 345, 326, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
403, d2zoqA_, 0.8497, 2.67, 0.472, 351, 326, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
404, d3v6rA_, 0.8495, 2.58, 0.483, 349, 327, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
405, d4x21B_, 0.8493, 2.21, 0.494, 336, 320, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
406, d4y5hA_, 0.8491, 2.74, 0.483, 349, 329, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
407, d4xozA_, 0.8491, 2.62, 0.471, 341, 323, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
408, d4s31A_, 0.8490, 2.75, 0.465, 347, 327, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 1 WTERK2 AT 1.45A
409, p5o7iA_, 0.8486, 2.60, 0.464, 340, 319, ERK5 IN COMPLEX WITH A PYRROLE INHIBITOR 
410, d4qteA_, 0.8482, 2.75, 0.471, 348, 327, STRUCTURE OF ERK2 IN COMPLEX WITH VTX-11E 4-{2-[(2-CHLORO-4- FLUOROPHENYL)AMINO]-5-METHYLPYRIMIDIN-4-YL}-N-[(1S)-1-(3- CHLOROPHENYL)-2-HYDROXYETHYL]-1H-PYRROLE-2-CARBOXAMIDE
411, d5hd4A_, 0.8481, 2.75, 0.468, 347, 327, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT WILD TYPE SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
412, d4izaC_, 0.8479, 2.37, 0.478, 335, 322, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
413, d4fv3A_, 0.8478, 2.74, 0.466, 346, 326, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK6
414, d4zslA_, 0.8477, 2.71, 0.458, 341, 321, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
415, d5lcjA_, 0.8476, 2.74, 0.463, 345, 326, IN-GEL ACTIVITY-BASED PROTEIN PROFILING OF A CLICKABLE COVALENT ERK 1/2 INHIBITOR
416, d4fv6A_, 0.8476, 2.35, 0.477, 332, 321, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E57
417, d3pg1A_, 0.8475, 2.33, 0.348, 341, 319, MAP KINASE LMAMPK10 FROM LEISHMANIA MAJOR (1.95 ANGS RESOLUTION)
418, p6g9hA_, 0.8474, 2.67, 0.463, 343, 324, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
419, p6ge0A_, 0.8473, 2.67, 0.466, 343, 324, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
420, d3i60A_, 0.8471, 2.54, 0.474, 335, 323, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-4-(2-(2-CHLOROPHENYLAMINO)-5- METHYLPYRIMIDIN-4-YL)-N-(2-HYDROXY-1-PHENYLETHYL)-1H-PYRROLE-2- CARBOXAMIDE
421, p6g91A_, 0.8468, 2.79, 0.465, 344, 325, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
422, d3pzeA_, 0.8466, 2.69, 0.474, 347, 329, JNK1 IN COMPLEX WITH INHIBITOR
423, d5nhoA_, 0.8465, 2.73, 0.466, 343, 326, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
424, p3o17B_, 0.8461, 2.87, 0.468, 357, 331, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
425, d4o6eA_, 0.8459, 2.30, 0.478, 328, 318, DISCOVERY OF 5678-TETRAHYDROPYRIDO[34-D]PYRIMIDINE INHIBITORS OF ERK2
426, d4s30A_, 0.8458, 2.67, 0.466, 342, 324, ERK2 INTRINSICALLY ACTIVE MUTANT (I84A)
427, d5bveA_, 0.8456, 2.42, 0.481, 330, 320, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
428, p4h3pA_, 0.8456, 2.53, 0.471, 342, 325, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
429, d4gsbA_, 0.8456, 2.73, 0.471, 343, 325, MONOCLINIC CRYSTAL FORM OF THE APO-ERK2
430, d1tvoA_, 0.8456, 2.91, 0.468, 350, 329, THE STRUCTURE OF ERK2 IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
431, d5lckA_, 0.8453, 2.73, 0.468, 345, 325, A CLICKABLE COVALENT ERK 1/2 INHIBITOR
432, d3odyX_, 0.8453, 2.36, 0.972, 321, 320, CRYSTAL STRUCTURE OF P38ALPHA Y323Q ACTIVE MUTANT
433, d5byzA_, 0.8449, 2.95, 0.455, 348, 325, ERK5 IN COMPLEX WITH SMALL MOLECULE
434, d4qtaA_, 0.8449, 2.55, 0.481, 335, 324, STRUCTURE OF HUMAN ERK2 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
435, d4fv8A_, 0.8449, 2.57, 0.471, 333, 323, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E63
436, p4ux9A_, 0.8447, 2.40, 0.470, 343, 321, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
437, d4kkhA_, 0.8443, 2.95, 0.482, 351, 332, THE CRYSTAL STRUCTURE OF INHIBITOR-BOUND JNK3
438, d3sa0A_, 0.8443, 2.78, 0.466, 354, 326, COMPLEX OF ERK2 WITH NORATHYRIOL
439, d4x21A_, 0.8442, 2.27, 0.487, 336, 320, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
440, p2g01B_, 0.8442, 2.78, 0.468, 356, 329, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
441, d2zoqB_, 0.8441, 2.69, 0.474, 351, 325, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
442, d5awmA_, 0.8440, 2.81, 0.473, 345, 328, THE CRYSTAL STRUCTURE OF JNK FROM DROSOPHILA MELANOGASTER REVEALS AN EVOLUTIONARILY CONSERVED TOPOLOGY WITH THAT OF MAMMALIAN JNK PROTEINS.
443, d4kkgA_, 0.8435, 2.91, 0.473, 353, 332, CRYSTAL STRUCTURE OF APO AND AMP-BOUND JNK3
444, d4g6oA_, 0.8435, 2.64, 0.469, 339, 322, CRYSTAL STRUCTURE OF THE ERK2
445, d4s34A_, 0.8433, 2.75, 0.465, 343, 325, ERK2 (I84A) IN COMPLEX WITH AMP-PNP
446, d5ci6B_, 0.8432, 2.70, 0.463, 350, 326, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
447, d4qp1B_, 0.8432, 2.64, 0.472, 343, 322, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
448, p4ux9C_, 0.8431, 2.38, 0.484, 333, 320, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
449, d4zzoA_, 0.8430, 2.55, 0.472, 339, 320, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
450, p6g9nA_, 0.8429, 2.66, 0.464, 344, 323, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
451, d4n4sA_, 0.8427, 2.75, 0.460, 342, 328, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
452, d4s33A_, 0.8426, 2.83, 0.462, 347, 327, ERK2 R65S MUTANT COMPLEXED WITH AMP-PNP
453, d5u6iA_, 0.8423, 2.65, 0.483, 339, 321, DISCOVERY OF MLI-2 AN ORALLY AVAILABLE AND SELECTIVE LRRK2 INHIBITOR THAT REDUCES BRAIN KINASE ACTIVITY
454, d4xrlA_, 0.8421, 2.56, 0.470, 337, 319, CRYSTAL STRUCTURE AT ROOM TEMPERATURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
455, d4qpaB_, 0.8421, 2.62, 0.463, 345, 322, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
456, d4kkeA_, 0.8420, 2.95, 0.467, 354, 332, THE CRYSTAL STRUCTURE OF AMP-BOUND JNK3
457, d5bvdA_, 0.8417, 2.37, 0.480, 330, 319, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
458, d2b9iA_, 0.8415, 2.47, 0.445, 338, 321, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM MSG5
459, p6g9mA_, 0.8414, 2.71, 0.467, 341, 323, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
460, d1pmuA_, 0.8414, 2.50, 0.486, 342, 323, THE CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PHENANTROLINE INHIBITOR
461, d4qp3A_, 0.8411, 2.55, 0.474, 339, 321, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
462, d4fv2A_, 0.8411, 2.78, 0.465, 344, 325, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK5
463, d4fv0A_, 0.8411, 2.64, 0.474, 341, 321, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK3
464, d3qywA_, 0.8411, 2.58, 0.475, 340, 320, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
465, d3w55A_, 0.8410, 2.63, 0.469, 335, 324, THE STRUCTURE OF ERK2 IN COMPLEX WITH FR148083
466, d2e14A_, 0.8410, 2.63, 0.469, 335, 324,  
467, d4zznA_, 0.8409, 2.56, 0.469, 338, 320, HUMAN ERK2 IN COMPLEX WITH AN INHIBITOR
468, d4xj0A_, 0.8409, 2.51, 0.469, 345, 320, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
469, d2ojiA_, 0.8409, 2.71, 0.477, 344, 323, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
470, d2b9hA_, 0.8409, 2.48, 0.445, 337, 321, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM STE7
471, d3r63A_, 0.8408, 2.80, 0.465, 347, 325, STRUCTURE OF ERK2 (SPE) MUTANT (S246E)
472, d4l7fA1, 0.8407, 2.47, 0.472, 343, 324, CO-CRYSTAL STRUCTURE OF JNK1 AND AX13587
473, d2wajA_, 0.8406, 3.06, 0.480, 348, 333, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH A 1-ARYL-34- DIHYDROISOQUINOLINE INHIBITOR
474, d4fv9A_, 0.8403, 2.54, 0.474, 331, 321, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E71
475, d4n4sB_, 0.8401, 2.60, 0.466, 337, 324, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
476, d4s32A_, 0.8399, 2.85, 0.459, 346, 327, CRYSTAL STRUCTURE OF ERK2 AMP-PNP COMPLEX
477, d5ke0A_, 0.8398, 2.69, 0.483, 340, 321, DISCOVERY OF 1-1H-PYRAZOLO 43-C PYRIDINE-6-YL UREA INHIBITORS OF EXTRACELLULAR SIGNAL REGULATED KINASE ERK FOR THE TREATMENT OF CANCERS
478, d4qp6A_, 0.8397, 2.46, 0.469, 339, 320, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
479, d3e7oA_, 0.8397, 2.69, 0.506, 342, 322, CRYSTAL STRUCTURE OF JNK2
480, d3cgfA_, 0.8397, 2.80, 0.473, 346, 328, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
481, p3teiA_, 0.8396, 2.57, 0.475, 339, 324, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
482, d2b9jA_, 0.8396, 2.71, 0.449, 337, 323, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM FAR1
483, d3g9nA_, 0.8392, 2.95, 0.480, 346, 331, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-PHENYLINDOLIN-2-ONE
484, d5k4iA_, 0.8389, 2.57, 0.486, 336, 323, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH COMPOUND 22
485, d4xp3A_, 0.8388, 2.66, 0.472, 339, 320, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
486, d3g90X_, 0.8388, 2.81, 0.477, 345, 329, JNK-3 BOUND TO (Z)-5-FLUORO-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL) METHYL)-3-(HYDROXYIMINO)INDOLIN-2-ONE
487, d4qnyB_, 0.8386, 2.67, 0.388, 339, 322, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
488, d4fv4A_, 0.8386, 2.51, 0.475, 329, 320, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK7
489, p6gdmA_, 0.8385, 2.81, 0.467, 341, 323, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
490, d5bvfA_, 0.8384, 2.36, 0.476, 327, 317, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
491, d5nguA_, 0.8383, 2.62, 0.464, 339, 321, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
492, d4g6nA_, 0.8379, 2.68, 0.470, 341, 321, CRYSTAL STRUCTURE OF THE ERK2
493, d2f49B_, 0.8379, 2.73, 0.448, 337, 324, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
494, d4n0sA_, 0.8377, 2.77, 0.467, 348, 323, COMPLEX OF ERK2 WITH CAFFEIC ACID
495, d2ojjA_, 0.8374, 2.79, 0.467, 344, 323, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-N-(1-(3- CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
496, d5buiA_, 0.8371, 2.50, 0.474, 338, 321, ERK2 COMPLEXED WITH 2-PYRIDIYL TETRAHYDROAZAINDAZOLE
497, d1pmnA_, 0.8371, 2.83, 0.480, 344, 327, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE- PYRIMIDINE INHIBITOR
498, d5nhfA_, 0.8369, 2.64, 0.464, 339, 321, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
499, d4xp2A_, 0.8368, 2.58, 0.461, 337, 319, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
500, d4zxtA_, 0.8367, 2.81, 0.460, 348, 324, COMPLEX OF ERK2 WITH CATECHOL
501, d3oxiA_, 0.8365, 1.88, 0.495, 322, 309, DESIGN AND SYNTHESIS OF DISUBSTITUTED THIOPHENE AND THIAZOLE BASED INHIBITORS OF JNK FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
502, d1jnkA_, 0.8365, 2.99, 0.479, 346, 330, THE C-JUN N-TERMINAL KINASE (JNK3S) COMPLEXED WITH MGAMP-PNP
503, d5nhpA_, 0.8359, 2.61, 0.469, 338, 320, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
504, d4qyyA_, 0.8359, 2.58, 0.470, 337, 319, DISCOVERY OF NOVEL DUAL MECHANISM ERK INHIBITORS BY AFFINITY SELECTION SCREENING OF AN INACTIVE KINASE STATE
505, p6gdqA_, 0.8356, 2.59, 0.464, 339, 319, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
506, d2f49A_, 0.8354, 2.70, 0.444, 335, 322, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
507, d4u79A_, 0.8353, 2.52, 0.489, 337, 321, CRYSTAL STRUCTURE OF HUMAN JNK3 IN COMPLEX WITH A BENZENESULFONAMIDE INHIBITOR.
508, p6g8xA_, 0.8352, 2.64, 0.475, 338, 318, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
509, d4w4wA_, 0.8352, 2.86, 0.473, 349, 328, JNK2/3 IN COMPLEX WITH N-(2-METHYLPYRIDIN-4-YL)-3-{4- [(PHENYLCARBAMOYL)AMINO]-1H-PYRAZOL-1-YL}BENZAMIDE
510, p6g92A_, 0.8350, 2.91, 0.466, 343, 324, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
511, d5bujA_, 0.8350, 2.48, 0.480, 331, 319, ERK2 COMPLEXED WITH A N-H TETRAHYDROAZAINDAZOLE
512, d3i5zA_, 0.8345, 2.61, 0.477, 331, 321, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-N-(2-HYDROXY-1-PHENYLETHYL)-4- (5-METHYL-2-(PHENYLAMINO)PYRIMIDIN-4-YL)-1H-PYRROLE-2-CARBOXAMIDE
513, d4fv1A_, 0.8341, 2.84, 0.463, 342, 324, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK4
514, d3eljA_, 0.8340, 2.89, 0.466, 347, 328, JNK1 COMPLEXED WITH A BIS-ANILINO-PYRROLOPYRIMIDINE INHIBITOR.
515, d4xp0A_, 0.8331, 2.66, 0.475, 336, 318, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
516, d2fa2A_, 0.8331, 2.62, 0.447, 333, 320, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
517, d3e7oB_, 0.8329, 2.12, 0.518, 326, 313, CRYSTAL STRUCTURE OF JNK2
518, d4qp1A_, 0.8327, 2.52, 0.473, 342, 317, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
519, d2b9fA_, 0.8324, 2.83, 0.453, 337, 322, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED FUS3
520, d3rtpA_, 0.8313, 2.37, 0.494, 331, 318, DESIGN AND SYNTHESIS OF BRAIN PENETRANT SELECTIVE JNK INHIBITORS WITH IMPROVED PHARMACOKINETIC PROPERTIES FOR THE PREVENTION OF NEURODEGENERATION
521, d2zdtA_, 0.8313, 2.84, 0.483, 342, 325, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
522, d4fv5A_, 0.8312, 2.51, 0.476, 330, 319, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK9
523, d4qp2A_, 0.8310, 2.50, 0.465, 336, 318, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
524, p4h3pD_, 0.8310, 2.57, 0.474, 338, 321, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
525, p4ux9D_, 0.8304, 2.78, 0.449, 344, 325, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
526, d3qyzA_, 0.8294, 2.60, 0.472, 339, 318, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
527, d5bueA_, 0.8289, 2.51, 0.478, 329, 318, ERK2 COMPLEXED WITH N-BENZYLPYRIDONE TETRAHYDROAZAINDAZOLE
528, p4ux9B_, 0.8287, 2.40, 0.484, 327, 314, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
529, d2f9gA_, 0.8286, 2.47, 0.454, 332, 317, CRYSTAL STRUCTURE OF FUS3 PHOSPHORYLATED ON TYR182
530, d1pmeA_, 0.8283, 2.54, 0.490, 333, 314, STRUCTURE OF PENTA MUTANT HUMAN ERK2 MAP KINASE COMPLEXED WITH A SPECIFIC INHIBITOR OF HUMAN P38 MAP KINASE
531, d4qp6B_, 0.8282, 2.86, 0.473, 334, 319, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
532, d3ohtB_, 0.8281, 2.81, 0.805, 331, 318, CRYSTAL STRUCTURE OF SALMO SALAR P38ALPHA
533, d2fa2B_, 0.8277, 2.67, 0.442, 332, 319, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
534, d3ohtA_, 0.8276, 2.83, 0.805, 331, 318, CRYSTAL STRUCTURE OF SALMO SALAR P38ALPHA
535, d3g9lX_, 0.8271, 2.76, 0.488, 336, 324, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-STYRYLINDOLIN-2-ONE
536, d4xj0B_, 0.8269, 2.61, 0.465, 338, 316, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
537, d5ci6A_, 0.8267, 2.63, 0.459, 335, 318, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
538, d2excX_, 0.8260, 2.59, 0.483, 335, 321, INHIBITOR COMPLEX OF JNK3
539, d4yr8A_, 0.8258, 2.15, 0.510, 320, 308, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
540, d4y46A_, 0.8255, 2.76, 0.491, 340, 320, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
541, d3ttiA_, 0.8250, 2.92, 0.483, 341, 325, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-930 AN ORALLY ACTIVE ANTI-FIBROTIC JNK INHIBITOR
542, d3oy1A_, 0.8250, 2.38, 0.491, 329, 316, HIGHLY SELECTIVE C-JUN N-TERMINAL KINASE (JNK) 2 AND 3 INHIBITORS WITH IN VITRO CNS-LIKE PHARMACOKINETIC PROPERTIES
543, d3o71A_, 0.8250, 3.00, 0.466, 340, 328, CRYSTAL STRUCTURE OF ERK2/DCC PEPTIDE COMPLEX
544, d4qnyA_, 0.8248, 2.66, 0.391, 333, 317, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
545, p4whzA_, 0.8247, 2.93, 0.486, 342, 325, DESIGN AND SYNTHESIS OF HIGHLY POTENT AND ISOFORM SELECTIVE JNK3 INHIBITORS: SAR STUDIES ON AMINOPYRAZOLE DERIVATIVES
546, d2z7lA_, 0.8243, 2.58, 0.482, 329, 313, UNPHOSPHORYLATED MITOGEN ACTIVATED PROTEIN KINASE ERK2 IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN 2-YL]AMINO}PHENYL)ACETIC ACID
547, d2xrwA1, 0.8238, 2.78, 0.486, 346, 323, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
548, d4w4yA_, 0.8234, 2.98, 0.486, 350, 325, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-METHYLPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
549, d1cm8B_, 0.8226, 2.81, 0.599, 327, 319, PHOSPHORYLATED MAP KINASE P38-GAMMA
550, d1cm8A_, 0.8225, 2.81, 0.599, 327, 319, PHOSPHORYLATED MAP KINASE P38-GAMMA
551, d4yr8C_, 0.8224, 2.01, 0.482, 318, 305, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
552, p3nieA_, 0.8221, 3.08, 0.367, 369, 327, CRYSTAL STRUCTURE OF PF11_0147
553, d3fv8A_, 0.8213, 2.36, 0.489, 331, 313, JNK3 BOUND TO PIPERAZINE AMIDE INHIBITOR SR2774.
554, d4qp3B_, 0.8210, 2.69, 0.478, 331, 314, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
555, d2ojgA_, 0.8207, 2.74, 0.473, 337, 317, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH NN-DIMETHYL-4-(4- PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
556, d4qp2B_, 0.8194, 2.83, 0.479, 329, 315, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
557, d3oz6A_, 0.8190, 2.84, 0.375, 343, 315, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
558, d4z9lA_, 0.8181, 2.71, 0.489, 333, 319, THE STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE-PYRIMIDINE INHIBITOR
559, d4qpaA_, 0.8179, 2.90, 0.468, 331, 316, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
560, d1pmvA_, 0.8170, 3.08, 0.470, 347, 328, THE STRUCTURE OF JNK3 IN COMPLEX WITH A DIHYDROANTHRAPYRAZOLE INHIBITOR
561, d4xoyA_, 0.8168, 2.29, 0.485, 326, 307, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
562, d4w4xA_, 0.8148, 3.03, 0.483, 342, 321, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-FLUOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
563, d3fi2A_, 0.8145, 2.58, 0.486, 326, 313, CRYSTAL STRUCTURE OF JNK3 WITH AMINO-PYRAZOLE INHIBITOR SR- 3451
564, p3nieB_, 0.8136, 3.07, 0.358, 367, 324, CRYSTAL STRUCTURE OF PF11_0147
565, d4w4vA_, 0.8134, 2.83, 0.483, 342, 319, JNK2/3 IN COMPLEX WITH 3-(4-{[(2-CHLOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
566, d4fuyA_, 0.8133, 2.59, 0.476, 329, 309, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK2
567, d2b1pA_, 0.8131, 2.61, 0.492, 331, 317, INHIBITOR COMPLEX OF JNK3
568, d3fi3A_, 0.8123, 2.56, 0.484, 328, 314, CRYSTAL STRUCTURE OF JNK3 WITH INDAZOLE INHIBITOR SR-3737
569, d3cgoA_, 0.8120, 2.77, 0.489, 332, 315, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
570, d3kvxA_, 0.8114, 2.45, 0.497, 327, 310, JNK3 BOUND TO AMINOPYRIMIDINE INHIBITOR SR-3562
571, d3ttjA_, 0.8110, 2.74, 0.483, 333, 317, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-359 A JNK INHIBITOR FOR THE PREVENTION OF ISCHEMIA-REPERFUSION INJURY
572, d2p33A_, 0.8110, 2.79, 0.489, 332, 315, SYNTHESIS AND SAR OF AMINOPYRIMIDINES AS NOVEL C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
573, d2ok1A_, 0.8104, 2.81, 0.495, 333, 319, CRYSTAL STRUCTURE OF JNK3 BOUND TO N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
574, d2zduA_, 0.8078, 2.58, 0.486, 330, 313, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
575, d3uibA_, 0.8077, 2.27, 0.360, 309, 303, MAP KINASE LMAMPK10 FROM LEISHMANIA MAJOR IN COMPLEX WITH SB203580
576, d2r9sB_, 0.8070, 2.36, 0.497, 325, 308, C-JUN N-TERMINAL KINASE 3 WITH 35-DISUBSTITUTED QUINOLINE INHIBITOR
577, d3da6A_, 0.8062, 2.59, 0.500, 328, 312, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-METHYL- 4-(3-(2-(METHYLAMINO)PYRIMIDIN-4-YL)PYRIDIN-2-YLOXY) NAPHTHALEN-1-YL)-1H-BENZO[D]IMIDAZOL-2-AMINE
578, d4yr8E_, 0.8054, 2.29, 0.510, 317, 304, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
579, p6cpwA_, 0.8053, 2.73, 0.471, 328, 310, DISCOVERY OF 3(S)-THIOMETHYL PYRROLIDINE ERK INHIBITORS FOR ONCOLOGY 
580, d2o0uA_, 0.8042, 2.80, 0.494, 331, 314, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-{3-CYANO-6-[3-(1- PIPERIDINYL)PROPANOYL]-4567-TETRAHYDROTHIENO[23-C]PYRIDIN-2-YL}- 1-NAPHTHALENECARBOXAMIDE
581, d2r9sA_, 0.8016, 2.44, 0.497, 325, 308, C-JUN N-TERMINAL KINASE 3 WITH 35-DISUBSTITUTED QUINOLINE INHIBITOR
582, p3n9xA_, 0.8005, 3.16, 0.368, 374, 323, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
583, d3oz6B_, 0.7985, 3.14, 0.373, 341, 316, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
584, p3n9xB_, 0.7957, 3.04, 0.377, 362, 318, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
585, d2o2uA_, 0.7913, 2.51, 0.502, 319, 305, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-CYANO-4567- TETRAHYDRO-1-BENZOTHIEN-2-YL)-2-FLUOROBENZAMIDE
586, d4yr8F_, 0.7794, 1.86, 0.470, 300, 287, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
587, d1j1cB_, 0.7490, 3.07, 0.306, 364, 288, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
588, d1j1bB_, 0.7483, 3.10, 0.306, 364, 288, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
589, d3i4bA_, 0.7474, 2.95, 0.308, 359, 286, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
590, d1r0eB_, 0.7468, 2.88, 0.311, 344, 283, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
591, d1r0eA_, 0.7460, 2.87, 0.307, 344, 283, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
592, d1h8fB_, 0.7455, 2.90, 0.311, 350, 283, GLYCOGEN SYNTHASE KINASE 3 BETA.
593, d2jd5B_, 0.7454, 3.45, 0.266, 360, 293, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
594, d1h8fA_, 0.7454, 2.89, 0.311, 352, 283, GLYCOGEN SYNTHASE KINASE 3 BETA.
595, d4nm0A1, 0.7450, 2.94, 0.305, 355, 285, CRYSTAL STRUCTURE OF PEPTIDE INHIBITOR-FREE GSK-3/AXIN COMPLEX
596, d4nm5A1, 0.7447, 3.09, 0.300, 360, 287, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 C-MOTIF
597, d4achA_, 0.7442, 2.99, 0.310, 350, 284, GSK3B IN COMPLEX WITH INHIBITOR
598, d1q97B_, 0.7440, 3.48, 0.266, 361, 293, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
599, d4achB_, 0.7438, 2.91, 0.307, 350, 283, GSK3B IN COMPLEX WITH INHIBITOR
600, d3sd0A_, 0.7435, 2.95, 0.307, 350, 283, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
601, d4acdB_, 0.7433, 3.01, 0.313, 350, 284, GSK3B IN COMPLEX WITH INHIBITOR
602, d4accA_, 0.7433, 3.02, 0.310, 350, 284, GSK3B IN COMPLEX WITH INHIBITOR
603, d4acdA_, 0.7432, 3.03, 0.306, 350, 284, GSK3B IN COMPLEX WITH INHIBITOR
604, d1q99B_, 0.7429, 3.47, 0.270, 364, 293, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
605, d4nm7A1, 0.7427, 3.04, 0.304, 354, 286, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 E-MOTIF
606, d1j1cA_, 0.7427, 2.97, 0.307, 354, 283, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
607, d1q8zB_, 0.7425, 3.42, 0.267, 364, 292, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
608, d4accB_, 0.7423, 3.01, 0.310, 350, 284, GSK3B IN COMPLEX WITH INHIBITOR
609, d4acgA_, 0.7418, 3.04, 0.310, 350, 284, GSK3B IN COMPLEX WITH INHIBITOR
610, d3sd0B_, 0.7417, 2.97, 0.307, 349, 283, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
611, d1j1bA_, 0.7416, 2.98, 0.307, 354, 283, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
612, d3pupB_, 0.7414, 3.02, 0.307, 347, 283, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
613, d3pupA_, 0.7414, 3.02, 0.307, 346, 283, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
614, d4acgB_, 0.7413, 2.99, 0.307, 350, 283, GSK3B IN COMPLEX WITH INHIBITOR
615, d1q8yB_, 0.7413, 3.45, 0.271, 357, 292, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
616, d5f94A_, 0.7410, 2.96, 0.307, 346, 283, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
617, d5f94B_, 0.7406, 2.95, 0.311, 349, 283, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
618, d2jldB_, 0.7405, 3.03, 0.311, 349, 283, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
619, d3i4bB_, 0.7403, 3.01, 0.311, 347, 283, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
620, d3m1sB_, 0.7398, 3.05, 0.311, 349, 283, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
621, d2jldA_, 0.7397, 3.02, 0.311, 349, 283, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
622, d4pteB_, 0.7377, 2.91, 0.312, 347, 282, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
623, d1q41B_, 0.7377, 2.84, 0.311, 343, 280, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
624, d4ptcB_, 0.7374, 3.02, 0.311, 347, 283, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
625, d1o9uA_, 0.7372, 2.83, 0.318, 349, 280, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE
626, d4cxaC_, 0.7370, 3.31, 0.304, 330, 289, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
627, d2ow3B_, 0.7370, 2.84, 0.311, 351, 280, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
628, d4ptcA_, 0.7369, 3.04, 0.311, 342, 283, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
629, d4pteA_, 0.7358, 2.98, 0.313, 341, 281, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
630, d3m1sA_, 0.7358, 2.95, 0.313, 348, 281, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
631, d3sayB_, 0.7357, 2.83, 0.311, 347, 280, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
632, d5hlnA_, 0.7355, 2.86, 0.307, 346, 280, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
633, d4j71B_, 0.7352, 2.78, 0.315, 347, 279, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
634, d3zrlA_, 0.7351, 2.88, 0.314, 345, 280, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
635, d3zrmA_, 0.7350, 2.86, 0.314, 344, 280, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
636, d1q8zA_, 0.7345, 3.59, 0.271, 354, 292, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
637, d4j71A_, 0.7340, 2.84, 0.314, 347, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
638, d5f95A_, 0.7339, 2.98, 0.314, 345, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
639, d2ow3A_, 0.7337, 2.68, 0.313, 346, 278, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
640, d3zrkB_, 0.7335, 2.96, 0.310, 348, 281, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
641, d3zrkA_, 0.7334, 2.90, 0.314, 345, 280, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
642, d4j1rA_, 0.7331, 2.85, 0.314, 343, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
643, d4j1rD_, 0.7330, 2.86, 0.314, 345, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
644, d3zrlB_, 0.7330, 2.87, 0.314, 347, 280, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
645, d1gngA_, 0.7329, 2.97, 0.309, 348, 282, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
646, d1q99A_, 0.7327, 3.55, 0.271, 354, 291, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
647, d3zrmB_, 0.7326, 2.87, 0.314, 347, 280, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
648, d4j1rC_, 0.7325, 2.88, 0.314, 344, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
649, d3q3bB_, 0.7320, 2.93, 0.313, 341, 278, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
650, d1q3dB_, 0.7319, 2.98, 0.317, 339, 278, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
651, d3q3bA_, 0.7317, 2.87, 0.317, 344, 278, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
652, d1q3wA_, 0.7315, 2.86, 0.317, 344, 278, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
653, d5hlnB_, 0.7312, 2.83, 0.315, 346, 279, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
654, d1q3wB_, 0.7308, 2.94, 0.317, 341, 278, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
655, d1uv5A_, 0.7306, 3.21, 0.310, 348, 284, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 6-BROMOINDIRUBIN-3 -OXIME
656, d1f5qA_, 0.7304, 2.39, 0.372, 296, 274, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
657, d4j1rB_, 0.7303, 2.87, 0.315, 346, 279, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
658, d1q5kA_, 0.7300, 3.05, 0.314, 345, 280, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
659, d1q3dA_, 0.7299, 2.86, 0.315, 339, 276, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
660, d2o5kA1, 0.7298, 3.04, 0.306, 350, 281, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A BENZOIMIDAZOL INHIBITOR
661, d5acbD_, 0.7295, 3.19, 0.310, 319, 284, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
662, d3sayA_, 0.7293, 2.88, 0.309, 347, 278, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
663, d1i09B_, 0.7291, 2.97, 0.317, 341, 278, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
664, d1howA_, 0.7285, 3.46, 0.272, 346, 287, THE X-RAY CRYSTAL STRUCTURE OF SKY1P AN SR PROTEIN KINASE IN YEAST
665, d1gngB_, 0.7276, 3.14, 0.310, 355, 284, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
666, d4yc3A1, 0.7272, 2.34, 0.358, 294, 271, CDK1/CYCLINB1/CKS2 APO
667, d1w98A2, 0.7268, 2.59, 0.382, 296, 275, THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
668, d3f88B_, 0.7267, 2.74, 0.315, 340, 276, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
669, d5acbC_, 0.7266, 3.35, 0.312, 324, 285, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
670, d3f88A_, 0.7265, 2.74, 0.315, 340, 276, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
671, d4afjA_, 0.7264, 2.91, 0.314, 342, 277, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
672, d2i6lA_, 0.7261, 2.86, 0.371, 292, 280, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
673, d1pyxA_, 0.7260, 2.96, 0.317, 343, 278, GSK-3 BETA COMPLEXED WITH AMP-PNP
674, d2jd5A_, 0.7258, 3.53, 0.263, 353, 289, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
675, d1q4lA_, 0.7258, 2.95, 0.315, 342, 276, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
676, d1finA_, 0.7258, 2.60, 0.380, 298, 274, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
677, d2bpmA2, 0.7255, 2.54, 0.385, 298, 273, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
678, d3du8B_, 0.7254, 2.90, 0.315, 339, 276, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
679, d3du8A_, 0.7254, 2.82, 0.316, 336, 275, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
680, d5hlpA_, 0.7253, 2.73, 0.316, 337, 275, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
681, d2i40C_, 0.7246, 2.62, 0.383, 296, 274, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
682, d2bpmC2, 0.7245, 2.65, 0.383, 298, 274, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
683, d3gb2A_, 0.7244, 2.90, 0.314, 340, 277, GSK3BETA INHIBITOR COMPLEX
684, d3f5xC_, 0.7243, 2.61, 0.380, 298, 274, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
685, d5if1A_, 0.7241, 2.54, 0.381, 298, 273, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
686, d1pyxB_, 0.7237, 2.95, 0.315, 338, 276, GSK-3 BETA COMPLEXED WITH AMP-PNP
687, d4cxaA_, 0.7236, 3.29, 0.308, 329, 286, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
688, d4cfwA1, 0.7233, 2.47, 0.384, 297, 271, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
689, d1okvA_, 0.7233, 2.63, 0.376, 295, 274, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
690, d1finC_, 0.7233, 2.66, 0.380, 298, 274, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
691, d4afjB_, 0.7231, 2.95, 0.307, 346, 277, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
692, d1pkdA1, 0.7229, 2.51, 0.382, 295, 272, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
693, d1fvvC_, 0.7228, 2.63, 0.380, 298, 274, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
694, d2wxvA1, 0.7227, 2.58, 0.377, 298, 273, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
695, d2wihA1, 0.7226, 2.57, 0.377, 298, 273, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
696, d1ol2A_, 0.7225, 2.63, 0.376, 296, 274, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
697, d1q97A_, 0.7224, 3.45, 0.269, 351, 286, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
698, d1h24A1, 0.7224, 2.46, 0.380, 292, 271, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
699, d2wxvC1, 0.7221, 2.69, 0.380, 298, 274, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
700, d1okwA_, 0.7220, 2.58, 0.377, 296, 273, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
701, d2wihC1, 0.7219, 2.67, 0.380, 298, 274, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
702, d2v22A_, 0.7219, 2.65, 0.383, 296, 274, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
703, d5if1C_, 0.7218, 2.66, 0.383, 296, 274, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
704, d3f7zB1, 0.7218, 2.80, 0.320, 338, 275, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
705, d2uueA_, 0.7217, 2.66, 0.383, 296, 274, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
706, d4iq6B_, 0.7216, 2.81, 0.322, 332, 273, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
707, d2c5tA_, 0.7216, 2.66, 0.383, 296, 274,  
708, d3f5xA_, 0.7215, 2.61, 0.377, 297, 273, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
709, d1h27A1, 0.7215, 2.48, 0.380, 295, 271, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
710, d1blxA_, 0.7215, 3.10, 0.331, 305, 281, P19INK4D/CDK6 COMPLEX
711, d1vywA1, 0.7214, 2.62, 0.381, 298, 273, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
712, d5cyiA1, 0.7213, 2.56, 0.382, 297, 272, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
713, d2iw6C2, 0.7213, 2.50, 0.382, 294, 272, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
714, d4bcmC1, 0.7212, 2.52, 0.382, 293, 272, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
715, d1jstA_, 0.7212, 2.33, 0.383, 297, 269, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
716, d2wfyA_, 0.7211, 2.59, 0.377, 295, 273, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
717, d2jgzA_, 0.7211, 2.48, 0.384, 288, 271, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B
718, d1h28C1, 0.7210, 2.64, 0.377, 295, 273, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
719, d1h25A1, 0.7209, 2.49, 0.380, 292, 271, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
720, d5nevA1, 0.7207, 2.55, 0.382, 294, 272, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
721, d1vywC1, 0.7207, 2.70, 0.380, 298, 274, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
722, d2c5nC_, 0.7206, 2.65, 0.383, 296, 274, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
723, d1ol1A_, 0.7205, 2.68, 0.376, 296, 274, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
724, d1h26A1, 0.7205, 2.55, 0.379, 295, 272, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
725, d1h1rA1, 0.7205, 2.54, 0.382, 295, 272, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
726, d4yc6G_, 0.7203, 2.57, 0.347, 285, 274, CDK1/CKS1
727, d2wmbA1, 0.7203, 2.56, 0.379, 295, 272, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
728, d1pkdC1, 0.7203, 2.55, 0.382, 295, 272, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
729, d5nevC1, 0.7202, 2.56, 0.382, 295, 272, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
730, d5l2wA1, 0.7202, 2.71, 0.378, 296, 275, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK2/CYCLINE AND DINACICLIB.
731, d4bcpA1, 0.7202, 2.50, 0.384, 297, 271, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
732, d1fvvA_, 0.7202, 2.67, 0.376, 298, 274, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
733, d4cfmA1, 0.7201, 2.50, 0.384, 295, 271, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
734, d5hlpB_, 0.7200, 2.69, 0.320, 335, 272, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
735, d4cfwC1, 0.7199, 2.56, 0.382, 295, 272, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
736, d5cyiC1, 0.7198, 2.54, 0.382, 295, 272, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
737, d2c4gA2, 0.7198, 2.74, 0.383, 297, 274, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
738, d1oi9C1, 0.7198, 2.51, 0.379, 295, 272, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
739, d1h28A1, 0.7198, 2.56, 0.375, 295, 272, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
740, d1h1sA1, 0.7198, 2.57, 0.382, 295, 272, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
741, d1e9hA_, 0.7198, 2.51, 0.376, 295, 271, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
742, d2wevC_, 0.7197, 2.58, 0.385, 296, 273, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
743, d1e9hC1, 0.7197, 2.56, 0.379, 295, 272, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
744, d4cfvA1, 0.7195, 2.58, 0.382, 297, 272, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
745, d2wmaA1, 0.7195, 2.56, 0.379, 295, 272, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
746, d2c5pC_, 0.7195, 2.58, 0.385, 296, 273,  
747, d4bcoA1, 0.7194, 2.59, 0.382, 297, 272, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
748, d4bcnC1, 0.7194, 2.55, 0.382, 293, 272, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
749, d2wpaA1, 0.7194, 2.66, 0.381, 298, 273, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
750, d2whbA_, 0.7194, 2.63, 0.385, 296, 273, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
751, d1oi9A1, 0.7194, 2.53, 0.384, 294, 271, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
752, d1h1rC1, 0.7194, 2.56, 0.382, 295, 272, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
753, d4eooC1, 0.7193, 2.56, 0.379, 295, 272, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
754, d1urcA_, 0.7193, 2.68, 0.383, 296, 274, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
755, d1h1qA1, 0.7193, 2.56, 0.382, 295, 272, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
756, d4un0C_, 0.7192, 2.97, 0.318, 308, 277, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
757, d4cfnA1, 0.7192, 2.41, 0.387, 293, 269, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
758, d2c4gC2, 0.7191, 2.75, 0.380, 298, 274, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
759, d2c5oA_, 0.7190, 2.69, 0.383, 296, 274, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
760, d2g9xA2, 0.7189, 2.59, 0.382, 297, 272, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
761, d2c5xA_, 0.7189, 2.69, 0.383, 296, 274, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
762, d3tnwA1, 0.7188, 2.41, 0.387, 294, 269, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
763, d3f7zA1, 0.7188, 2.83, 0.319, 338, 273, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
764, d2whaA_, 0.7187, 2.70, 0.383, 296, 274,  
765, d2iw8A1, 0.7187, 2.58, 0.382, 296, 272, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
766, d2v22C_, 0.7186, 2.63, 0.385, 296, 273, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
767, d2bkzC2, 0.7186, 2.75, 0.380, 297, 274, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
768, d1p5eC1, 0.7186, 2.59, 0.382, 295, 272, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
769, d1okuC_, 0.7186, 2.68, 0.383, 296, 274,  
770, d2wipA1, 0.7185, 2.61, 0.379, 293, 272, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
771, d2c5tC_, 0.7185, 2.64, 0.385, 296, 273,  
772, d1h1sC1, 0.7185, 2.57, 0.382, 295, 272, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
773, d2x1nA_, 0.7184, 2.70, 0.383, 296, 274, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
774, d2c5oC_, 0.7184, 2.69, 0.383, 296, 274, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
775, d1q8yA_, 0.7184, 3.39, 0.270, 351, 285, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
776, d1q4lB_, 0.7184, 2.98, 0.314, 337, 274, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
777, d2uueC_, 0.7183, 2.65, 0.385, 296, 273, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
778, d2c5nA_, 0.7183, 2.70, 0.380, 296, 274, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
779, d2wpaC1, 0.7182, 2.77, 0.380, 298, 274, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
780, d2wfyC_, 0.7182, 2.64, 0.377, 296, 273, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
781, d2bkzA2, 0.7182, 2.71, 0.377, 298, 273, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
782, d1q5kB_, 0.7182, 3.08, 0.314, 344, 277, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
783, d1okwC_, 0.7182, 2.63, 0.377, 296, 273, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
784, d1okuA_, 0.7182, 2.69, 0.376, 296, 274,  
785, d2whbC_, 0.7181, 2.65, 0.385, 296, 273, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
786, d1ol1C_, 0.7181, 2.61, 0.385, 296, 273, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
787, d1gy3C_, 0.7181, 2.59, 0.375, 295, 272, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
788, d4bcnA1, 0.7180, 2.49, 0.385, 295, 270, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
789, d4bcmA1, 0.7180, 2.43, 0.387, 292, 269, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
790, d3dogA1, 0.7180, 2.55, 0.384, 296, 271, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
791, d2wipC1, 0.7180, 2.71, 0.381, 291, 273, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
792, d2whaC_, 0.7180, 2.70, 0.383, 296, 274,  
793, d2c5vC_, 0.7180, 2.69, 0.383, 296, 274, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
794, d2c5vA_, 0.7180, 2.69, 0.380, 296, 274, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
795, d4cfuA1, 0.7179, 2.48, 0.378, 295, 270, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
796, d2i40A_, 0.7179, 2.25, 0.386, 291, 267, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
797, d1h24C1, 0.7179, 2.60, 0.382, 292, 272, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
798, d4yc6C_, 0.7178, 2.60, 0.347, 285, 274, CDK1/CKS1
799, d2cjmC_, 0.7178, 2.54, 0.384, 294, 271, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
800, d4fx3A_, 0.7177, 2.66, 0.381, 298, 273, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
801, d3ddpA1, 0.7177, 2.59, 0.382, 296, 272, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
802, d2x1nC_, 0.7176, 2.72, 0.383, 296, 274, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
803, d1q41A_, 0.7176, 2.88, 0.318, 339, 274, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
804, d1oiyC1, 0.7176, 2.60, 0.382, 295, 272, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
805, d3tnwC_, 0.7175, 2.59, 0.382, 291, 272, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
806, d3bhvA1, 0.7174, 2.49, 0.385, 295, 270, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
807, d1ol2C_, 0.7174, 2.62, 0.385, 296, 273, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
808, d2wevA_, 0.7173, 2.72, 0.383, 296, 274, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
809, d4ptgA_, 0.7172, 2.88, 0.322, 333, 273, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
810, d4cfnC1, 0.7172, 2.59, 0.382, 293, 272, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
811, d2c5xC_, 0.7172, 2.64, 0.385, 296, 273, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
812, d2c5pA_, 0.7172, 2.72, 0.383, 296, 274,  
813, d1gy3A_, 0.7172, 2.61, 0.379, 295, 272, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
814, d4nstA_, 0.7171, 3.24, 0.317, 322, 281, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
815, d1urcC_, 0.7169, 2.74, 0.383, 296, 274, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
816, d4yc6A_, 0.7168, 2.62, 0.354, 285, 274, CDK1/CKS1
817, d1h1qC1, 0.7168, 2.59, 0.382, 295, 272, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
818, d4fx3C_, 0.7167, 2.76, 0.380, 298, 274, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
819, d1oguA1, 0.7167, 2.44, 0.387, 293, 269, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
820, d5lmkA1, 0.7164, 2.52, 0.385, 295, 270, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
821, d4cjyC_, 0.7164, 3.06, 0.318, 303, 277,  
822, d3my5A1, 0.7164, 2.45, 0.379, 294, 269, CDK2/CYCLINA IN COMPLEX WITH DRB
823, d1oiyA1, 0.7164, 2.45, 0.387, 292, 269, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
824, d3ddpC1, 0.7163, 2.64, 0.382, 297, 272, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
825, d3bhuA1, 0.7163, 2.52, 0.381, 295, 270, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
826, d3bhtA2, 0.7163, 2.51, 0.381, 295, 270, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
827, d2pk9A_, 0.7163, 2.19, 0.368, 287, 266, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
828, d2iw6A1, 0.7163, 2.45, 0.387, 291, 269, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
829, d1okvC_, 0.7163, 2.66, 0.377, 296, 273, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
830, d4eomA1, 0.7162, 2.52, 0.378, 294, 270, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
831, d3eidA_, 0.7162, 2.36, 0.384, 292, 268, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
832, d1p5eA1, 0.7162, 2.48, 0.381, 295, 270, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
833, d4eoqA1, 0.7160, 2.46, 0.383, 293, 269, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
834, d5hq0A1, 0.7159, 2.46, 0.351, 289, 271, TERNARY COMPLEX OF HUMAN PROTEINS CDK1 CYCLIN B AND CKS2 BOUND TO AN INHIBITOR
835, d4y72A1, 0.7159, 2.46, 0.351, 289, 271, HUMAN CDK1/CYCLINB1/CKS2 WITH INHIBITOR
836, d3ddqA1, 0.7159, 2.54, 0.385, 295, 270, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
837, d2cchA2, 0.7159, 2.65, 0.379, 295, 272, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
838, d1oiuA1, 0.7159, 2.45, 0.387, 293, 269, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
839, d4or5F_, 0.7158, 3.37, 0.330, 324, 285, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
840, d2cciA2, 0.7158, 2.64, 0.375, 295, 272, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
841, d3eidC_, 0.7157, 2.38, 0.384, 290, 268, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
842, d2uzlC_, 0.7157, 2.65, 0.379, 295, 272, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
843, d1f5qC_, 0.7154, 2.24, 0.368, 288, 266, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
844, d4bchA_, 0.7153, 3.26, 0.326, 308, 282, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
845, d4yc6E_, 0.7152, 2.50, 0.346, 285, 272, CDK1/CKS1
846, d4nstC_, 0.7152, 3.03, 0.317, 317, 278, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
847, d2uzeA_, 0.7151, 2.65, 0.379, 295, 272, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
848, d2uzeC_, 0.7150, 2.67, 0.379, 295, 272, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
849, d4eokC1, 0.7145, 2.66, 0.382, 296, 272, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
850, d3my1A_, 0.7144, 3.24, 0.335, 314, 281, STRUCTURE OF CDK9/CYCLINT1 IN COMPLEX WITH DRB
851, d2cjmA_, 0.7144, 2.37, 0.386, 285, 267, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
852, d2iw9A2, 0.7142, 2.43, 0.388, 292, 268, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
853, d4bckA1, 0.7141, 2.65, 0.384, 296, 271, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
854, d2c6tC_, 0.7141, 2.69, 0.382, 295, 272, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
855, d4eooA1, 0.7140, 2.43, 0.381, 292, 268, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
856, d2uzlA_, 0.7140, 2.67, 0.382, 295, 272, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
857, d3lq5A_, 0.7139, 3.14, 0.332, 307, 280, STRUCTURE OF CDK9/CYCLINT IN COMPLEX WITH S-CR8
858, d2uzdC_, 0.7136, 2.64, 0.384, 295, 271, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
859, d2cchC2, 0.7134, 2.70, 0.379, 295, 272, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
860, d4imyA_, 0.7133, 3.24, 0.331, 314, 281, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
861, d4eorA1, 0.7133, 2.45, 0.388, 292, 268, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
862, d4bcqA1, 0.7132, 2.62, 0.381, 289, 270, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
863, d4bckC1, 0.7132, 2.63, 0.380, 291, 271, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
864, d4imyC_, 0.7131, 3.24, 0.331, 310, 281, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
865, d2cciC2, 0.7128, 2.69, 0.375, 295, 272, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
866, d4i3zA_, 0.7126, 2.70, 0.379, 295, 272, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
867, d2b54A_, 0.7126, 2.81, 0.351, 298, 276, HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2)COMPLEXED WITH DIN- 232305
868, d1jstC_, 0.7126, 2.54, 0.378, 297, 270, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
869, d4bcgA_, 0.7125, 3.23, 0.338, 312, 281, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
870, d4imyE_, 0.7124, 3.23, 0.325, 313, 280, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
871, d2uzbA_, 0.7124, 2.71, 0.382, 295, 272, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
872, d4krdA_, 0.7123, 2.76, 0.359, 294, 273, CRYSTAL STRUCTURE OF PHO85-PCL10 COMPLEX
873, d4bcqC1, 0.7123, 2.72, 0.382, 291, 272, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
874, d1v0bA_, 0.7123, 2.75, 0.360, 286, 275, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
875, d4i3zC_, 0.7122, 2.71, 0.379, 295, 272, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
876, d1unlA_, 0.7122, 2.75, 0.364, 292, 272, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
877, d1g3nE_, 0.7122, 2.70, 0.351, 293, 271, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
878, d4ii5A_, 0.7120, 2.71, 0.379, 295, 272, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
879, d3miaA_, 0.7120, 3.17, 0.332, 324, 280, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH ATP-BOUND HUMAN P-TEFB
880, d4ii5C_, 0.7119, 2.72, 0.379, 295, 272, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
881, d4bcfA_, 0.7119, 3.23, 0.331, 307, 281, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
882, d3qhrC1, 0.7119, 2.72, 0.379, 295, 272, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
883, d2c6tA_, 0.7119, 2.69, 0.376, 295, 271, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
884, d4or5A_, 0.7118, 3.33, 0.330, 319, 282, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
885, d1g3nA_, 0.7118, 2.71, 0.351, 293, 271, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
886, d4eoiC1, 0.7117, 2.69, 0.382, 295, 272, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
887, d4eojA1, 0.7115, 2.48, 0.381, 293, 268, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
888, d4bcjA_, 0.7115, 3.32, 0.337, 309, 282, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
889, d4bciA_, 0.7114, 3.20, 0.339, 308, 280, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
890, d3qhrA1, 0.7113, 2.73, 0.379, 295, 272, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
891, d3mi9A_, 0.7111, 3.27, 0.331, 328, 281, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB
892, d2pmiC_, 0.7110, 2.12, 0.365, 285, 263, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
893, d4eopC1, 0.7109, 2.71, 0.382, 295, 272, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
894, d1qmzA1, 0.7109, 2.71, 0.375, 295, 272, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
895, d4eosC1, 0.7108, 2.70, 0.382, 295, 272, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
896, d1qmzC1, 0.7108, 2.71, 0.379, 295, 272, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
897, d5efqA_, 0.7107, 3.23, 0.306, 321, 278, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
898, d3qhwC1, 0.7106, 2.74, 0.379, 295, 272, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
899, d3tn8A_, 0.7105, 3.21, 0.323, 304, 279, CDK9/CYCLIN T IN COMPLEX WITH CAN508
900, d5efqC_, 0.7104, 3.14, 0.313, 325, 278, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
901, d3qhwA1, 0.7104, 2.74, 0.379, 295, 272, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
902, d4eosA1, 0.7102, 2.58, 0.387, 293, 269, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
903, d4eolC1, 0.7101, 2.73, 0.379, 296, 272, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
904, d1jwhA_, 0.7100, 3.24, 0.295, 336, 278, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
905, d2uzbC_, 0.7099, 2.57, 0.387, 292, 269, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
906, d2b53A_, 0.7097, 2.59, 0.360, 294, 272, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN- 234325
907, d2uzdA_, 0.7096, 2.70, 0.376, 295, 271, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
908, d1ungA_, 0.7096, 3.04, 0.358, 288, 274, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
909, d1buhA_, 0.7095, 2.45, 0.361, 287, 269, CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITH CELL CYCLE-REGULATORY PROTEIN CKSHS1
910, d1ykrA_, 0.7094, 2.75, 0.360, 298, 275, CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINE INHIBITOR
911, d5f95B_, 0.7089, 2.99, 0.321, 338, 271, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
912, d5uq2A_, 0.7088, 2.91, 0.388, 296, 273, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
913, d1i09A_, 0.7088, 2.81, 0.320, 338, 269, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
914, d1unlB_, 0.7085, 3.01, 0.353, 292, 275, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
915, d4eoiA1, 0.7084, 2.54, 0.388, 293, 268, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
916, d5m4cA_, 0.7079, 3.08, 0.293, 329, 276, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER LOW-SALT CONDITIONS
917, d4krcA_, 0.7078, 2.89, 0.358, 297, 274, CRYSTAL STRUCTURE OF PHO85-PCL10-ATP-GAMMA-S COMPLEX
918, d4un0D_, 0.7076, 2.52, 0.331, 276, 266, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
919, d4eonA1, 0.7075, 2.73, 0.380, 297, 271, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
920, d4bbmA1, 0.7075, 3.30, 0.292, 306, 281, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
921, d4kd1A_, 0.7073, 2.75, 0.354, 298, 274, CDK2 IN COMPLEX WITH DINACICLIB
922, d4eonC1, 0.7072, 2.75, 0.380, 296, 271, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
923, d3e3pB_, 0.7072, 3.14, 0.299, 337, 278, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
924, d3e3pA_, 0.7071, 3.27, 0.294, 337, 279, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
925, d3nizA1, 0.7070, 2.58, 0.363, 284, 270, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH ADP BOUND.
926, d3qqlA_, 0.7068, 2.65, 0.360, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR L3
927, d5a14A_, 0.7066, 2.61, 0.388, 284, 268, HUMAN CDK2 WITH TYPE II INHIBITOR
928, d4eopA1, 0.7066, 2.54, 0.388, 294, 268, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
929, d5nqcA_, 0.7065, 3.17, 0.298, 331, 275, CK2ALPHA IN COMPLEX WITH NMR154
930, d2oxyA_, 0.7064, 3.30, 0.272, 327, 279, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
931, d4eokA1, 0.7062, 2.56, 0.386, 292, 267, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
932, d3wikA_, 0.7061, 3.32, 0.290, 334, 279, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND10 COMPLEX
933, d4dglC_, 0.7060, 3.23, 0.293, 334, 276, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
934, d3o0gA_, 0.7060, 2.61, 0.366, 289, 268, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
935, d4ez7A1, 0.7059, 2.94, 0.364, 298, 275, CDK2 IN COMPLEX WITH STAUROSPORINE AND 2 MOLECULES OF 8-ANILINO-1- NAPHTHALENE SULFONIC ACID
936, d3l1sA_, 0.7059, 2.78, 0.320, 336, 269, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
937, d1j91A_, 0.7059, 3.40, 0.271, 327, 280, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
938, d1fq1B_, 0.7056, 2.74, 0.371, 295, 272, CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2
939, d5m4fA_, 0.7055, 3.12, 0.297, 330, 276, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER LOW-SALT CONDITIONS
940, d2exmA_, 0.7055, 2.80, 0.354, 298, 274, HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE
941, d3r83A_, 0.7053, 2.68, 0.360, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-92
942, d3r8pA_, 0.7052, 2.64, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-6
943, d1pw2A_, 0.7051, 2.62, 0.354, 294, 271, APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2
944, d4eolA1, 0.7050, 2.68, 0.379, 293, 269, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
945, d5k5nA_, 0.7049, 2.91, 0.314, 331, 271, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
946, d3pxzA1, 0.7049, 2.93, 0.369, 298, 274, CDK2 TERNARY COMPLEX WITH JWS648 AND ANS
947, d3pxfA1, 0.7049, 2.90, 0.369, 298, 274, CDK2 IN COMPLEX WITH TWO MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
948, d5lqfA1, 0.7048, 2.67, 0.358, 284, 268, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
949, d1h1pA1, 0.7048, 2.76, 0.380, 295, 271, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
950, d5b0xA_, 0.7046, 3.31, 0.291, 329, 278, CRYSTAL STRUCTURE OF THE CK2A/BENZOIC ACID DERIVATIVE COMPLEX
951, d4ptgB_, 0.7046, 3.02, 0.322, 332, 270, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
952, d2pmiA_, 0.7046, 2.25, 0.366, 284, 262, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
953, d5n1vB_, 0.7043, 3.39, 0.295, 331, 278, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
954, d1hclA_, 0.7043, 2.72, 0.359, 294, 273, HUMAN CYCLIN-DEPENDENT KINASE 2
955, d5k5nB_, 0.7042, 3.02, 0.315, 334, 270, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
956, d5aneA_, 0.7040, 2.64, 0.354, 294, 271, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-METHOXY-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
957, d5n1vA_, 0.7039, 3.44, 0.290, 331, 279, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
958, d3wowA_, 0.7039, 3.44, 0.289, 334, 280, CRYSTAL STRUCTURE OF HUMAN CK2A WITH AMPPNP
959, d3r71A_, 0.7039, 2.64, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-162
960, d3blqA_, 0.7038, 3.06, 0.337, 295, 273, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH ATP
961, d3pxqA1, 0.7037, 2.85, 0.374, 294, 273, CDK2 IN COMPLEX WITH 3 MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
962, d2rkpA_, 0.7033, 3.22, 0.298, 334, 275,  
963, d1hckA_, 0.7033, 2.65, 0.354, 294, 271, HUMAN CYCLIN-DEPENDENT KINASE 2
964, d3rm6A_, 0.7032, 2.69, 0.360, 293, 272, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-80
965, d5csvA_, 0.7031, 3.18, 0.299, 327, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 6 BOUND
966, d4ogrE_, 0.7030, 3.27, 0.323, 310, 279, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
967, d2xnbA_, 0.7029, 2.74, 0.357, 296, 272, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
968, d1h27C1, 0.7029, 2.57, 0.383, 290, 266, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
969, d1h1pC1, 0.7028, 2.89, 0.379, 295, 272, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
970, d5cspA_, 0.7027, 3.18, 0.299, 327, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
971, d3rpoA_, 0.7027, 2.65, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-156
972, d3r7yA_, 0.7027, 2.67, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-88
973, d2zjwA_, 0.7027, 3.40, 0.287, 332, 279, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH ELLAGIC ACID
974, d2clxA_, 0.7027, 2.63, 0.356, 293, 270, 4-ARYLAZO-35-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY CRYSTAL STRUCTURE IN COMPLEX WITH CDK2 SELECTIVITY AND CELLULAR EFFECTS
975, d1pjkA_, 0.7027, 3.38, 0.291, 331, 278, CRYSTAL STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
976, p4f9bA_, 0.7025, 3.03, 0.269, 318, 275, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND PHA767491
977, d3h30A_, 0.7023, 3.23, 0.298, 333, 275, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
978, d1pxiA_, 0.7021, 2.68, 0.354, 294, 271, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(25-DICHLORO-THIOPHEN-3-YL)-PYRIMIDIN-2- YLAMINE
979, d2a0cX_, 0.7020, 2.68, 0.358, 294, 271, HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II A NOVEL 269- TRISUBSTITUTED PURINE CYCLIN-DEPENDENT KINASE INHIBITOR
980, d1pxjA_, 0.7020, 2.67, 0.358, 294, 271, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINE
981, d5anjA_, 0.7019, 2.65, 0.351, 291, 271, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH N-(9H-PURIN-6-YL) THIOPHENE-2-CARBOXAMIDE  PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
982, d4md7E_, 0.7018, 3.41, 0.295, 332, 278, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
983, d3juhA_, 0.7017, 3.15, 0.299, 334, 274, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
984, d3raiA_, 0.7016, 2.68, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-160
985, d3c13A_, 0.7016, 3.25, 0.302, 328, 275, LOW PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
986, d3bqcA_, 0.7015, 3.25, 0.302, 328, 275, HIGH PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
987, d3r7vA_, 0.7013, 2.80, 0.357, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-9
988, d3r7eA_, 0.7013, 2.82, 0.357, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-67
989, d4md7H_, 0.7012, 3.43, 0.295, 330, 278, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
990, d3rpsA_, 0.7012, 3.30, 0.293, 334, 276, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
991, d3qx2A_, 0.7011, 2.72, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-190
992, d4md7G_, 0.7010, 3.44, 0.295, 332, 278, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
993, d3qxoA_, 0.7010, 2.70, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-84
994, d3r6xA_, 0.7007, 2.85, 0.357, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-158
995, d3r28A_, 0.7007, 2.81, 0.357, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-140
996, d3pxrA_, 0.7007, 2.77, 0.360, 294, 272, APO CDK2 CRYSTALLIZED FROM JEFFAMINE
997, d2ds1A_, 0.7007, 2.55, 0.362, 290, 268, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
998, d5motA_, 0.7006, 3.31, 0.298, 328, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0627 BOUND
999, d1j91B_, 0.7006, 3.27, 0.271, 327, 277, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
1000, d4md7F_, 0.7005, 3.44, 0.295, 332, 278, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
1001, d3ofmA_, 0.7004, 3.30, 0.308, 325, 276, STRUCTURE OF A HUMAN CK2ALPHA PRIME THE PARALOG ISOFORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM HOMO SAPIENS
1002, d3r73A_, 0.7003, 2.87, 0.357, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-164
1003, d3qzhA_, 0.7003, 2.85, 0.357, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-124
1004, d4iq6A_, 0.7002, 2.77, 0.328, 324, 265, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
1005, d3rm7A_, 0.7002, 2.84, 0.357, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-91
1006, d3qrtA_, 0.7002, 2.84, 0.366, 294, 273, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC2-55
1007, d3q9wA_, 0.7002, 3.23, 0.303, 328, 274, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 8.5
1008, d3mb6A_, 0.7002, 3.35, 0.304, 329, 276, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (CPA)
1009, d5lqfD1, 0.7001, 2.52, 0.366, 282, 265, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
1010, d3w8lA_, 0.7001, 3.15, 0.292, 326, 274, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
1011, d3gc0A_, 0.7001, 2.71, 0.349, 278, 269, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA IN COMPLEX WITH AMP
1012, d3fe3B_, 0.7001, 2.77, 0.230, 317, 269, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
1013, d5m4uA_, 0.7000, 3.51, 0.308, 332, 279, ORTHORHOMBIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
1014, d5h8bA_, 0.7000, 3.44, 0.295, 331, 278, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
1015, p4nh1A_, 0.7000, 3.45, 0.290, 330, 279, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
1016, d4aguC_, 0.7000, 2.80, 0.306, 278, 268, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
1017, p4nh1B_, 0.6999, 3.45, 0.290, 332, 279, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
1018, d3kxhA_, 0.6998, 3.40, 0.273, 326, 278, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR (2-DYMETHYLAMMINO-4567-TETRABROMOBENZOIMIDAZOL-1YL- ACETIC ACID (K66)
1019, d3r1qA_, 0.6997, 2.86, 0.357, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-102
1020, d3qzfA_, 0.6997, 2.86, 0.357, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-52
1021, d3qwkA_, 0.6997, 2.88, 0.366, 294, 273, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-150
1022, d3qqfA_, 0.6997, 2.85, 0.357, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR L1
1023, d3owlA_, 0.6997, 3.37, 0.296, 330, 277, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
1024, d4l42A_, 0.6994, 2.87, 0.259, 299, 270, CRYSTAL STRUCTURES OF HUMAN P70S6K1-PIF
1025, d3royA_, 0.6994, 2.89, 0.357, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-154
1026, d3r1yA_, 0.6993, 2.75, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-134
1027, d2xmyA_, 0.6993, 2.79, 0.357, 295, 272, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
1028, d2c5yA_, 0.6993, 2.68, 0.368, 290, 269, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
1029, d1pxpA_, 0.6993, 2.78, 0.347, 294, 271, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- N N -DIMETHYL-BENZENE-14-DIAMINE
1030, d3r1sA_, 0.6992, 2.74, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-127
1031, d3qziA_, 0.6992, 2.94, 0.359, 294, 273, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-126
1032, d4fbxA_, 0.6991, 3.31, 0.297, 333, 276, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT CRYSTALLIZED IN THE PRESENCE OF A BISUBSTRATE INHIBITOR
1033, d3l1sB_, 0.6990, 3.07, 0.321, 330, 268, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
1034, d3axwA_, 0.6990, 3.34, 0.297, 329, 276, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA COMPLEXED WITH A POTENT INHIBITOR
1035, d4rj3A_, 0.6989, 2.62, 0.358, 287, 268, CDK2 WITH EGFR INHIBITOR COMPOUND 8
1036, p4md8E_, 0.6989, 3.48, 0.290, 332, 279, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1037, d1pxoA_, 0.6989, 2.77, 0.358, 294, 271, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YL]-(3-NITRO-PHENYL)-AMINE
1038, p5omyA_, 0.6988, 3.38, 0.289, 332, 277, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
1039, d4rllA_, 0.6988, 3.27, 0.302, 329, 275, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
1040, d3owjA_, 0.6988, 3.33, 0.301, 328, 276, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A PYRIDOCARBAZOLE DERIVATIVE INHIBITOR
1041, d3lfsA_, 0.6988, 2.66, 0.364, 290, 269, CRYSTAL STRUCTURE OF CDK2 WITH SAR37 AN AMINOINDAZOLE TYPE INHIBITOR
1042, d2c6iA_, 0.6988, 2.70, 0.352, 292, 270, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
1043, d2c69A_, 0.6988, 2.65, 0.361, 292, 269, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
1044, d3wilA_, 0.6987, 3.53, 0.290, 331, 279, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND3 COMPLEX
1045, d3ngaB_, 0.6987, 3.48, 0.295, 331, 278, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
1046, d5t1hA_, 0.6986, 3.33, 0.292, 331, 277, CRYSTAL STRUCTURE OF CK2
1047, p4md8G_, 0.6986, 3.48, 0.290, 332, 279, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1048, d2pvrA_, 0.6986, 3.36, 0.293, 328, 276, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 (C- TERMINAL DELETION MUTANT 1-335) IN COMPLEX WITH TWO SULFATE IONS
1049, d2c6kA_, 0.6985, 2.71, 0.356, 292, 270, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
1050, d4ub7A_, 0.6984, 3.48, 0.291, 334, 278, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26) SHOWING AN EXTREME DISTORTION OF THE ATP-BINDING LOOP COMBINED WITH A PI-HALOGEN BOND
1051, d3qx4A_, 0.6984, 2.77, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-78
1052, d3bw5A_, 0.6984, 3.13, 0.300, 334, 273,  
1053, d2oxyB_, 0.6984, 3.31, 0.274, 327, 277, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
1054, d5xvuC_, 0.6983, 3.19, 0.303, 321, 274, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
1055, d5xvuB_, 0.6983, 3.19, 0.303, 321, 274, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
1056, d5h8gA_, 0.6983, 3.21, 0.296, 324, 274, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7B
1057, p3u9cA_, 0.6983, 3.36, 0.290, 331, 276, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
1058, d1ymiA_, 0.6983, 3.13, 0.300, 334, 273,  
1059, d3q9xB_, 0.6982, 3.43, 0.292, 330, 277, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
1060, d1y8yA_, 0.6981, 2.66, 0.357, 292, 269, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
1061, d4cjyD_, 0.6980, 2.50, 0.340, 272, 262,  
1062, p5ooiA_, 0.6979, 3.41, 0.307, 329, 277, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
1063, d2c6mA_, 0.6979, 2.71, 0.356, 290, 270, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
1064, d2c6lA_, 0.6979, 2.61, 0.362, 291, 268, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
1065, d5xvuA_, 0.6978, 3.18, 0.303, 321, 274, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
1066, p4md9L_, 0.6978, 3.48, 0.295, 328, 278, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1067, d3h30B_, 0.6977, 2.98, 0.299, 333, 271, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
1068, p4gubA_, 0.6976, 3.45, 0.291, 329, 278, CASEIN KINASE II BOUND TO INHIBITOR
1069, d4bxaA_, 0.6976, 3.52, 0.295, 331, 278,  
1070, d3rp0C_, 0.6976, 3.38, 0.289, 329, 277,  
1071, d3qwjA_, 0.6976, 2.82, 0.360, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-142
1072, d5cvgA_, 0.6975, 3.10, 0.295, 326, 271, CRYSTAL STRUCTURE OF CK2ALPHA WITH A NOVEL CLOSED CONFORMATION OF THE AD LOOP
1073, p4md8H_, 0.6975, 3.51, 0.290, 331, 279, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1074, d4fklA_, 0.6975, 2.57, 0.360, 290, 267, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
1075, d3owkA_, 0.6975, 3.41, 0.300, 330, 277, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
1076, d3blrA_, 0.6975, 3.19, 0.336, 300, 274, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH FLAVOPIRIDOL
1077, d1ds5B_, 0.6975, 3.39, 0.270, 328, 278, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1078, d5mohA_, 0.6974, 3.23, 0.300, 326, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0583 BOUND.
1079, p4md9G_, 0.6974, 3.45, 0.295, 329, 278, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1080, p4ib5C_, 0.6974, 3.53, 0.294, 332, 279, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
1081, d3u87A_, 0.6974, 3.50, 0.291, 329, 278, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
1082, d2vtlA_, 0.6974, 2.58, 0.363, 290, 267, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1083, d2v0dA_, 0.6974, 2.73, 0.359, 292, 270, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
1084, d1h4lB_, 0.6974, 2.64, 0.371, 278, 264, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
1085, d5m56B_, 0.6973, 3.48, 0.306, 328, 278, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
1086, d3ngaA_, 0.6973, 3.40, 0.292, 331, 277, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
1087, d1na7A_, 0.6973, 3.30, 0.291, 326, 275, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2
1088, d4anmA1, 0.6972, 3.50, 0.269, 327, 279, COMPLEX OF CK2 WITH A CDC7 INHIBITOR
1089, d2uzoA_, 0.6972, 2.71, 0.359, 290, 270, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
1090, d4grbA_, 0.6971, 3.27, 0.296, 327, 274, CASEIN KINASE 2 (CK2) BOUND TO INHIBITOR
1091, d3qa0B_, 0.6971, 3.39, 0.297, 330, 276, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
1092, d3pj8A1, 0.6971, 2.53, 0.371, 287, 267, STRUCTURE OF CDK2 IN COMPLEX WITH A PYRAZOLO[43-D]PYRIMIDINE BIOISOSTERE OF ROSCOVITINE.
1093, p3e3bX_, 0.6971, 3.39, 0.310, 334, 277, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2ALPHA PRIME WITH A POTENT INDAZOLE-DERIVATIVE INHIBITOR
1094, d2vtmA_, 0.6971, 2.57, 0.363, 290, 267, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1095, d1v0pA_, 0.6971, 2.58, 0.367, 277, 267, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
1096, d5m4iA_, 0.6969, 3.37, 0.289, 331, 277, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
1097, d3fwqB_, 0.6969, 3.19, 0.297, 334, 273, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
1098, d1jwhB_, 0.6969, 3.60, 0.287, 335, 282, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
1099, d5h8eA_, 0.6968, 3.40, 0.296, 331, 277, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
1100, d1h0uA_, 0.6968, 2.63, 0.358, 291, 268,  
1101, d1b38A_, 0.6968, 2.60, 0.360, 290, 267, HUMAN CYCLIN-DEPENDENT KINASE 2
1102, d4ogrA_, 0.6967, 3.24, 0.329, 314, 277, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
1103, d3q9yA_, 0.6967, 3.31, 0.295, 327, 275, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 8.5
1104, d2c68A_, 0.6967, 2.70, 0.361, 290, 269, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
1105, d5m56A_, 0.6966, 3.46, 0.310, 331, 277, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
1106, p3u9cB_, 0.6966, 3.39, 0.293, 331, 276, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
1107, d3qruA_, 0.6966, 2.90, 0.363, 295, 273, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-12
1108, d3lfqA_, 0.6966, 2.61, 0.367, 289, 267, CRYSTAL STRUCTURE OF CDK2 WITH SAR60 AN AMINOINDAZOLE TYPE INHIBITOR
1109, d5cu4A_, 0.6965, 3.30, 0.291, 327, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
1110, p4md8F_, 0.6965, 3.53, 0.290, 332, 279, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1111, d3juhB_, 0.6965, 3.16, 0.300, 334, 273, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
1112, d2r3fA_, 0.6965, 2.60, 0.360, 290, 267, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1113, d1oirA_, 0.6965, 2.57, 0.365, 286, 266, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
1114, p4md9E_, 0.6964, 3.40, 0.289, 329, 277, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1115, d3r0tA_, 0.6964, 3.29, 0.299, 327, 274, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-5279
1116, d3nszA_, 0.6964, 3.13, 0.294, 327, 272, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH AMPPN
1117, p3be9A_, 0.6964, 3.58, 0.275, 327, 280, STRUCTURE-BASED DESIGN AND SYNTHESIS OF NOVEL MACROCYCLIC PYRAZOLO[15-A] [135]TRIAZINE COMPOUNDS AS POTENT INHIBITORS OF PROTEIN KINASE CK2 AND THEIR ANTICANCER ACTIVITIES
1118, d3amyA_, 0.6964, 2.86, 0.299, 318, 268, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH APIGENIN
1119, d1lr4A_, 0.6964, 3.50, 0.269, 327, 279, ROOM TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
1120, p5n9kA_, 0.6963, 3.41, 0.301, 329, 276, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF107 (5)
1121, d4l44A_, 0.6963, 3.20, 0.256, 321, 277, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM II)
1122, d3rkbA_, 0.6963, 2.84, 0.373, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-2-73
1123, d3q04A_, 0.6963, 3.38, 0.297, 328, 276, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 8.5
1124, d1h4lA_, 0.6963, 2.66, 0.371, 278, 264, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
1125, p5os8A_, 0.6962, 3.34, 0.295, 327, 275, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 11
1126, d4fkuA_, 0.6962, 2.90, 0.369, 293, 271, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1127, d3tiyA_, 0.6962, 2.84, 0.351, 293, 271, CDK2 IN COMPLEX WITH NSC 35676
1128, d3pvgA_, 0.6962, 3.47, 0.273, 326, 278, CRYSTAL STRUCTURE OF Z. MAYS CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMO-1-CARBOXYMETHYLBENZIMIDAZOLE (K68)
1129, d3kxjA_, 0.6962, 3.47, 0.273, 326, 278,  
1130, d1w8cA_, 0.6962, 2.59, 0.360, 290, 267, CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H- PURIN-2-YLAMINE AND MONOMERIC CDK2
1131, d1b39A_, 0.6962, 2.71, 0.362, 290, 268, HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160
1132, d3r9dA_, 0.6961, 2.87, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-2-135
1133, d2c6oA_, 0.6961, 2.70, 0.357, 290, 269, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
1134, d1h07A_, 0.6961, 2.61, 0.378, 285, 267, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
1135, p5oo0A_, 0.6960, 2.70, 0.372, 288, 269, CDK2(WT) COVALENT ADDUCT WITH D28 AT C177
1136, d4ek3A_, 0.6960, 2.60, 0.367, 287, 267, CRYSTAL STRUCTURE OF APO CDK2
1137, d2qnjA1, 0.6960, 3.02, 0.247, 317, 271, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
1138, d1zoeA_, 0.6960, 3.46, 0.273, 325, 278, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
1139, d1gz8A_, 0.6960, 2.64, 0.362, 290, 268, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3 -METHYL-2 -OXO)BUTOXYPURINE
1140, d4bxaB_, 0.6959, 3.54, 0.295, 331, 278,  
1141, d3r8uA_, 0.6959, 2.85, 0.357, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR RC-1-132
1142, d3blhA1, 0.6959, 2.92, 0.340, 291, 268, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1
1143, d1lp4A_, 0.6959, 3.49, 0.272, 327, 279, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 WITH MG-AMPPNP
1144, d3rk7A_, 0.6957, 2.83, 0.362, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-2-71
1145, d3rk5A_, 0.6957, 2.94, 0.360, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR RC-2-72
1146, d3qxpA_, 0.6957, 2.84, 0.365, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
1147, d3mb7A_, 0.6957, 3.51, 0.303, 330, 277, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (AMR)
1148, d1zohA_, 0.6957, 3.43, 0.274, 326, 277, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
1149, p4md9P_, 0.6956, 3.27, 0.295, 328, 275, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1150, d3pe1A_, 0.6956, 3.30, 0.299, 327, 274, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-4945
1151, d5cqwA_, 0.6955, 3.40, 0.297, 331, 276, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
1152, d3rk9A_, 0.6955, 2.84, 0.362, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-2-74
1153, d3g33A_, 0.6955, 2.94, 0.335, 291, 269, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
1154, d2vtrA_, 0.6955, 2.60, 0.360, 290, 267, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1155, d1ds5C_, 0.6955, 3.39, 0.274, 328, 277, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1156, d3qqkA_, 0.6954, 2.84, 0.369, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR L4
1157, d3iggA_, 0.6954, 2.62, 0.363, 290, 267, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFQ WITH CDK-2
1158, d1dawA_, 0.6954, 3.46, 0.277, 327, 278, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-AMPPNP
1159, p5otzA_, 0.6953, 3.29, 0.296, 327, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 1
1160, d4kwpA_, 0.6953, 3.36, 0.298, 329, 275, CRYSTAL STRUCTURE OF HUMAN CK2-ALPHA IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR (K164) AT 1.25 A RESOLUTION
1161, d1lpuA_, 0.6953, 3.51, 0.272, 327, 279, LOW TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
1162, d3pzhA_, 0.6952, 3.49, 0.273, 327, 278, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH EMODIN AT 1.92 A RESOLUTION
1163, d3pe2A_, 0.6952, 3.25, 0.300, 327, 273, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR CX-5011
1164, d5t1hB_, 0.6951, 3.42, 0.297, 331, 276, CRYSTAL STRUCTURE OF CK2
1165, d5movA_, 0.6951, 3.25, 0.297, 325, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0633 BOUND
1166, d4gcjA1, 0.6951, 3.26, 0.366, 298, 276, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
1167, d4ek4A_, 0.6951, 2.57, 0.365, 287, 266, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
1168, d3qtwA_, 0.6951, 2.85, 0.354, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-2-13
1169, d3q9zB_, 0.6951, 3.49, 0.296, 332, 277, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
1170, d1pf8A_, 0.6951, 2.93, 0.360, 298, 272, CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH A NUCLEOSIDE INHIBITOR
1171, d3ql8A_, 0.6950, 2.87, 0.362, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-260
1172, d2qnjB1, 0.6950, 3.28, 0.241, 321, 274, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
1173, d4erwA_, 0.6949, 2.66, 0.381, 292, 268, CDK2 IN COMPLEX WITH STAUROSPORINE
1174, d3rpsB_, 0.6949, 3.25, 0.299, 334, 274, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
1175, d3pwdA_, 0.6949, 3.55, 0.272, 327, 279, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH NBC (Z1)
1176, d2r3rA_, 0.6949, 2.64, 0.363, 290, 267, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1177, d1h0vA_, 0.6949, 2.65, 0.362, 288, 268, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R)-PYRROLIDINO-5 -YL]METHOXYPURINE
1178, d1h01A_, 0.6949, 2.59, 0.361, 286, 266, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
1179, d2qc6A_, 0.6948, 3.52, 0.272, 326, 279, PROTEIN KINASE CK2 IN COMPLEX WITH DBC
1180, d1dayA_, 0.6948, 3.47, 0.277, 327, 278, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-GMPPNP
1181, d3le6A_, 0.6947, 2.51, 0.366, 283, 265, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A PYRAZOLOBENZODIAZEPINE INHIBITOR
1182, d5h8bB_, 0.6946, 3.46, 0.292, 331, 277, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
1183, d4bxbA_, 0.6946, 3.31, 0.296, 328, 274,  
1184, d3s00A_, 0.6946, 2.87, 0.353, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR L4-14
1185, d3r9hA_, 0.6946, 2.85, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-2-142
1186, d3qqjA_, 0.6946, 2.90, 0.347, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR L2
1187, d5cquA_, 0.6945, 3.31, 0.296, 328, 274, MONOCLINIC COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
1188, d4lynA_, 0.6945, 2.74, 0.384, 287, 268, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH (2S)-N-(5-(((5-TERT-BUTYL-13-OXAZOL-2-YL)METHYL)SULFANYL)-13- THIAZOL-2-YL)-2-PHENYLPROPANAMIDE
1189, d3rpvA_, 0.6945, 2.95, 0.375, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR RC-2-88
1190, d3qtqA_, 0.6945, 2.85, 0.369, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-1-137
1191, p5owlB_, 0.6944, 3.42, 0.293, 332, 276, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
1192, d5kwhA_, 0.6944, 3.38, 0.293, 331, 276, CRYSTAL STRUCTURE OF CK2
1193, d3uliA_, 0.6944, 2.77, 0.369, 286, 268, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) BOUND TO AZABENZIMIDAZOLE DERIVATIVE
1194, p5oulA_, 0.6943, 3.38, 0.295, 327, 275, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 9
1195, d3qa0A_, 0.6943, 3.40, 0.293, 330, 276, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
1196, d2r3pA_, 0.6943, 2.60, 0.361, 289, 266, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1197, d1ds5A_, 0.6943, 3.45, 0.270, 328, 278, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1198, d3rniA_, 0.6942, 2.93, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-3-86
1199, d1om1A_, 0.6942, 3.57, 0.269, 325, 279, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH IQA
1200, p5n9nA_, 0.6941, 3.35, 0.302, 329, 275, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF85 (4A)
1201, p5n9lA_, 0.6941, 3.39, 0.297, 329, 276, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE DIBENZOFURAN INHIBITOR TF (4B)
1202, d4l46A_, 0.6940, 2.87, 0.259, 317, 270, CRYSTAL STRUCTURES OF HUMAN P70S6K1-WT
1203, d4ez3A_, 0.6940, 2.97, 0.353, 294, 272, CDK2 IN COMPLEX WITH NSC 134199
1204, d4ek5A_, 0.6940, 2.60, 0.365, 289, 266, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
1205, d3s0oA_, 0.6940, 2.88, 0.351, 293, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-1-138
1206, d5cu2A_, 0.6939, 3.51, 0.296, 328, 277, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
1207, d4rlkA_, 0.6939, 3.60, 0.272, 327, 279, CRYSTAL STRUCTURE OF Z. MAYS CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
1208, p2pvnA_, 0.6939, 3.49, 0.277, 327, 278, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1209, d3u4uA_, 0.6938, 3.30, 0.296, 327, 274, CASEIN KINASE 2 IN COMPLEX WITH AZ-INHIBITOR
1210, d3kxgA_, 0.6938, 3.52, 0.270, 326, 278, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 34567-PENTABROMO-1H-INDAZOLE (K64)
1211, d3g33C_, 0.6938, 2.76, 0.335, 291, 266, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
1212, d3fwqA_, 0.6938, 3.14, 0.298, 334, 272, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
1213, d5h8eB_, 0.6937, 3.47, 0.292, 331, 277, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
1214, d4dgnA_, 0.6937, 3.51, 0.270, 325, 278, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR LUTEOLIN
1215, d3u87B_, 0.6937, 3.48, 0.289, 329, 277, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
1216, d1m2pA_, 0.6937, 3.50, 0.270, 325, 278, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO- ANTHRAQUINONE/CK2 KINASE COMPLEX
1217, d5cqwB_, 0.6936, 3.42, 0.293, 331, 276, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
1218, p4ib5A_, 0.6936, 3.54, 0.291, 331, 278, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
1219, d4dgoA_, 0.6936, 3.43, 0.274, 325, 277, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH TYRPHOSTIN AG99
1220, d3py1A1, 0.6936, 3.36, 0.367, 298, 278, CDK2 TERNARY COMPLEX WITH SU9516 AND ANS
1221, d3kxnA_, 0.6936, 3.35, 0.272, 327, 276, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR TETRAIODOBENZIMIDAZOLE (K88)
1222, d4ubaA_, 0.6935, 3.58, 0.291, 333, 278, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
1223, d4dgmA_, 0.6934, 3.51, 0.270, 326, 278, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR APIGENIN
1224, d2r3oA_, 0.6934, 2.62, 0.357, 289, 266, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1225, d1ds5D_, 0.6934, 3.47, 0.270, 328, 278, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1226, d5kwhB_, 0.6933, 3.47, 0.292, 331, 277, CRYSTAL STRUCTURE OF CK2
1227, d4ogrI_, 0.6933, 3.34, 0.327, 318, 278, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
1228, p4jqeA_, 0.6933, 3.39, 0.272, 369, 276, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH AMPPN
1229, d3fl5A_, 0.6933, 3.51, 0.273, 324, 278, PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR QUINALIZARIN
1230, d1pxlA_, 0.6933, 2.65, 0.363, 290, 267, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- (4-TRIFLUOROMETHYL-PHENYL)-AMINE
1231, d3r8lA_, 0.6932, 2.86, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR L3-4
1232, d1jamA_, 0.6932, 3.54, 0.277, 327, 278, CRYSTAL STRUCTURE OF APO-FORM OF Z. MAYS CK2 PROTEIN KINASE ALPHA SUBUNIT
1233, d4ubaB_, 0.6931, 3.32, 0.296, 333, 274, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
1234, d3r8vA_, 0.6931, 2.92, 0.353, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR RC-1-135
1235, d3qzgA_, 0.6931, 2.97, 0.347, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-76
1236, d3qtuA_, 0.6931, 2.87, 0.352, 294, 270, CDK2 IN COMPLEX WITH INHIBITOR RC-2-132
1237, d3fe3A_, 0.6931, 2.84, 0.239, 317, 268, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
1238, p4md9K_, 0.6930, 3.35, 0.293, 328, 276, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1239, p4ib5B_, 0.6930, 3.52, 0.291, 329, 278, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
1240, d3rp0B_, 0.6930, 3.35, 0.291, 329, 275,  
1241, d3ns9A_, 0.6929, 2.64, 0.357, 289, 266, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR BS-194
1242, d2i6lB_, 0.6929, 2.75, 0.362, 269, 265, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
1243, d3q9xA_, 0.6928, 3.43, 0.293, 330, 276, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
1244, d3qu0A_, 0.6927, 2.91, 0.354, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-2-38
1245, d3lfnA_, 0.6927, 2.67, 0.386, 285, 267, CRYSTAL STRUCTURE OF CDK2 WITH SAR57 AN AMINOINDAZOLE TYPE INHIBITOR
1246, d3at2A_, 0.6927, 3.35, 0.295, 334, 275, CRYSTAL STRUCTURE OF CK2ALPHA
1247, p2pvkA_, 0.6927, 3.59, 0.272, 327, 279, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1248, d5cvfA_, 0.6926, 3.31, 0.297, 325, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
1249, d1e1vA_, 0.6926, 2.71, 0.358, 290, 268, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058
1250, d4l45A_, 0.6925, 2.82, 0.257, 317, 269, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389E
1251, d3kxmA_, 0.6925, 3.54, 0.273, 326, 278, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR K74
1252, d1ob3A_, 0.6925, 2.66, 0.375, 277, 267, STRUCTURE OF P. FALCIPARUM PFPK5
1253, d2r3iA_, 0.6924, 2.63, 0.361, 289, 266, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1254, p4md9M_, 0.6923, 3.61, 0.290, 331, 279, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1255, d4aguA_, 0.6923, 2.91, 0.307, 277, 267, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
1256, d5mp8A_, 0.6922, 3.29, 0.293, 325, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1257, d3qtxA_, 0.6922, 2.97, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-2-35
1258, p5owlA_, 0.6921, 3.47, 0.297, 331, 276, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
1259, d5ku8B_, 0.6921, 3.48, 0.292, 331, 277, CRYSTAL STRUCTURE OF CK2
1260, d5ctpB_, 0.6921, 3.41, 0.295, 327, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
1261, d2r3hA_, 0.6921, 2.64, 0.361, 289, 266, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1262, d2oxdA_, 0.6921, 3.48, 0.274, 325, 277, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE K17 K22 AND K32 INHIBITORS
1263, d1aq1A_, 0.6921, 2.31, 0.375, 277, 261, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE
1264, d1v0oA_, 0.6920, 2.31, 0.387, 276, 261, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
1265, d5cvhA_, 0.6919, 3.38, 0.292, 327, 274, CRYSTAL STRUCTURE OF CK2ALPHA
1266, d5clpB_, 0.6919, 3.29, 0.299, 327, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
1267, d3tizA_, 0.6919, 2.92, 0.344, 293, 270, CDK2 IN COMPLEX WITH NSC 111848
1268, d5mowA1, 0.6918, 3.34, 0.300, 326, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1269, p4md9F_, 0.6918, 3.48, 0.296, 327, 277, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1270, d1pxnA_, 0.6918, 2.89, 0.348, 294, 270, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-METHYL-2-METHYLAMINO-THIAZOL-5-YL)- PYRIMIDIN-2-YLAMINO]-PHENOL
1271, p2pvhA_, 0.6917, 3.59, 0.272, 327, 279, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1272, d1unhA_, 0.6917, 2.67, 0.366, 276, 262, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
1273, p2pvmA_, 0.6916, 3.44, 0.274, 327, 277, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1274, d2b52A_, 0.6916, 2.60, 0.383, 283, 266, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH- 042562
1275, d2a4lA_, 0.6916, 2.52, 0.371, 286, 264, HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE
1276, d1unhB_, 0.6916, 2.67, 0.366, 276, 262, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
1277, d5cu6A_, 0.6914, 3.27, 0.297, 327, 273, CRYSTAL STRUCTURE OF CK2ALPHA
1278, d3rp0A_, 0.6914, 3.46, 0.290, 329, 276,  
1279, d3qqgA_, 0.6914, 2.95, 0.354, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR L2-5
1280, d3q9zA_, 0.6914, 3.53, 0.296, 332, 277, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
1281, d5jq5A_, 0.6913, 2.61, 0.366, 287, 265, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0942
1282, d1pxkA_, 0.6913, 2.70, 0.363, 290, 267, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)PYRIMIDIN-2-YL]- N -HYDROXYIMINOFORMAMIDE
1283, d1m2qA_, 0.6913, 3.49, 0.274, 327, 277, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO-XANTEN-9- ONE/CK2 KINASE COMPLEX
1284, d5ku8A_, 0.6912, 3.31, 0.296, 328, 274, CRYSTAL STRUCTURE OF CK2
1285, d5mowB_, 0.6911, 3.35, 0.297, 324, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1286, d3qqhA_, 0.6911, 3.01, 0.354, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR L2-2
1287, d2vtoA_, 0.6911, 2.63, 0.385, 283, 265, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1288, d2oxxA_, 0.6911, 3.43, 0.279, 325, 276, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
1289, d4aguB_, 0.6910, 2.82, 0.314, 276, 264, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
1290, d3ti1A_, 0.6910, 2.89, 0.359, 294, 270, CDK2 IN COMPLEX WITH SUNITINIB
1291, d2wzjA_, 0.6910, 2.81, 0.230, 310, 265, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
1292, d5mmfA_, 0.6909, 3.46, 0.295, 326, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
1293, d3qtzA_, 0.6909, 2.89, 0.367, 294, 270, CDK2 IN COMPLEX WITH INHIBITOR RC-2-36
1294, d2wzjC_, 0.6909, 2.93, 0.229, 310, 266, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
1295, d1y91A_, 0.6908, 2.81, 0.378, 286, 267, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
1296, d1f0qA_, 0.6908, 3.57, 0.273, 329, 278, CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT OF PROTEIN KINASE CK2 IN COMPLEX WITH THE NUCLEOTIDE COMPETITIVE INHIBITOR EMODIN
1297, p4md9H_, 0.6907, 3.58, 0.295, 328, 278, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1298, d4au8B_, 0.6907, 2.58, 0.369, 277, 263, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
1299, d5ctpA_, 0.6906, 3.35, 0.297, 324, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
1300, d5mpjA_, 0.6905, 3.39, 0.292, 326, 274, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
1301, d5cx9A_, 0.6905, 3.43, 0.295, 328, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
1302, d5cu0B_, 0.6905, 3.38, 0.299, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
1303, d1wccA_, 0.6905, 2.60, 0.377, 283, 265, SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY
1304, d5mo5B_, 0.6904, 3.37, 0.297, 325, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1305, d4fkvA_, 0.6903, 2.58, 0.377, 282, 265, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1306, d3rp0D_, 0.6903, 3.47, 0.290, 329, 276,  
1307, d5ct0A_, 0.6902, 3.38, 0.299, 326, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
1308, d2wzjD_, 0.6902, 3.00, 0.231, 313, 268, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
1309, d5mmfB_, 0.6900, 3.36, 0.297, 325, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
1310, d5ieyA_, 0.6900, 2.64, 0.357, 286, 266, CRYSTAL STRUCTURE OF A CDK INHIBITOR BOUND TO CDK2
1311, d3r8zA_, 0.6900, 2.80, 0.361, 290, 269, CDK2 IN COMPLEX WITH INHIBITOR RC-1-136
1312, d1pxmA_, 0.6900, 2.80, 0.348, 290, 267, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 3-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL
1313, d5mo6B_, 0.6899, 3.36, 0.297, 324, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1314, d5cvhB_, 0.6899, 3.38, 0.297, 324, 273, CRYSTAL STRUCTURE OF CK2ALPHA
1315, d4fkiA_, 0.6899, 2.72, 0.365, 287, 266, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
1316, d3wblA_, 0.6899, 2.62, 0.374, 283, 265, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR
1317, p2pvlA_, 0.6898, 3.53, 0.278, 327, 277, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1318, p2pvjA_, 0.6898, 3.51, 0.274, 326, 277, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1319, d5modB_, 0.6897, 3.38, 0.297, 324, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1320, d5cu0A_, 0.6897, 3.39, 0.299, 327, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
1321, d3rjcA_, 0.6897, 2.92, 0.348, 294, 270, CDK2 IN COMPLEX WITH INHIBITOR L4-12
1322, d3at3A_, 0.6896, 3.59, 0.291, 332, 278, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVATIVE
1323, d4l43A_, 0.6895, 2.86, 0.260, 316, 269, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM I)
1324, d3sqqA_, 0.6895, 3.02, 0.387, 288, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-3-96
1325, d3fz1A_, 0.6895, 2.76, 0.376, 284, 266, CRYSTAL STRUCTURE OF A BENZTHIOPHENE INHIBITOR BOUND TO HUMAN CYCLIN-DEPENDENT KINASE-2 (CDK-2)
1326, d2r7iA_, 0.6895, 3.26, 0.305, 322, 272, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1327, p5otyA_, 0.6893, 3.44, 0.295, 327, 275, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712
1328, d2wzjF_, 0.6893, 2.95, 0.236, 310, 267, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
1329, d2wzjB_, 0.6893, 2.93, 0.236, 310, 267, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
1330, d1jsvA_, 0.6893, 2.59, 0.364, 287, 264, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[(6-AMINO-4-PYRIMIDINYL) AMINO]BENZENESULFONAMIDE
1331, d5mmrA_, 0.6892, 3.40, 0.299, 326, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
1332, d5mhqA1, 0.6892, 2.72, 0.361, 288, 266, CCT068127 IN COMPLEX WITH CDK2
1333, d5cx9B_, 0.6892, 3.37, 0.297, 325, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
1334, d4aaaA1, 0.6892, 3.16, 0.293, 290, 273, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN
1335, d1e1xA_, 0.6892, 2.74, 0.360, 290, 267, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027
1336, d2vtsA_, 0.6891, 2.60, 0.390, 282, 264, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1337, d2r3gA_, 0.6891, 2.60, 0.364, 287, 264, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1338, d5modA_, 0.6889, 3.43, 0.296, 327, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1339, d5mmrB_, 0.6889, 3.37, 0.297, 325, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
1340, d3pxyA_, 0.6889, 3.00, 0.354, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR JWS648
1341, d1zogA_, 0.6889, 3.38, 0.284, 325, 275, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES
1342, d5mo7A_, 0.6888, 3.41, 0.299, 327, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1343, d5mo6A_, 0.6888, 3.38, 0.297, 325, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1344, d4fkwA_, 0.6887, 2.48, 0.376, 280, 263, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1345, d2r7iC_, 0.6887, 3.21, 0.306, 321, 271, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1346, d5mo7B_, 0.6886, 3.36, 0.300, 325, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1347, d5cshA_, 0.6886, 3.39, 0.297, 324, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
1348, d3warA_, 0.6886, 3.39, 0.299, 334, 274, CRYSTAL STRUCTURE OF HUMAN CK2A
1349, d3gbzA_, 0.6886, 2.85, 0.346, 274, 266, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA
1350, d3at4A_, 0.6886, 3.58, 0.292, 331, 277, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVERTIVE
1351, d2r7iB_, 0.6886, 3.21, 0.303, 322, 271, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1352, d2wzjE_, 0.6885, 2.91, 0.229, 310, 266, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
1353, d5moeA_, 0.6884, 3.35, 0.293, 325, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1354, d3w8lB_, 0.6883, 3.44, 0.291, 326, 275, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
1355, d2r7iD_, 0.6883, 3.26, 0.298, 322, 272, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1356, d1m2rA_, 0.6883, 3.44, 0.276, 327, 275, CRYSTAL STRUCTURE OF 58-DI-AMINO-14-DI-HYDROXY- ANTHRAQUINONE/CK2 KINASE COMPLEX
1357, d4fkgA_, 0.6882, 2.69, 0.370, 286, 265, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
1358, d5mo5A_, 0.6881, 3.38, 0.297, 326, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1359, d5mo8A_, 0.6880, 3.43, 0.296, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1360, d5ct0B_, 0.6879, 3.39, 0.297, 326, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
1361, p4lfiB_, 0.6879, 3.64, 0.266, 371, 278, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1362, p4lfiA_, 0.6879, 3.64, 0.266, 370, 278, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1363, p4mwhA_, 0.6878, 3.48, 0.269, 371, 275, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
1364, d5mpjB_, 0.6877, 3.40, 0.293, 324, 273, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
1365, d3unkA_, 0.6876, 3.12, 0.353, 295, 272, CDK2 IN COMPLEX WITH INHIBITOR YL5-083
1366, d5ievA_, 0.6875, 2.65, 0.389, 284, 265, CRYSTAL STRUCTURE OF BAY 1000394 (RONICICLIB) BOUND TO CDK2
1367, d2vu3A_, 0.6873, 2.80, 0.370, 285, 265, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1368, d5iexA_, 0.6872, 2.68, 0.361, 285, 266, CRYSTAL STRUCTURE OF (RS)-S-{4-[(5-BROMO-4-{[(2R3R)-2-HYDROXY-1- METHYLPROPYL]OXY}- PYRIMIDIN-2-YL)AMINO]PHENYL}-S- CYCLOPROPYLSULFOXIMIDE BOUND TO CDK2
1369, d3py0A_, 0.6871, 3.08, 0.352, 294, 270, CDK2 IN COMPLEX WITH INHIBITOR SU9516
1370, d2r3qA_, 0.6871, 2.58, 0.365, 286, 263, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1371, d5m44A_, 0.6870, 3.28, 0.295, 329, 271, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
1372, d5cu2B_, 0.6870, 3.35, 0.301, 325, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
1373, d2w17A_, 0.6870, 2.46, 0.378, 278, 262, CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE COMPOUND (S)-8B
1374, d5k4jA1, 0.6869, 2.54, 0.380, 281, 263, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH COMPOUND 22
1375, p4fi1A_, 0.6868, 3.44, 0.269, 371, 275, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
1376, d2vtpA_, 0.6867, 2.60, 0.384, 281, 263, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1377, d2hakE_, 0.6865, 2.97, 0.239, 318, 268, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
1378, d5cu3A_, 0.6863, 3.43, 0.297, 325, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
1379, d5mp8B_, 0.6859, 3.34, 0.295, 323, 271, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1380, d5mo8B_, 0.6859, 3.43, 0.297, 324, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1381, d5moeB_, 0.6856, 3.38, 0.294, 323, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1382, d1fvtA_, 0.6856, 2.60, 0.380, 282, 263, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH AN OXINDOLE INHIBITOR
1383, d3unjA_, 0.6854, 3.13, 0.352, 294, 270, CDK2 IN COMPLEX WITH INHIBITOR YL1-038-31
1384, d2vv9A_, 0.6851, 2.50, 0.374, 279, 262, CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE
1385, d1di8A_, 0.6851, 2.63, 0.375, 283, 264, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3-HYDROXYANILINO]-67-DIMETHOXYQUINAZOLINE
1386, d3iw4C_, 0.6850, 3.16, 0.238, 332, 269, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1387, d1xo2B_, 0.6846, 3.06, 0.351, 289, 268, CRYSTAL STRUCTURE OF A HUMAN CYCLIN-DEPENDENT KINASE 6 COMPLEX WITH A FLAVONOL INHIBITOR FISETIN
1388, d5fp6A_, 0.6844, 2.64, 0.367, 278, 264, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 3-(47-DICHLORO-1H-INDOL-3-YL)PROP-2-YN-1-OL (AT17833) IN AN ALTERNATE BINDING SITE.
1389, d3r7iA_, 0.6844, 2.63, 0.371, 282, 264, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-74
1390, d2w1hA_, 0.6841, 2.72, 0.379, 283, 264, FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4-YL UREA (AT9283) A MULTI-TARGETED KINASE INHIBITOR WITH POTENT AURORA KINASE ACTIVITY
1391, d3r7uA_, 0.6840, 2.58, 0.369, 282, 263, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-75
1392, d5cu3B_, 0.6839, 3.46, 0.293, 324, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
1393, d5cshB_, 0.6838, 3.35, 0.300, 323, 270, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
1394, d1ckpA_, 0.6838, 2.66, 0.382, 279, 262, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B
1395, d2qkrA1, 0.6836, 2.42, 0.388, 269, 258, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH INDIRUBIN 3 -MONOXIME BOUND
1396, d1ke7A_, 0.6836, 2.64, 0.380, 281, 263, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(22- DIOXIDO-13-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5- (13-OXAZOL-5-YL)-13-DIHYDRO-2H-INDOL-2-ONE
1397, d2w06A_, 0.6835, 2.72, 0.379, 282, 264, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5C
1398, d1h0wA_, 0.6835, 2.59, 0.365, 283, 263, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[CYCLOHEX-3-ENYL]METHOXYPURINE
1399, d1ke8A_, 0.6833, 2.81, 0.377, 282, 265, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO- 12-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(13- THIAZOL-2-YL)BENZENESULFONAMIDE
1400, d4dglD_, 0.6831, 3.69, 0.295, 328, 278, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
1401, d1h00A_, 0.6830, 2.57, 0.382, 278, 262, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
1402, d4ditA_, 0.6826, 2.89, 0.322, 328, 261, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A IMIDAZOPYRIDINE INHIBITOR
1403, d2r3mA_, 0.6826, 2.55, 0.383, 278, 261, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1404, d1jsuA_, 0.6825, 2.78, 0.381, 285, 260, P27(KIP1)/CYCLIN A/CDK2 COMPLEX
1405, d5aniA_, 0.6823, 2.48, 0.372, 280, 261, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-CHLORO-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1406, d2w99B_, 0.6823, 3.23, 0.332, 291, 271, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
1407, d2uznA_, 0.6823, 2.58, 0.383, 279, 261, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
1408, d3s2pA_, 0.6822, 2.69, 0.382, 279, 262, CRYSTAL STRUCTURE OF CDK2 WITH A 2-AMINOPYRIMIDINE COMPOUND
1409, d1h08A_, 0.6822, 2.92, 0.374, 283, 265, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
1410, d4bbmB1, 0.6821, 3.12, 0.316, 288, 266, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
1411, d1ke5A_, 0.6820, 2.67, 0.380, 281, 263, CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO-12-DIHYDRO-3H- INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
1412, d5cs6A_, 0.6818, 3.60, 0.297, 327, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
1413, d2vtiA_, 0.6817, 2.64, 0.382, 280, 262, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1414, d4fkrA_, 0.6816, 2.75, 0.375, 282, 264, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1415, d4fkqA_, 0.6816, 2.77, 0.366, 283, 265, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1416, d1v0oB_, 0.6816, 2.39, 0.388, 274, 258, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
1417, d3ezvA_, 0.6815, 2.45, 0.373, 277, 260, CDK-2 WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
1418, d5clpA_, 0.6814, 3.36, 0.296, 322, 270, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
1419, d4nj3A_, 0.6814, 2.52, 0.375, 277, 261, MODULATING THE INTERACTION BETWEEN CDK2 AND CYCLIN A WITH A QUINOLINE- BASED INHIBITOR
1420, d1ke9A_, 0.6814, 2.59, 0.382, 281, 262, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4- ({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2- OXO-23-DIHYDRO-1H-INDOLE
1421, p4jr7A_, 0.6811, 3.48, 0.271, 367, 273, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1422, d1ke6A_, 0.6810, 2.54, 0.383, 280, 261, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4- [2-(7-OXO-67-DIHYDRO-8H-[13]THIAZOLO[54-E]INDOL-8- YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE
1423, d5eakA_, 0.6809, 2.88, 0.246, 305, 264, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
1424, d4au8A1, 0.6809, 2.55, 0.380, 274, 258, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
1425, d4bzdA_, 0.6807, 2.48, 0.365, 277, 260, STRUCTURE OF CDK2 IN COMPLEX WITH A BENZIMIDAZOPYRIMIDINE
1426, d2hakF_, 0.6804, 3.13, 0.235, 318, 268, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
1427, d3r9oA_, 0.6803, 2.66, 0.376, 282, 263, CDK2 IN COMPLEX WITH INHIBITOR RC-2-143
1428, d2r64A_, 0.6803, 2.61, 0.383, 279, 261, CRYSTAL STRUCTURE OF A 3-AMINOINDAZOLE COMPOUND WITH CDK2
1429, d4ek6A_, 0.6802, 2.64, 0.383, 278, 261, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
1430, d1w0xC_, 0.6802, 2.62, 0.385, 280, 262, CRYSTAL STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR OLOMOUCINE.
1431, d4fktA_, 0.6800, 2.69, 0.382, 278, 262, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1432, d2w05A_, 0.6800, 2.45, 0.378, 276, 259, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5B
1433, d4fkjA_, 0.6797, 2.64, 0.383, 278, 261, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
1434, d4fkoA_, 0.6795, 3.06, 0.363, 291, 267, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
1435, d4ek8A_, 0.6793, 2.70, 0.382, 280, 262, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
1436, d3ig7A_, 0.6793, 2.56, 0.385, 278, 260, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFP WITH CDK-2
1437, d2r3jA_, 0.6793, 2.62, 0.379, 278, 261, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1438, d3iw4A_, 0.6792, 3.15, 0.239, 330, 268, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1439, d3iw4B_, 0.6791, 3.10, 0.247, 325, 267, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1440, d2vthA_, 0.6791, 2.57, 0.385, 278, 260, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN
1441, d3rahA_, 0.6790, 2.76, 0.364, 282, 264, CDK2 IN COMPLEX WITH INHIBITOR RC-2-22
1442, d2r3kA_, 0.6790, 2.53, 0.385, 277, 260, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1443, d1h06A_, 0.6790, 2.50, 0.381, 277, 260,  
1444, d3r8mA_, 0.6789, 2.99, 0.363, 286, 267, CDK2 IN COMPLEX WITH INHIBITOR L3-3
1445, d1v1kA_, 0.6788, 2.51, 0.381, 277, 260, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
1446, d3rzbA_, 0.6784, 2.85, 0.386, 282, 264, CDK2 IN COMPLEX WITH INHIBITOR RC-2-23
1447, d1h25C1, 0.6784, 2.53, 0.395, 277, 256, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
1448, d1giiA_, 0.6783, 2.67, 0.368, 279, 261, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
1449, d5jq8A_, 0.6782, 2.62, 0.377, 278, 260, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0943
1450, d4fksA_, 0.6782, 2.56, 0.381, 275, 260, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1451, d3qtsA_, 0.6781, 2.67, 0.365, 282, 263, CDK2 IN COMPLEX WITH INHIBITOR RC-2-12
1452, d2b55A_, 0.6781, 2.48, 0.378, 276, 259, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH INDENOPYRAXOLE DIN-101312
1453, d1g5sA_, 0.6781, 2.42, 0.384, 275, 258, CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH THE INHIBITOR H717
1454, p6gihA_, 0.6780, 3.50, 0.298, 324, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH CAM187 BOUND 
1455, d2vtaA_, 0.6780, 2.61, 0.385, 278, 260, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1456, d4fkpA_, 0.6779, 2.66, 0.383, 279, 261, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1457, d5anoA_, 0.6778, 2.49, 0.386, 277, 259, CRYSTAL STRUCTURE OF CDK2 PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1458, d5andA_, 0.6778, 2.55, 0.386, 273, 259, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 2-IMIDAZOL-1-YL-1H- BENZIMIDAZOLE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1459, d4acmA_, 0.6778, 2.50, 0.371, 277, 259, CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL] SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE
1460, d3rprA_, 0.6777, 2.79, 0.364, 282, 264, CDK2 IN COMPLEX WITH INHIBITOR RC-2-49
1461, d3r9nA_, 0.6777, 2.70, 0.361, 282, 263, CDK2 IN COMPLEX WITH INHIBITOR RC-2-21
1462, d2fvdA_, 0.6777, 2.68, 0.379, 284, 261, CYCLIN DEPENDENT KINASE 2 (CDK2) WITH DIAMINOPYRIMIDINE INHIBITOR
1463, d3zduA_, 0.6776, 3.08, 0.332, 297, 268, CRYSTAL STRUCTURE OF THE HUMAN CDKL3 KINASE DOMAIN
1464, d3a8xA1, 0.6776, 2.97, 0.227, 331, 264, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1465, d3qtrA_, 0.6774, 2.86, 0.364, 282, 264, CDK2 IN COMPLEX WITH INHIBITOR RC-1-148
1466, d2pk9C_, 0.6774, 2.17, 0.375, 266, 251, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
1467, d1vyzA_, 0.6772, 2.75, 0.383, 279, 261, STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227
1468, d2vtjA_, 0.6770, 2.52, 0.386, 276, 259, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1469, d3iecA_, 0.6769, 2.94, 0.248, 311, 262, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1470, d2bhhA_, 0.6769, 2.38, 0.377, 274, 257, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4-HYDROXYPIPERINDINESULFONYL-INDIRUBINE
1471, d1gihA_, 0.6769, 2.51, 0.378, 276, 259, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
1472, d2f2cB_, 0.6766, 3.03, 0.366, 280, 262, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLINWITH THE INHIBITOR AMINOPURVALANOL
1473, d4ra4A_, 0.6763, 3.20, 0.239, 317, 268, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE C ALPHA IN COMPLEX WITH COMPOUND 28 ((R)-6-((3S4S)-13-DIMETHYL-PIPERIDIN-4-YL)-7-(2-FLUORO- PHENYL)-4-METHYL-210-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1474, d3ezrA_, 0.6762, 2.35, 0.375, 273, 256, CDK-2 WITH INDAZOLE INHIBITOR 17 BOUND AT ITS ACTIVE SITE
1475, d2vtqA_, 0.6762, 2.41, 0.381, 274, 257, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1476, d3iecB_, 0.6760, 2.98, 0.236, 313, 263, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1477, d2jedB1, 0.6759, 3.16, 0.267, 315, 266, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
1478, d2i0eB_, 0.6757, 2.94, 0.251, 300, 263, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
1479, d1zmwB_, 0.6757, 2.87, 0.241, 302, 261, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
1480, d4eojC1, 0.6756, 2.63, 0.395, 278, 256, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
1481, d2vtnA_, 0.6753, 2.41, 0.377, 274, 257, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1482, d2r3lA_, 0.6751, 2.48, 0.376, 275, 258, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1483, d2btrA_, 0.6750, 2.52, 0.376, 275, 258, STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873
1484, d1zmwA_, 0.6750, 2.83, 0.242, 302, 260, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
1485, p6ehuA_, 0.6749, 3.64, 0.291, 327, 275, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
1486, d1dm2A_, 0.6748, 2.46, 0.381, 274, 257, HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE
1487, d3iecC_, 0.6747, 2.97, 0.248, 311, 262, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1488, d3rmfA_, 0.6746, 2.65, 0.365, 278, 260, CDK2 IN COMPLEX WITH INHIBITOR RC-2-33
1489, d1ua2C_, 0.6746, 2.64, 0.372, 286, 258, CRYSTAL STRUCTURE OF HUMAN CDK7
1490, d2i0eA_, 0.6745, 3.05, 0.254, 326, 264, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
1491, d2hakD_, 0.6745, 2.85, 0.245, 309, 261, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
1492, d3a8wB1, 0.6744, 2.99, 0.228, 324, 263, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1493, d3sw7A_, 0.6742, 2.66, 0.365, 278, 260, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
1494, d1ungB_, 0.6742, 2.57, 0.370, 268, 254, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
1495, d3rpyA_, 0.6741, 2.58, 0.371, 277, 259, CDK2 IN COMPLEX WITH INHIBITOR RC-2-40
1496, d2j9mA_, 0.6741, 2.50, 0.380, 275, 258, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC AMINOPYRIMIDINE
1497, d5k00A_, 0.6738, 3.06, 0.265, 311, 264, MELK IN COMPLEX WITH NVS-MELK5
1498, d1r78A_, 0.6738, 2.41, 0.379, 273, 256, CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR
1499, d4ixpA_, 0.6736, 3.30, 0.237, 334, 270, CRYSTAL STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK)
1500, p6ehuB_, 0.6735, 3.68, 0.295, 327, 275, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
1501, d1ua2B_, 0.6734, 2.68, 0.372, 286, 258, CRYSTAL STRUCTURE OF HUMAN CDK7
1502, d1ua2D_, 0.6730, 2.68, 0.372, 286, 258, CRYSTAL STRUCTURE OF HUMAN CDK7
1503, d3s1hA_, 0.6728, 2.63, 0.367, 277, 259, CDK2 IN COMPLEX WITH INHIBITOR RC-2-39
1504, d3sw4A_, 0.6726, 2.56, 0.372, 279, 258, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
1505, d2jedA_, 0.6726, 2.95, 0.282, 324, 262, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
1506, d3nuxA_, 0.6724, 2.07, 0.364, 261, 250, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
1507, d2btsA_, 0.6724, 2.48, 0.381, 274, 257, STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032
1508, d5l2sA_, 0.6723, 2.12, 0.375, 263, 251, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND ABEMACICLIB.
1509, d5es1A_, 0.6723, 2.69, 0.257, 304, 257, CRYSTAL STRUCTURE OF MICROTUBULE AFFINITY-REGULATING KINASE 4 CATALYTIC DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
1510, d2r0iA_, 0.6722, 2.74, 0.248, 300, 258, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
1511, d5cs6B_, 0.6721, 3.34, 0.298, 316, 265, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
1512, d2hakC_, 0.6721, 3.01, 0.244, 310, 262, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
1513, d1zrzA_, 0.6721, 2.92, 0.225, 310, 262, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF ATYPICAL PROTEIN KINASE C-IOTA
1514, d3iecD_, 0.6720, 3.01, 0.248, 311, 262, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1515, d2x39A_, 0.6720, 2.90, 0.267, 316, 262, STRUCTURE OF 4-AMINO-N-(4-CHLOROBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE BOUND TO PKB
1516, d3cqwA_, 0.6717, 3.16, 0.272, 318, 265, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
1517, d2vttA_, 0.6717, 2.40, 0.384, 272, 255, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1518, d2r3nA_, 0.6717, 2.58, 0.372, 275, 258, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1519, d2r0iB_, 0.6716, 2.77, 0.248, 300, 258, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
1520, d3ocbA_, 0.6715, 3.04, 0.270, 315, 263, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
1521, d2bheA_, 0.6715, 2.51, 0.381, 274, 257, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO-INDIRUBINE
1522, d3rakA_, 0.6714, 2.66, 0.367, 277, 259, CDK2 IN COMPLEX WITH INHIBITOR RC-2-32
1523, d1ua2A_, 0.6714, 2.69, 0.372, 286, 258, CRYSTAL STRUCTURE OF HUMAN CDK7
1524, d1v0pB_, 0.6710, 2.19, 0.392, 258, 250, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
1525, d1urwA_, 0.6707, 2.56, 0.374, 274, 257, CDK2 IN COMPLEX WITH AN IMIDAZO[12-B]PYRIDAZINE
1526, d4bghA_, 0.6705, 2.56, 0.370, 275, 257, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PAN-CDK INHIBITOR
1527, d5l2tA_, 0.6704, 2.06, 0.357, 261, 249, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND RIBOCICLIB.
1528, d3wf9A_, 0.6703, 2.85, 0.268, 287, 257, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 1-OXO-1-[(4-SULFAMOYLPHENYL)AMINO]PROPAN-2-YL-2-METHYL-1 234-TETRAHYDROACRIDINE-9-CARBOXYLATE
1529, d3ralA_, 0.6703, 2.69, 0.378, 277, 259, CDK2 IN COMPLEX WITH INHIBITOR RC-2-34
1530, d2xh5A_, 0.6703, 2.96, 0.267, 316, 262, STRUCTURE OF 4-(4-TERT-BUTYLBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDIN-4-AMINE BOUND TO PKB
1531, d3wf8A_, 0.6702, 2.86, 0.268, 287, 257, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 2-OXO-2-[(4-SULFAMOYLPHENYL)AMINO]ETHYL 78910- TETRAHYDRO-6H-CYCLOHEPTA[B]QUINOLINE-11-CARBOXYLATE
1532, d1v0bB_, 0.6702, 2.20, 0.382, 261, 251, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
1533, d2jdoA_, 0.6701, 2.86, 0.269, 314, 260, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
1534, d5ankA_, 0.6699, 2.49, 0.388, 273, 255, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 246-TRIOXO-1- PHENYL-HEXAHYDROPYRIMIDINE-5-CARBOXAMIDE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1535, d1ob3B_, 0.6699, 2.21, 0.392, 258, 250, STRUCTURE OF P. FALCIPARUM PFPK5
1536, d5eakB_, 0.6698, 2.80, 0.248, 300, 258, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
1537, d2w9zB_, 0.6698, 3.02, 0.333, 287, 264, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
1538, d3ocbB_, 0.6695, 3.01, 0.267, 319, 262, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
1539, d3a8xB1, 0.6692, 3.01, 0.230, 325, 261, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1540, d3pvwA2, 0.6691, 3.42, 0.207, 343, 270, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD103A)
1541, d2uw9A_, 0.6691, 3.03, 0.251, 316, 263, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH 4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
1542, d2eufB_, 0.6688, 3.06, 0.367, 282, 259, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLIN IN COMPLEX WITH THE INHIBITOR PD0332991
1543, d1p2aA_, 0.6687, 2.55, 0.377, 271, 257, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A TRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR
1544, d4otgA_, 0.6683, 3.36, 0.228, 322, 268, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH LESTAURTINIB
1545, d1zmvB_, 0.6680, 2.73, 0.242, 296, 256, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: K82R MUTANT
1546, d1gijA_, 0.6680, 2.51, 0.383, 273, 256, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
1547, d3ow4A_, 0.6679, 3.14, 0.270, 317, 263, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1548, d1pyeA_, 0.6677, 2.29, 0.377, 266, 252, CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR
1549, d1oitA_, 0.6677, 2.62, 0.383, 273, 256, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
1550, d3a8wA1, 0.6673, 2.96, 0.231, 323, 260, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1551, d4otdA_, 0.6672, 3.42, 0.228, 334, 268, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN
1552, d2duvA_, 0.6670, 2.56, 0.395, 272, 256, STRUCTURE OF CDK2 WITH A 3-HYDROXYCHROMONES
1553, d4eorC1, 0.6669, 2.40, 0.394, 269, 249, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
1554, d4eklA_, 0.6663, 3.17, 0.269, 329, 264, AKT1 WITH GDC0068
1555, d2jdrA_, 0.6663, 3.07, 0.251, 316, 263, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH THE INHIBITOR A- 443654
1556, d5ihcA_, 0.6662, 3.04, 0.261, 305, 261, MELK IN COMPLEX WITH NVS-MELK12B
1557, d5angA_, 0.6658, 2.41, 0.379, 268, 253, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 7-HYDROXY-4-( MORPHOLINOMETHYL)CHROMEN-2-ONE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1558, d1zmuB_, 0.6657, 2.77, 0.246, 296, 256, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
1559, d4eoqC1, 0.6654, 2.44, 0.406, 271, 249, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
1560, d3pvuA2, 0.6654, 3.51, 0.211, 340, 270, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD101)
1561, d4q9zB_, 0.6649, 3.16, 0.266, 308, 263, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
1562, d4crsA1, 0.6648, 3.26, 0.223, 329, 264, HUMAN PROTEIN KINASE N2 (PKN2 PRKCL2) IN COMPLEX WITH ATPGAMMAS
1563, d3o0gB_, 0.6648, 2.64, 0.378, 264, 251, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
1564, d5li9A1, 0.6646, 3.08, 0.221, 328, 263, STRUCTURE OF A NUCLEOTIDE-BOUND FORM OF PKCIOTA CORE KINASE DOMAIN
1565, d1o6kA_, 0.6646, 3.18, 0.246, 317, 264, STRUCTURE OF ACTIVATED FORM OF PKB KINASE DOMAIN S474D WITH GSK3 PEPTIDE AND AMP-PNP
1566, d4l3lA_, 0.6645, 2.72, 0.270, 291, 256, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN (ZINC ANOMALOUS)
1567, d2hakA_, 0.6645, 2.87, 0.246, 309, 260, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
1568, d4ez5A_, 0.6644, 2.07, 0.368, 258, 247, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
1569, d4dfyE_, 0.6643, 2.97, 0.260, 312, 258, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
1570, d5li1A1, 0.6638, 3.23, 0.226, 329, 265, STRUCTURE OF A PAR3-INHIBITORY PEPTIDE BOUND TO PKCIOTA CORE KINASE DOMAIN
1571, d5d1jA_, 0.6638, 2.28, 0.384, 265, 250, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH N-[5-[[[5-(11-DIMETHYLETHYL)-2-OXAZOLYL] METHYL]THIO]-2-THIAZOLYL]- 4-PIPERIDINECARBOXAMIDE (BMS-387032)
1572, d2g9xC2, 0.6638, 2.46, 0.410, 273, 249, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
1573, d1oiqA_, 0.6638, 2.36, 0.386, 264, 251, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
1574, d4ra5A1, 0.6636, 3.31, 0.264, 331, 265, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1575, d4gv1A1, 0.6635, 3.26, 0.265, 328, 264, PKB ALPHA IN COMPLEX WITH AZD5363
1576, d3ow4B_, 0.6633, 3.20, 0.270, 317, 263, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1577, d1o6lA_, 0.6633, 3.06, 0.252, 316, 262, CRYSTAL STRUCTURE OF AN ACTIVATED AKT/PROTEIN KINASE B (PKB-PIF CHIMERA) TERNARY COMPLEX WITH AMP-PNP AND GSK3 PEPTIDE
1578, d5l2iA_, 0.6632, 2.18, 0.367, 260, 248, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND PALBOCICLIB.
1579, d4zy4B_, 0.6632, 2.78, 0.228, 292, 254, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
1580, d5f9eB_, 0.6631, 3.05, 0.273, 293, 260, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
1581, d4eomC1, 0.6631, 2.48, 0.406, 271, 249, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
1582, d3mv5A_, 0.6630, 3.12, 0.271, 315, 262, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
1583, d4ra5B_, 0.6626, 3.23, 0.270, 310, 263, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1584, d3qkkA_, 0.6626, 3.22, 0.269, 326, 264, SPIROCHROMANE AKT INHIBITORS
1585, d1ym7A3, 0.6625, 3.46, 0.190, 347, 269, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
1586, d3krwA2, 0.6623, 3.54, 0.215, 349, 270, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (SOAK)
1587, d1ym7D3, 0.6623, 3.46, 0.190, 340, 269, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
1588, d4zy5B_, 0.6622, 2.78, 0.228, 287, 254, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
1589, d3pscA2, 0.6622, 3.49, 0.208, 344, 269, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
1590, d1jowB_, 0.6621, 2.81, 0.373, 277, 255, CRYSTAL STRUCTURE OF A COMPLEX OF HUMAN CDK6 AND A VIRAL CYCLIN
1591, d1j3hA_, 0.6620, 3.18, 0.238, 329, 260, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
1592, d4q9zA1, 0.6619, 3.30, 0.265, 330, 264, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
1593, d4bgqA_, 0.6619, 3.04, 0.337, 276, 261, CRYSTAL STRUCTURE OF THE HUMAN CDKL5 KINASE DOMAIN
1594, d2bcjA3, 0.6619, 3.47, 0.208, 348, 269, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GALPHA-Q AND GBETAGAMMA SUBUNITS
1595, d1ym7C3, 0.6619, 3.48, 0.190, 346, 269, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
1596, d5fp5A_, 0.6618, 2.36, 0.394, 264, 251, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 4-FLUOROBENZOIC ACID (AT222) IN AN ALTERNATE BINDING SITE.
1597, d1zmvA_, 0.6618, 2.72, 0.232, 293, 254, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: K82R MUTANT
1598, d1ym7B3, 0.6618, 3.47, 0.190, 347, 269, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
1599, d1j3hB_, 0.6617, 3.16, 0.238, 327, 260, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
1600, d5f9eA1, 0.6615, 3.38, 0.263, 331, 266, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
1601, d5ih9A_, 0.6613, 3.14, 0.262, 308, 260, MELK IN COMPLEX WITH NVS-MELK8A
1602, d4bcpC1, 0.6613, 2.41, 0.409, 266, 247, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1603, d5ih8A_, 0.6612, 3.19, 0.261, 306, 261, MELK IN COMPLEX WITH NVS-MELK1
1604, d3krxA2, 0.6612, 3.56, 0.211, 349, 270, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (CO-CRYSTAL)
1605, d3we4A_, 0.6611, 2.76, 0.271, 286, 255, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRIMIDINE DERIVATIVE PF-4708671 2-{[4-(5-ETHYLPYRIMIDIN-4-YL)PIPERAZIN-1- YL]METHYL}-5-(TRIFLUOROMETHYL)-1H-BENZIMIDAZOLE
1606, d1omwA3, 0.6611, 3.48, 0.190, 344, 269, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN G PROTEIN-COUPLED RECEPTOR KINASE 2 AND HETEROTRIMERIC G PROTEIN BETA 1 AND GAMMA 2 SUBUNITS
1607, d3qklA_, 0.6610, 3.25, 0.270, 317, 263, SPIROCHROMANE AKT INHIBITORS
1608, d4l3jA_, 0.6607, 2.80, 0.273, 291, 256, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN
1609, d4dfyA_, 0.6606, 2.90, 0.258, 310, 256, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
1610, d4d1xA_, 0.6606, 2.67, 0.378, 274, 254, CDK2 IN COMPLEX WITH LUCIFERIN
1611, d4cfuC1, 0.6602, 2.43, 0.409, 269, 247, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
1612, d1zmuA_, 0.6602, 2.71, 0.249, 293, 253, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
1613, d3cquA_, 0.6600, 3.24, 0.266, 318, 263, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
1614, d3qkmA_, 0.6598, 3.28, 0.258, 329, 264, SPIROCYCLIC SULFONAMIDES AS AKT INHIBITORS
1615, d3o7lD_, 0.6598, 3.25, 0.241, 333, 261, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
1616, d5he2A2, 0.6593, 3.60, 0.207, 353, 270, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224406
1617, d4ntsB_, 0.6592, 3.17, 0.238, 341, 260, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
1618, d3bhvC1, 0.6592, 2.45, 0.405, 269, 247, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
1619, d3cikA2, 0.6591, 3.55, 0.208, 347, 269, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
1620, d4ae6A_, 0.6588, 3.26, 0.245, 319, 261, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
1621, d3mvhA_, 0.6588, 3.14, 0.242, 311, 260, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
1622, d4cztA1, 0.6587, 3.41, 0.240, 289, 267, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270
1623, d4pnkA2, 0.6586, 3.62, 0.207, 350, 270, G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GSK180736A
1624, d3zh8A_, 0.6586, 3.38, 0.217, 318, 267, A NOVEL SMALL MOLECULE APKC INHIBITOR
1625, p4d28B_, 0.6584, 3.47, 0.228, 277, 267, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
1626, d1oguC1, 0.6583, 2.45, 0.405, 269, 247, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
1627, d5ihaA_, 0.6582, 3.15, 0.266, 303, 259, MELK IN COMPLEX WITH NVS-MELK8F
1628, d3e87B_, 0.6581, 3.43, 0.245, 321, 265, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1629, d3e87A_, 0.6581, 3.43, 0.245, 321, 265, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1630, p4d28C_, 0.6579, 3.53, 0.228, 279, 268, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
1631, d4bcoC1, 0.6579, 2.42, 0.407, 268, 246, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1632, d1y8gB_, 0.6579, 2.88, 0.251, 292, 255, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: INACTIVE DOUBLE MUTANT WITH SELENOMETHIONINE
1633, d3bhtC1, 0.6577, 2.48, 0.405, 269, 247, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
1634, d1y8gA_, 0.6577, 2.83, 0.252, 292, 254, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: INACTIVE DOUBLE MUTANT WITH SELENOMETHIONINE
1635, d3e88B_, 0.6576, 3.43, 0.245, 319, 265, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1636, d3e88A_, 0.6576, 3.43, 0.245, 319, 265, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1637, d1bi8C_, 0.6575, 2.47, 0.331, 264, 248, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURES CDK6-P19INK4D INHIBITOR COMPLEX
1638, d1bi8A_, 0.6575, 2.47, 0.331, 264, 248, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURES CDK6-P19INK4D INHIBITOR COMPLEX
1639, d6b16B_, 0.6574, 2.73, 0.219, 281, 251, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
1640, d3d0eB_, 0.6574, 3.43, 0.260, 322, 265, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
1641, d3bhuC1, 0.6573, 2.48, 0.409, 269, 247, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
1642, d2qvsE_, 0.6573, 3.33, 0.241, 323, 261, CRYSTAL STRUCTURE OF TYPE IIA HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
1643, d3d0eA_, 0.6572, 3.40, 0.245, 322, 265, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
1644, d5he0A2, 0.6569, 3.55, 0.208, 346, 269, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG215022
1645, d3zuuA_, 0.6569, 2.94, 0.206, 281, 257, THE STRUCTURE OF OST1 (D160A S175D) KINASE IN COMPLEX WITH GOLD
1646, d5he1A2, 0.6567, 3.66, 0.211, 342, 270, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224062
1647, d3zutA_, 0.6567, 2.94, 0.214, 281, 257, THE STRUCTURE OF OST1 (D160A) KINASE
1648, d4ntsA_, 0.6566, 3.35, 0.230, 341, 261, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
1649, d4ae9A_, 0.6566, 3.27, 0.245, 321, 261, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
1650, d3e8dB_, 0.6565, 3.46, 0.245, 317, 265, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1651, d5deyB_, 0.6561, 2.72, 0.219, 281, 251, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
1652, d4auaA_, 0.6561, 2.14, 0.371, 256, 245, LIGANDED X-RAY CRYSTAL STRUCTURE OF CYCLIN DEPENDENT KINASE 6 (CDK6)
1653, d4czuD1, 0.6558, 3.46, 0.244, 296, 266, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
1654, d3zh8C_, 0.6557, 3.28, 0.227, 312, 264, A NOVEL SMALL MOLECULE APKC INHIBITOR
1655, d3zh8B_, 0.6557, 3.32, 0.219, 317, 265, A NOVEL SMALL MOLECULE APKC INHIBITOR
1656, d5ukmA2, 0.6555, 3.61, 0.190, 353, 269, BOVINE GRK2 IN COMPLEX WITH HUMAN GBETAGAMMA SUBUNITS AND CCG258208 (14AS)
1657, d3uc3A_, 0.6555, 2.96, 0.267, 272, 255, THE CRYSTAL STRUCTURE OF SNF1-RELATED KINASE 2.3
1658, d4cztD1, 0.6553, 3.47, 0.244, 296, 266, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270
1659, d3nupA_, 0.6553, 2.10, 0.365, 252, 244, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
1660, d1stcE_, 0.6553, 3.26, 0.250, 334, 260, CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH STAUROSPORINE
1661, d5he3A2, 0.6552, 3.67, 0.207, 346, 270, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224411
1662, d3e8dA_, 0.6548, 3.34, 0.247, 315, 263, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1663, d4zy6B_, 0.6546, 2.71, 0.220, 280, 250, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
1664, d1ctpE_, 0.6545, 3.30, 0.242, 332, 260, STRUCTURE OF THE MAMMALIAN CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND AN INHIBITOR PEPTIDE DISPLAYS AN OPEN CONFORMATION
1665, d1cmkE_, 0.6544, 3.29, 0.242, 348, 260, CRYSTAL STRUCTURES OF THE MYRISTYLATED CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE REVEAL OPEN AND CLOSED CONFORMATIONS
1666, d5dewB_, 0.6542, 2.87, 0.218, 281, 252, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
1667, d1bx6A_, 0.6540, 3.25, 0.242, 337, 260, CRYSTAL STRUCTURE OF THE POTENT NATURAL PRODUCT INHIBITOR BALANOL IN COMPLEX WITH THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1668, p4d28A_, 0.6538, 3.63, 0.225, 274, 267, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
1669, d2iw9C2, 0.6534, 2.45, 0.412, 267, 245, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
1670, d4cztC_, 0.6532, 3.52, 0.248, 286, 266, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270
1671, d1fotA_, 0.6531, 3.10, 0.226, 299, 257, STRUCTURE OF THE UNLIGANDED CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT FROM SACCHAROMYCES CEREVISIAE
1672, d1bi7A_, 0.6530, 2.78, 0.325, 269, 252, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURE OF THE CDK6-P16INK4A TUMOR SUPPRESSOR COMPLEX
1673, d4czuA1, 0.6529, 3.40, 0.242, 291, 265, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
1674, d3wf7A_, 0.6525, 3.07, 0.272, 288, 257, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PURINE DERIVATIVE 1-(9H-PURIN-6-YL)-N-[3-(TRIFLUOROMETHYL)PHENYL]PIPERIDINE- 4-CARBOXAMIDE
1675, d4czuB1, 0.6522, 3.47, 0.245, 283, 265, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
1676, d3ag9B_, 0.6521, 3.35, 0.249, 317, 261, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
1677, d5uklA2, 0.6519, 3.70, 0.190, 353, 269, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG222886 (14BD)
1678, d1jvpP_, 0.6519, 2.60, 0.375, 268, 251, CRYSTAL STRUCTURE OF HUMAN CDK2 (UNPHOSPHORYLATED) IN COMPLEX WITH PKF049-365
1679, d3v5wA2, 0.6518, 3.68, 0.190, 355, 269, HUMAN G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH SOLUBLE GBETAGAMMA SUBUNITS AND PAROXETINE
1680, d4czuC_, 0.6515, 3.37, 0.247, 281, 263, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
1681, d3daeA_, 0.6515, 2.19, 0.272, 248, 243, CRYSTAL STRUCTURE OF PHOSPHORYLATED SNF1 KINASE DOMAIN
1682, d1szmA_, 0.6511, 3.35, 0.258, 317, 260, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
1683, d3zutB_, 0.6509, 3.22, 0.212, 282, 260, THE STRUCTURE OF OST1 (D160A) KINASE
1684, d3uc4A_, 0.6505, 3.22, 0.200, 295, 260, THE CRYSTAL STRUCTURE OF SNF1-RELATED KINASE 2.6
1685, d4b9dA1, 0.6503, 3.51, 0.192, 286, 265, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
1686, d3zuuB_, 0.6503, 3.13, 0.213, 282, 258, THE STRUCTURE OF OST1 (D160A S175D) KINASE IN COMPLEX WITH GOLD
1687, d4cfvC1, 0.6502, 2.43, 0.403, 263, 243, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
1688, d4d1zA_, 0.6501, 2.48, 0.387, 258, 248, CDK2 IN COMPLEX WITH A LUCIFERIN DERIVATE
1689, d4cztB1, 0.6500, 3.50, 0.245, 283, 265, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270
1690, d1h26C1, 0.6497, 2.41, 0.412, 266, 243, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
1691, d3my5C1, 0.6496, 2.43, 0.407, 265, 243, CDK2/CYCLINA IN COMPLEX WITH DRB
1692, d4cfmC1, 0.6494, 2.37, 0.413, 265, 242, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
1693, d4o0tB_, 0.6490, 2.89, 0.215, 280, 251, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1694, d4apcA1, 0.6490, 3.40, 0.202, 289, 263, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
1695, d2j4zB_, 0.6487, 2.91, 0.245, 269, 253, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
1696, d3ag9A_, 0.6486, 3.47, 0.226, 323, 261, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
1697, d5d9kA_, 0.6485, 2.69, 0.241, 280, 249, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
1698, d5d9kB_, 0.6481, 2.72, 0.261, 280, 249, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
1699, d3dogC1, 0.6480, 2.46, 0.403, 266, 243, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
1700, d3agmA_, 0.6476, 3.43, 0.254, 337, 260, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-670
1701, d2wmbC1, 0.6476, 2.46, 0.399, 265, 243, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
1702, d1xjdA_, 0.6476, 3.02, 0.287, 280, 254, CRYSTAL STRUCTURE OF PKC-THETA COMPLEXED WITH STAUROSPORINE AT 2A RESOLUTION
1703, d3l9lA_, 0.6475, 3.34, 0.251, 338, 259, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
1704, d2y7jA_, 0.6475, 3.16, 0.266, 284, 252, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1705, d1rekA_, 0.6475, 3.34, 0.247, 336, 259, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 8
1706, d4j8mA_, 0.6474, 2.84, 0.259, 265, 251, AURORA A IN COMPLEX WITH CD532
1707, d1rejA_, 0.6473, 3.35, 0.243, 333, 259, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 1
1708, d1sykA_, 0.6472, 3.49, 0.215, 348, 261, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
1709, d3l9mA_, 0.6471, 3.35, 0.251, 338, 259, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
1710, d2jdvA_, 0.6471, 3.37, 0.255, 334, 259, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH A-443654
1711, d4apcB1, 0.6469, 3.47, 0.205, 291, 263, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
1712, d1bkxA_, 0.6467, 3.34, 0.243, 337, 259, A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND ADENOSINE FURTHER DEFINES CONFORMATIONAL FLEXIBILITY
1713, d1sykB_, 0.6466, 3.50, 0.215, 323, 261, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
1714, d5kbqB_, 0.6465, 2.72, 0.215, 273, 247, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
1715, d4b9dB1, 0.6465, 3.49, 0.202, 291, 263, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
1716, d1f3mC_, 0.6465, 2.84, 0.240, 287, 250, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1
1717, d3daeB_, 0.6464, 2.17, 0.274, 246, 241, CRYSTAL STRUCTURE OF PHOSPHORYLATED SNF1 KINASE DOMAIN
1718, d2uw7A_, 0.6464, 3.45, 0.258, 335, 260, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
1719, d2oh0E_, 0.6463, 3.45, 0.250, 336, 260, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
1720, d1xhaA_, 0.6463, 3.39, 0.254, 348, 260, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1721, d1oiuC1, 0.6462, 2.36, 0.407, 264, 241, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
1722, d4o0rB_, 0.6461, 2.71, 0.215, 282, 246, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1723, d1xh8A_, 0.6460, 3.35, 0.251, 337, 259, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1724, p4d28D_, 0.6459, 3.62, 0.223, 271, 264, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
1725, d2zmcA_, 0.6459, 2.70, 0.248, 260, 250, CRYSTAL STRUCTURE OF HUMAN MITOTIC CHECKPOINT KINASE MPS1 CATALYTIC DOMAIN APO FORM
1726, d1okyA_, 0.6459, 3.01, 0.262, 281, 252, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1727, d2iw8C2, 0.6457, 2.45, 0.405, 264, 242, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
1728, d2f7xE_, 0.6457, 3.45, 0.254, 336, 260, PROTEIN KINASE A BOUND TO (S)-2-(1H-INDOL-3-YL)-1-[5-((E)-2- PYRIDIN-4-YL-VINYL)-PYRIDIN-3-YLOXYMETHYL]-ETHYLAMINE
1729, d3ddqC1, 0.6456, 2.45, 0.405, 265, 242, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
1730, d2xchA_, 0.6456, 2.91, 0.263, 278, 251, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
1731, d2uzuE_, 0.6453, 3.45, 0.250, 336, 260, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1732, d2jdtA_, 0.6451, 3.38, 0.255, 334, 259, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
1733, d3e8eI_, 0.6449, 3.45, 0.254, 345, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1734, d3dneA_, 0.6449, 3.46, 0.250, 336, 260, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1735, d2wmaC1, 0.6449, 2.45, 0.405, 264, 242, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
1736, d3uc4B_, 0.6447, 3.12, 0.214, 277, 257, THE CRYSTAL STRUCTURE OF SNF1-RELATED KINASE 2.6
1737, d3nuuA_, 0.6447, 3.09, 0.257, 276, 253, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT11
1738, d2uw4A_, 0.6447, 3.46, 0.254, 334, 260, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-(5-METHYL- 1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1739, d1smhA_, 0.6447, 3.45, 0.254, 348, 260, PROTEIN KINASE A VARIANT COMPLEX WITH COMPLETELY ORDERED N- TERMINAL HELIX
1740, d2ojfE_, 0.6446, 3.47, 0.250, 336, 260, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
1741, d2gngA_, 0.6446, 3.45, 0.262, 338, 260, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE
1742, d3nusA_, 0.6445, 3.01, 0.262, 276, 252, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT8
1743, d3ambA_, 0.6443, 3.48, 0.250, 340, 260, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR VX- 680
1744, d2vo0A_, 0.6443, 3.53, 0.258, 340, 260, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
1745, d2f7eE_, 0.6443, 3.48, 0.254, 336, 260, PKA COMPLEXED WITH (S)-2-(1H-INDOL-3-YL)-1-(5-ISOQUINOLIN-6- YL-PYRIDIN-3-YLOXYMETHYL-ETYLAMINE
1746, d1xh5A_, 0.6443, 3.38, 0.251, 335, 259, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1747, d1okzA_, 0.6443, 2.92, 0.267, 276, 251, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH UCN-01
1748, d3nuyA_, 0.6442, 3.02, 0.262, 276, 252, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT17
1749, d3hmpA_, 0.6442, 2.63, 0.242, 258, 248, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH A QUINAZOLIN LIGAND COMPOUND 4
1750, d2biyA_, 0.6442, 3.27, 0.259, 287, 255, STRUCTURE OF PDK1-S241A MUTANT KINASE DOMAIN
1751, d2c1aA_, 0.6441, 3.47, 0.250, 335, 260, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL)AMIDE
1752, d1q8wA_, 0.6441, 3.36, 0.251, 334, 259, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR FASUDIL (HA-1077)
1753, d5ho7A_, 0.6440, 3.02, 0.262, 280, 252, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1754, d2gnfA_, 0.6440, 3.47, 0.262, 339, 260, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH Y- 27632
1755, d4ynzA1, 0.6439, 3.49, 0.257, 306, 261, STRUCTURE OF THE N-TERMINAL DOMAIN OF SAD
1756, d4o22A1, 0.6439, 3.43, 0.242, 333, 260, BINARY COMPLEX OF METAL-FREE PKAC WITH SP20.
1757, d4nusA_, 0.6439, 3.03, 0.242, 301, 252, RSK2 N-TERMINAL KINASE IN COMPLEX WITH LJH685
1758, d3l9mB_, 0.6439, 3.39, 0.251, 336, 259, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
1759, d3dndA_, 0.6439, 3.48, 0.250, 334, 260, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1760, d2uvxA_, 0.6439, 3.48, 0.254, 335, 260, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 7-AZAINDOLE
1761, d5lmkC1, 0.6437, 2.50, 0.405, 264, 242, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
1762, d3mvjE_, 0.6437, 3.51, 0.249, 334, 261, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
1763, d3l9lB_, 0.6437, 3.43, 0.251, 337, 259, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
1764, d1uvrA_, 0.6437, 2.95, 0.263, 284, 251, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-8
1765, d1uu9A_, 0.6437, 3.11, 0.261, 276, 253, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-3
1766, d1svhA_, 0.6437, 3.47, 0.250, 335, 260, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 8
1767, d1re8A_, 0.6437, 3.43, 0.242, 337, 260, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 2
1768, d3udbB_, 0.6436, 3.14, 0.211, 278, 256, CRYSTAL STRUCTURE OF SNRK2.6
1769, d2y7jC_, 0.6436, 3.14, 0.271, 284, 251, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1770, d2welA_, 0.6436, 2.92, 0.294, 304, 248, CRYSTAL STRUCTURE OF SU6656-BOUND CALCIUM/CALMODULIN- DEPENDENT PROTEIN KINASE II DELTA IN COMPLEX WITH CALMODULIN
1771, d1uu8A_, 0.6435, 3.03, 0.266, 277, 252, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-1
1772, d3sc1A_, 0.6433, 3.06, 0.262, 278, 252, NOVEL ISOQUINOLONE PDK1 INHIBITORS DISCOVERED THROUGH FRAGMENT-BASED LEAD DISCOVERY
1773, d3orxH_, 0.6433, 2.99, 0.251, 274, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1774, d3orxG_, 0.6433, 2.99, 0.255, 274, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1775, d3orxF_, 0.6432, 2.99, 0.255, 274, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1776, d5ho8A_, 0.6431, 3.04, 0.266, 278, 252, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1777, d3iopA_, 0.6430, 2.98, 0.259, 275, 251, PDK-1 IN COMPLEX WITH THE INHIBITOR COMPOUND-8I
1778, d2r7bA_, 0.6430, 2.98, 0.259, 274, 251, CRYSTAL STRUCTURE OF THE PHOSPHOINOSITIDE-DEPENDENT KINASE- 1 (PDK-1)CATALYTIC DOMAIN BOUND TO A DIBENZONAPHTHYRIDINE INHIBITOR
1779, d3kk8A_, 0.6429, 3.12, 0.299, 283, 251, CAMKII SUBSTRATE COMPLEX A
1780, d3aglB_, 0.6429, 3.49, 0.250, 335, 260, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
1781, d2qurA_, 0.6428, 3.41, 0.247, 338, 259, CRYSTAL STRUCTURE OF F327A/K285P MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
1782, d2gnhA_, 0.6428, 3.41, 0.263, 338, 259, PKA FIVE FOLD MUTANT MODEL OF RHO-KINASE WITH H1152P
1783, d2v7oA1, 0.6427, 3.23, 0.298, 297, 252, CRYSTAL STRUCTURE OF HUMAN CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE II GAMMA
1784, d1q8uA_, 0.6427, 3.49, 0.250, 341, 260, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR H-1152P
1785, d3e8cD_, 0.6426, 3.49, 0.254, 344, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1786, d3e8cB_, 0.6426, 3.49, 0.254, 344, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1787, d1ydsE_, 0.6426, 3.43, 0.255, 334, 259, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H8 PROTEIN KINASE INHIBITOR [N-(2-METHYLAMINO)ETHYL]-5- ISOQUINOLINESULFONAMIDE
1788, d5jzjA_, 0.6425, 3.10, 0.308, 271, 250, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
1789, d2zmdA_, 0.6425, 2.77, 0.241, 259, 249, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN T686A MUTANT IN COMPLEX WITH SP600125 INHIBITOR
1790, d2vo3A_, 0.6425, 3.50, 0.254, 334, 260, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
1791, d2gnlA_, 0.6425, 3.52, 0.254, 338, 260, PKA THREEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR H- 1152P
1792, d1uu3A_, 0.6425, 3.05, 0.262, 276, 252, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH LY333531
1793, d1ydrE_, 0.6424, 3.50, 0.250, 334, 260, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H7 PROTEIN KINASE INHIBITOR 1-(5- ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE
1794, d3e8cF_, 0.6423, 3.50, 0.254, 341, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1795, d3e8cE_, 0.6423, 3.50, 0.254, 336, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1796, d1xh9A_, 0.6422, 3.50, 0.258, 336, 260, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1797, d3mvjB_, 0.6421, 3.44, 0.227, 320, 260, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
1798, d2vnwA_, 0.6421, 3.55, 0.254, 334, 260, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)METHANAMINE
1799, d2uw6A_, 0.6421, 3.43, 0.255, 334, 259, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (S)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1800, d2uw0A_, 0.6421, 3.55, 0.258, 334, 260, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  6-(4-(4-(4- CHLORO-PHENYL)-PIPERIDIN-4-YL)-PHENYL)-9H-PURINE
1801, d5oneA_, 0.6420, 2.66, 0.255, 257, 247, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH FMF-03-145-1 (COMPOUND 2)
1802, d3wf5A_, 0.6420, 2.60, 0.282, 277, 245, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-BENZIMIDAZOL-2-YL)PIPERIDIN-1- YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
1803, d3e8cC_, 0.6420, 3.50, 0.254, 341, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1804, d3e8cA_, 0.6420, 3.50, 0.254, 341, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1805, d2xckA_, 0.6420, 2.87, 0.257, 275, 249, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
1806, d2c1bA_, 0.6420, 3.52, 0.250, 335, 260, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ( 4R2S)-5 -(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2- YLMETHANESULFONYL)ISOQUINOLINE
1807, d5hngA_, 0.6418, 3.07, 0.262, 280, 252, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1808, d2gniA_, 0.6418, 3.42, 0.266, 338, 259, PKA FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR FASUDIL (HA1077)
1809, d1uu7A_, 0.6418, 3.19, 0.261, 280, 253, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-2
1810, d1sveA_, 0.6418, 3.49, 0.250, 341, 260, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 1
1811, d5imeB_, 0.6417, 2.81, 0.215, 280, 246, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
1812, d4nw5A1, 0.6417, 3.06, 0.261, 296, 253, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 8
1813, d3h9oA_, 0.6417, 3.01, 0.259, 275, 251, PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK-1) IN COMPLEX WITH COMPOUND 9
1814, d2erzE_, 0.6417, 3.51, 0.242, 334, 260, CRYSTAL STRUCTURE OF C-AMP DEPENDENT KINASE (PKA) BOUND TO HYDROXYFASUDIL
1815, d3e8eE_, 0.6415, 3.50, 0.254, 341, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1816, d3aqvA_, 0.6415, 3.05, 0.264, 267, 254, HUMAN AMP-ACTIVATED PROTEIN KINASE ALPHA 2 SUBUNIT KINASE DOMAIN (T172D) COMPLEXED WITH COMPOUND C
1817, d1vebA_, 0.6415, 3.49, 0.250, 338, 260, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 5
1818, d5ukkA2, 0.6413, 3.90, 0.212, 348, 269, HUMAN GRK2 IN COMPLEX WITH HUMAN G-BETA-GAMMA SUBUNITS AND CCG211998 (14AK)
1819, d2uw3A_, 0.6413, 3.44, 0.255, 334, 259, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 5-METHYL-4- PHENYL-1H-PYRAZOLE
1820, d2gnjA_, 0.6413, 3.51, 0.254, 335, 260, PKA THREE FOLD MUTANT MODEL OF RHO-KINASE WITH Y-27632
1821, d1q61A_, 0.6413, 3.51, 0.254, 335, 260, PKA TRIPLE MUTANT MODEL OF PKB
1822, d4zegA_, 0.6411, 2.64, 0.232, 260, 246, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
1823, d4ynzB1, 0.6411, 3.61, 0.255, 316, 263, STRUCTURE OF THE N-TERMINAL DOMAIN OF SAD
1824, d4nw6A1, 0.6411, 3.08, 0.261, 296, 253, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 27
1825, d2uvyA_, 0.6411, 3.45, 0.255, 333, 259, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH METHYL-(4-(9H- PURIN-6-YL)-BENZYL)-AMINE
1826, d4yxrA_, 0.6410, 3.53, 0.250, 334, 260, CRYSTAL STRUCTURE OF PKA IN COMPLEX WITH INHIBITOR.
1827, d3dbqA_, 0.6410, 2.71, 0.239, 259, 247, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN
1828, d2vo7A_, 0.6410, 3.53, 0.250, 335, 260, STRUCTURE OF PKA COMPLEXED WITH 4-(4-CHLOROBENZYL)-1-(7H- PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN-4-YLAMINE
1829, d2gfcA_, 0.6410, 3.52, 0.254, 335, 260, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1830, d5nttA1, 0.6409, 2.68, 0.231, 268, 247, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) C604Y MUTANT IN COMPLEX WITH NMS-P715
1831, d3orxE_, 0.6409, 2.99, 0.252, 274, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1832, d1svgA_, 0.6409, 3.51, 0.250, 338, 260, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 4
1833, d1h1wA_, 0.6409, 3.07, 0.263, 284, 251, HIGH RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PDK1 CATALYTIC DOMAIN
1834, d3rwqA_, 0.6408, 3.21, 0.257, 283, 253, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
1835, d3nx8A_, 0.6407, 3.51, 0.254, 333, 260, HUMAN CAMP DEPENDENT PROTEIN KINASE IN COMPLEX WITH PHENOL
1836, d2vnyA_, 0.6407, 3.57, 0.258, 334, 260, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)AMINE
1837, d2uztA_, 0.6407, 3.54, 0.246, 336, 260, PKA STRUCTURES OF AKT INDAZOLE-PYRIDINE INHIBITORS
1838, d4j7bA_, 0.6406, 2.84, 0.282, 284, 248, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
1839, d3udbD_, 0.6406, 3.20, 0.212, 279, 255, CRYSTAL STRUCTURE OF SNRK2.6
1840, d2uzvA_, 0.6406, 3.46, 0.251, 336, 259, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1841, d1jluE_, 0.6406, 3.52, 0.242, 337, 260, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PHOSPHORYLATED SUBSTRATE PEPTIDE AND DETERGENT
1842, d1jbpE_, 0.6406, 3.48, 0.242, 339, 260, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE COMPLEXED WITH A SUBSTRATE PEPTIDE ADP AND DETERGENT
1843, d5vndB_, 0.6405, 3.24, 0.268, 295, 254, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
1844, d4ae6B_, 0.6405, 3.64, 0.222, 321, 261, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
1845, d3q53A_, 0.6404, 2.99, 0.223, 291, 247, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN IN COMPLEX WITH ATP
1846, d3oogA_, 0.6404, 3.53, 0.250, 333, 260, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH A SMALL FRAGMENT
1847, d2f7zE_, 0.6404, 3.45, 0.251, 336, 259, PROTEIN KINASE A BOUND TO (R)-1-(1H-INDOL-3-YLMETHYL)-2-(2- PYRIDIN-4-YL-[17]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
1848, d3qcqA_, 0.6403, 3.09, 0.262, 276, 252, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-(3- AMINO-1H-INDAZOL-6-YL)-N4-ETHYL-24-PYRIMIDINEDIAMINE
1849, d3nunA_, 0.6403, 3.17, 0.257, 278, 253, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH LEAD COMPOUND
1850, d3rwpA_, 0.6402, 3.09, 0.258, 277, 252, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
1851, d2uzwE_, 0.6402, 3.54, 0.250, 336, 260, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1852, d5n84A1, 0.6401, 2.52, 0.242, 253, 244, TTK KINASE DOMAIN IN COMPLEX WITH MPS-BAY2B
1853, d3p0mA_, 0.6401, 3.54, 0.250, 335, 260, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1854, d2uw8A_, 0.6401, 3.53, 0.254, 334, 260, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-CHLORO- PHENYL)-2-PHENYL-ETHYLAMINE
1855, d2owbA_, 0.6401, 2.84, 0.286, 294, 248, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
1856, d3udbA_, 0.6400, 3.18, 0.216, 275, 255, CRYSTAL STRUCTURE OF SNRK2.6
1857, d2pe0A_, 0.6400, 3.11, 0.262, 275, 252, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 5-HYDROXY-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-13-DIHYDRO- INDOL-2-ONE COMPLEX
1858, d4js8A_, 0.6399, 2.71, 0.243, 259, 247, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401348
1859, d2pe2A_, 0.6399, 3.02, 0.263, 275, 251, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 3-{5-[2-OXO-5-UREIDO-12-DIHYDRO-INDOL-(3Z)-YLIDENEMETHYL]-1H- PYRROL-3-YL}-N-(2-PIPERIDIN-1-YL-ETHYL)-BENZAMIDE COMPLEX
1860, d6b4wA_, 0.6398, 2.61, 0.240, 259, 246, TTK IN COMPLEX WITH INHIBITOR
1861, d1xh6A_, 0.6398, 3.40, 0.256, 331, 258, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1862, d1q8tA_, 0.6398, 3.54, 0.250, 338, 260, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH RHO-KINASE INHIBITOR Y-27632
1863, d5ei6A1, 0.6397, 2.81, 0.238, 261, 248, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
1864, d3q4zB_, 0.6397, 2.74, 0.208, 279, 245, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
1865, d3pooA_, 0.6397, 3.56, 0.250, 331, 260, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1866, d3l9nA_, 0.6397, 3.58, 0.258, 332, 260, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 27
1867, d1q62A_, 0.6397, 3.54, 0.250, 336, 260, PKA DOUBLE MUTANT MODEL OF PKB
1868, d1xh7A_, 0.6396, 3.52, 0.250, 337, 260, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1869, d1szmB_, 0.6396, 3.62, 0.226, 320, 261, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
1870, d1ydtE_, 0.6395, 3.47, 0.251, 334, 259, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H89 PROTEIN KINASE INHIBITOR N-[2- (4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE
1871, d4ckrA1, 0.6394, 3.52, 0.210, 294, 257, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH DDR1-IN-1
1872, d4bkiA1, 0.6394, 3.52, 0.210, 294, 257,  
1873, d3qd3A_, 0.6394, 3.18, 0.257, 278, 253, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL {(3R6S)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-6-METHYL-3-PIPERIDINYL}CARBAMATE
1874, d3hmnA_, 0.6394, 2.54, 0.241, 255, 245, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH ATP
1875, d5vndA_, 0.6393, 3.09, 0.258, 302, 252, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
1876, d3wf6A_, 0.6393, 2.72, 0.289, 277, 246, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-INDOL-3-YL)-36- DIHYDROPYRIDIN-1(2H)-YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
1877, d3qcsA_, 0.6393, 3.18, 0.257, 276, 253, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-[2- AMINO-6-(4-MORPHOLINYL)-4-PYRIMIDINYL]-1H-INDAZOL-3-AMINE
1878, d3ionA_, 0.6393, 2.91, 0.261, 274, 249, PDK1 IN COMPLEX WITH COMPOUND 8H
1879, d3amaA_, 0.6393, 3.60, 0.250, 342, 260, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR JNJ- 7706621
1880, d1yhvA_, 0.6393, 3.05, 0.227, 293, 247, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH TWO POINT MUTATIONS (K299R T423E)
1881, d1f3mD_, 0.6393, 2.74, 0.233, 285, 245, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1
1882, d3e8eP_, 0.6392, 3.55, 0.250, 341, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1883, d2jdsA_, 0.6392, 3.54, 0.254, 334, 260, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A- 443654
1884, d2gu8A_, 0.6392, 3.57, 0.246, 335, 260, DISCOVERY OF 2-PYRIMIDYL-5-AMIDOTHIOPHENES AS NOVEL AND POTENT INHIBITORS FOR AKT: SYNTHESIS AND SAR STUDIES
1885, d1yhwA_, 0.6392, 2.93, 0.228, 293, 246, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH ONE POINT MUTATIONS (K299R)
1886, d5hkmA_, 0.6391, 3.01, 0.260, 272, 250, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1887, d4j53A_, 0.6391, 2.77, 0.287, 293, 247, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH TAK-960
1888, d3rcjA_, 0.6391, 3.01, 0.257, 281, 249, RAPID PREPARATION OF TRIAZOLYL SUBSTITUTED NH-HETEROCYCLIC KINASE INHIBITORS VIA ONE-POT SONOGASHIRA COUPLING TMS-DEPROTECTION CUAAC SEQUENCE
1889, d1z5mA_, 0.6391, 3.02, 0.263, 275, 251, CRYSTAL STRUCTURE OF N1-[3-[[5-BROMO-2-[[3-[(1-PYRROLIDINYLCARBONYL) AMINO]PHENYL]AMINO]-4-PYRIMIDINYL]AMINO]PROPYL]-22- DIMETHYLPROPANEDIAMIDE COMPLEXED WITH HUMAN PDK1
1890, d5lvoA_, 0.6390, 3.19, 0.258, 285, 252, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PSE10 BOUND TO THE PIF-POCKET
1891, d4xcuA1, 0.6390, 3.06, 0.259, 287, 251, CRYSTAL STRUCTURE OF FGFR4 WITH AN IRREVERSIBLE INHIBITOR
1892, d3fc2A_, 0.6390, 2.86, 0.286, 293, 248, PLK1 IN COMPLEX WITH BI6727
1893, d2ou7A_, 0.6390, 2.94, 0.289, 292, 249, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
1894, d4xx9A_, 0.6389, 3.20, 0.258, 288, 252, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RF4
1895, d3wzkA_, 0.6389, 2.68, 0.236, 258, 246, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH N- CYCLOPROPYL-4-(8-((THIOPHEN-2-YLMETHYL)AMINO)IMIDAZO[12-A]PYRAZIN-3- YL)BENZAMIDE
1896, d3fxzA_, 0.6389, 3.06, 0.231, 292, 247, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX LAMBDA-FL172
1897, d3e8eL_, 0.6389, 3.55, 0.254, 336, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1898, d2vo6A_, 0.6389, 3.57, 0.254, 335, 260, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4- CHLOROBENZYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YLAMINE
1899, d2uvzA_, 0.6389, 3.49, 0.255, 334, 259, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH C-PHENYL-C-(4-( 9H-PURIN-6-YL)-PHENYL)-METHYLAMINE
1900, d5lvlA_, 0.6387, 3.20, 0.262, 285, 252, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND PS653 BOUND TO THE ATP-BINDING SITE
1901, d3hmoA_, 0.6387, 2.64, 0.252, 257, 246, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH THE INHIBITOR STAUROSPORINE
1902, d3etaB_, 0.6386, 3.62, 0.208, 292, 259, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
1903, d3cekA1, 0.6386, 2.43, 0.239, 252, 243, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK)
1904, d5te0A_, 0.6385, 3.54, 0.205, 316, 258, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH BIBF 1120
1905, d5hhwA_, 0.6385, 3.81, 0.201, 306, 264, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH CIS-(R)-7-(3-(AZETIDIN-1-YLMETHYL)CYCLOBUTYL)-5-(3-((TETRAHYDRO-2H- PYRAN-2-YL)METHOXY)PHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE.
1906, d3q52A_, 0.6385, 2.97, 0.228, 292, 246, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN
1907, d5mrdA_, 0.6384, 3.10, 0.252, 283, 250, HUMAN PDK1-PKCIOTA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS267 BOUND TO THE PIF-POCKET
1908, d4rqvA_, 0.6384, 3.20, 0.258, 288, 252, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS2
1909, d3qcxA_, 0.6384, 3.20, 0.257, 276, 253, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-{2- AMINO-6-[(3R)-3-METHYL-4-MORPHOLINYL]-4-PYRIMIDINYL}-1H-INDAZOL-3- AMINE
1910, d2uw5A_, 0.6384, 3.49, 0.255, 333, 259, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (R)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1911, d1xh4A_, 0.6384, 3.47, 0.251, 334, 259, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1912, d1irkA_, 0.6384, 3.58, 0.202, 303, 258, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HUMAN INSULIN RECEPTOR
1913, d5ap6A1, 0.6382, 2.69, 0.248, 259, 246, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
1914, d3orzD_, 0.6382, 3.27, 0.252, 278, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
1915, d5vloA_, 0.6381, 3.19, 0.304, 290, 250, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1916, d5lvmA_, 0.6380, 3.10, 0.256, 283, 250, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENINE BOUND TO THE ATP- BINDING SITE
1917, d3js2B_, 0.6380, 3.00, 0.255, 291, 251, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
1918, d4rwiB_, 0.6379, 3.24, 0.257, 280, 253, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
1919, d3e8eB_, 0.6379, 3.57, 0.250, 337, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1920, d1q24A_, 0.6379, 3.58, 0.250, 335, 260, PKA DOUBLE MUTANT MODEL OF PKB IN COMPLEX WITH MGATP
1921, d6aywA_, 0.6378, 3.18, 0.304, 293, 250, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1922, d5dfpA_, 0.6378, 2.95, 0.232, 292, 246, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND FRAX1036
1923, d4rqkA_, 0.6378, 3.22, 0.262, 285, 252, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS1
1924, d4o6lB_, 0.6378, 2.60, 0.249, 256, 245, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
1925, d2pe1A_, 0.6378, 3.06, 0.263, 275, 251, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) {2-OXO-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-23-DIHYDRO-1H- INDOL-5-YL}-UREA {BX-517} COMPLEX
1926, d3qcyA_, 0.6377, 3.17, 0.258, 275, 252, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 4-[2- AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-N-PHENYL-2- MORPHOLINECARBOXAMIDE
1927, d3idbA_, 0.6377, 3.51, 0.243, 341, 259, CRYSTAL STRUCTURE OF (108-268)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
1928, d1apmE_, 0.6377, 3.57, 0.242, 338, 260, 2.0 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PEPTIDE INHIBITOR AND DETERGENT
1929, d4uwcB_, 0.6376, 2.99, 0.255, 301, 251, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
1930, d3tt0A_, 0.6376, 3.32, 0.264, 305, 254, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
1931, d3orzB_, 0.6375, 3.28, 0.252, 278, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
1932, d3wzjA_, 0.6374, 2.66, 0.237, 257, 245, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(6- (CYCLOHEXYLAMINO)-8-(((TETRAHYDRO-2H-PYRAN-4-YL)METHYL)AMINO) IMIDAZO[12-B]PYRIDAZIN-3-YL)-N-CYCLOPROPYLBENZAMIDE
1933, d3w1fA_, 0.6373, 2.71, 0.236, 259, 246, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 5-(5- ETHOXY-6-(1-METHYL-1H-PYRAZOL-4-YL)-1H-INDAZOL-3-YL)-2- METHYLBENZENESULFONAMIDE
1934, d3orxC_, 0.6373, 3.09, 0.260, 283, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1935, d4j7bD_, 0.6372, 3.04, 0.273, 281, 249, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
1936, d3orxA_, 0.6372, 3.09, 0.260, 283, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1937, d3nayB_, 0.6372, 3.06, 0.260, 278, 250, PDK1 IN COMPLEX WITH INHIBITOR MP6
1938, d2rkuA_, 0.6372, 2.89, 0.286, 294, 248, STRUCTURE OF PLK1 IN COMPLEX WITH BI2536
1939, d5ta6A_, 0.6371, 2.89, 0.290, 294, 248, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR.
1940, d3wyxA_, 0.6371, 2.71, 0.240, 258, 246, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 6- ((3-(CYANOMETHOXY)-4-(1-METHYL-1H-PYRAZOL-4-YL)PHENYL)AMINO)-2- (CYCLOHEXYLAMINO)NICOTINONITRILE
1941, d3e8eA_, 0.6371, 3.51, 0.251, 341, 259, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1942, d3rhxA_, 0.6370, 3.11, 0.254, 289, 252, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
1943, d3qamE_, 0.6370, 3.60, 0.238, 348, 260, CRYSTAL STRUCTURE OF GLU208ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1944, d5n7vA1, 0.6369, 2.63, 0.245, 257, 245, TTK KINASE DOMAIN IN COMPLEX WITH MPI-0479605
1945, d4wbbB_, 0.6369, 3.51, 0.243, 334, 259, SINGLE TURNOVER AUTOPHOSPHORYLATION CYCLE OF THE PKA RIIB HOLOENZYME
1946, d3h9fA1, 0.6369, 2.51, 0.246, 256, 244, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYRIMIDO-DIAZEPIN LIGAND
1947, d2y7jB_, 0.6369, 3.22, 0.268, 281, 250, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1948, d5ew8A_, 0.6368, 3.11, 0.254, 291, 252, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
1949, d5d9lA_, 0.6368, 3.05, 0.256, 299, 250, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BIS-PHENOL PYRAZOLE
1950, d5ackA_, 0.6368, 3.25, 0.258, 286, 252, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND 7 BOUND TO THE PIF-POCKET
1951, d3o7lB_, 0.6368, 3.55, 0.243, 326, 259, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
1952, d4c4jA1, 0.6367, 2.63, 0.238, 258, 244, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
1953, d3orzC_, 0.6367, 3.13, 0.258, 276, 252, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
1954, d3orzA_, 0.6367, 3.13, 0.258, 276, 252, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
1955, d5ehyA1, 0.6366, 2.43, 0.244, 251, 242, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
1956, d1fmoE_, 0.6366, 3.60, 0.246, 336, 260, CRYSTAL STRUCTURE OF A POLYHISTIDINE-TAGGED RECOMBINANT CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH THE PEPTIDE INHIBITOR PKI(5-24) AND ADENOSINE
1957, d1atpE_, 0.6364, 3.51, 0.240, 334, 258, 2.2 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH MNATP AND A PEPTIDE INHIBITOR
1958, d3tnqB_, 0.6363, 3.63, 0.242, 331, 260, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
1959, d3hrcA_, 0.6363, 3.13, 0.256, 279, 250, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ATP
1960, d4o21A_, 0.6362, 3.58, 0.242, 333, 260, PRODUCT COMPLEX OF METAL-FREE PKAC ATP-GAMMA-S AND SP20.
1961, d4j52A_, 0.6362, 2.83, 0.287, 293, 247, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A PYRIMIDODIAZEPINONE INHIBITOR
1962, d4c4eA1, 0.6362, 2.62, 0.238, 253, 244, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
1963, d3zosA_, 0.6362, 3.60, 0.213, 301, 258, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
1964, d3ow3A_, 0.6362, 3.53, 0.243, 334, 259, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1965, d3hrfA_, 0.6362, 3.19, 0.255, 284, 251, CRYSTAL STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN ALLOSTERIC ACTIVATOR BOUND TO THE PIF-POCKET
1966, d2hy81_, 0.6362, 3.09, 0.227, 293, 247, PAK1 COMPLEX WITH ST2001
1967, d5ew8B_, 0.6361, 3.05, 0.263, 290, 251, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
1968, d2vn9B_, 0.6361, 3.17, 0.293, 301, 249, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
1969, d2hakG_, 0.6361, 2.91, 0.249, 297, 249, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
1970, d5ig1A_, 0.6360, 3.47, 0.265, 300, 253, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
1971, d4eqcA1, 0.6360, 3.01, 0.232, 292, 246, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN IN COMPLEX WITH FRAX597 INHIBITOR
1972, d3etaA_, 0.6360, 3.73, 0.204, 293, 260, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
1973, d3c4fB_, 0.6360, 3.33, 0.264, 290, 254, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
1974, d2bdwA_, 0.6360, 3.19, 0.283, 309, 251, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
1975, d5lvnA_, 0.6358, 3.14, 0.256, 283, 250, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENOSINE BOUND TO THE ATP- BINDING SITE
1976, d4ae9B_, 0.6358, 3.71, 0.222, 321, 261, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
1977, d3aglA_, 0.6358, 3.69, 0.257, 338, 261, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
1978, d5ei2A_, 0.6357, 2.64, 0.249, 256, 245, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
1979, d4x6rA_, 0.6357, 3.63, 0.246, 347, 260, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
1980, d4uwbB_, 0.6357, 3.07, 0.259, 299, 251, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
1981, d2vn9A_, 0.6357, 3.17, 0.293, 301, 249, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
1982, d5am7A_, 0.6356, 3.06, 0.263, 294, 251, FGFR1 MUTANT WITH AN INHIBITOR
1983, d3qd4A_, 0.6356, 3.05, 0.260, 276, 250, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL{(3R5R)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-5-METHYL-3-PIPERIDINYL}CARBAMATE
1984, d1kobB_, 0.6356, 3.38, 0.238, 352, 252, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
1985, d4qqjA_, 0.6354, 3.15, 0.262, 282, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN HARBORING THE V550L GATE-KEEPER MUTATION
1986, d3oxtA_, 0.6354, 3.69, 0.250, 335, 260, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1987, d3lm5A1, 0.6354, 2.99, 0.286, 267, 248, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B) IN COMPLEX WITH QUERCETIN
1988, d3js2A_, 0.6354, 3.05, 0.255, 295, 251, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
1989, d5jznB_, 0.6353, 2.99, 0.306, 266, 245, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
1990, d3zosB1, 0.6353, 3.62, 0.221, 301, 258, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
1991, d3fy0A_, 0.6353, 3.03, 0.228, 292, 246, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX DW1
1992, d5n9sA1, 0.6352, 2.69, 0.233, 256, 245, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1161909
1993, d5jznA_, 0.6352, 3.09, 0.308, 268, 247, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
1994, d4ct1A_, 0.6352, 3.16, 0.256, 283, 250, HUMAN PDK1-PKCZETA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS315 BOUND TO THE PIF-POCKET
1995, d2wtvC_, 0.6352, 3.23, 0.250, 261, 252, AURORA-A INHIBITOR STRUCTURE
1996, d3qd0A_, 0.6351, 3.16, 0.259, 274, 251, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH (2R5S)- 1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-6-METHYL-N- PHENYL-3-PIPERIDINECARBOXAMIDE
1997, d3orxD_, 0.6351, 3.08, 0.261, 282, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1998, d2yacA_, 0.6351, 2.78, 0.293, 290, 246, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH NMS-P937
1999, d5a46A_, 0.6350, 3.18, 0.258, 289, 252, FGFR1 IN COMPLEX WITH DOVITINIB
2000, d4zsaA_, 0.6350, 3.16, 0.238, 289, 252, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
2001, d3vquA_, 0.6350, 2.71, 0.241, 258, 245, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4- [(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2- YL)AMINO]BENZAMIDE
2002, d3mvjA_, 0.6350, 3.50, 0.248, 334, 258, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
2003, d3fjqE_, 0.6350, 3.54, 0.243, 334, 259, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA IN COMPLEX WITH PEPTIDE INHIBITOR PKI ALPHA (6-25)
2004, d4qrcA_, 0.6349, 3.13, 0.262, 297, 252, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 4 IN COMPLEX WITH PONATINIB
2005, d4o6lA_, 0.6349, 2.73, 0.245, 257, 245, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
2006, d3wyyA_, 0.6349, 2.77, 0.236, 258, 246, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH (E)- 3-(4-((6-(((3S5S7S)-ADAMANTAN-1-YL)AMINO)-4-AMINO-5-CYANOPYRIDIN-2- YL)AMINO)-2-(CYANOMETHOXY)PHENYL)-N-(2-METHOXYETHYL)ACRYLAMIDE
2007, d3mfuA_, 0.6349, 3.40, 0.292, 302, 250, CASK-4M CAM KINASE DOMAIN AMPPNP-MN2+
2008, d3ma6B_, 0.6349, 3.24, 0.289, 266, 253, CRYSTAL STRUCTURE OF KINASE DOMAIN OF TGCDPK1 IN PRESENCE OF 3BRB-PP1
2009, d1ql6A_, 0.6349, 3.20, 0.287, 281, 251, THE CATALYTIC MECHANISM OF PHOSPHORYLASE KINASE PROBED BY MUTATIONAL STUDIES
2010, d1cdkB_, 0.6349, 3.64, 0.250, 342, 260, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
2011, d5nkgA_, 0.6348, 3.21, 0.198, 292, 252, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3D
2012, d3c4fA_, 0.6348, 3.18, 0.266, 290, 252, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
2013, d2wtvB_, 0.6348, 3.15, 0.251, 261, 251, AURORA-A INHIBITOR STRUCTURE
2014, d1tkiB_, 0.6348, 3.18, 0.208, 321, 250, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
2015, d1tkiA_, 0.6348, 3.18, 0.208, 321, 250, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
2016, d1kobA_, 0.6348, 3.34, 0.250, 352, 252, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
2017, d1koaA2, 0.6348, 3.23, 0.247, 350, 251, TWITCHIN KINASE FRAGMENT (C.ELEGANS) AUTOREGULATED PROTEIN KINASE AND IMMUNOGLOBULIN DOMAINS
2018, d5ek7B_, 0.6347, 2.97, 0.196, 286, 250, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
2019, d4dawA_, 0.6347, 3.04, 0.228, 293, 246, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH THE RUTHENIUM PHTHALIMIDE COMPLEX
2020, d2bfxA_, 0.6347, 3.08, 0.209, 269, 249, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
2021, d5nkfA_, 0.6346, 3.21, 0.202, 291, 252, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3B
2022, d5a4cB1, 0.6346, 3.16, 0.255, 284, 251, FGFR1 LIGAND COMPLEX
2023, d5a46B_, 0.6346, 3.15, 0.258, 297, 252, FGFR1 IN COMPLEX WITH DOVITINIB
2024, d4uwcA_, 0.6346, 3.16, 0.254, 300, 252, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
2025, d4a06A_, 0.6346, 3.17, 0.256, 282, 250, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS114 BOUND TO THE PIF-POCKET
2026, d1fgkA_, 0.6346, 3.11, 0.255, 278, 251, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
2027, d3wj6B_, 0.6345, 3.25, 0.258, 277, 252,  
2028, d2fumB_, 0.6345, 2.87, 0.251, 262, 247, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
2029, d5am6A1, 0.6344, 3.08, 0.259, 294, 251, NATIVE FGFR1 WITH AN INHIBITOR
2030, d3qalE_, 0.6344, 3.63, 0.238, 339, 260, CRYSTAL STRUCTURE OF ARG280ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
2031, d4x6qC_, 0.6343, 3.60, 0.242, 334, 260, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
2032, d4rwlA_, 0.6343, 3.19, 0.250, 282, 252, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
2033, d4qqtA_, 0.6343, 3.00, 0.268, 283, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 TYROSINE KINASE DOMAIN
2034, d2qg5B1, 0.6343, 3.01, 0.270, 275, 248, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
2035, d1u7eA_, 0.6343, 3.57, 0.243, 338, 259,  
2036, d1fgiA_, 0.6343, 3.29, 0.269, 283, 253, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
2037, d6aywB_, 0.6342, 3.35, 0.303, 293, 251, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2038, d5am7B_, 0.6342, 3.14, 0.255, 287, 251, FGFR1 MUTANT WITH AN INHIBITOR
2039, d3wj6A_, 0.6342, 3.19, 0.262, 282, 252,  
2040, d3tnpF_, 0.6342, 3.61, 0.242, 334, 260, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
2041, d3tnpC_, 0.6342, 3.61, 0.242, 334, 260, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
2042, d3nayA_, 0.6342, 3.11, 0.260, 278, 250, PDK1 IN COMPLEX WITH INHIBITOR MP6
2043, d3mftA_, 0.6342, 3.37, 0.292, 302, 250, CASK-4M CAM KINASE DOMAIN MN2+
2044, d3gfwA1, 0.6342, 2.43, 0.249, 249, 241, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYROLO-PYRIDIN LIGAND
2045, d5ek7A_, 0.6341, 2.97, 0.196, 286, 250, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
2046, d3d5uA_, 0.6341, 2.93, 0.282, 288, 248, CRYSTAL STRUCTURE OF A WILDTYPE POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
2047, d5b7vA_, 0.6340, 3.19, 0.258, 282, 252, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
2048, d5ap1A1, 0.6340, 2.65, 0.238, 264, 244, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
2049, d3mfrA_, 0.6340, 3.37, 0.292, 302, 250, CASK-4M CAM KINASE DOMAIN NATIVE
2050, d3fhiA_, 0.6340, 3.58, 0.243, 336, 259, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN THE CATALYTIC AND REGULATORY (RI{ALPHA}) SUBUNITS OF PKA
2051, d5hznG_, 0.6339, 3.38, 0.176, 296, 256, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2052, d5hznA_, 0.6339, 3.46, 0.176, 296, 256, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2053, d5ehlA1, 0.6339, 2.60, 0.246, 254, 244, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
2054, d5hznC_, 0.6338, 3.38, 0.176, 296, 256, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2055, d3hyhA_, 0.6338, 2.23, 0.274, 238, 237, CRYSTAL STRUCTURE OF THE PROTEIN KINASE DOMAIN OF YEAST AMP-ACTIVATED PROTEIN KINASE SNF1
2056, d1rdqE_, 0.6338, 3.57, 0.239, 340, 259, HYDROLYSIS OF ATP IN THE CRYSTAL OF Y204A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
2057, d5nadA1, 0.6337, 2.53, 0.245, 253, 241, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1217389
2058, d5dewA_, 0.6337, 2.93, 0.234, 295, 244, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
2059, d5b7vB_, 0.6337, 3.17, 0.259, 277, 251, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
2060, d4uwbA_, 0.6337, 3.21, 0.258, 299, 252, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
2061, d4u42A_, 0.6337, 3.07, 0.235, 282, 247, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
2062, d2cpkE_, 0.6337, 3.65, 0.242, 333, 260, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CYCLIC ADENOSINE MONOPHOSPHATE-DEPENDENT PROTEIN KINASE
2063, d4f63A_, 0.6336, 3.13, 0.255, 278, 251, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
2064, d4bi0A1, 0.6336, 2.54, 0.244, 251, 242, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
2065, d3lm0A1, 0.6336, 3.02, 0.278, 271, 248, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B)
2066, d5n87A1, 0.6334, 2.55, 0.239, 252, 243, TTK KINASE DOMAIN IN COMPLEX WITH NTRC 0066-0
2067, d4bhzA1, 0.6334, 2.53, 0.244, 248, 242, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
2068, d3mfsA_, 0.6334, 3.50, 0.291, 303, 251, CASK-4M CAM KINASE DOMAIN AMPPNP
2069, d4a4lA_, 0.6333, 2.81, 0.297, 290, 246, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 5-(2-AMINO-PYRIMIDIN-4-YL)-1H-PYRROLE INHIBITOR
2070, d2vgoA_, 0.6333, 3.06, 0.210, 268, 248, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
2071, d5n93A1, 0.6331, 2.60, 0.239, 256, 243, TTK KINASE DOMAIN IN COMPLEX WITH TC-MPS1-12
2072, d5ap7A1, 0.6331, 2.58, 0.239, 253, 243, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
2073, d5u94A_, 0.6330, 3.00, 0.249, 263, 249, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PASTA KINASE PKNB IN COMPLEX WITH THE POTENTIAL THERAPUTIC KINASE INHIBITOR GSK690693.
2074, d4rwiA_, 0.6330, 3.11, 0.259, 305, 251, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
2075, d3orxB_, 0.6330, 3.08, 0.262, 280, 248, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2076, d3famB_, 0.6330, 2.25, 0.274, 239, 237,  
2077, d2y7jD_, 0.6330, 3.34, 0.268, 281, 250, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
2078, d2w5bA1, 0.6330, 2.73, 0.232, 263, 246, HUMAN NEK2 KINASE ATPGAMMAS-BOUND
2079, d2fumA_, 0.6330, 2.83, 0.252, 263, 246, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
2080, d2eueB_, 0.6330, 2.25, 0.270, 239, 237,  
2081, d1agwA_, 0.6330, 3.17, 0.259, 278, 251, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
2082, d3ky2B_, 0.6329, 3.03, 0.253, 280, 249, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
2083, d2bfyA_, 0.6329, 3.14, 0.197, 270, 249, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
2084, d2w5aA1, 0.6328, 2.76, 0.215, 259, 246, HUMAN NEK2 KINASE ADP-BOUND
2085, d5nkbA_, 0.6327, 3.19, 0.203, 285, 251, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4A
2086, d4lg4A_, 0.6326, 3.09, 0.223, 289, 251, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2087, d4bkjA1, 0.6326, 3.62, 0.191, 294, 257, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
2088, d3kb7A_, 0.6326, 2.90, 0.296, 289, 247, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
2089, d2fgiA_, 0.6326, 3.16, 0.251, 274, 251, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
2090, d1l3rE_, 0.6326, 3.66, 0.242, 338, 260, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
2091, d5hznE_, 0.6325, 3.30, 0.177, 296, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2092, d4c2vA_, 0.6325, 2.98, 0.220, 270, 246, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
2093, d4a4oA_, 0.6325, 2.83, 0.289, 290, 246, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 2- (2-AMINO-PYRIMIDIN-4-YL)-1567-TETRAHYDRO-PYRROLOPYRIDIN- 4-ONE INHIBITOR
2094, d2qcsA_, 0.6325, 3.70, 0.246, 335, 260, A COMPLEX STRUCTURE BETWEEN THE CATALYTIC AND REGULATORY SUBUNIT OF PROTEIN KINASE A THAT REPRESENTS THE INHIBITED STATE
2095, d5vloB_, 0.6324, 3.39, 0.303, 293, 251, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2096, d4f64A_, 0.6324, 3.17, 0.255, 278, 251, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
2097, d4c2wB_, 0.6324, 3.14, 0.221, 277, 249, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
2098, d4a07A_, 0.6324, 3.16, 0.257, 282, 249, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS171 BOUND TO THE PIF-POCKET
2099, d3idcA_, 0.6324, 3.65, 0.242, 341, 260, CRYSTAL STRUCTURE OF (102-265)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
2100, d3c0hB_, 0.6324, 3.41, 0.276, 300, 250, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
2101, d5ta8A_, 0.6323, 2.98, 0.290, 294, 248, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR
2102, d5nk9A_, 0.6323, 3.21, 0.207, 285, 251, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2E
2103, d5mrbA1, 0.6323, 2.67, 0.242, 259, 244, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH CPD-5
2104, d5hznF_, 0.6323, 3.44, 0.176, 296, 256, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2105, d5hznB_, 0.6323, 3.44, 0.176, 296, 256, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2106, d4othA_, 0.6323, 3.04, 0.213, 305, 249, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH RO-31-8220
2107, d2vrxA_, 0.6323, 3.08, 0.210, 268, 248, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
2108, d2bujA1, 0.6323, 3.29, 0.214, 283, 248, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
2109, d5ljjA1, 0.6322, 2.60, 0.247, 260, 243, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH REVERSINE
2110, d3ujgA_, 0.6322, 3.53, 0.228, 290, 259, CRYSTAL STRUCTURE OF SNRK2.6 IN COMPLEX WITH HAB1
2111, d3rhxB_, 0.6322, 3.14, 0.260, 275, 250, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
2112, d3udbF_, 0.6321, 3.25, 0.189, 273, 254, CRYSTAL STRUCTURE OF SNRK2.6
2113, d3qquA_, 0.6321, 3.75, 0.185, 285, 260, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
2114, d2wtvD_, 0.6321, 3.02, 0.253, 262, 249, AURORA-A INHIBITOR STRUCTURE
2115, d4v05A_, 0.6320, 3.16, 0.259, 287, 251, FGFR1 IN COMPLEX WITH AZD4547.
2116, d4bkjB1, 0.6320, 3.64, 0.195, 296, 257, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
2117, d2wtvA_, 0.6320, 3.03, 0.253, 262, 249, AURORA-A INHIBITOR STRUCTURE
2118, d5h9bA_, 0.6319, 3.28, 0.289, 269, 249, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/AMPPN
2119, d4b8mA_, 0.6318, 3.03, 0.211, 270, 247, AURORA B KINASE IN COMPLEX WITH VX-680
2120, d4zsaB_, 0.6316, 3.26, 0.255, 282, 251, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
2121, d2bfxB_, 0.6316, 3.08, 0.222, 275, 248, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
2122, d1cdkA_, 0.6316, 3.62, 0.251, 342, 259, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
2123, d5vamA_, 0.6315, 3.31, 0.221, 269, 249, BRAF IN COMPLEX WITH RAF709
2124, d2vrxB_, 0.6315, 3.10, 0.230, 274, 248, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
2125, d5nk6A_, 0.6314, 3.23, 0.203, 284, 251, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2D
2126, d4jt3A_, 0.6314, 2.69, 0.250, 254, 244, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 400740
2127, d5hznH_, 0.6313, 3.42, 0.176, 303, 255, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2128, d4zk5A_, 0.6313, 2.94, 0.236, 286, 246, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
2129, d4rwkB_, 0.6313, 2.96, 0.254, 282, 248, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
2130, d4cv8A1, 0.6313, 2.65, 0.235, 252, 243, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
2131, d3ky2A1, 0.6313, 3.18, 0.255, 305, 251, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
2132, d3c0hA_, 0.6312, 3.42, 0.276, 300, 250, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
2133, d2f57A1, 0.6312, 3.12, 0.231, 290, 247, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
2134, d5veeA_, 0.6311, 3.15, 0.251, 289, 247, PAK4 KINASE DOMAIN IN COMPLEX WITH FRAX486
2135, d5hznD_, 0.6311, 3.54, 0.183, 304, 257, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2136, d3ztxA_, 0.6311, 3.12, 0.198, 269, 248, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
2137, d3bwjA_, 0.6311, 3.64, 0.251, 338, 259, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR LEAD COMPOUND ARC-1034
2138, d4wsqA_, 0.6310, 3.66, 0.202, 317, 257, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2139, d4rwlB_, 0.6310, 2.99, 0.254, 285, 248, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
2140, d4rwjA1, 0.6310, 3.18, 0.259, 306, 251, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
2141, d4bi1A1, 0.6310, 2.52, 0.245, 249, 241, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
2142, d4obpA_, 0.6309, 3.02, 0.236, 285, 246, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
2143, d4aw0A_, 0.6309, 3.16, 0.257, 283, 249, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS182 BOUND TO THE PIF-POCKET
2144, d3uokA_, 0.6309, 3.07, 0.249, 265, 249, AURORA A IN COMPLEX WITH YL5-81-1
2145, d2vgoB_, 0.6309, 3.16, 0.210, 277, 248, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
2146, d1m7nA_, 0.6309, 3.80, 0.178, 299, 259, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
2147, d3uokB_, 0.6308, 3.07, 0.249, 265, 249, AURORA A IN COMPLEX WITH YL5-81-1
2148, d3qquB_, 0.6308, 3.62, 0.182, 288, 258, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
2149, d3otuA_, 0.6308, 3.11, 0.262, 276, 248, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR JS30
2150, d5ehoA1, 0.6307, 2.65, 0.247, 255, 243, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
2151, d5deyA_, 0.6307, 2.99, 0.230, 295, 244, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
2152, d4w9wA_, 0.6307, 3.71, 0.209, 306, 258, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH SMALL MOLECULE AZD-7762
2153, d4nksB_, 0.6307, 3.12, 0.265, 271, 249, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
2154, d4c2wA_, 0.6307, 3.18, 0.198, 268, 248, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
2155, d4aw1A_, 0.6307, 3.29, 0.259, 283, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS210 BOUND TO THE PIF-POCKET
2156, d4yomB1, 0.6306, 4.30, 0.241, 320, 270, STRUCTURE OF SAD KINASE
2157, d4bi2A1, 0.6306, 2.53, 0.241, 250, 241, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
2158, d3eknA_, 0.6305, 3.92, 0.217, 297, 263, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
2159, d2vgpB_, 0.6305, 3.08, 0.222, 277, 248, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
2160, d1agwB_, 0.6305, 3.04, 0.258, 272, 248, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
2161, d4c2vB_, 0.6304, 3.12, 0.222, 280, 248, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
2162, d1zwsF_, 0.6304, 3.29, 0.300, 278, 250, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2163, d5nk1A_, 0.6303, 3.07, 0.209, 284, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1K
2164, d4v05B_, 0.6303, 3.16, 0.252, 286, 250, FGFR1 IN COMPLEX WITH AZD4547.
2165, d3cc6A_, 0.6303, 3.07, 0.181, 269, 248, CRYSTAL STRUCTURE OF KINASE DOMAIN OF PROTEIN TYROSINE KINASE 2 BETA (PTK2B)
2166, d3bhhB1, 0.6303, 3.13, 0.293, 288, 246, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2167, d2fh9A_, 0.6303, 3.15, 0.273, 255, 249, STRUCTURE AND DIMERIZATION OF THE KINASE DOMAIN FROM YEAST SNF1
2168, d5i9xA_, 0.6302, 3.00, 0.210, 284, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH BOSUTINIB (SKI-606)
2169, d5l8kA_, 0.6301, 3.16, 0.232, 266, 250, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 2)
2170, d5i9yA_, 0.6301, 2.96, 0.206, 287, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DASATINIB
2171, d5a4cA_, 0.6301, 3.10, 0.253, 294, 249, FGFR1 LIGAND COMPLEX
2172, d4c4iA1, 0.6301, 2.52, 0.249, 250, 241, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
2173, d1m7nB_, 0.6301, 3.72, 0.178, 299, 258, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
2174, d4lg4F_, 0.6300, 2.51, 0.233, 276, 240, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2175, d3o23A_, 0.6299, 3.71, 0.187, 293, 257, HUMAN UNPHOSPHORYLATED IGF1-R KINASE DOMAIN IN COMPLEX WITH AN HYDANTOIN INHIBITOR
2176, d3db6A_, 0.6299, 2.94, 0.279, 287, 247, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 902
2177, d1fgkB_, 0.6299, 2.96, 0.255, 272, 247, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
2178, d3thbA_, 0.6298, 2.85, 0.294, 287, 245, STRUCTURE OF PLK1 KINASE DOMAIN IN COMPLEX WITH A BENZOLACTAM-DERIVED INHIBITOR
2179, d2qg5A1, 0.6298, 3.19, 0.281, 268, 249, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
2180, d1phkA_, 0.6298, 3.09, 0.287, 277, 247, TWO STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHORYLASE KINASE: AN ACTIVE PROTEIN KINASE COMPLEXED WITH NUCLEOTIDE SUBSTRATE-ANALOGUE AND PRODUCT
2181, d4uwyA_, 0.6297, 3.34, 0.262, 296, 252, FGFR1 APO STRUCTURE
2182, d2bdwB_, 0.6297, 3.30, 0.293, 309, 249, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
2183, d4b8mB_, 0.6296, 3.05, 0.223, 279, 247, AURORA B KINASE IN COMPLEX WITH VX-680
2184, d3lw0C_, 0.6296, 3.85, 0.177, 292, 260, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
2185, d3lw0A_, 0.6296, 3.85, 0.177, 292, 260, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
2186, d5nk7A_, 0.6295, 3.10, 0.209, 284, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2A
2187, d5ap0A1, 0.6295, 2.55, 0.241, 250, 241, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
2188, d4u44A_, 0.6295, 3.10, 0.235, 286, 247, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
2189, d4gu6A_, 0.6295, 3.27, 0.215, 271, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
2190, d4cvaA1, 0.6295, 2.55, 0.241, 250, 241, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
2191, d1p4oA_, 0.6295, 3.80, 0.178, 308, 259, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
2192, d5nkcA_, 0.6294, 3.02, 0.210, 286, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2H
2193, d2j4zA_, 0.6294, 3.05, 0.254, 263, 248, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
2194, d2fgiB_, 0.6294, 2.90, 0.260, 272, 246, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
2195, d6babD_, 0.6293, 3.28, 0.306, 291, 248, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2196, d4utdA_, 0.6293, 2.97, 0.246, 266, 248, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION
2197, d4u45A_, 0.6293, 3.00, 0.240, 289, 246, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
2198, d3lw0D_, 0.6293, 3.86, 0.173, 292, 260, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
2199, d3lw0B_, 0.6293, 3.85, 0.177, 292, 260, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
2200, d3c0iA_, 0.6293, 3.29, 0.279, 298, 247, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P212121 FORM
2201, d4f64B_, 0.6292, 2.96, 0.263, 272, 247, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
2202, d3uo6A_, 0.6292, 2.96, 0.247, 264, 247, AURORA A IN COMPLEX WITH YL5-083
2203, d5k3yB_, 0.6291, 3.07, 0.211, 277, 247, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
2204, d5ap3A1, 0.6291, 2.60, 0.237, 250, 241, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
2205, d4wnpB_, 0.6291, 3.00, 0.269, 272, 245, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2206, d4f63B_, 0.6291, 2.96, 0.255, 271, 247, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
2207, d3uo6B_, 0.6291, 2.96, 0.247, 264, 247, AURORA A IN COMPLEX WITH YL5-083
2208, d3bhhA1, 0.6291, 3.08, 0.294, 287, 245, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2209, d2x9eA_, 0.6291, 2.75, 0.250, 253, 244, HUMAN MPS1 IN COMPLEX WITH NMS-P715
2210, d5o21B_, 0.6290, 3.41, 0.245, 273, 253, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
2211, d5nk2A_, 0.6290, 3.11, 0.209, 290, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2B
2212, d5d7aA_, 0.6290, 2.87, 0.229, 289, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
2213, d4c4fA1, 0.6290, 2.49, 0.237, 250, 240, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
2214, d3ztxB_, 0.6290, 3.03, 0.228, 272, 246, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
2215, d1p4oB_, 0.6289, 3.67, 0.179, 314, 257, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
2216, d3ii5A_, 0.6288, 3.06, 0.228, 262, 246, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
2217, d1zwsD_, 0.6288, 3.33, 0.300, 278, 250, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2218, d5k3yA_, 0.6287, 3.12, 0.198, 267, 247, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
2219, d1zwsG_, 0.6286, 3.27, 0.297, 278, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2220, d4rwkA1, 0.6285, 3.24, 0.255, 307, 251, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
2221, d4nkaB_, 0.6285, 3.11, 0.246, 287, 248, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
2222, d4lg4C_, 0.6285, 3.16, 0.223, 288, 251, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2223, d4cv9A1, 0.6285, 2.57, 0.237, 250, 241, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
2224, d2x7fB_, 0.6285, 2.78, 0.222, 288, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
2225, d1muoA_, 0.6285, 2.78, 0.239, 251, 243, CRYSTAL STRUCTURE OF AURORA-2 AN ONCOGENIC SERINE- THREONINE KINASE
2226, d1u5qA_, 0.6284, 3.28, 0.229, 308, 249, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
2227, d4otiA_, 0.6283, 2.97, 0.215, 303, 247, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH TOFACITINIB
2228, d3a62A_, 0.6283, 2.45, 0.277, 263, 238, CRYSTAL STRUCTURE OF PHOSPHORYLATED P70S6K1
2229, d5fg8A_, 0.6282, 3.36, 0.285, 269, 249, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
2230, d4wsqB_, 0.6282, 3.73, 0.206, 310, 257, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2231, d3uohB_, 0.6282, 2.99, 0.251, 264, 247, AURORA A IN COMPLEX WITH RPM1722
2232, d3uohA_, 0.6282, 2.99, 0.247, 264, 247, AURORA A IN COMPLEX WITH RPM1722
2233, d3bhyA1, 0.6282, 3.03, 0.302, 267, 245, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH A BETA-CARBOLINE LIGAND
2234, d2xuuA_, 0.6282, 3.27, 0.305, 301, 249, CRYSTAL STRUCTURE OF A DAP-KINASE 1 MUTANT
2235, d2x0gA_, 0.6282, 3.41, 0.299, 318, 251, X-RAY STRUCTURE OF A DAP-KINASE CALMODULIN COMPLEX
2236, d2vgpA_, 0.6282, 3.11, 0.223, 265, 247, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
2237, d5ap2A1, 0.6281, 2.60, 0.245, 253, 241, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
2238, d4wnpA_, 0.6280, 3.09, 0.268, 273, 246, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2239, d4w9xA_, 0.6280, 3.68, 0.214, 300, 257, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH BARICITINIB
2240, d4deeA_, 0.6280, 3.39, 0.244, 271, 254, AURORA A IN COMPLEX WITH ADP
2241, d2gcdA_, 0.6280, 3.29, 0.229, 308, 249, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
2242, d5eykA_, 0.6279, 3.02, 0.195, 263, 246, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
2243, d5d7aB_, 0.6279, 2.97, 0.232, 286, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
2244, d5ap5A1, 0.6279, 2.50, 0.250, 248, 240, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
2245, d4b4lA_, 0.6279, 3.22, 0.298, 299, 248, CRYSTAL STRUCTURE OF AN ARD DAP-KINASE 1 MUTANT
2246, d1mruB_, 0.6279, 2.96, 0.251, 271, 247, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
2247, d1jkkA_, 0.6278, 3.21, 0.300, 277, 247, 2.4A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MG.
2248, d3uojB_, 0.6277, 3.03, 0.251, 263, 247, AURORA A IN COMPLEX WITH RPM1715
2249, d3uojA_, 0.6277, 3.03, 0.251, 263, 247, AURORA A IN COMPLEX WITH RPM1715
2250, d3qc4A_, 0.6277, 3.17, 0.269, 276, 249, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
2251, d3c0gA_, 0.6277, 3.44, 0.277, 309, 249, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
2252, d2bfyB_, 0.6277, 3.10, 0.211, 278, 247, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
2253, d1lufA_, 0.6277, 3.30, 0.188, 275, 250, CRYSTAL STRUCTURE OF THE MUSK TYROSINE KINASE: INSIGHTS INTO RECEPTOR AUTOREGULATION
2254, d5b2lA_, 0.6276, 3.00, 0.243, 288, 247, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
2255, d4tthB_, 0.6276, 2.77, 0.392, 256, 240, CRYSTAL STRUCTURE OF A CDK6/VCYCLIN COMPLEX WITH INHIBITOR BOUND
2256, d4nk9A_, 0.6276, 3.19, 0.249, 281, 249, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
2257, d1u5rA_, 0.6276, 3.19, 0.226, 308, 248, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
2258, d5j95A_, 0.6275, 3.00, 0.237, 284, 245, MAP4K4 IN COMPLEX WITH INHIBITOR
2259, d5eykB_, 0.6275, 3.11, 0.202, 275, 247, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
2260, d5ap4A1, 0.6275, 2.65, 0.241, 253, 241, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
2261, d3bu6A_, 0.6275, 3.56, 0.208, 294, 255, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PHOSPHOPEPTIDE
2262, d2x7fC_, 0.6275, 2.76, 0.223, 285, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
2263, d4nkaA_, 0.6274, 3.20, 0.245, 279, 249, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
2264, d3naxA_, 0.6274, 2.93, 0.265, 278, 245, PDK1 IN COMPLEX WITH INHIBITOR MP7
2265, d3dfcB1, 0.6274, 3.19, 0.304, 276, 247, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH AMPPNP
2266, d2zm3B2, 0.6274, 3.43, 0.174, 295, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2267, d1jktA_, 0.6274, 3.33, 0.296, 276, 250, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2268, d5nkdA_, 0.6273, 3.09, 0.210, 287, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2I
2269, d5d7aC_, 0.6273, 2.94, 0.220, 286, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
2270, d3unzB_, 0.6273, 3.07, 0.251, 263, 247, AURORA A IN COMPLEX WITH RPM1679
2271, d2yzaA_, 0.6273, 2.79, 0.266, 258, 244, CRYSTAL STRUCTURE OF KINASE DOMAIN OF HUMAN 5 -AMP-ACTIVATED PROTEIN KINASE ALPHA-2 SUBUNIT MUTANT (T172D)
2272, d3unzA_, 0.6272, 3.07, 0.251, 263, 247, AURORA A IN COMPLEX WITH RPM1679
2273, d1zwsB_, 0.6272, 3.30, 0.297, 278, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2274, d3qquD_, 0.6271, 3.97, 0.180, 292, 261, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
2275, d2g15A_, 0.6271, 3.16, 0.208, 301, 250, STRUCTURAL CHARACTERIZATION OF AUTOINHIBITED C-MET KINASE
2276, d4zloA_, 0.6270, 2.92, 0.225, 277, 244, SERINE/THREONINE-PROTEIN KINASE PAK1 COMPLEXED WITH A DIBENZODIAZEPINE: IDENTIFICATION OF AN ALLOSTERIC SITE ON PAK1
2277, d1o6yA_, 0.6270, 2.95, 0.248, 260, 246, CATALYTIC DOMAIN OF PKNB KINASE FROM MYCOBACTERIUM TUBERCULOSIS
2278, d5nk4A_, 0.6269, 3.10, 0.206, 290, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2C
2279, d5fdxA_, 0.6269, 3.53, 0.209, 280, 254, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
2280, d1zwsE_, 0.6269, 3.29, 0.297, 278, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2281, d5auyA_, 0.6268, 3.20, 0.300, 275, 247, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH MORIN.
2282, d3ehaA1, 0.6268, 3.20, 0.300, 275, 247, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH AMPPNP
2283, d2w5hA1, 0.6268, 2.69, 0.239, 257, 243, HUMAN NEK2 KINASE APO
2284, d5ia2A_, 0.6267, 3.12, 0.201, 287, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 66
2285, d4p41B_, 0.6267, 2.79, 0.379, 256, 240,  
2286, d2c6eA_, 0.6267, 2.74, 0.251, 251, 243, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
2287, d1zwsH_, 0.6267, 3.30, 0.297, 278, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2288, d1ig1A_, 0.6267, 3.23, 0.300, 280, 247, 1.8A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MN.
2289, d4nk9B_, 0.6266, 3.07, 0.247, 282, 247, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
2290, d4eqmA_, 0.6266, 3.00, 0.262, 269, 248, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2291, d2yakA_, 0.6266, 3.39, 0.297, 277, 249, STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 (DAPK1) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OSV)
2292, d1wvwA_, 0.6266, 3.27, 0.302, 275, 248, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
2293, d4v01B_, 0.6265, 3.16, 0.246, 275, 248, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
2294, d4eqmC_, 0.6264, 3.02, 0.266, 269, 248, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2295, d4eqmB_, 0.6264, 3.01, 0.262, 269, 248, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2296, d3gu7A1, 0.6264, 3.21, 0.300, 276, 247, CRYSTAL STRUCTURE OF DAPKQ23V-ADP-MG2+
2297, d2i1mA_, 0.6264, 3.37, 0.235, 311, 251, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
2298, d1jksA_, 0.6264, 3.22, 0.296, 280, 247, 1.5A X-RAY STRUCTURE OF APO FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2299, d4lg4B_, 0.6263, 3.33, 0.224, 284, 250, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2300, d3f5pH1, 0.6263, 3.43, 0.182, 298, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2301, d5os5A_, 0.6262, 3.28, 0.251, 267, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2302, d3qquC_, 0.6262, 3.87, 0.181, 293, 260, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
2303, d2z8cA1, 0.6262, 3.57, 0.200, 297, 255, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN-2- YL]AMINO}PHENYL)ACETIC ACID
2304, d5autA_, 0.6261, 3.17, 0.305, 274, 246, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH ANS.
2305, d3h10A_, 0.6261, 3.41, 0.245, 268, 253, AURORA A INHIBITOR COMPLEX
2306, d3f5pC1, 0.6261, 3.43, 0.182, 300, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2307, d2qg5D1, 0.6261, 3.23, 0.293, 267, 249, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
2308, d4nksA_, 0.6260, 3.12, 0.250, 265, 248, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
2309, d3mn3A_, 0.6260, 2.79, 0.262, 252, 244, AN INHIBITED CONFORMATION FOR THE PROTEIN KINASE DOMAIN OF THE SACCHAROMYCES CEREVISIAE AMPK HOMOLOG SNF1
2310, d2gcdB_, 0.6260, 3.33, 0.229, 308, 249, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
2311, d4rwjB_, 0.6259, 3.01, 0.248, 282, 246, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
2312, d3f5pD1, 0.6259, 3.43, 0.182, 296, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2313, d3d5wA_, 0.6259, 3.22, 0.279, 284, 247, CRYSTAL STRUCTURE OF A PHOSPHORYLATED POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH ADP.
2314, d3c0gB_, 0.6259, 3.40, 0.278, 320, 248, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
2315, d3gu4A1, 0.6258, 3.22, 0.304, 276, 247, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP
2316, d1zwsA_, 0.6258, 3.33, 0.297, 278, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2317, d4v04B_, 0.6257, 3.00, 0.244, 287, 246, FGFR1 IN COMPLEX WITH PONATINIB.
2318, d4eqmD_, 0.6257, 2.86, 0.272, 268, 246, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2319, p3hdmA_, 0.6257, 2.95, 0.231, 285, 247, CRYSTAL STRUCTURE OF SERUM AND GLUCOCORTICOID-REGULATED KINASE 1 IN COMPLEX WITH COMPOUND 1
2320, d3gu5A1, 0.6257, 3.22, 0.304, 276, 247, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP-MG2+
2321, d1uwhB_, 0.6257, 2.95, 0.225, 264, 244, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
2322, d5nk3A_, 0.6256, 3.24, 0.205, 281, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1L
2323, d5na0A1, 0.6256, 2.61, 0.237, 250, 241, TTK KINASE DOMAIN IN COMPLEX WITH A PEG-LINKED PYRIMIDO-INDOLIZINE
2324, d5av3A_, 0.6256, 3.23, 0.300, 275, 247, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF IODIDE IONS.
2325, d3nw6A_, 0.6256, 3.88, 0.174, 301, 259, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (11A)
2326, d3f5pG1, 0.6256, 3.44, 0.182, 298, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2327, d3f5pB1, 0.6256, 3.44, 0.182, 297, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2328, d3beaA_, 0.6256, 3.46, 0.243, 310, 251, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH A PYRIMIDINOPYRIDONE INHIBITOR
2329, d3f5pA1, 0.6255, 3.44, 0.182, 298, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2330, d2e9oA_, 0.6255, 3.14, 0.260, 269, 246, STRUCTURE OF H-CHK1 COMPLEXED WITH AA582939
2331, d5ig1B_, 0.6254, 3.50, 0.267, 304, 251, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
2332, d5av2A_, 0.6254, 3.23, 0.300, 275, 247, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF BROMIDE IONS.
2333, d4v04A_, 0.6254, 3.09, 0.243, 290, 247, FGFR1 IN COMPLEX WITH PONATINIB.
2334, d3f5pE1, 0.6254, 3.44, 0.182, 298, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2335, d2x4fB_, 0.6254, 3.11, 0.275, 288, 247, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
2336, d2fumD_, 0.6254, 2.86, 0.236, 258, 246, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
2337, d3ik3B1, 0.6253, 3.36, 0.216, 285, 250, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
2338, d2i0yA_, 0.6253, 3.46, 0.243, 289, 251, CFMS TYROSINE KINASE (FGF KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
2339, d1fgiB_, 0.6253, 3.04, 0.255, 272, 247, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
2340, d5av1A_, 0.6252, 3.16, 0.301, 275, 246, CRYSTAL STRUCTURE OF DAPK1 IN THE PRESENCE OF BROMIDE IONS.
2341, d3i81A_, 0.6252, 3.75, 0.175, 296, 257, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH BMS-754807 [1-(4-((5-CYCLOPROPYL- 1H-PYRAZOL-3-YL)AMINO)PYRROLO[21-F][124]TRIAZIN-2-YL)-N- (6-FLUORO-3-PYRIDINYL)-2-METHYL-L-PROLINAMIDE]
2342, d3g0eA1, 0.6252, 3.67, 0.243, 330, 255, KIT KINASE DOMAIN IN COMPLEX WITH SUNITINIB
2343, d3f5pF1, 0.6252, 3.46, 0.182, 298, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2344, d3e5aA_, 0.6252, 3.20, 0.255, 264, 247, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH VX-680 AND TPX2
2345, d3d94A_, 0.6252, 3.68, 0.175, 288, 257, CRYSTAL STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE IN COMPLEX WITH PQIP
2346, d1jklA_, 0.6252, 3.24, 0.304, 280, 247, 1.6A X-RAY STRUCTURE OF BINARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE
2347, d5av0A_, 0.6251, 3.23, 0.300, 275, 247, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH 73 4 - TRIHYDROXYISOFLAVONE.
2348, d2w4jA_, 0.6251, 3.32, 0.298, 276, 248, X-RAY STRUCTURE OF A DAP-KINASE 2-277
2349, p5oatF_, 0.6250, 3.36, 0.199, 359, 251, PINK1 STRUCTURE
2350, d4ct2A_, 0.6250, 3.09, 0.261, 277, 245, HUMAN PDK1-PKCZETA KINASE CHIMERA
2351, d5auvA_, 0.6249, 3.24, 0.300, 275, 247, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH APIGENIN.
2352, d4uv0A_, 0.6249, 3.37, 0.301, 300, 249, STRUCTURE OF A SEMISYNTHETIC PHOSPHORYLATED DAPK
2353, d4eqmF_, 0.6249, 2.88, 0.272, 268, 246, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2354, d2w96B_, 0.6249, 2.94, 0.357, 267, 244, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
2355, d1vzoA_, 0.6249, 3.00, 0.245, 319, 245, THE STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF MSK1 REVEALS A NOVEL AUTOINHIBITORY CONFORMATION FOR A DUAL KINASE PROTEIN
2356, d5o21A_, 0.6248, 3.43, 0.242, 272, 252, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
2357, d5di1A_, 0.6248, 3.05, 0.245, 285, 245, MAP4K4 IN COMPLEX WITH AN INHIBITOR
2358, d5auxA_, 0.6248, 3.18, 0.301, 275, 246, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH KAEMPFEROL.
2359, d3f5pT1, 0.6248, 3.47, 0.182, 294, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2360, d3ewhA1, 0.6248, 3.35, 0.224, 295, 250, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDYL-PYRIMIDINE BENZIMIDAZOLE INHIBITOR
2361, d5m51A1, 0.6247, 2.52, 0.239, 253, 238, NEK2 BOUND TO ARYLAMINOPURINE COMPOUND 8
2362, d3nw5A_, 0.6247, 3.68, 0.175, 302, 257, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (11B)
2363, d3gu6A1, 0.6247, 3.25, 0.300, 276, 247, CRYSTAL STRUCTURE OF DAPKQ23V-ADP
2364, d3f5gA1, 0.6247, 3.24, 0.300, 275, 247, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH ADP AND MG2+
2365, d4fzaB1, 0.6246, 2.79, 0.193, 280, 243, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX
2366, d3eh9A1, 0.6246, 3.25, 0.296, 274, 247, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH ADP
2367, d1zwsC_, 0.6246, 3.33, 0.297, 278, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2368, d1u5qB_, 0.6246, 3.34, 0.229, 308, 249, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
2369, d5cwzB_, 0.6245, 2.80, 0.230, 284, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
2370, d4eqmE_, 0.6245, 2.89, 0.272, 268, 246, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2371, d2c6dA_, 0.6245, 3.04, 0.252, 254, 246, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH ADPNP
2372, d1mruA_, 0.6245, 3.00, 0.244, 269, 246, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
2373, d5m57A1, 0.6244, 2.53, 0.235, 253, 238, NEK2 BOUND TO ARYLAMINOPURINE 6
2374, d5bvkA_, 0.6244, 3.68, 0.203, 278, 256, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
2375, d4c4gA1, 0.6244, 2.53, 0.251, 247, 239, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
2376, d3h4jB1, 0.6244, 3.69, 0.268, 325, 254, CRYSTAL STRUCTURE OF POMBE AMPK KDAID FRAGMENT
2377, d3h10D_, 0.6244, 3.17, 0.250, 255, 248, AURORA A INHIBITOR COMPLEX
2378, d2xzsA_, 0.6244, 3.46, 0.308, 301, 250, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
2379, d3kfaB1, 0.6243, 3.34, 0.225, 283, 249, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
2380, d2h6dA_, 0.6243, 2.73, 0.264, 256, 242, PROTEIN KINASE DOMAIN OF THE HUMAN 5 -AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-2 (AMPK ALPHA-2 CHAIN)
2381, d5nkeA_, 0.6242, 2.96, 0.199, 292, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3A
2382, d4pf4A1, 0.6242, 3.24, 0.304, 277, 247, 1.1A X-RAY STRUCTURE OF THE APO CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE 1 AA 1-277
2383, d4p90B_, 0.6242, 2.75, 0.218, 262, 238, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
2384, d3txoA_, 0.6242, 3.29, 0.229, 317, 249, PKC ETA KINASE IN COMPLEX WITH A NAPHTHYRIDINE
2385, d2aypA_, 0.6242, 3.05, 0.257, 268, 245, CRYSTAL STRUCTURE OF CHK1 WITH AN INDOL INHIBITOR
2386, d5i9zA_, 0.6241, 2.72, 0.202, 273, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DANUSERTIB (PHA739358)
2387, d4v01A_, 0.6241, 3.12, 0.243, 273, 247, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
2388, d4o0sA_, 0.6241, 3.19, 0.249, 265, 249, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
2389, d3bu3A_, 0.6241, 3.64, 0.204, 294, 255, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE
2390, d2weiA1, 0.6241, 3.56, 0.272, 269, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE IN COMPLEX WITH 3- MB-PP1
2391, d4zp5A_, 0.6240, 3.14, 0.236, 284, 246, MAP4K4 IN COMPLEX WITH INHIBITOR
2392, d3h10B_, 0.6240, 3.50, 0.233, 267, 253, AURORA A INHIBITOR COMPLEX
2393, d3g0fA_, 0.6240, 3.46, 0.242, 291, 252, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
2394, d3f5uA1, 0.6240, 3.21, 0.301, 275, 246, CRYSTAL STRUCTURE OF THE DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH AMPPNP AND MG2+
2395, d2zm3D2, 0.6240, 3.58, 0.181, 292, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2396, d2x4fA_, 0.6240, 3.26, 0.270, 289, 248, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
2397, d4f65B_, 0.6239, 3.14, 0.247, 279, 247, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
2398, d3w10A_, 0.6239, 3.39, 0.234, 263, 252, AURORA KINASE A COMPLEXED TO PYRAZOLE AMINOQUINOLINE I
2399, d5nkhA_, 0.6238, 2.97, 0.199, 295, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3E
2400, d3uolB_, 0.6238, 3.06, 0.252, 263, 246, AURORA A IN COMPLEX WITH SO2-162
2401, d3uolA_, 0.6238, 3.06, 0.252, 263, 246, AURORA A IN COMPLEX WITH SO2-162
2402, d3f5pS1, 0.6238, 3.48, 0.182, 294, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2403, d4ymjB1, 0.6237, 3.19, 0.215, 272, 246, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
2404, d3kfaA1, 0.6237, 3.26, 0.222, 283, 248, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
2405, d5fdpA_, 0.6236, 3.57, 0.209, 285, 254, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2099 INHIBITOR AT 2.25 ANGSTROMS RESOLUTION.
2406, d5auzA_, 0.6236, 3.14, 0.302, 274, 245, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH GENISTEIN.
2407, d3f5pM1, 0.6236, 3.48, 0.182, 294, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2408, d2wkmA_, 0.6236, 3.35, 0.204, 286, 250, X-RAY STRUCTURE OF PHA-00665752 BOUND TO THE KINASE DOMAIN OF C-MET
2409, d2i0vA_, 0.6236, 3.51, 0.243, 303, 251, C-FMS TYROSINE KINASE IN COMPLEX WITH A QUINOLONE INHIBITOR
2410, d2bujB1, 0.6236, 3.08, 0.217, 277, 244, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
2411, d5osdA_, 0.6235, 3.31, 0.248, 266, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2412, d5bvnA_, 0.6235, 3.62, 0.208, 278, 255, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
2413, d5av4A_, 0.6235, 3.21, 0.301, 274, 246, CRYSTAL STRUCTURE OF DAPK1-GENISTEIN COMPLEX IN THE PRESENCE OF BROMIDE IONS.
2414, d4h58C_, 0.6235, 3.45, 0.221, 272, 249, BRAF IN COMPLEX WITH COMPOUND 3
2415, d3dgkA1, 0.6235, 3.21, 0.301, 276, 246, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN
2416, d4tl0A_, 0.6234, 3.40, 0.297, 300, 249, CRYSTAL STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 WITH A CRUCIAL PHOSPHOMIMICKING MUTATION
2417, d2y0aA_, 0.6234, 3.46, 0.304, 300, 250, STRUCTURE OF DAPK1 CONSTRUCT RESIDUES 1-304
2418, d2ghgA1, 0.6234, 3.28, 0.262, 269, 248, H-CHK1 COMPLEXED WITH A431994
2419, d5nk5A_, 0.6233, 2.99, 0.199, 287, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1M
2420, d5grnA_, 0.6233, 3.51, 0.246, 285, 252, CRYSTAL STRUCTURE OF PDGFRA IN COMPLEX WITH WQ-C-159
2421, d3kulB_, 0.6233, 3.09, 0.216, 271, 245, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
2422, d3f5pI1, 0.6233, 3.49, 0.182, 293, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2423, d2ydiA_, 0.6233, 3.12, 0.265, 279, 245, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
2424, d5bvoA_, 0.6232, 3.60, 0.212, 276, 255, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
2425, d4o0rA_, 0.6232, 3.29, 0.224, 293, 246, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2426, d4jiaA_, 0.6232, 3.34, 0.224, 298, 250, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 9
2427, d3gu8A1, 0.6232, 3.28, 0.300, 276, 247, CRYSTAL STRUCTURE OF DAPKL93G WITH N6-CYCLOPENTYLADENOSINE
2428, d2e9nA_, 0.6232, 3.15, 0.257, 269, 245, STRUCTURE OF H-CHK1 COMPLEXED WITH A767085
2429, d1k3aA_, 0.6232, 3.66, 0.180, 288, 255, STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR KINASE
2430, d4uynA_, 0.6231, 2.88, 0.248, 249, 242, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
2431, d1uwhA_, 0.6231, 3.05, 0.234, 264, 244, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
2432, d5wevA_, 0.6230, 3.34, 0.220, 293, 250, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
2433, d5uyjA1, 0.6230, 3.04, 0.253, 279, 245, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
2434, d5cwzA_, 0.6230, 2.83, 0.226, 284, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
2435, d5auuA_, 0.6230, 3.23, 0.301, 274, 246, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH LUTEOLIN.
2436, d3f5pL1, 0.6230, 3.51, 0.182, 292, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2437, d4txcA_, 0.6229, 3.40, 0.297, 276, 249, CRYSTAL STRUCTURE OF DAPK1 KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
2438, d3oy3A1, 0.6229, 3.35, 0.217, 283, 249, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
2439, d2x8dA_, 0.6229, 3.15, 0.261, 279, 245, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
2440, d4w8eA_, 0.6228, 3.11, 0.225, 290, 244, STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF-06645342)
2441, d3hyhB_, 0.6228, 2.18, 0.289, 233, 232, CRYSTAL STRUCTURE OF THE PROTEIN KINASE DOMAIN OF YEAST AMP-ACTIVATED PROTEIN KINASE SNF1
2442, d3f5pK1, 0.6228, 3.52, 0.182, 292, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2443, d3f3zA_, 0.6228, 3.06, 0.279, 271, 244, CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840 IN PRESENCE OF INDIRUBIN E804
2444, d4qmwA_, 0.6227, 3.21, 0.220, 286, 245, MST3 IN COMPLEX WITH PP-121 1-CYCLOPENTYL-3-(1H-PYRROLO[23- B]PYRIDIN-5-YL)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
2445, d4c4hA1, 0.6227, 2.41, 0.253, 245, 237, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
2446, d3u6jA1, 0.6227, 3.41, 0.239, 305, 251, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
2447, d3k5vA1, 0.6227, 3.32, 0.223, 281, 247, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
2448, d3bu5A_, 0.6227, 3.80, 0.214, 291, 257, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE AND ATP
2449, d2ckeD_, 0.6227, 3.45, 0.309, 300, 249, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2450, d5oryA_, 0.6226, 3.18, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2451, d5ci7A_, 0.6226, 3.29, 0.267, 276, 247, STRUCTURE OF ULK1 BOUND TO A SELECTIVE INHIBITOR
2452, d5auwA_, 0.6226, 3.23, 0.301, 274, 246, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH QUERCETIN.
2453, d4at4A1, 0.6226, 3.27, 0.215, 289, 246, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH EX429
2454, d3oy3B1, 0.6226, 3.44, 0.220, 283, 250, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
2455, d3f5pR1, 0.6226, 3.50, 0.182, 293, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2456, d1zysA_, 0.6226, 3.09, 0.258, 271, 244, CO-CRYSTAL STRUCTURE OF CHECKPOINT KINASE CHK1 WITH A PYRROLO-PYRIDINE INHIBITOR
2457, d1u5rB_, 0.6226, 3.30, 0.226, 308, 248, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
2458, d4tygA1, 0.6225, 3.09, 0.260, 290, 246, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
2459, d4gmyA_, 0.6225, 3.35, 0.220, 298, 250, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH 26-DICHLORO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
2460, d4aszA1, 0.6225, 3.26, 0.206, 286, 247, CRYSTAL STRUCTURE OF APO TRKB KINASE DOMAIN
2461, d3gqlA_, 0.6225, 2.96, 0.262, 287, 244, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
2462, d3famA_, 0.6225, 2.29, 0.279, 235, 233,  
2463, d3dlsA_, 0.6225, 3.14, 0.232, 285, 246, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2464, d2zm3A2, 0.6225, 3.57, 0.181, 299, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2465, d2eueA_, 0.6225, 2.29, 0.279, 235, 233,  
2466, d1yrpB_, 0.6225, 3.22, 0.297, 275, 246, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
2467, d1yrpA_, 0.6225, 3.22, 0.297, 275, 246, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
2468, d1wvxA_, 0.6225, 3.27, 0.305, 275, 246, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
2469, d5fdxB_, 0.6224, 3.45, 0.211, 274, 251, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
2470, d4ythA_, 0.6224, 3.26, 0.225, 287, 249, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
2471, d2hiwB1, 0.6224, 3.25, 0.219, 270, 247, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
2472, d2ckeC_, 0.6224, 3.41, 0.293, 300, 249, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2473, d5l8lA_, 0.6223, 3.09, 0.244, 263, 246, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 1)
2474, d4wnoA_, 0.6223, 3.15, 0.269, 272, 245, STRUCTURE OF ULK1 BOUND TO AN INHIBITOR
2475, d3is5F1, 0.6223, 3.09, 0.309, 259, 246, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
2476, d2c30A_, 0.6223, 3.34, 0.235, 289, 247, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 6
2477, d5bvwA_, 0.6222, 3.66, 0.209, 274, 254, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
2478, d4ymjA1, 0.6222, 3.07, 0.217, 267, 244, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
2479, d4uxqA_, 0.6222, 3.29, 0.264, 286, 250, FGFR4 IN COMPLEX WITH PONATINIB
2480, d4figB_, 0.6222, 3.25, 0.241, 292, 245, CATALYTIC DOMAIN OF HUMAN PAK4
2481, d3f5pJ1, 0.6222, 3.53, 0.182, 292, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2482, d1rqqB_, 0.6222, 3.75, 0.207, 294, 256, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
2483, d5uy6A1, 0.6221, 2.99, 0.258, 280, 244, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
2484, d4f0iB_, 0.6221, 3.22, 0.198, 294, 248, CRYSTAL STRUCTURE OF APO TRKA
2485, d4e26A_, 0.6221, 2.99, 0.221, 270, 244, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
2486, d3uo5A_, 0.6221, 3.36, 0.240, 267, 250, AURORA A IN COMPLEX WITH YL1-038-31
2487, d3k5uA_, 0.6221, 3.04, 0.239, 260, 247, IDENTIFICATION SAR STUDIES AND X-RAY COCRYSTAL ANALYSIS OF A NOVEL FURANO-PYRIMIDINE AURORA KINASE A INHIBITOR
2488, d3a7gB_, 0.6221, 3.27, 0.215, 290, 247, HUMAN MST3 KINASE
2489, d2yaaB_, 0.6221, 3.50, 0.296, 299, 250, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
2490, d2xzsB_, 0.6221, 3.40, 0.310, 293, 248, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
2491, d6babB_, 0.6220, 3.29, 0.310, 285, 245, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2492, d4ypdA1, 0.6220, 3.30, 0.300, 276, 247, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT 4-METHYLPYRIDAZINE
2493, d4yo4A1, 0.6220, 3.23, 0.301, 276, 246, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT PHTHALAZINE
2494, d3up2A_, 0.6220, 3.45, 0.243, 266, 251, AURORA A IN COMPLEX WITH RPM1686
2495, d3udbE_, 0.6219, 3.15, 0.215, 255, 246, CRYSTAL STRUCTURE OF SNRK2.6
2496, d4f1tA1, 0.6217, 3.03, 0.198, 267, 243, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO THE ROCK INHIBITOR H1152
2497, d3a7hB_, 0.6217, 3.28, 0.215, 290, 247, HUMAN MST3 KINASE IN COMPLEX WITH ATP
2498, d2e9uA_, 0.6217, 3.05, 0.266, 269, 244, STRUCTURE OF H-CHK1 COMPLEXED WITH A780125
2499, d1jqhB_, 0.6217, 3.58, 0.173, 287, 254, IGF-1 RECEPTOR KINASE DOMAIN
2500, d5dnrA_, 0.6216, 3.30, 0.249, 264, 249, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P41212
2501, d4deaA_, 0.6216, 3.42, 0.243, 266, 251, AURORA A IN COMPLEX WITH YL1-038-18
2502, d4o0wA_, 0.6215, 3.27, 0.241, 259, 249, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
2503, d4jbqA_, 0.6215, 2.88, 0.246, 257, 244, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
2504, d4h58B_, 0.6215, 2.98, 0.227, 262, 242, BRAF IN COMPLEX WITH COMPOUND 3
2505, d3krjA_, 0.6215, 3.47, 0.244, 304, 250, CFMS TYROSINE KINASE IN COMPLEX WITH 4-CYANO-1H-IMIDAZOLE-2-CARBOXYLIC ACID (2-CYCLOHEX-1-ENYL-4-PIPERIDIN-4-YL-PHENYL)-AMIDE
2506, d5osfA_, 0.6214, 3.20, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2507, d5orwA_, 0.6214, 3.20, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2508, d2z7rA_, 0.6214, 2.94, 0.270, 265, 241, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO STAUROSPORINE
2509, d2yabB_, 0.6214, 3.52, 0.296, 299, 250, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
2510, d2hyyA_, 0.6214, 3.21, 0.224, 263, 246, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
2511, d1opjB1, 0.6214, 3.40, 0.218, 284, 248, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
2512, d5orzA_, 0.6213, 3.21, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2513, d4wnpD_, 0.6213, 3.01, 0.276, 272, 243, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2514, d4figA_, 0.6213, 3.19, 0.242, 292, 244, CATALYTIC DOMAIN OF HUMAN PAK4
2515, d4debA_, 0.6213, 3.32, 0.249, 264, 249, AURORA A IN COMPLEX WITH RK2-17-01
2516, d4d2rA_, 0.6213, 3.78, 0.175, 300, 257, HUMAN IGF IN COMPLEX WITH A DYRK1B INHIBITOR
2517, d3gubA1, 0.6213, 3.30, 0.296, 276, 247, CRYSTAL STRUCTURE OF DAPKL93G COMPLEXED WITH N6-(2- PHENYLETHYL)ADENOSINE
2518, d2w4kA_, 0.6213, 3.43, 0.297, 301, 249, X-RAY STRUCTURE OF A DAP-KINASE 2-302
2519, d2ckeB_, 0.6213, 3.45, 0.293, 300, 249, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2520, d5oseA_, 0.6212, 3.21, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2521, d5orrA_, 0.6212, 3.21, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2522, d5csxA_, 0.6212, 3.18, 0.220, 261, 245, CRYSTAL STRUCTURE OF B-RAF IN COMPLEX WITH BI 882370
2523, d4at3A1, 0.6212, 3.34, 0.218, 286, 248, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH CPD5N
2524, d5os3A_, 0.6211, 3.21, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2525, d5am6B_, 0.6211, 2.93, 0.263, 280, 243, NATIVE FGFR1 WITH AN INHIBITOR
2526, d3ik3A1, 0.6211, 3.30, 0.206, 279, 247, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
2527, d5os1A_, 0.6210, 3.22, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2528, d5orpA_, 0.6210, 3.23, 0.246, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2529, d5kmjA_, 0.6210, 3.20, 0.204, 300, 245, TRKA JM-KINASE WITH {N}-(2-PYRIDYLMETHYL)-2-[2-(2-THIENYL)INDOL-1- YL]ACETAMIDE
2530, d3lvpA_, 0.6210, 3.78, 0.178, 289, 258, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
2531, d3is5A1, 0.6210, 2.67, 0.317, 254, 240, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
2532, d3g0fB_, 0.6210, 3.53, 0.250, 293, 252, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
2533, d3bhhD1, 0.6210, 3.29, 0.290, 285, 245, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2534, d3bhhC1, 0.6210, 3.26, 0.290, 284, 245, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2535, d2ywpA_, 0.6210, 3.15, 0.265, 269, 245, CRYSTAL STRUCTURE OF CHK1 WITH A UREA INHIBITOR
2536, d2a2aD_, 0.6210, 3.48, 0.292, 303, 250, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2537, d1jqhA_, 0.6210, 3.59, 0.173, 291, 254, IGF-1 RECEPTOR KINASE DOMAIN
2538, d1iepA1, 0.6210, 3.22, 0.224, 270, 246, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
2539, d5vamB_, 0.6209, 3.04, 0.240, 260, 242, BRAF IN COMPLEX WITH RAF709
2540, d5orvA_, 0.6209, 3.21, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2541, d5oroA_, 0.6209, 3.22, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2542, d4o0tA_, 0.6209, 3.35, 0.228, 292, 246, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2543, d4at5A1, 0.6209, 3.25, 0.211, 291, 247, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH GW2580
2544, d3vntA_, 0.6209, 3.61, 0.229, 301, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
2545, d2fgaA_, 0.6209, 3.15, 0.265, 269, 245,  
2546, d5os0A_, 0.6208, 3.21, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2547, d5dn3A_, 0.6208, 3.34, 0.257, 264, 249, AURORA A IN COMPLEX WITH ATP AND AA35.
2548, d4qmxA_, 0.6208, 3.06, 0.222, 287, 243, MST3 IN COMPLEX WITH SARACATINIB
2549, d4asdA_, 0.6208, 3.61, 0.229, 305, 253, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SORAFENIB (BAY 43-9006)
2550, d5orxA_, 0.6207, 3.21, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2551, d5ornA_, 0.6207, 3.21, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2552, d4qmsA_, 0.6207, 3.15, 0.217, 283, 244, MST3 IN COMPLEX WITH DASATINIB
2553, d4qmnA_, 0.6207, 3.16, 0.221, 283, 244, MST3 IN COMPLEX WITH BOSUTINIB
2554, d2yabA_, 0.6207, 3.46, 0.297, 299, 249, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
2555, d5orsA_, 0.6206, 3.25, 0.246, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2556, d5ax9A_, 0.6206, 2.86, 0.228, 282, 241, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
2557, d4k9yA_, 0.6206, 3.17, 0.198, 271, 248, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-[4-(6-AMINO- PURIN-9-YL)-PHENYL]-3-(5-TERT-BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-UREA
2558, d3is5C1, 0.6206, 2.75, 0.307, 254, 241, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
2559, d1jqhC_, 0.6206, 3.60, 0.173, 291, 254, IGF-1 RECEPTOR KINASE DOMAIN
2560, d4fc0B_, 0.6205, 3.01, 0.219, 263, 242, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
2561, d3zzeA_, 0.6205, 3.39, 0.204, 286, 250, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH N - ((3Z)-4-CHLORO-7-METHYL-2-OXO-12-DIHYDRO-3H-INDOL-3- YLIDENE)-2-(4-HYDROXYPHENYL)PROPANOHYDRAZIDE
2562, d3kckA_, 0.6205, 3.29, 0.225, 285, 249, A NOVEL CHEMOTYPE OF KINASE INHIBITORS
2563, d2wqnA_, 0.6205, 2.73, 0.225, 259, 240, STRUCTURE OF ADP-BOUND HUMAN NEK7
2564, d5kmnA1, 0.6204, 3.28, 0.198, 290, 247, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
2565, d5dt3A_, 0.6204, 3.29, 0.246, 263, 248, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
2566, d3d5xA_, 0.6204, 2.88, 0.274, 279, 241, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH WORTMANNIN.
2567, d5ortA_, 0.6203, 3.30, 0.249, 264, 249, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2568, d4agdA_, 0.6203, 3.55, 0.221, 303, 253, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SUNITINIB (SU11248) (N-2- DIETHYLAMINOETHYL)-5-((Z)-(5-FLUORO-2-OXO-1H-INDOL-3- YLIDENE)METHYL)-24-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE)
2569, d3nw7A_, 0.6203, 3.92, 0.178, 297, 259, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (34)
2570, d2a27D_, 0.6203, 3.38, 0.298, 304, 248, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2571, d1iepB1, 0.6203, 3.38, 0.218, 270, 248, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
2572, d5ax9C_, 0.6202, 3.04, 0.230, 282, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
2573, d4e26B_, 0.6202, 2.84, 0.229, 264, 240, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
2574, d4aseA_, 0.6202, 3.59, 0.225, 305, 253, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH TIVOZANIB (AV-951)
2575, d2a2aC_, 0.6202, 3.43, 0.297, 303, 249, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2576, d4h1jA_, 0.6201, 3.02, 0.184, 263, 244, CRYSTAL STRUCTURE OF PYK2 WITH THE PYRAZOLE 13A
2577, d3ikaA_, 0.6201, 3.48, 0.224, 310, 250, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
2578, d4d2sA_, 0.6200, 2.61, 0.251, 249, 239, HUMAN TTK IN COMPLEX WITH A DYRK1B INHIBITOR
2579, d3a7iA_, 0.6200, 3.06, 0.222, 286, 243, HUMAN MST3 KINASE IN COMPLEX WITH ADENINE
2580, d3uo4A_, 0.6199, 3.37, 0.252, 266, 250, AURORA A IN COMPLEX WITH RPM1680
2581, d1uwjB_, 0.6199, 3.03, 0.227, 263, 242, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
2582, d1u59A1, 0.6199, 3.22, 0.203, 276, 246, CRYSTAL STRUCTURE OF THE ZAP-70 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2583, d1fpuA1, 0.6199, 3.32, 0.219, 271, 247, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
2584, d4qmyA_, 0.6198, 3.07, 0.222, 287, 243, MST3 IN COMPLEX WITH STAUROSPORINE
2585, d4hvsA1, 0.6198, 3.47, 0.264, 323, 250, CRYSTAL STRUCTURE OF KIT KINASE DOMAIN WITH A SMALL MOLECULE INHIBITOR PLX647
2586, d2yaaA_, 0.6198, 3.55, 0.296, 300, 250, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
2587, d2ckeA_, 0.6198, 3.47, 0.297, 301, 249, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2588, d5fxsA1, 0.6197, 3.78, 0.175, 307, 257, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
2589, d3vo3A_, 0.6197, 3.62, 0.225, 303, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH IMIDAZO[1 2-B]PYRIDAZINE DERIVATIVE
2590, d3ii5B_, 0.6197, 2.96, 0.224, 257, 241, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
2591, d2ya9B_, 0.6197, 3.55, 0.300, 299, 250, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
2592, d3uodA_, 0.6196, 3.45, 0.240, 266, 250, AURORA A IN COMPLEX WITH RPM1693
2593, d5kmlA1, 0.6195, 3.29, 0.198, 290, 247, TRKA JM-KINASE WITH 1-(5-METHYL-3-PHENYL-12-OXAZOL-4-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
2594, d5ia0B_, 0.6195, 3.00, 0.193, 266, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
2595, d4uwyB_, 0.6195, 2.93, 0.264, 273, 242, FGFR1 APO STRUCTURE
2596, d4dbnB_, 0.6195, 2.96, 0.216, 263, 241, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
2597, d3q96B_, 0.6195, 3.06, 0.211, 262, 242, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
2598, d4f0fA1, 0.6194, 3.32, 0.204, 274, 245, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM
2599, d2a27H_, 0.6194, 3.47, 0.301, 304, 249, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2600, d1t46A_, 0.6194, 3.53, 0.246, 297, 252, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C-KIT TYROSINE KINASE
2601, d1jktB_, 0.6194, 3.14, 0.293, 276, 246, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2602, d5e1sA_, 0.6193, 3.41, 0.216, 284, 250, THE CRYSTAL STRUCTURE OF INSR TYROSINE KINASE IN COMPLEX WITH THE INHIBITOR BI 885578
2603, d3ugcA_, 0.6193, 3.14, 0.215, 274, 246, STRUCTURAL BASIS OF JAK2 INHIBITION BY THE TYPE II INHIBTOR NVP-BBT594
2604, d3lauA1, 0.6193, 2.95, 0.244, 250, 242, CRYSTAL STRUCTURE OF AURORA2 KINASE IN COMPLEX WITH A GSK3BETA INHIBITOR
2605, d3h3cA_, 0.6193, 3.00, 0.185, 263, 243, CRYSTAL STRUCTURE OF PYK2 IN COMPLEX WITH SULFOXIMINE- SUBSTITUTED TRIFLUOROMETHYLPYRIMIDINE ANALOG
2606, d2a27F_, 0.6193, 3.40, 0.298, 303, 248, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2607, d5os4A_, 0.6192, 3.25, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2608, d4ibmB_, 0.6192, 3.67, 0.216, 294, 255, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
2609, d3wzeA_, 0.6192, 3.62, 0.229, 298, 253, KDR IN COMPLEX WITH LIGAND SORAFENIB
2610, d3is5B1, 0.6192, 2.84, 0.311, 255, 241, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
2611, d2phkA_, 0.6192, 3.29, 0.272, 277, 246, THE CRYSTAL STRUCTURE OF A PHOSPHORYLASE KINASE PEPTIDE SUBSTRATE COMPLEX: KINASE SUBSTRATE RECOGNITION
2612, d5os6A_, 0.6191, 3.25, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2613, d5kbqA_, 0.6191, 3.38, 0.220, 289, 246, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
2614, d4qnaA_, 0.6191, 3.19, 0.221, 284, 244, MST3 IN COMPLEX WITH 2-(46-DIAMINO-135-TRIAZIN-2-YL)PHENOL
2615, d3up7A_, 0.6191, 3.28, 0.250, 264, 248, AURORA A IN COMPLEX WITH YL1-038-09
2616, d2zm3C2, 0.6191, 3.64, 0.181, 295, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2617, d5ia3A_, 0.6190, 2.78, 0.212, 275, 241, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH PD173955
2618, d4qmzA_, 0.6190, 3.09, 0.226, 286, 243, MST3 IN COMPLEX WITH SUNITINIB
2619, d4agcA_, 0.6190, 3.58, 0.230, 304, 252, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-( 3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL)- BENZAMIDE)
2620, d3gvuA1, 0.6190, 3.18, 0.233, 261, 245, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH GLEEVEC
2621, d2a27G_, 0.6190, 3.40, 0.298, 303, 248, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2622, d1i44A_, 0.6190, 3.43, 0.215, 282, 251, CRYSTALLOGRAPHIC STUDIES OF AN ACTIVATION LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
2623, d4rfzA_, 0.6189, 3.29, 0.169, 263, 248, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-8-FLUORO-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5- (MORPHOLINE-4-CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3- PYRIDYL]PHENYL]ISOQUINOLIN-1-ONE
2624, d4r7hA_, 0.6189, 3.69, 0.237, 308, 253, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX3397
2625, d4f1oA1, 0.6189, 3.31, 0.201, 274, 244, CRYSTAL STRUCTURE OF THE L1180T MUTANT ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO APPCP
2626, d5l8jA_, 0.6188, 3.15, 0.233, 253, 245, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 S93R
2627, d4wnpC_, 0.6188, 3.10, 0.276, 271, 243, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2628, d4u0iA_, 0.6188, 3.56, 0.250, 297, 252, CRYSTAL STRUCTURE OF KIT IN COMPLEX WITH PONATINIB
2629, d3nrmA_, 0.6188, 3.20, 0.239, 263, 247, IMIDAZO[12-A]PYRAZINE-BASED AURORA KINASE INHIBITORS
2630, d3fdnA_, 0.6188, 3.11, 0.243, 261, 247, STRUCTURE-BASED DRUG DESIGN OF NOVEL AURORA KINASE A INHIBITORS: STRUCTURE BASIS FOR POTENCY AND SPECIFICITY
2631, p2y8oA1, 0.6188, 1.37, 0.995, 224, 219, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A MAPK DOCKING PEPTIDE
2632, d5dg5B_, 0.6187, 3.45, 0.221, 297, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
2633, d4ibmA_, 0.6187, 3.88, 0.202, 301, 258, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
2634, d3eqrB_, 0.6187, 3.25, 0.211, 271, 246, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
2635, d2a27B_, 0.6187, 3.48, 0.301, 303, 249, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2636, d4cegA_, 0.6186, 3.25, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA A 122-403 C290A C393A BOUND TO ADP
2637, d3r21A_, 0.6186, 3.10, 0.241, 254, 245, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
2638, d3ha6A1, 0.6186, 3.26, 0.248, 262, 246, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH TPX2 AND COMPOUND 10
2639, d2e9vA_, 0.6186, 3.11, 0.254, 268, 244, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
2640, d3pixA_, 0.6185, 3.00, 0.184, 268, 244, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-ISOPROPYL-7- (4-METHYL-PIPERAZIN-1-YL)-4-(5-METHYL-2H-PYRAZOL-3-YLAMINO)-2H- PHTHALAZIN-1-ONE
2641, d3idpA_, 0.6185, 2.87, 0.233, 255, 240, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
2642, d3ekkA_, 0.6185, 3.29, 0.214, 285, 248, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
2643, d2ya9A_, 0.6185, 3.50, 0.297, 299, 249, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
2644, d2a27C_, 0.6185, 3.41, 0.298, 303, 248, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2645, d5fxqA1, 0.6184, 3.67, 0.176, 301, 255, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
2646, d5c9cA_, 0.6184, 2.90, 0.226, 254, 239, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
2647, d4j8nC_, 0.6184, 3.34, 0.253, 266, 249, AURORA A KINASE APO
2648, d3fzoA_, 0.6184, 2.96, 0.186, 262, 242, CRYSTAL STRUCTURE OF PYK2-APO PROLINE-RICH TYROSINE KINASE
2649, d3dpkA_, 0.6184, 3.38, 0.243, 279, 247, CFMS TYROSINE KINASE IN COMPLEX WITH A PYRIDOPYRIMIDINONE INHIBITOR
2650, d1t45A_, 0.6184, 3.64, 0.242, 331, 252, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C- KIT TYROSINE KINASE
2651, d5ko1A_, 0.6183, 3.41, 0.163, 265, 251, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 4.
2652, d4o0uA_, 0.6183, 3.15, 0.235, 259, 247, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
2653, d4i23A_, 0.6183, 3.59, 0.213, 304, 253, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH DACOMITINIB (SOAKED)
2654, d3idpB_, 0.6183, 2.81, 0.230, 256, 239, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
2655, d4ag8A_, 0.6182, 3.67, 0.229, 296, 253, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-(3-((E)-2-PYRIDIN-2-YL-VINYL)-1H- INDAZOL-6- YLSULFANYL)-BENZAMIDE)
2656, d2hiwA1, 0.6182, 3.27, 0.220, 270, 246, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
2657, d2a2aB_, 0.6182, 3.48, 0.293, 303, 249, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2658, d2a27E_, 0.6182, 3.42, 0.298, 303, 248, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2659, d1uwjA_, 0.6182, 3.00, 0.228, 264, 241, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
2660, d4zjiD_, 0.6181, 3.14, 0.215, 280, 247, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
2661, d1opjA1, 0.6181, 3.33, 0.220, 282, 246, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
2662, d5oq5A_, 0.6180, 3.17, 0.284, 265, 243, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
2663, d4j8nB_, 0.6180, 3.34, 0.253, 266, 249, AURORA A KINASE APO
2664, d4b6lA_, 0.6180, 3.17, 0.289, 281, 246, DISCOVERY OF ORAL POLO-LIKE KINASE (PLK) INHIBITORS WITH ENHANCED SELECTIVITY PROFILE USING RESIDUE TARGETED DRUG DESIGN
2665, d2a27A_, 0.6180, 3.43, 0.298, 304, 248, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2666, d5walA1, 0.6179, 3.52, 0.220, 285, 250, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
2667, d4xlvA_, 0.6179, 3.93, 0.206, 307, 257, CRYSTAL STRUCTURE OF THE ACTIVATED INSULIN RECEPTOR TYROSINE KINASE DIMER
2668, d4ot5A_, 0.6179, 3.31, 0.173, 263, 248, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4-TERT-BUTYL-N- (3-{8-[4-(4-METHYL-PIPERAZINE-1-CARBONYL)-PHENYLAMINO]-IMIDAZO[12- A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
2669, d4jboA_, 0.6179, 3.27, 0.245, 266, 249, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
2670, d4j8nA_, 0.6179, 3.35, 0.253, 266, 249, AURORA A KINASE APO
2671, d3lvpB_, 0.6179, 3.62, 0.173, 295, 255, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
2672, d3fzpA_, 0.6179, 2.79, 0.187, 259, 240, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH ATPGS
2673, d5dr9A_, 0.6178, 3.12, 0.241, 257, 245, AURORA A KINASE IN COMPLEX WITH AA29 AND JNJ-7706621 IN SPACE GROUP P6122
2674, d4rg0A_, 0.6178, 3.30, 0.169, 263, 248, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[8-FLUORO-2- [2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(4-METHYLPIPERAZIN-1-YL)-2- PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-1-OXO-34-DIHYDROISOQUINOLIN- 6-YL]-2-METHYL-PROPANENITRILE
2675, d4qmuA_, 0.6178, 3.12, 0.222, 286, 243, MST3 IN COMPLEX WITH JNJ-7706621 4-({5-AMINO-1-[(26-DIFLUOROPHENYL) CARBONYL]-1H-124-TRIAZOL-3-YL}AMINO)BENZENESULFONAMIDE
2676, d4mwiA_, 0.6178, 3.52, 0.166, 266, 253, CRYSTAL STRUCTURE OF THE HUMAN MLKL PSEUDOKINASE DOMAIN
2677, d3zclA_, 0.6178, 3.40, 0.213, 289, 249, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-3-(1-(1H-PYRROLO(23-B)PYRIDIN-3-YL)ETHYL)-N-ISOPROPYL-( 124)TRIAZOLO(43-B)PYRIDAZIN-6-AMINE
2678, d3qriA1, 0.6178, 3.39, 0.215, 270, 247, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
2679, d3kulA_, 0.6178, 3.05, 0.219, 267, 242, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
2680, d2x4zA1, 0.6178, 3.24, 0.243, 289, 243, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH PF-03758309
2681, d1m52B_, 0.6178, 3.33, 0.224, 272, 246, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
2682, d4j8nD_, 0.6177, 3.26, 0.250, 265, 248, AURORA A KINASE APO
2683, d3ue4B_, 0.6177, 3.32, 0.216, 268, 245, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
2684, d3dlsD_, 0.6177, 3.18, 0.234, 284, 244, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2685, p5x02A_, 0.6176, 3.38, 0.250, 305, 248, CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR FF- 10101
2686, d5vgoA1, 0.6176, 3.31, 0.169, 264, 248, BRUTON S TYROSINE KINASE (BTK) WITH COMPOUND G-744
2687, d5jzjB_, 0.6176, 3.04, 0.325, 261, 240, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
2688, d3dfaA1, 0.6176, 3.57, 0.277, 262, 253, CRYSTAL STRUCTURE OF KINASE DOMAIN OF CALCIUM-DEPENDENT PROTEIN KINASE CGD3_920 FROM CRYPTOSPORIDIUM PARVUM
2689, d5kupA1, 0.6175, 3.32, 0.169, 264, 248, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 9
2690, d5hu3A_, 0.6175, 3.42, 0.280, 266, 246, DROSOPHILA CAMKII-D136N IN COMPLEX WITH A PHOSPHORYLATED FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
2691, d4uzhA1, 0.6175, 2.99, 0.244, 250, 242, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
2692, d4r7iA_, 0.6175, 3.55, 0.239, 290, 251, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR GLEEVEC
2693, d4mxcA_, 0.6175, 3.42, 0.221, 290, 249, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
2694, d4jajA_, 0.6175, 3.34, 0.253, 265, 249, CRYSTAL STRUCTURE OF AURORA KINASE A IN COMPLEX WITH BENZO[C][1 8]NAPHTHYRIDIN-6(5H)-ONE
2695, d4f1mA1, 0.6175, 3.23, 0.201, 274, 244, CRYSTAL STRUCTURE OF THE G1179S ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM.
2696, d2wqmA_, 0.6175, 2.77, 0.225, 258, 240, STRUCTURE OF APO HUMAN NEK7
2697, d1ia8A_, 0.6175, 3.18, 0.272, 272, 243, THE 1.7 A CRYSTAL STRUCTURE OF HUMAN CELL CYCLE CHECKPOINT KINASE CHK1
2698, d4otqA_, 0.6174, 3.32, 0.173, 263, 248, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 1-[5-[3-(7-TERT- BUTYL-4-OXO-QUINAZOLIN-3-YL)-2-METHYL-PHENYL]-1-METHYL-2-OXO-3- PYRIDYL]-3-METHYL-UREA
2699, d4dedA_, 0.6174, 3.39, 0.253, 265, 249, AURORA A IN COMPLEX WITH YL1-038-21
2700, d3rhkB_, 0.6174, 3.84, 0.211, 299, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
2701, d2z2wA_, 0.6174, 3.01, 0.187, 260, 241, HUMAND WEE1 KINASE COMPLEXED WITH INHIBITOR PF0335770
2702, d2a2aA_, 0.6174, 3.50, 0.301, 304, 249, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2703, d5dg5A_, 0.6173, 3.49, 0.221, 297, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
2704, d3v5qB1, 0.6173, 3.21, 0.208, 262, 245, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
2705, d5orlA_, 0.6172, 3.27, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2706, d4b8lA_, 0.6172, 2.90, 0.195, 249, 241, AURORA B KINASE P353G MUTANT
2707, d2etmA_, 0.6172, 3.02, 0.216, 262, 245, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
2708, d5ukfA_, 0.6171, 3.58, 0.181, 322, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
2709, d5njzA_, 0.6171, 2.75, 0.204, 273, 240, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1G
2710, d5kmiA_, 0.6171, 3.24, 0.200, 300, 245, TRKA JM-KINASE WITH 1-(9{H}-FLUOREN-9-YL)-3-(2-METHYL-4-PHENYL- PYRIMIDIN-5-YL)UREA
2711, d3ms9B1, 0.6171, 3.17, 0.225, 267, 244, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
2712, d3fzrA_, 0.6171, 2.95, 0.186, 261, 242, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-431396
2713, d2wgjA_, 0.6171, 3.41, 0.213, 289, 249, X-RAY STRUCTURE OF PF-02341066 BOUND TO THE KINASE DOMAIN OF C-MET
2714, d2oh4A1, 0.6171, 3.30, 0.223, 296, 247, CRYSTAL STRUCTURE OF VEGFR2 WITH A BENZIMIDAZOLE-UREA INHIBITOR
2715, d1m52A_, 0.6171, 3.29, 0.220, 271, 245, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
2716, d4y95D_, 0.6170, 3.35, 0.173, 265, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
2717, d4rfyA_, 0.6170, 3.32, 0.173, 263, 248, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(MORPHOLINE-4- CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-34- DIHYDROISOQUINOLIN-1-ONE
2718, d2r2pA1, 0.6170, 3.17, 0.209, 276, 244, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 5 (EPHA5)
2719, d1x8bA_, 0.6170, 3.08, 0.182, 259, 242, STRUCTURE OF HUMAN WEE1A KINASE: KINASE DOMAIN COMPLEXED WITH INHIBITOR PD0407824
2720, d5objA_, 0.6169, 3.23, 0.244, 260, 246, AURORA A KINASE IN COMPLEX WITH 2-(3-FLUOROPHENYL)QUINOLINE-4- CARBOXYLIC ACID AND ATP
2721, d5o23B1, 0.6169, 3.30, 0.234, 276, 248, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE
2722, d4y95A1, 0.6169, 3.35, 0.173, 265, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
2723, d4otrA_, 0.6169, 3.32, 0.169, 263, 248, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-CYCLOPROPYL-2- [3-[5-[[5-(4-ETHYLPIPERAZIN-1-YL)-2-PYRIDYL]AMINO]-1-METHYL-6-OXO-3- PYRIDYL]-2-(HYDROXYMETHYL)PHENYL]-8-FLUORO-ISOQUINOLIN-1-ONE
2724, d3rhkA_, 0.6169, 3.68, 0.206, 298, 253, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
2725, d3cr0A_, 0.6169, 2.93, 0.187, 257, 240, WEE1 KINASE COMPLEX WITH INHIBITOR PD259_809
2726, d2f57B1, 0.6169, 3.23, 0.243, 293, 243, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
2727, d5ia4A_, 0.6168, 3.29, 0.206, 269, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH FORETINIB (XL880)
2728, d4pmsA1, 0.6168, 3.34, 0.208, 279, 245, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 4-NAPHTHALEN-1-YL- 1-[(5-PHENYL-124-OXADIAZOL-3-YL)METHYL]-1H-PYRROLO[32-C]PYRIDINE- 2-CARBOXYLIC ACID
2729, d4f65A_, 0.6167, 3.25, 0.244, 279, 246, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
2730, d2j50B_, 0.6167, 2.85, 0.254, 249, 240, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
2731, d2j50A_, 0.6167, 2.85, 0.254, 249, 240, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
2732, d2hznA2, 0.6167, 3.23, 0.224, 268, 245, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AFG210
2733, d5xgnA_, 0.6166, 3.43, 0.221, 302, 249, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
2734, d5ugbA_, 0.6166, 3.50, 0.215, 307, 251, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN IN COMPLEX WITH 4-(4-{[2- {[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9-(PROPAN-2-YL)-9H-PURIN-6- YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
2735, d4zy4A_, 0.6166, 3.11, 0.228, 288, 241, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
2736, d4ks7A_, 0.6166, 3.13, 0.244, 286, 242, PAK6 KINASE DOMAIN IN COMPLEX WITH PF-3758309
2737, d4c7tA_, 0.6166, 3.06, 0.225, 259, 244, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
2738, d3f69B_, 0.6166, 3.26, 0.226, 282, 248, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
2739, d2e9vB_, 0.6166, 3.14, 0.262, 268, 244, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
2740, d6bu6A_, 0.6165, 3.66, 0.184, 322, 255, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
2741, d5knjB_, 0.6165, 3.09, 0.163, 259, 245, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 1.
2742, d5eobA_, 0.6165, 3.41, 0.214, 288, 248, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
2743, d4qmtA_, 0.6165, 3.23, 0.221, 284, 244, MST3 IN COMPLEX WITH HESPERADIN
2744, d4m67A_, 0.6165, 3.41, 0.164, 264, 250, CRYSTAL STRUCTURE OF THE HUMAN MLKL KINASE-LIKE DOMAIN
2745, d2dylA_, 0.6165, 2.78, 0.230, 272, 239, CRYSTAL STRUCTURE OF HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 7 ACTIVATED MUTANT (S287D T291D)
2746, d3qrkA1, 0.6164, 3.18, 0.217, 268, 244, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DP- 987
2747, d2rl5A1, 0.6164, 3.02, 0.226, 290, 243, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A 23-DIHYDRO-14-BENZOXAZINE INHIBITOR
2748, d2hziA_, 0.6164, 3.34, 0.220, 268, 245, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
2749, d1rqqA_, 0.6164, 3.85, 0.211, 294, 256, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
2750, d1fpuB1, 0.6164, 3.26, 0.220, 266, 245, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
2751, d5j87A_, 0.6163, 3.31, 0.173, 263, 248, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
2752, d4y95C1, 0.6163, 3.38, 0.177, 265, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
2753, d4y95B1, 0.6163, 3.38, 0.177, 265, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
2754, d4bbeD_, 0.6163, 3.44, 0.217, 288, 249, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2755, d4bbeA_, 0.6163, 3.45, 0.217, 288, 249, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2756, d1p14A_, 0.6163, 3.44, 0.217, 287, 249, CRYSTAL STRUCTURE OF A CATALYTIC-LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
2757, d4bbfC_, 0.6162, 3.43, 0.217, 288, 249, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2758, d3ocsA1, 0.6162, 3.31, 0.169, 262, 248, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI1746
2759, d5fxrA1, 0.6161, 3.81, 0.176, 299, 256, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
2760, d5dr6A_, 0.6161, 3.08, 0.246, 257, 244, AURORA A KINASE IN COMPLEX WITH AA30 AND JNJ-7706621 IN SPACE GROUP P6122
2761, d4rvtA_, 0.6161, 3.00, 0.241, 281, 241, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
2762, d4hw7A_, 0.6161, 3.54, 0.240, 289, 250, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX647-OME
2763, d4bbeB_, 0.6161, 3.46, 0.221, 288, 249, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2764, d3lcdA_, 0.6161, 3.25, 0.241, 290, 245, INHIBITOR BOUND TO A DFG-IN STRUCTURE OF THE KINASE DOMAIN OF CSF-1R
2765, d2fo0A3, 0.6161, 3.37, 0.216, 291, 245, ORGANIZATION OF THE SH3-SH2 UNIT IN ACTIVE AND INACTIVE FORMS OF THE C-ABL TYROSINE KINASE
2766, d1ir3A_, 0.6161, 3.84, 0.207, 300, 256, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH PEPTIDE SUBSTRATE AND ATP ANALOG
2767, d5ar2B_, 0.6160, 3.29, 0.207, 285, 246, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
2768, d5ajqA_, 0.6160, 3.41, 0.217, 280, 249, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
2769, d4u8zA_, 0.6160, 3.45, 0.222, 289, 248, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06447475)
2770, d4bbeC_, 0.6160, 3.48, 0.221, 288, 249, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2771, d3tudA1, 0.6160, 2.94, 0.191, 255, 241, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH N-(4-METHYL-3-(8-METHYL-7- OXO-2-(PHENYLAMINO)-78-DIHYDROPYRIDO[23-D]PYRIMIDIN-6-YL)PHENYL)-3- (TRIFLUOROMETHYL)BENZAMIDE
2772, d2hz4A_, 0.6160, 3.24, 0.234, 262, 244, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
2773, d6bruA_, 0.6159, 3.66, 0.180, 322, 255, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
2774, d5ia5A_, 0.6159, 3.30, 0.206, 273, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH GOLVATINIB (E7050)
2775, d5e8xA_, 0.6159, 3.54, 0.219, 304, 247, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F) IN COMPLEX WITH STAUROSPORINE
2776, d4zogB_, 0.6159, 3.21, 0.225, 268, 244, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
2777, d4li5A1, 0.6159, 3.86, 0.214, 303, 257, EGFR-K IN COMPLEX WITH N-[3-[[5-CHLORO-4-(1H-INDOL-3-YL)PYRIMIDIN-2- YL]AMINO]-4-METHOXY-PHENYL] PROP-2-ENAMIDE
2778, d4lg4E_, 0.6159, 3.08, 0.242, 275, 244, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2779, d4bbfB_, 0.6159, 3.45, 0.217, 288, 249, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2780, d1ol7A_, 0.6159, 3.33, 0.239, 261, 247, STRUCTURE OF HUMAN AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288
2781, d5kmmA1, 0.6158, 3.25, 0.200, 300, 245, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(1- NAPHTHYL)UREA
2782, d5kmkA1, 0.6158, 3.22, 0.201, 302, 244, TRKA JM-KINASE WITH 2-FLUORO-{N}-[2-(4-FLUOROPHENYL)-6-METHYL-3- PYRIDYL]-4-(TRIFLUOROMETHYL)BENZAMIDE
2783, d2g2hB_, 0.6158, 3.43, 0.223, 272, 247, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
2784, d1gagA_, 0.6158, 3.86, 0.207, 300, 256, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH A BISUBSTRATE INHIBITOR
2785, d5uoxA_, 0.6157, 3.09, 0.299, 263, 241, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2786, d5u9dA_, 0.6157, 3.43, 0.181, 271, 249, DISCOVERY OF A POTENT BTK INHIBITOR WITH A NOVEL BINDING MODE USING PARALLEL SELECTIONS WITH A DNA-ENCODED CHEMICAL LIBRARY
2787, d5htiA_, 0.6157, 3.44, 0.217, 290, 249, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH LXM108
2788, d4rx5A1, 0.6157, 3.35, 0.169, 264, 248, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 23
2789, d4bn1A_, 0.6157, 3.36, 0.243, 261, 247, CRYSTAL STRUCTURE OF V174M MUTANT OF AURORA-A KINASE
2790, d4ap7A_, 0.6157, 3.43, 0.209, 289, 249, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( (6-(4- FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN-3-YL)METHYL) PHENOL
2791, d2x7fA_, 0.6157, 2.76, 0.227, 276, 238, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
2792, d2g2hA_, 0.6157, 3.53, 0.222, 272, 248, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
2793, d1oplB2, 0.6157, 3.34, 0.216, 267, 245, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
2794, d6babA_, 0.6156, 3.54, 0.304, 290, 247, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2795, d5nkaA_, 0.6156, 2.83, 0.196, 271, 240, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2G
2796, d3zxzA_, 0.6156, 3.44, 0.213, 289, 249, X-RAY STRUCTURE OF PF-04217903 BOUND TO THE KINASE DOMAIN OF C-MET
2797, d3m11A_, 0.6156, 3.07, 0.246, 256, 244, CRYSTAL STRUCTURE OF AURORA A KINASE COMPLEXED WITH INHIBITOR
2798, d2j0lA_, 0.6156, 3.12, 0.213, 274, 244, CRYSTAL STRUCTURE OF A THE ACTIVE CONFORMATION OF THE KINASE DOMAIN OF FOCAL ADHESION KINASE WITH A PHOSPHORYLATED ACTIVATION LOOP.
2799, d5os2A_, 0.6155, 3.16, 0.241, 261, 245, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2800, d4i6hA_, 0.6155, 3.34, 0.255, 285, 247, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE ALPHA-SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2801, d2gdoA_, 0.6155, 3.11, 0.269, 269, 242, 4-(AMINOALKYLAMINO)-3-BENZIMIDAZOLE-QUINOLINONES AS POTENT CHK1 INHIBITORS
2802, d2e9pA_, 0.6155, 3.30, 0.252, 269, 246, STRUCTURE OF H-CHK1 COMPLEXED WITH A771129
2803, d4i5pA_, 0.6154, 3.43, 0.254, 284, 248, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2804, d2xruA_, 0.6154, 3.12, 0.246, 253, 244, AURORA-A T288E COMPLEXED WITH PHA-828300
2805, d2brbA_, 0.6154, 3.24, 0.272, 272, 243, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2806, d1yvjA_, 0.6154, 3.60, 0.215, 288, 251, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN IN COMPLEX WITH A STAUROSPORINE ANALOGUE
2807, d6bkuA1, 0.6153, 3.07, 0.256, 264, 242, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO GSK650394
2808, d5v24B_, 0.6153, 3.08, 0.295, 263, 241, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
2809, d5ng2B_, 0.6153, 3.40, 0.202, 278, 247, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
2810, d5kbrB_, 0.6153, 2.70, 0.218, 260, 234, PAK1 IN COMPLEX WITH 7-AZAINDOLE INHIBITOR
2811, d5ikwA_, 0.6153, 3.58, 0.218, 297, 252, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2812, d4pmmA1, 0.6153, 3.27, 0.201, 281, 244, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N-(3-CYCLOPROPYL- 1-PHENYL-1H-PYRAZOL-5-YL)-2-{4-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1- YL)PHENYL]-1H-123-TRIAZOL-1-YL}ACETAMIDE
2813, d4byiA_, 0.6153, 3.13, 0.246, 254, 244, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
2814, d5lwmA_, 0.6152, 3.47, 0.201, 290, 249, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 4 (FM381)
2815, d5ia0C_, 0.6152, 2.64, 0.203, 269, 237, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
2816, d5dpvA_, 0.6152, 3.12, 0.238, 257, 244, AURORA A KINASE IN COMPLEX WITH AA35 AND JNJ-7706621 IN SPACE GROUP P6122
2817, d3et7A_, 0.6152, 3.01, 0.182, 261, 242, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-2318841
2818, d6b16A_, 0.6151, 3.02, 0.230, 285, 239, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
2819, d5vedA_, 0.6151, 3.34, 0.246, 289, 244, PAK4 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2820, d5l3aA_, 0.6151, 3.57, 0.220, 290, 250, FRAGMENT-BASED DISCOVERY OF 6-ARYLINDAZOLE JAK INHIBITORS
2821, d4zjiC_, 0.6151, 3.33, 0.222, 281, 248, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
2822, d4w8dA_, 0.6151, 3.48, 0.222, 289, 248, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06454589).
2823, d4uxlA_, 0.6151, 3.25, 0.245, 288, 245, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH PF-06463922
2824, d4qmmA_, 0.6151, 3.47, 0.222, 288, 248, MST3 IN COMPLEX WITH AT-9283 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]- 1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
2825, d4e4mE_, 0.6151, 3.51, 0.228, 296, 250, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
2826, d4aoiA_, 0.6151, 3.46, 0.209, 289, 249, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( 3-((1H- PYRROLO(23-B)PYRIDIN-3-YL)METHYL)-(124)TRIAZOLO( 43-B)(124) TRIAZIN-6-YL)BENZONITRILE
2827, d3krlA_, 0.6151, 3.37, 0.240, 281, 246, CFMS TYROSINE KINASE IN COMPLEX WITH 5-CYANO-FURAN-2-CARBOXYLIC ACID [4-(4-METHYL-PIPERAZIN-1-YL)-2-PIPERIDIN-1-YL-PHENYL]-AMIDE
2828, d2clqA_, 0.6151, 3.04, 0.293, 263, 239, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
2829, d5obrA_, 0.6150, 3.07, 0.243, 255, 243, AURORA A KINASE IN COMPLEX WITH 2-(3-CHLORO-5-FLUOROPHENYL)QUINOLINE- 4-CARBOXYLIC ACID AND JNJ-7706621
2830, d4yc8B_, 0.6150, 3.30, 0.214, 264, 243, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
2831, d4pmpA1, 0.6150, 3.29, 0.205, 276, 244, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 1-CYCLOPROPYL-1- [3-(13-THIAZOL-2-YL)BENZYL]-3-[4-(TRIFLUOROMETHOXY)PHENYL]UREA
2832, d4otfA1, 0.6150, 3.33, 0.169, 261, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH GDC0834
2833, d3zbxA_, 0.6150, 3.44, 0.217, 282, 249, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR 6- ((6-(4-FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN- 3-YL)METHYL)QUINOLINE.
2834, d3op5A_, 0.6150, 3.80, 0.176, 320, 256, HUMAN VACCINIA-RELATED KINASE 1
2835, d3og7B_, 0.6150, 3.07, 0.242, 254, 240, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
2836, d3k5vB1, 0.6150, 3.33, 0.221, 279, 244, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
2837, d3cohB_, 0.6150, 2.89, 0.246, 247, 240, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
2838, d3h0zA_, 0.6149, 2.86, 0.254, 248, 240, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
2839, d2fumC_, 0.6149, 2.77, 0.237, 254, 240, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
2840, d5lwnA_, 0.6148, 3.48, 0.209, 290, 249, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 5 (FM409)
2841, d5i9vA_, 0.6148, 3.07, 0.193, 279, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH AGS
2842, d5dr2A1, 0.6148, 3.32, 0.243, 263, 247, AURORA A KINASE IN COMPLEX WITH AA30 AND ATP IN SPACE GROUP P6122
2843, d4twpB_, 0.6148, 3.36, 0.212, 271, 245, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
2844, d4mneC_, 0.6148, 3.40, 0.216, 260, 245, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
2845, d4i6fA_, 0.6148, 3.45, 0.254, 285, 248, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2846, d4hyiA_, 0.6148, 3.07, 0.266, 269, 241, X-RAY CRYSTAL STRUCTURE OF COMPOUND 40 BOUND TO HUMAN CHK1 KINASE DOMAIN
2847, d4e4mA_, 0.6148, 3.52, 0.228, 296, 250, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
2848, d3lctA_, 0.6148, 3.23, 0.178, 308, 247, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
2849, d3dlsC_, 0.6148, 3.09, 0.236, 281, 242, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2850, d3comB_, 0.6148, 3.29, 0.248, 279, 246, CRYSTAL STRUCTURE OF MST1 KINASE
2851, d5ia1A_, 0.6147, 2.81, 0.201, 261, 239, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH MLN8054
2852, d4e6qA_, 0.6147, 3.45, 0.225, 296, 249, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
2853, d5i3oB_, 0.6146, 3.71, 0.209, 302, 253, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2854, d4ytcA_, 0.6146, 3.35, 0.230, 284, 248, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
2855, d4uy9B_, 0.6146, 3.28, 0.271, 315, 247, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
2856, d4rioA_, 0.6146, 3.31, 0.211, 285, 246, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE CARBOXAMIDE INHIBITOR
2857, d4gt5A_, 0.6146, 3.23, 0.191, 290, 246, CRYSTAL STRUCTURE OF THE INACTIVE TRKA KINASE DOMAIN
2858, d3q32B1, 0.6146, 3.52, 0.228, 293, 250, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
2859, d3cs9A_, 0.6146, 3.24, 0.214, 264, 243, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
2860, d2p2hA1, 0.6146, 2.99, 0.231, 289, 242, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDINYL-TRIAZINE INHIBITOR
2861, d5l6pA_, 0.6145, 3.04, 0.211, 274, 242, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 6)
2862, d5i9uA_, 0.6145, 2.94, 0.207, 281, 241, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
2863, d5cf4B_, 0.6145, 3.48, 0.232, 291, 250, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
2864, d4zimB1, 0.6145, 3.55, 0.227, 292, 251, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
2865, d4ivaA_, 0.6145, 3.51, 0.224, 290, 250, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-[(8AS)- 2-[(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(8AH)- YL]CYCLOHEXANECARBONITRILE
2866, d4i6bA_, 0.6145, 3.36, 0.255, 285, 247, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2867, d3gqlC_, 0.6145, 2.75, 0.265, 275, 238, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
2868, d5wr7A_, 0.6144, 3.36, 0.194, 301, 247, CRYSTAL STRUCTURE OF TRK-A COMPLEXED WITH A SELECTIVE INHIBITOR CH7057288
2869, d5cf5B1, 0.6144, 3.55, 0.231, 292, 251, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
2870, d4nwmA_, 0.6144, 3.38, 0.169, 261, 248, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
2871, d3op5B_, 0.6144, 3.83, 0.172, 319, 256, HUMAN VACCINIA-RELATED KINASE 1
2872, d3cohA_, 0.6144, 2.90, 0.246, 247, 240, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
2873, d2clqB_, 0.6144, 2.85, 0.304, 259, 237, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
2874, d6btwA_, 0.6143, 3.68, 0.181, 317, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
2875, d5j87C_, 0.6143, 3.36, 0.173, 261, 248, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
2876, d5dosA_, 0.6143, 3.26, 0.241, 259, 245, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
2877, d3zc5A_, 0.6143, 3.47, 0.213, 289, 249, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-6-(1-(6-(1-METHYL-1H-PYRAZOL-4-YL)-(124)TRIAZOLO(43- B)PYRIDAZIN-3-YL)ETHYL)QUINOLINE.
2878, d3d4qA_, 0.6143, 3.09, 0.223, 264, 242, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
2879, d3an0A_, 0.6143, 3.83, 0.202, 291, 257,  
2880, d5dt4A_, 0.6142, 3.25, 0.241, 259, 245, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
2881, d4zs0A_, 0.6142, 3.23, 0.246, 257, 244, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO SB-6-OH
2882, d4kspB_, 0.6142, 2.87, 0.218, 256, 238, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
2883, d4e4mD_, 0.6142, 3.51, 0.228, 296, 250, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
2884, d3mj2A_, 0.6142, 3.20, 0.163, 259, 245, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH INHIBITOR BMS-509744
2885, d2yexA_, 0.6142, 3.23, 0.266, 269, 244, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
2886, d2q0nA_, 0.6142, 3.38, 0.245, 293, 245, STRUCTURE OF HUMAN P21 ACTIVATING KINASE 4 (PAK4) IN COMPLEX WITH A CONSENSUS PEPTIDE
2887, d2jkmA_, 0.6142, 2.95, 0.228, 260, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
2888, d5uvfA_, 0.6141, 3.70, 0.181, 317, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
2889, d5mjbB_, 0.6141, 3.23, 0.201, 278, 244, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
2890, d4xeyA_, 0.6141, 3.17, 0.222, 269, 243, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
2891, d4lmnA1, 0.6141, 3.33, 0.221, 291, 249, CRYSTAL STRUCTURE OF MEK1 KINASE BOUND TO GDC0973
2892, d4ewhB_, 0.6141, 3.40, 0.206, 273, 248, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
2893, d4e4mB_, 0.6141, 3.51, 0.228, 296, 250, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
2894, d3tt0B_, 0.6141, 2.79, 0.265, 272, 238, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
2895, d3q32A_, 0.6141, 3.53, 0.227, 291, 251, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
2896, d1zltA_, 0.6141, 3.16, 0.263, 272, 243, CRYSTAL STRUCTURE OF CHK1 COMPLEXED WITH A HYMENALDISINE ANALOG
2897, d5p9gA_, 0.6140, 3.40, 0.173, 265, 248, STRUCTURE OF BTK WITH RN486
2898, d5p9fA_, 0.6140, 3.41, 0.173, 266, 248, BTK IN COMPLEX WITH GDC-0834
2899, d5drdA_, 0.6140, 3.22, 0.245, 259, 245, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
2900, d4dhfB_, 0.6140, 3.09, 0.243, 258, 243, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
2901, d3vn9A_, 0.6140, 3.84, 0.202, 291, 257, RIFINED CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED MAP2K6 IN A PUTATIVE AUTO-INHIBITION STATE
2902, d3lvpC_, 0.6140, 3.59, 0.183, 293, 252, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
2903, d2w9fB_, 0.6140, 3.21, 0.364, 261, 242, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
2904, d2c6eB_, 0.6140, 2.73, 0.248, 246, 238, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
2905, d4tyeA_, 0.6139, 2.88, 0.250, 292, 240, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
2906, d4r1vA_, 0.6139, 3.43, 0.218, 289, 248, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITORS
2907, d4nwmB_, 0.6139, 3.39, 0.173, 261, 248, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
2908, d6bqqA1, 0.6138, 3.14, 0.255, 269, 243, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH BI2526
2909, d4o0vA1, 0.6138, 3.27, 0.247, 289, 243, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2910, d4mneG_, 0.6138, 3.51, 0.215, 259, 246, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
2911, d3zzwA_, 0.6138, 3.26, 0.179, 269, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF ROR2
2912, d3w2oA1, 0.6138, 3.58, 0.200, 304, 250, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH TAK-285
2913, d2hxqA_, 0.6138, 3.08, 0.266, 272, 241, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2
2914, d5i9wA_, 0.6137, 2.78, 0.202, 267, 238, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ANP
2915, d5hibA_, 0.6137, 3.50, 0.201, 314, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH A PYRAZOLOPYRIMIDINE INHIBITOR
2916, d4ytiA_, 0.6137, 3.28, 0.224, 284, 246, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
2917, d4dbnA_, 0.6137, 2.83, 0.214, 257, 238, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
2918, d4brxA_, 0.6137, 2.99, 0.231, 259, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
2919, d3ce3A_, 0.6137, 3.30, 0.206, 293, 247, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOPYRIDINEPYRIDONE BASED INHIBITOR
2920, d3a7fA_, 0.6137, 3.49, 0.222, 283, 248, HUMAN MST3 KINASE
2921, d2hxlA_, 0.6137, 3.18, 0.264, 272, 242, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1
2922, d1ol5A_, 0.6137, 3.27, 0.249, 263, 245, STRUCTURE OF AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288 AND BOUND TO TPX2 1-43
2923, d5mjbA_, 0.6136, 3.23, 0.200, 276, 245, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
2924, d4ot6A_, 0.6136, 3.42, 0.173, 265, 248, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4- METHANESULFONYL-N-(3-{8-[4-(MORPHOLINE-4-CARBONYL)-PHENYLAMINO]- IMIDAZO[12-A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
2925, d5ng3A_, 0.6135, 3.59, 0.190, 283, 252, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
2926, d5bmsA1, 0.6135, 3.29, 0.247, 289, 243, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 4 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
2927, d4z16B_, 0.6135, 3.34, 0.212, 276, 245, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
2928, d3w2qA1, 0.6135, 3.39, 0.194, 306, 247, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH HKI-272
2929, d3ppkB_, 0.6135, 3.21, 0.222, 264, 243, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
2930, d3jy9A_, 0.6135, 3.28, 0.224, 282, 246, JANUS KINASE 2 INHIBITORS
2931, d3dlsE_, 0.6135, 3.21, 0.235, 282, 243, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2932, d2vwxA_, 0.6135, 3.38, 0.198, 274, 248, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
2933, d5h3qA_, 0.6134, 3.26, 0.193, 302, 243, CRYSTAL STRUCTURE OF TRKA KINASE WITH LIGAND
2934, d4xliB_, 0.6134, 3.36, 0.253, 264, 245, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
2935, d4u43A_, 0.6134, 3.11, 0.230, 287, 243, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
2936, d4qmoA_, 0.6134, 3.47, 0.215, 288, 247, MST3 IN COMPLEX WITH IMIDAZOLO-OXINDOLE PKR INHIBITOR C16
2937, d3qc4B1, 0.6134, 3.11, 0.264, 268, 242, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
2938, d2v7aB_, 0.6134, 3.42, 0.228, 268, 246, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
2939, d5ct7A_, 0.6133, 2.92, 0.218, 257, 239, BRAF IN COMPLEX WITH RAF265
2940, d4ewhA_, 0.6133, 3.34, 0.206, 274, 247, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
2941, d2yerA_, 0.6133, 3.25, 0.266, 268, 244, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
2942, d2vwyA_, 0.6133, 3.38, 0.202, 274, 248, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
2943, d2etmB_, 0.6133, 2.83, 0.229, 263, 240, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
2944, d2br1A_, 0.6133, 3.11, 0.261, 272, 241, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2945, d1opkA3, 0.6133, 3.47, 0.216, 291, 245, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
2946, d6brcA1, 0.6132, 3.18, 0.259, 263, 243, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
2947, d4zy6A_, 0.6132, 3.02, 0.235, 284, 238, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
2948, d4ztrA_, 0.6132, 2.93, 0.245, 249, 241, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1141
2949, d4jdiA_, 0.6132, 3.39, 0.246, 289, 244, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
2950, d2w1gA1, 0.6132, 3.16, 0.239, 254, 243, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
2951, d2vx1A_, 0.6132, 3.38, 0.198, 274, 248, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
2952, d2vx0A_, 0.6132, 3.29, 0.198, 273, 247, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
2953, d2vwzA_, 0.6132, 3.38, 0.202, 274, 248, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
2954, d2j0mB_, 0.6132, 2.84, 0.222, 257, 239, CRYSTAL STRUCTURE A TWO-CHAIN COMPLEX BETWEEN THE FERM AND KINASE DOMAINS OF FOCAL ADHESION KINASE.
2955, d1oplA3, 0.6132, 3.49, 0.229, 291, 245, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
2956, d5ng0B_, 0.6131, 3.41, 0.211, 282, 246, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
2957, d5i3rB_, 0.6131, 3.73, 0.209, 302, 253, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2958, d4eevA_, 0.6131, 3.25, 0.212, 283, 245, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH LY2801653
2959, d4e6qB_, 0.6131, 3.46, 0.221, 296, 249, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
2960, d3w2pA1, 0.6131, 3.48, 0.197, 307, 249, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 2
2961, d5m53A1, 0.6130, 2.45, 0.249, 248, 233, NEK2 BOUND TO ARYLAMINOPURINE INHIBITOR 11
2962, d4qmlA_, 0.6130, 3.19, 0.222, 280, 243, MST3 IN COMPLEX WITH AMP-PNP
2963, d3v5qA1, 0.6130, 3.20, 0.198, 260, 243, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
2964, d3gqlB_, 0.6130, 2.92, 0.264, 276, 239, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
2965, d3dlsF_, 0.6130, 3.12, 0.236, 281, 242, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2966, d5ur1B_, 0.6129, 2.93, 0.272, 265, 239, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
2967, d4o0xA1, 0.6129, 3.37, 0.242, 289, 244, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2968, d4bicB_, 0.6129, 2.91, 0.295, 259, 237, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2969, d2jiuA_, 0.6129, 3.45, 0.210, 303, 248, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
2970, d1mq4A_, 0.6129, 3.39, 0.243, 261, 247, CRYSTAL STRUCTURE OF AURORA-A PROTEIN KINASE
2971, d5p9kA_, 0.6128, 3.47, 0.173, 271, 249, CRYSTAL STRUCTURE OF BTK WITH CNX 774
2972, d5p9iA_, 0.6128, 3.50, 0.172, 271, 250, BTK1 SOAKED WITH IBRUTINIB-REV
2973, d4dhfA_, 0.6128, 3.01, 0.244, 258, 242, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
2974, d3d4qB_, 0.6128, 3.11, 0.223, 264, 242, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
2975, d2e2bA1, 0.6128, 3.09, 0.224, 266, 241, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
2976, d5dh3B_, 0.6127, 3.24, 0.238, 283, 244, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
2977, d4ztsA_, 0.6127, 2.99, 0.249, 249, 241, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1142
2978, d4qmvA_, 0.6127, 3.51, 0.218, 288, 248, MST3 IN COMPLEX WITH PF-03814735 N-{2-[(1S4R)-6-{[4- (CYCLOBUTYLAMINO)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL]AMINO}-1234- TETRAHYDRO-14-EPIMINONAPHTHALEN-9-YL]-2-OXOETHYL}ACETAMIDE
2979, d2gqgB1, 0.6127, 3.37, 0.221, 270, 244, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
2980, d5xdkA_, 0.6126, 3.57, 0.205, 307, 249, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH CO-1686
2981, d5j87D_, 0.6126, 3.39, 0.181, 263, 248, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
2982, d4k8aB_, 0.6126, 3.08, 0.218, 258, 243, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
2983, d3iokA_, 0.6126, 3.43, 0.217, 285, 249, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
2984, d2x6dA_, 0.6126, 3.21, 0.251, 255, 243, AURORA-A BOUND TO AN INHIBITOR
2985, d4u5jB_, 0.6125, 3.29, 0.259, 267, 243, C-SRC IN COMPLEX WITH RUXOLITINIB
2986, d4qmqA_, 0.6125, 3.46, 0.219, 289, 247, MST3 IN COMPLEX WITH CP-673451
2987, d4bbfD_, 0.6125, 3.52, 0.217, 288, 249, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2988, d3ue4A_, 0.6125, 3.40, 0.232, 270, 246, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
2989, d2wd1A_, 0.6125, 3.35, 0.220, 289, 246, HUMAN C-MET KINASE IN COMPLEX WITH AZAINDOLE INHIBITOR
2990, d2w1eA1, 0.6125, 3.09, 0.244, 252, 242, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
2991, d2j6mA_, 0.6125, 3.54, 0.209, 306, 249, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AEE788
2992, d5j87B_, 0.6124, 3.32, 0.170, 274, 247, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
2993, d5iugA_, 0.6124, 3.14, 0.180, 285, 244, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5A
2994, d5ar4B_, 0.6124, 3.08, 0.216, 279, 241, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
2995, d4o2pA_, 0.6124, 2.99, 0.247, 265, 239, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
2996, d4gihA1, 0.6124, 3.62, 0.220, 287, 250, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}BENZAMIDE
2997, d3e63A_, 0.6124, 3.56, 0.228, 290, 250, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
2998, d5vc5A_, 0.6123, 3.14, 0.178, 261, 242, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PD- 166285
2999, d5mjaB_, 0.6123, 3.26, 0.201, 274, 244, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
3000, d5kmoA1, 0.6123, 3.39, 0.201, 290, 244, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(2- PYRIDYL)UREA
3001, d5bpyA1, 0.6123, 3.40, 0.165, 262, 248, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
3002, d4gu9B_, 0.6123, 3.01, 0.222, 255, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
3003, d3mblA_, 0.6122, 3.38, 0.213, 290, 249, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGADP
3004, d3l9pA_, 0.6122, 3.26, 0.182, 303, 247, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
3005, d6bp0A_, 0.6121, 3.72, 0.181, 317, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3006, d5uorB_, 0.6121, 3.01, 0.289, 262, 239, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3007, d4f0gA1, 0.6121, 2.91, 0.203, 260, 237, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM
3008, d4bbfA_, 0.6121, 3.54, 0.217, 288, 249, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3009, d3wzdA_, 0.6121, 3.13, 0.227, 278, 242, KDR IN COMPLEX WITH LIGAND LENVATINIB
3010, d3bi6A_, 0.6121, 3.00, 0.184, 258, 239, WEE1 KINASE COMPLEX WITH INHIBITOR PD352396
3011, d2xvdA_, 0.6121, 3.15, 0.201, 270, 244, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3012, d2w1fA1, 0.6121, 3.18, 0.243, 253, 243, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3013, d2oj9A_, 0.6121, 3.93, 0.174, 295, 258, STRUCTURE OF IGF-1R KINASE DOMAIN COMPLEXED WITH A BENZIMIDAZOLE INHIBITOR
3014, d2itwA_, 0.6121, 3.49, 0.206, 300, 248, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AFN941
3015, d2bvaB_, 0.6121, 2.93, 0.245, 274, 237, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
3016, d1wvyA_, 0.6121, 3.37, 0.306, 273, 245, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
3017, d4uy9A_, 0.6120, 3.36, 0.271, 313, 247, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
3018, d4prjA_, 0.6120, 3.26, 0.253, 251, 245, AURORA A KINASE DOMAIN WITH COMPOUND 2 (N-[1-(3-CYANOBENZYL)-1H- PYRAZOL-4-YL]-6-(1H-PYRAZOL-4-YL)-1H-INDAZOLE-3-CARBOXAMIDE)
3019, d4mneB_, 0.6120, 3.46, 0.224, 270, 246, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3020, d4cnhB_, 0.6120, 3.27, 0.183, 293, 246, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
3021, d3hmiA_, 0.6120, 3.41, 0.237, 268, 245, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
3022, d2x9fA_, 0.6120, 3.16, 0.209, 265, 244, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3023, d2cguA_, 0.6120, 2.95, 0.255, 263, 239, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
3024, d5gmpA_, 0.6119, 3.38, 0.211, 305, 246, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH XTF-262
3025, d4wunB_, 0.6119, 2.82, 0.261, 268, 238, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
3026, d4d0xA_, 0.6119, 3.58, 0.227, 291, 251, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
3027, d3c4cB1, 0.6119, 2.92, 0.214, 256, 238, B-RAF KINASE IN COMPLEX WITH PLX4720
3028, d2eb2A_, 0.6119, 3.47, 0.206, 305, 248, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (G719S)
3029, d6b8uA_, 0.6118, 2.90, 0.223, 253, 238, CRYSTALS STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINYL BENZAMIDE INHIBITOR
3030, d5dt0A_, 0.6118, 3.18, 0.242, 259, 244, AURORA A KINASE IN COMPLEX WITH JNJ-7706621 IN SPACE GROUP P6122
3031, d4f09A_, 0.6118, 3.38, 0.219, 288, 247, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
3032, d3pp1A1, 0.6118, 3.32, 0.210, 290, 248, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGATP
3033, d2wotA_, 0.6118, 3.60, 0.211, 303, 247, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
3034, d2broA_, 0.6118, 3.20, 0.256, 272, 242, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3035, d2brnA_, 0.6118, 3.05, 0.268, 268, 239, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3036, d4zogA_, 0.6117, 3.36, 0.225, 269, 244, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
3037, d4f0iA_, 0.6117, 3.23, 0.202, 284, 243, CRYSTAL STRUCTURE OF APO TRKA
3038, d4cd0A_, 0.6117, 3.23, 0.184, 295, 245, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPANE-12-DIOL
3039, d4arkA1, 0.6117, 3.43, 0.220, 290, 250, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN MAP KINASE KINASE 1 (MEK1) IN COMPLEX WITH  A SMALL MOLECULE INHIBITOR AND ADP
3040, d3zhpC1, 0.6117, 3.27, 0.211, 267, 246, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
3041, d3t9tA_, 0.6117, 3.47, 0.169, 263, 249, CRYSTAL STRUCTURE OF BTK MUTANT (F435TK596R) COMPLEXED WITH IMIDAZO[15-A]QUINOXALINE
3042, d3fztA_, 0.6117, 2.97, 0.175, 259, 240, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-4618433
3043, d2cgvA_, 0.6117, 2.93, 0.261, 264, 238, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
3044, d5p9hA_, 0.6116, 3.39, 0.173, 264, 248, BTK1 COCRYSTALLIZED WITH RN983
3045, d4yhfA_, 0.6116, 3.35, 0.186, 268, 247, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
3046, d4gj3A1, 0.6116, 3.63, 0.220, 287, 250, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
3047, d4gj2A1, 0.6116, 3.63, 0.220, 287, 250, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
3048, d4fc0A_, 0.6116, 2.89, 0.228, 254, 237, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
3049, d2yjrA_, 0.6116, 3.00, 0.183, 278, 240, STRUCTURE OF F1174L MUTANT ANAPLASTIC LYMPHOMA KINASE
3050, d2dwbA_, 0.6116, 3.29, 0.245, 259, 245, AURORA-A KINASE COMPLEXED WITH AMPPNP
3051, d4o0yA1, 0.6115, 3.39, 0.250, 289, 244, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3052, d3f66A_, 0.6115, 3.61, 0.205, 288, 249, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
3053, d1r0pA_, 0.6115, 3.02, 0.194, 301, 242, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH THE MICROBIAL ALKALOID K-252A
3054, d5tq5A_, 0.6114, 3.58, 0.228, 291, 250, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3055, d5l4qB_, 0.6114, 3.67, 0.209, 287, 249, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
3056, d4qmpA_, 0.6114, 3.49, 0.219, 289, 247, MST3 IN COMPLEX WITH CDK1/2 INHIBITOR III 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
3057, d3lcsA_, 0.6114, 3.27, 0.182, 304, 247, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
3058, d5t18A1, 0.6113, 3.33, 0.175, 259, 246, CRYSTAL STRUCTURE OF BRUTON AGAMMABULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-986142 AKA (2S)-6-FLUORO-5-[3-(8-FLUORO-1-METHYL-24-DIOXO- 1234-TETRAHYDROQUINAZOLIN-3-YL)-2-METHYLPHENYL]-2-(2- HYDROXYPROPAN-2-YL)-2349-TETRAHYDRO-1H-CARBAZOLE-8-CARBOXAMIDE
3059, d4zlyA_, 0.6113, 3.61, 0.167, 270, 251, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE BOUND TO A CINNOLINE FRAGMENT
3060, d4mkcA_, 0.6113, 3.25, 0.183, 303, 246, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE COMPLEXED WITH LDK378
3061, d4hvgA_, 0.6113, 3.44, 0.215, 281, 246, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-2-HYDROXY-12-DIMETHYL-PROPYL)- AMIDE
3062, d3plsA_, 0.6113, 3.45, 0.199, 298, 251, RON IN COMPLEX WITH LIGAND AMP-PNP
3063, d2c3kA_, 0.6113, 3.07, 0.262, 262, 240, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
3064, d5oopA_, 0.6112, 2.91, 0.283, 261, 237, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMP-PNP
3065, d4h58A_, 0.6112, 2.96, 0.222, 263, 239, BRAF IN COMPLEX WITH COMPOUND 3
3066, d3mssB1, 0.6112, 3.15, 0.217, 260, 240, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
3067, d3g6gA_, 0.6112, 3.03, 0.251, 264, 239, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
3068, d3cthA_, 0.6112, 3.21, 0.205, 295, 244, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
3069, d2itxA_, 0.6112, 3.57, 0.209, 307, 249, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AMP- PNP
3070, d2itqA_, 0.6112, 3.40, 0.206, 300, 247, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AFN941
3071, d2cgxA_, 0.6112, 3.04, 0.268, 265, 239, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
3072, d5j7bB_, 0.6111, 3.19, 0.211, 281, 242, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
3073, d5i3oA_, 0.6111, 3.60, 0.227, 302, 251, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3074, d5c9cB_, 0.6111, 2.83, 0.220, 251, 236, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
3075, d3mssC1, 0.6111, 3.12, 0.229, 260, 240, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
3076, d3mssA1, 0.6111, 3.12, 0.229, 260, 240, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
3077, d2hziB_, 0.6111, 3.27, 0.223, 264, 242, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
3078, d5gtzA_, 0.6110, 3.40, 0.211, 317, 247, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH JTS-1-39
3079, d5cavA_, 0.6110, 3.65, 0.208, 306, 250, EGFR KINASE DOMAIN WITH COMPOUND 41A
3080, d4z3vA_, 0.6110, 3.53, 0.172, 271, 250, FRAGMENT-BASED DISCOVERY OF A SMALL MOLECULE REVERSIBLE INHIBITOR OF BRUTON S TYROSINE KINASE
3081, d4u41A_, 0.6110, 3.19, 0.240, 275, 242, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
3082, d4mneF_, 0.6110, 3.05, 0.221, 258, 240, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3083, d4jdhA_, 0.6110, 3.36, 0.243, 289, 243, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
3084, d4bibB_, 0.6110, 2.70, 0.286, 258, 234, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3085, d3zewA_, 0.6110, 3.20, 0.215, 269, 242, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
3086, d3r22A_, 0.6110, 3.03, 0.248, 255, 242, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
3087, d3mssD1, 0.6110, 3.15, 0.212, 260, 240, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
3088, d3d2iA_, 0.6110, 3.24, 0.246, 255, 244, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH 1-{5-[2-(1-METHYL-1H- PYRAZOLO[43-D]PYRIMIDIN-7-YLAMINO)-ETHYL]-THIAZOL-2-YL}-3- (3-TRIFLUOROMETHYL-PHENYL)-UREA
3089, d5iuhA_, 0.6109, 3.12, 0.177, 285, 243, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5D
3090, d5drbA_, 0.6109, 3.46, 0.242, 273, 248, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH WNK463
3091, d3lxlA_, 0.6109, 3.59, 0.213, 281, 249, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
3092, d3dlsB_, 0.6109, 3.20, 0.241, 280, 241, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3093, d2xngA_, 0.6109, 3.12, 0.244, 253, 242, STRUCTURE OF AURORA-A BOUND TO A SELECTIVE IMIDAZOPYRAZINE INHIBITOR
3094, d2xkdA1, 0.6109, 2.50, 0.235, 243, 234, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 12
3095, d4yznA_, 0.6108, 3.39, 0.210, 269, 243, HUMANIZED ROCO4 BOUND TO COMPOUND 19
3096, d4gu6B_, 0.6108, 2.96, 0.228, 258, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
3097, d4giiA1, 0.6108, 3.66, 0.224, 287, 250, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
3098, d3eqhA_, 0.6108, 3.61, 0.215, 314, 251, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH U0126 ADP AND MG2P
3099, d3e8nA1, 0.6108, 3.40, 0.213, 290, 249, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) COMPLEXED WITH A POTENT INHIBITOR RDEA119 AND MGATP
3100, d2v7aA_, 0.6108, 3.31, 0.225, 269, 244, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
3101, d2f4jA_, 0.6108, 3.52, 0.227, 287, 247, STRUCTURE OF THE KINASE DOMAIN OF AN IMATINIB-RESISTANT ABL MUTANT IN COMPLEX WITH THE AURORA KINASE INHIBITOR VX-680
3102, d5uvfB_, 0.6107, 3.72, 0.178, 316, 253, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
3103, d5em8A_, 0.6107, 3.50, 0.206, 303, 247, EGFR KINASE DOMAIN WITH PYRIDONE COMPOUND 13: 4-[(2-METHOXYPHENYL) AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2-OXIDANYLIDENE-1~{H}- PYRIDINE-3-CARBOXAMIDE
3104, d4tt7A_, 0.6107, 3.36, 0.182, 291, 247, CRYSTAL STRUCTURE OF HUMAN ALK WITH A COVALENT MODIFICATION
3105, d2xnmA1, 0.6107, 2.80, 0.244, 250, 238, STRUCTURE OF NEK2 BOUND TO CCT
3106, d2fb8A_, 0.6107, 3.04, 0.229, 259, 240, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
3107, d5j9yA_, 0.6106, 3.62, 0.204, 300, 250, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1B
3108, d5aaeA_, 0.6106, 3.25, 0.246, 252, 244, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14D)
3109, d4yhfB_, 0.6106, 3.39, 0.178, 269, 247, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
3110, d4r5sA_, 0.6106, 3.26, 0.213, 299, 244, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH FIIN-3
3111, d4kspA_, 0.6106, 2.82, 0.219, 257, 237, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
3112, d4hyhA_, 0.6106, 3.14, 0.271, 263, 240, X-RAY CRYSTAL STRUCTURE OF COMPOUND 39 BOUND TO HUMAN CHK1 KINASE DOMAIN
3113, d4aqcB_, 0.6106, 3.60, 0.228, 295, 250, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
3114, d3c4dB1, 0.6106, 2.75, 0.220, 256, 236,  
3115, d2itpA_, 0.6106, 3.47, 0.206, 305, 248, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AEE788
3116, d5vdkA_, 0.6105, 3.23, 0.194, 260, 242, CRYSTAL STRUCTURE OF HUMAN WEE2 KINASE DOMAIN IN COMPLEX WITH MK1775
3117, d5usyB_, 0.6105, 3.29, 0.220, 287, 245, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
3118, d5uq0B_, 0.6105, 2.89, 0.270, 256, 237, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
3119, d5l4qA_, 0.6105, 3.77, 0.208, 293, 250, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
3120, d5cf6B1, 0.6105, 3.45, 0.231, 288, 247, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3121, d4u43B_, 0.6105, 3.50, 0.209, 302, 249, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
3122, d4fijA_, 0.6105, 3.45, 0.246, 291, 244, CATALYTIC DOMAIN OF HUMAN PAK4
3123, d3ppzB_, 0.6105, 3.33, 0.236, 264, 242, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
3124, d3piyA_, 0.6105, 2.81, 0.190, 262, 237, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH R406
3125, d3eqpB_, 0.6105, 3.23, 0.210, 270, 243, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
3126, d3cqeA_, 0.6105, 3.02, 0.188, 258, 239, WEE1 KINASE COMPLEX WITH INHIBITOR PD074291
3127, d3b2wA_, 0.6105, 3.05, 0.244, 261, 242, CRYSTAL STRUCTURE OF PYRIMIDINE AMIDE 11 BOUND TO LCK
3128, d5ar7B_, 0.6104, 3.11, 0.199, 278, 241, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
3129, d4twnA1, 0.6104, 2.98, 0.221, 275, 240, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH BIRB796
3130, d4nfmA_, 0.6104, 3.44, 0.221, 293, 249, HUMAN TAU TUBULIN KINASE 1 (TTBK1)
3131, d4gg7A_, 0.6104, 3.52, 0.215, 278, 247, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
3132, d3prfA_, 0.6104, 2.99, 0.226, 262, 239, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
3133, d3eqfA_, 0.6104, 3.73, 0.218, 314, 252, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH K252A AND MG2P
3134, d5usyA_, 0.6103, 3.41, 0.228, 287, 246, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
3135, d5aafA_, 0.6103, 3.24, 0.246, 254, 244, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14A)
3136, d4yhtB_, 0.6103, 2.98, 0.238, 258, 239, BRAF COMPLEXED WITH AN INHIBITOR
3137, d4gg5A_, 0.6103, 3.40, 0.209, 274, 244, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
3138, d3vjnA_, 0.6103, 3.43, 0.202, 297, 247, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH AMPPNP.
3139, d3dk3B_, 0.6103, 3.28, 0.223, 269, 242, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3140, d5ur1A_, 0.6102, 3.02, 0.259, 278, 239, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
3141, d5p9mA_, 0.6102, 3.57, 0.176, 271, 250, BTK1 BINDS COVALENTLY TO HY-15771 ONO-4059
3142, d4z55A_, 0.6102, 3.23, 0.176, 294, 245, ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE DERIVATIVE OF LDK378
3143, d4b0gA_, 0.6102, 2.70, 0.258, 247, 236, COMPLEX OF AURORA-A BOUND TO AN IMIDAZOPYRIDINE-BASED INHIBITOR
3144, d3qriB_, 0.6102, 3.37, 0.215, 262, 242, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
3145, d3dk7A_, 0.6102, 3.20, 0.220, 265, 241, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3146, d5ftoA1, 0.6101, 3.31, 0.179, 297, 246, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH ENTRECTINIB
3147, d4zy5A_, 0.6101, 3.06, 0.231, 283, 238, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
3148, d4f08A_, 0.6101, 3.38, 0.227, 288, 247, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
3149, d3dj7A_, 0.6101, 3.38, 0.248, 257, 246, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 130.
3150, d3a7jA_, 0.6101, 3.34, 0.222, 286, 243, HUMAN MST3 KINASE IN COMPLEX WITH MNADP
3151, d2ogvA_, 0.6101, 3.71, 0.232, 317, 250, CRYSTAL STRUCTURE OF THE AUTOINHIBITED HUMAN C-FMS KINASE DOMAIN
3152, d5i3rA_, 0.6100, 3.63, 0.223, 302, 251, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3153, d5fd2A_, 0.6100, 3.16, 0.214, 264, 243, B-RAF WILD-TYPE KINASE DOMAIN IN COMPLEX WITH A PURINYLPYRIDINYLAMINO- BASED INHIBITOR
3154, d4bb4A_, 0.6100, 2.96, 0.203, 265, 241, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3155, d3pjcA_, 0.6100, 3.34, 0.220, 286, 245, CRYSTAL STRUCTURE OF JAK3 COMPLEXED WITH A POTENT ATP SITE INHIBITOR SHOWING HIGH SELECTIVITY WITHIN THE JANUS KINASE FAMILY
3156, d3eqrA_, 0.6100, 3.24, 0.210, 270, 243, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
3157, d4u7zA1, 0.6099, 3.39, 0.214, 290, 248, MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK1) BOUND TO G805
3158, d4oboA_, 0.6099, 3.30, 0.239, 275, 243, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
3159, d2xynC_, 0.6099, 3.18, 0.252, 262, 242, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
3160, d5ootA_, 0.6098, 2.85, 0.271, 260, 236, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
3161, d4jdkA_, 0.6098, 3.41, 0.247, 288, 243, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
3162, d3eyhA_, 0.6098, 3.69, 0.220, 285, 250, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
3163, d3d14A1, 0.6098, 3.41, 0.256, 257, 246, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-{5-[2-(THIENO[32-D]PYRIMIDIN-4-YLAMINO)- ETHYL]- THIAZOL-2-YL}-3-(3-TRIFLUOROMETHYL-PHENYL)-UREA
3164, d2xkfA1, 0.6098, 2.58, 0.231, 242, 234, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 2
3165, d2fb8B_, 0.6098, 3.04, 0.229, 259, 240, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
3166, d5u6bB1, 0.6097, 3.48, 0.218, 289, 248, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
3167, d5tq8A_, 0.6097, 3.57, 0.225, 291, 249, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3168, d5oorA_, 0.6097, 2.87, 0.266, 273, 237, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH STAUROSPORINE
3169, d3zhpD_, 0.6097, 3.29, 0.208, 264, 245, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
3170, d3dk3A_, 0.6097, 3.21, 0.224, 266, 241, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3171, d3d15A_, 0.6097, 3.28, 0.242, 256, 244, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-(3-CHLORO-PHENYL)-3-{5-[2-(THIENO[32- D]PYRIMIDIN-4-YLAMINO)- ETHYL]-THIAZOL-2-YL}-UREA [SNS-314]
3172, d2cgwA_, 0.6097, 2.95, 0.256, 262, 238, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
3173, d5ukfC_, 0.6096, 3.93, 0.168, 317, 256, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
3174, d5nkiA_, 0.6096, 2.69, 0.208, 268, 236, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4B
3175, d4zlzA_, 0.6096, 3.48, 0.173, 270, 249, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH A SUBSTITUTED CINNOLINE
3176, d4l67A_, 0.6096, 3.42, 0.246, 289, 244, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF PAK4
3177, d4fihA_, 0.6096, 3.36, 0.244, 291, 242, CATALYTIC DOMAIN OF HUMAN PAK4 WITH QKFTGLPRQW PEPTIDE
3178, d3zbfA_, 0.6096, 3.05, 0.254, 281, 240, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH CRIZOTINIB
3179, d3sxsA1, 0.6096, 3.10, 0.199, 261, 241, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEXED WITH PP2
3180, d3krrA1, 0.6096, 3.66, 0.227, 290, 251, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT QUINOXALINE ATP SITE INHIBITOR
3181, d3eqgA_, 0.6096, 3.53, 0.220, 314, 250, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH PD ADP AND MG2P
3182, d3dajA_, 0.6096, 2.77, 0.254, 245, 236, CRYSTAL STRUCTURE OF AURORA A COMPLEXED WITH AN INHIBITOR DISCOVERED THROUGH SITE-DIRECTED DYNAMIC TETHERING
3183, d5nk0A_, 0.6095, 2.80, 0.197, 273, 238, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1J
3184, p4e3cC1, 0.6095, 3.28, 0.242, 290, 244, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
3185, d4d55A_, 0.6095, 3.00, 0.225, 260, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3186, d4bicA_, 0.6095, 2.89, 0.294, 260, 235, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3187, d4appA1, 0.6095, 3.41, 0.243, 290, 243, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH (S)-N-(5-(3-BENZYL-1-METHYLPIPERAZINE-4- CARBONYL)-66-DIMETHYL-1456-TETRAHYDROPYRROLO(34-C) PYRAZOL-3-YL)-3-PHENOXYBENZAMIDE
3188, d5usqA_, 0.6094, 3.56, 0.208, 299, 245, ALK-5 KINASE INHIBITOR COMPLEX
3189, d5ia0A_, 0.6094, 2.82, 0.197, 263, 238, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
3190, d4h1mA_, 0.6094, 2.93, 0.155, 256, 239, CRYSTAL STRUCTURE OF PYK2 WITH THE INDOLE 10C
3191, d4bidB_, 0.6094, 2.96, 0.300, 258, 237, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3192, d4aotB1, 0.6094, 3.00, 0.225, 277, 240, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
3193, d3a4pA_, 0.6094, 3.44, 0.224, 285, 246, HUMAN C-MET KINASE DOMAIN COMPLEXED WITH 6-BENZYLOXYQUINOLINE INHIBITOR
3194, d1mqbA_, 0.6094, 2.95, 0.192, 263, 240, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
3195, d5valB_, 0.6093, 2.94, 0.232, 254, 237, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
3196, d5cf6A_, 0.6093, 3.36, 0.224, 285, 246, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3197, d4qt1A_, 0.6093, 3.36, 0.214, 277, 243, JAK3 KINASE DOMAIN IN COMPLEX WITH 1-[(3S)-1-ISOBUTYLSULFONYL-3- PIPERIDYL]-3-(5H-PYRROLO[23-B]PYRAZIN-2-YL)UREA
3198, d4gk4A_, 0.6093, 3.05, 0.203, 275, 241, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 90
3199, d3sxrA1, 0.6093, 3.13, 0.203, 257, 241, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
3200, d3q96A_, 0.6093, 2.97, 0.232, 253, 237, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
3201, d3ppkA_, 0.6093, 2.98, 0.226, 262, 239, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
3202, d3nsvC_, 0.6093, 3.20, 0.252, 262, 242,  
3203, d3eqpA_, 0.6093, 3.25, 0.210, 268, 243, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
3204, d4xliA_, 0.6092, 3.16, 0.246, 264, 240, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
3205, d4x7lA_, 0.6092, 3.14, 0.222, 260, 239, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-{2-AMINO-4-METHYL-3-[2- (METHYLAMINO)-13-BENZOTHIAZOL-6-YL]BENZOYL}-1-METHYL-25-DIPHENYL-1 2-DIHYDRO-3H-PYRAZOL-3-ONE INHIBITOR
3206, d4x7kA_, 0.6092, 3.14, 0.222, 260, 239, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-{2-AMINO-3-[5-FLUORO-2- (METHYLAMINO)QUINAZOLIN-6-YL]-4-METHYLBENZOYL}-1-METHYL-25-DIPHENYL- 12-DIHYDRO-3H-PYRAZOL-3-ONE INHIBITOR
3207, d4u40A_, 0.6092, 3.23, 0.229, 295, 245, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
3208, d4py1A_, 0.6092, 3.61, 0.225, 289, 249, CRYSTAL STRUCTURE OF TYK2 IN COMPLEX WITH COMPOUND 15 6-((25- DIMETHOXYPHENYL)THIO)-3-(1-METHYL-1H-PYRAZOL-4-YL)-[124]TRIAZOLO[4 3-B]PYRIDAZINE
3209, d4mnfA_, 0.6092, 3.07, 0.226, 257, 239, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
3210, d4fsnA_, 0.6092, 2.99, 0.265, 270, 238, CRYSTAL STRUCTURE OF THE CHK1
3211, d2np8A_, 0.6092, 3.13, 0.244, 256, 242, STRUCTURAL BASIS FOR THE INHIBITION OF AURORA A KINASE BY A NOVEL CLASS OF HIGH AFFINITY DISUBSTITUTED PYRIMIDINE INHIBITORS
3212, d2hz4C_, 0.6092, 3.19, 0.216, 259, 241, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
3213, d1fvrB_, 0.6092, 3.15, 0.212, 300, 240, TIE2 KINASE DOMAIN
3214, d5p9jA_, 0.6091, 3.47, 0.170, 263, 247, BTK1 COCRYSTALLIZED WITH IBRUTINIB
3215, d5ng3D_, 0.6091, 3.56, 0.192, 278, 250, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
3216, d5i0bA_, 0.6091, 3.36, 0.248, 288, 242, STRUCTURE OF PAK4
3217, d4fobA_, 0.6091, 3.30, 0.175, 295, 246, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 1
3218, d4fnyA_, 0.6091, 3.09, 0.178, 273, 241, CRYSTAL STRUCTURE OF THE R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
3219, p4e3cF1, 0.6091, 3.13, 0.240, 290, 242, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
3220, d4d1sA_, 0.6091, 3.22, 0.222, 280, 243, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
3221, d3udbC_, 0.6091, 3.47, 0.201, 261, 249, CRYSTAL STRUCTURE OF SNRK2.6
3222, d3ms9A1, 0.6091, 3.07, 0.230, 261, 239, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
3223, d1xwsA_, 0.6091, 3.01, 0.244, 273, 238, CRYSTAL STRUCTURE OF THE HUMAN PIM1 KINASE DOMAIN
3224, d5vefA_, 0.6090, 3.38, 0.243, 289, 243, PAK4 KINASE DOMAIN IN COMPLEX WITH FASUDIL
3225, d5j7bA_, 0.6090, 3.13, 0.216, 277, 241, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
3226, d4hctA_, 0.6090, 3.50, 0.165, 265, 249, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 52
3227, d3b8rA1, 0.6090, 3.14, 0.228, 282, 241, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
3228, d2jitA_, 0.6090, 3.53, 0.214, 299, 248, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
3229, d5u6bD1, 0.6089, 3.49, 0.214, 289, 248, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
3230, d5l6oA_, 0.6089, 3.16, 0.202, 267, 242, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 3)
3231, d5flfE_, 0.6089, 2.94, 0.265, 258, 238, DISEASE LINKED MUTATION IN FGFR
3232, d5aepA_, 0.6089, 3.44, 0.227, 287, 247, NOVEL PYRROLE CARBOXAMIDE INHIBITORS OF JAK2 AS POTENTIAL TREATMENT OF MYELOPROLIFERATIVE DISORDERS
3233, d4zjiA_, 0.6089, 3.01, 0.237, 278, 240, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
3234, d4x7hA_, 0.6089, 2.97, 0.224, 256, 237, CO-CRYSTAL STRUCTURE OF PERK BOUND TO N-{5-[(67-DIMETHOXYQUINOLIN-4- YL)OXY]PYRIDIN-2-YL}-1-METHYL-3-OXO-2-PHENYL-5-(PYRIDIN-4-YL)-23- DIHYDRO-1H-PYRAZOLE-4-CARBOXAMIDE INHIBITOR
3235, d4qo9B_, 0.6089, 3.37, 0.205, 285, 244, MST3 IN COMPLEX WITH DANUSERTIB
3236, d4cljA_, 0.6089, 3.27, 0.180, 295, 245, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
3237, d4c8bB_, 0.6089, 3.11, 0.208, 281, 240, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
3238, d3zfxA_, 0.6089, 3.21, 0.214, 267, 243, CRYSTAL STRUCTURE OF EPHB1
3239, d3l8vA_, 0.6089, 3.32, 0.205, 293, 244, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A BIARYLAMINE BASED INHIBITOR
3240, d2qocA_, 0.6089, 3.17, 0.206, 283, 243, HUMAN EPHA3 KINASE DOMAIN PHOSPHORYLATED AMP-PNP BOUND STRUCTURE
3241, d4jdjA_, 0.6088, 3.48, 0.242, 288, 244, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
3242, d4hcuA_, 0.6088, 3.43, 0.161, 263, 248, CRYSTAL STRUCTURE OF ITK IN COMPLEXT WITH COMPOUND 40
3243, d3dtwB_, 0.6088, 3.08, 0.233, 269, 240, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
3244, p2y4iC_, 0.6088, 3.79, 0.209, 313, 253, KSR2-MEK1 HETERODIMER
3245, d2qohA2, 0.6088, 3.26, 0.227, 270, 242, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
3246, d5ttvA_, 0.6087, 3.46, 0.211, 280, 246, JAK3 WITH COVALENT INHIBITOR 6
3247, d5op7A_, 0.6087, 2.95, 0.265, 261, 238, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
3248, d4zjjA_, 0.6087, 3.08, 0.237, 280, 241, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
3249, d4yhtA_, 0.6087, 2.88, 0.236, 256, 237, BRAF COMPLEXED WITH AN INHIBITOR
3250, d4c3rA_, 0.6087, 3.09, 0.245, 252, 241, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP
3251, d3zfxD_, 0.6087, 3.21, 0.214, 265, 243, CRYSTAL STRUCTURE OF EPHB1
3252, d3zepC_, 0.6087, 3.51, 0.216, 276, 245, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3253, d3f69A_, 0.6087, 3.08, 0.239, 270, 243, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
3254, d6brcB_, 0.6086, 3.11, 0.262, 260, 240, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
3255, d5opvA_, 0.6086, 3.00, 0.269, 261, 238, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
3256, d5j95B_, 0.6086, 3.44, 0.201, 300, 249, MAP4K4 IN COMPLEX WITH INHIBITOR
3257, d5edpA_, 0.6086, 3.20, 0.202, 295, 243, EGFR KINASE (T790M/L858R) APO
3258, d4ft9A_, 0.6086, 3.06, 0.264, 270, 239, CRYSTAL STRUCTURE OF THE CHK1
3259, d3nsvB_, 0.6086, 3.35, 0.255, 264, 243,  
3260, d3dv3A_, 0.6086, 3.31, 0.215, 288, 246, MEK1 WITH PF-04622664 BOUND
3261, d2jkkA_, 0.6086, 3.07, 0.228, 258, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
3262, d1nvrA_, 0.6086, 3.02, 0.265, 264, 238, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/STAUROSPORINE
3263, d4x7nA_, 0.6085, 3.14, 0.222, 259, 239, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-[2-AMINO-4-METHYL-3-(2- METHYLQUINOLIN-6-YL)BENZOYL]-1-METHYL-25-DIPHENYL-12-DIHYDRO-3H- PYRAZOL-3-ONE INHIBITOR
3264, d4jbpA_, 0.6085, 3.14, 0.247, 255, 243, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
3265, d3zfxH_, 0.6085, 3.21, 0.214, 266, 243, CRYSTAL STRUCTURE OF EPHB1
3266, d3dk6A_, 0.6085, 3.19, 0.225, 262, 240, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3267, d3be2A1, 0.6085, 3.10, 0.225, 285, 240, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZAMIDE INHIBITOR
3268, d2jkqA_, 0.6085, 3.06, 0.228, 258, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
3269, d1nvqA_, 0.6085, 3.02, 0.265, 264, 238, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/UCN-01
3270, d5tq3B_, 0.6084, 3.49, 0.222, 285, 248, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3271, d4tyjA1, 0.6084, 2.97, 0.254, 275, 240, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
3272, d3tubA_, 0.6084, 3.08, 0.200, 253, 240, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-3-((1R2S)-2- PHENYLCYCLOPROPYL)UREA
3273, d3io7A_, 0.6084, 3.38, 0.228, 282, 246, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
3274, d2qo9A_, 0.6084, 3.07, 0.207, 277, 241, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION PHOSPHORYLATED AMP-PNP BOUND
3275, d2cl1A_, 0.6084, 2.75, 0.250, 250, 236,  
3276, d1p4fA_, 0.6084, 3.20, 0.304, 269, 240, DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH BOUND INHIBITOR FRAGMENT
3277, d5jkgA_, 0.6083, 2.71, 0.264, 266, 235, THE CRYSTAL STRUCTURE OF FGFR4 KINASE DOMAIN IN COMPLEX WITH LY2874455
3278, d5hg8A_, 0.6083, 3.51, 0.215, 300, 247, EGFR (L858R T790M V948R) IN COMPLEX WITH N-[3-({2-[(1-METHYL-1H- PYRAZOL-4-YL)AMINO]-7H-PYRROLO[23-D]PYRIMIDIN-4-YL}OXY)PHENYL]PROP- 2-ENAMIDE
3279, d4qyeA_, 0.6083, 3.02, 0.265, 271, 238, CHK1 KINASE DOMAIN IN COMPLEX WITH DIARYLPYRAZINE COMPOUND 1
3280, d3dxnA_, 0.6083, 3.49, 0.297, 258, 246, CRYSTAL STRUCTURE OF THE CALCIUM-DEPENDENT KINASE FROM TOXOPLASMA GONDII 541.M00134 KINASE DOMAIN.
3281, d3c4dA1, 0.6083, 3.05, 0.222, 257, 239,  
3282, d2oiqA_, 0.6083, 3.02, 0.255, 265, 239, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
3283, d2in6A_, 0.6083, 2.98, 0.186, 256, 237, WEE1 KINASE COMPLEX WITH INHIBITOR PD311839
3284, d1ol6A_, 0.6083, 3.00, 0.252, 245, 238, STRUCTURE OF UNPHOSPHORYLATED D274N MUTANT OF AURORA-A
3285, d5jfsA_, 0.6082, 2.83, 0.207, 277, 237, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-00593174
3286, d4p5qA_, 0.6082, 3.03, 0.212, 275, 240, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
3287, d4kabB_, 0.6082, 3.10, 0.222, 258, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
3288, d4as0A_, 0.6082, 3.02, 0.244, 273, 238, CYCLOMETALATED PHTHALIMIDES AS PROTEIN KINASE INHIBITORS
3289, d3mygA_, 0.6082, 3.25, 0.247, 252, 243, AURORA A KINASE COMPLEXED WITH SCH 1473759
3290, d3dkfA1, 0.6082, 3.17, 0.219, 293, 242, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
3291, d2wouA_, 0.6082, 3.61, 0.211, 299, 246, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
3292, d2cdzA_, 0.6082, 3.38, 0.248, 289, 242, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH CGP74514A
3293, d6bleA1, 0.6081, 3.24, 0.269, 263, 242, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CP673451
3294, d5nk8A_, 0.6081, 2.87, 0.197, 266, 238, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2F
3295, d5ar7A_, 0.6081, 3.21, 0.212, 278, 241, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
3296, d3genA_, 0.6081, 3.51, 0.177, 264, 248, THE 1.6 A CRYSTAL STRUCTURE OF HUMAN BRUTON S TYROSINE KINASE BOUND TO A PYRROLOPYRIMIDINE-CONTAINING COMPOUND
3297, d1rw8A_, 0.6081, 3.49, 0.207, 301, 246, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH ATP SITE INHIBITOR
3298, d5vc6A_, 0.6080, 3.17, 0.187, 259, 240, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PHA- 848125
3299, d5valA_, 0.6080, 2.90, 0.233, 254, 236, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
3300, d5uq0A_, 0.6080, 3.06, 0.255, 266, 239, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
3301, d5jrsA1, 0.6080, 3.39, 0.175, 257, 246, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
3302, d5iuiA_, 0.6080, 3.29, 0.183, 303, 246, CRYSTAL STRUCTURE OF ANAPLASTIC LYPHOMA KINASE (ALK) IN COMPLEX WITH 4
3303, d5hu9A1, 0.6080, 3.30, 0.215, 262, 242, CRYSTAL STRUCTURE OF ABL1 IN COMPLEX WITH CHMFL-074
3304, d5hg5A_, 0.6080, 3.51, 0.215, 302, 247, EGFR (L858R T790M V948R) IN COMPLEX WITH N-{3-[(2-{[4-(4- METHYLPIPERAZIN-1-YL)PHENYL]AMINO}-7H-PYRROLO[23-D]PYRIMIDIN-4-YL) OXY]PHENYL}PROP-2-ENAMIDE
3305, d4qyfA_, 0.6080, 3.00, 0.270, 269, 237, CHK1 KINASE DOMAIN IN COMPLEX WITH AMINOPYRAZINE COMPOUND 13
3306, d4id7A_, 0.6080, 3.16, 0.202, 268, 242, ACK1 KINASE IN COMPLEX WITH THE INHIBITOR CIS-3-[8-AMINO-1-(4- PHENOXYPHENYL)IMIDAZO[15-A]PYRAZIN-3-YL]CYCLOBUTANOL
3307, d2wotA1, 0.6080, 3.58, 0.208, 301, 245, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
3308, d2vz6A1, 0.6080, 3.44, 0.292, 285, 243, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
3309, d5v19B_, 0.6079, 3.01, 0.305, 260, 236, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3310, d5aagA_, 0.6079, 3.25, 0.243, 253, 243, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14B)
3311, d4zjiB_, 0.6079, 3.03, 0.242, 276, 240, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
3312, d4j95B_, 0.6079, 3.52, 0.245, 282, 245, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
3313, d4g5pA_, 0.6079, 3.55, 0.222, 299, 248, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
3314, d3sxrB1, 0.6079, 3.03, 0.201, 255, 239, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
3315, d3dk7B_, 0.6079, 3.26, 0.220, 268, 241, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3316, d2qu5A_, 0.6079, 3.36, 0.220, 292, 246, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR
3317, d2gs2A_, 0.6079, 3.37, 0.204, 305, 245, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN
3318, d1nvsA_, 0.6079, 3.03, 0.265, 264, 238, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/SB218078
3319, d6bruC_, 0.6078, 3.80, 0.174, 315, 253, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3320, d5up3A_, 0.6078, 2.90, 0.298, 258, 235, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3321, d5tq3A_, 0.6078, 3.46, 0.223, 282, 247, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3322, d5ng0A_, 0.6078, 3.27, 0.215, 274, 242, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
3323, d5e8wA1, 0.6078, 3.59, 0.208, 302, 245, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH STAUROSPORINE
3324, d5dh3A_, 0.6078, 3.33, 0.238, 287, 244, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
3325, d5ax9B_, 0.6078, 3.05, 0.231, 274, 238, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
3326, d4x7jA_, 0.6078, 3.03, 0.219, 257, 237, CO-CRYSTAL STRUCTURE OF PERK WITH 2-AMINO-N-[4-METHOXY-3- (TRIFLUOROMETHYL)PHENYL]-4-METHYL-3-[2-(METHYLAMINO)QUINAZOLIN-6- YL]BENZAMIDE INHIBITOR
3327, d4u44B_, 0.6078, 3.34, 0.215, 296, 247, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
3328, d4rvtB_, 0.6078, 3.46, 0.209, 297, 249, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
3329, d4ks8A_, 0.6078, 3.40, 0.243, 286, 243, PAK6 KINASE DOMAIN IN COMPLEX WITH SUNITINIB
3330, d4gt4B_, 0.6078, 3.47, 0.196, 273, 245, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
3331, d4btkA_, 0.6078, 3.48, 0.226, 287, 248, TTBK1 IN COMPLEX WITH INHIBITOR
3332, d4anlA_, 0.6078, 3.39, 0.166, 292, 247, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE
3333, d3b8rB_, 0.6078, 3.04, 0.243, 267, 239, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
3334, d3b8qB_, 0.6078, 3.18, 0.228, 271, 241, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
3335, d2xynB_, 0.6078, 3.28, 0.252, 264, 242, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
3336, d2eb3A_, 0.6078, 3.29, 0.205, 294, 244, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (L858R) IN COMPLEX WITH AMPPNP
3337, d6btwC_, 0.6077, 3.84, 0.174, 315, 253, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
3338, d5tozA_, 0.6077, 3.41, 0.216, 278, 245, JAK3 WITH COVALENT INHIBITOR PF-06651600
3339, d5aadA_, 0.6077, 3.20, 0.248, 252, 242, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (7A)
3340, d4hvhA_, 0.6077, 3.43, 0.217, 278, 244, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-2-HYDROXY-12-DIMETHYL-PROPYL
3341, d3vjoA_, 0.6077, 3.39, 0.204, 298, 245, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH AMPPNP.
3342, d3jvrA_, 0.6077, 3.24, 0.254, 258, 240, CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE
3343, d2y6oA_, 0.6077, 2.92, 0.214, 263, 238, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH DASATINIB.
3344, d2w1dA1, 0.6077, 3.14, 0.245, 251, 241, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3345, d1vr2A_, 0.6077, 2.98, 0.226, 275, 239, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN
3346, d5jfxA_, 0.6076, 2.84, 0.198, 277, 237, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-06273340
3347, d5di1B_, 0.6076, 3.48, 0.205, 300, 249, MAP4K4 IN COMPLEX WITH AN INHIBITOR
3348, d5cf5A1, 0.6076, 3.40, 0.228, 286, 246, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3349, d4j99B_, 0.6076, 3.52, 0.249, 291, 245, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
3350, d4hcvA_, 0.6076, 3.49, 0.161, 263, 248, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 53
3351, d3ot3A_, 0.6076, 2.87, 0.263, 259, 236, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22K BOUND TO HUMAN CHK1 KINASE DOMAIN
3352, d3eqiA_, 0.6076, 3.76, 0.225, 315, 253, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ADP AND MG2P
3353, d3ckxA_, 0.6076, 3.05, 0.222, 276, 239, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24) IN COMPLEX WITH STAUROSPORINE
3354, d4gvjA1, 0.6075, 3.64, 0.221, 288, 249, TYK2 (JH1) IN COMPLEX WITH ADENOSINE DI-PHOSPHATE
3355, d3prfB_, 0.6075, 2.96, 0.227, 262, 238, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
3356, d2xnnA1, 0.6075, 2.62, 0.231, 243, 234, STRUCTURE OF NEK2 BOUND TO CCT242430
3357, d2xikA_, 0.6075, 3.49, 0.220, 288, 245, STRUCTURE OF HUMAN YSK1 (YEAST SPS1-STE20-RELATED KINASE 1)
3358, d2qokA_, 0.6075, 3.11, 0.220, 281, 241, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:S768A TRIPLE MUTANT
3359, d2qhmA_, 0.6075, 3.16, 0.285, 268, 239, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2A
3360, d5o23A_, 0.6074, 3.36, 0.248, 269, 246, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE
3361, d4zp5B_, 0.6074, 3.47, 0.205, 300, 249, MAP4K4 IN COMPLEX WITH INHIBITOR
3362, d4ypsA1, 0.6074, 3.32, 0.202, 275, 242, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
3363, d3lxnA_, 0.6074, 3.63, 0.222, 287, 248, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
3364, d3eqdA_, 0.6074, 3.69, 0.219, 315, 251, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ATP-GS AND MG2P
3365, d2p55A2, 0.6074, 3.43, 0.215, 288, 247, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
3366, d2j5eA_, 0.6074, 3.64, 0.205, 309, 249, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 13-JAB
3367, d4zjjD_, 0.6073, 3.21, 0.215, 274, 242, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
3368, d4aqcA_, 0.6073, 3.51, 0.226, 289, 248, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
3369, d2pl0A_, 0.6073, 3.49, 0.252, 268, 246, LCK BOUND TO IMATINIB
3370, d2gqgA1, 0.6073, 3.43, 0.230, 271, 244, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
3371, d6bu6C_, 0.6072, 3.75, 0.175, 315, 252, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
3372, d5cxhA1, 0.6072, 3.38, 0.208, 273, 245, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT ORALLY BIOAVAILABLE THIAZOLE INHIBITOR
3373, d4mnfB_, 0.6072, 3.07, 0.223, 257, 238, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
3374, d4f08B_, 0.6072, 3.47, 0.227, 288, 247, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
3375, d4e20A_, 0.6072, 3.56, 0.223, 282, 247, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
3376, d4cmoA_, 0.6072, 3.27, 0.184, 295, 244, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 2-((1R)-1-((3-AMINO-6-(2- METHOXYPYRIDIN- -YL)PYRAZIN-2-YL)OXY)ETHYL)-4-FLUORO-N-METHYLBENZAMIDE
3377, d2io6A_, 0.6072, 3.03, 0.186, 252, 237, WEE1 KINASE COMPLEXED WITH INHIBITOR PD330961
3378, d2e2bB1, 0.6072, 2.96, 0.215, 258, 237, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
3379, d1fvrA_, 0.6072, 3.21, 0.221, 299, 240, TIE2 KINASE DOMAIN
3380, d5ew3B_, 0.6071, 3.13, 0.225, 266, 240, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
3381, d3zlsA_, 0.6071, 3.77, 0.214, 315, 252, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 6
3382, d3zfxE_, 0.6071, 3.17, 0.215, 262, 242, CRYSTAL STRUCTURE OF EPHB1
3383, d1iasB_, 0.6071, 3.99, 0.202, 324, 252, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3384, d5xgmA_, 0.6070, 3.10, 0.212, 288, 241, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH GO6976
3385, d5v5yA_, 0.6070, 3.10, 0.184, 259, 239, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH MK1775
3386, d5op5A_, 0.6070, 2.88, 0.271, 259, 236, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
3387, d5ng2A_, 0.6070, 3.28, 0.207, 274, 242, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
3388, d5hlwA_, 0.6070, 3.15, 0.224, 284, 241, CRYSTAL STRUCTURE OF C-MET MUTANT Y1230H IN COMPLEX WITH COMPOUND 14
3389, d5c8mA_, 0.6070, 3.29, 0.206, 302, 243, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 17
3390, d3tkiA_, 0.6070, 3.08, 0.269, 272, 238, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S25
3391, d3nz0A1, 0.6070, 3.75, 0.220, 283, 250, NON-PHOSPHORYLATED TYK2 KINASE WITH CMP6
3392, d5lohA_, 0.6069, 2.86, 0.258, 248, 236, KINASE DOMAIN OF HUMAN GREATWALL
3393, d5ghvB_, 0.6069, 3.10, 0.196, 265, 240, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3394, d4xg5B_, 0.6069, 3.10, 0.196, 265, 240,  
3395, d4qq5A1, 0.6069, 2.91, 0.277, 272, 238, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
3396, d4ji9B_, 0.6069, 3.51, 0.231, 288, 247, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
3397, d4deiA_, 0.6069, 3.48, 0.216, 287, 245, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 24
3398, d3cjgA_, 0.6069, 3.24, 0.241, 280, 241, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
3399, d2z7sA_, 0.6069, 2.65, 0.276, 256, 232, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO PURVALNOL A
3400, d5vc4A_, 0.6068, 3.28, 0.186, 261, 242, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB-ISOMER
3401, d5jfvA_, 0.6068, 2.86, 0.203, 277, 237, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05206283
3402, d4yjoA_, 0.6068, 3.29, 0.193, 267, 244, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000222
3403, d4xyfA_, 0.6068, 3.61, 0.198, 290, 248, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (S)-5-(8-FLUORO-3-(1-(3-(2- METHOXYETHOXY)QUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43-A]PYRIDIN-6- YL)-3-METHYLISOXAZOLE
3404, d4u45B_, 0.6068, 3.38, 0.219, 295, 247, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
3405, d4rvkA_, 0.6068, 3.04, 0.261, 264, 238, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 8: N-[3-(6-CYANO-9H- PYRROLO[23-B:54-C ]DIPYRIDIN-3-YL)PHENYL]ACETAMIDE
3406, d4ftuA_, 0.6068, 3.09, 0.265, 270, 238, CRYSTAL STRUCTURE OF THE CHK1
3407, d3ug1A_, 0.6068, 3.48, 0.204, 296, 245, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN THE APO FORM
3408, d3h0zC_, 0.6068, 2.96, 0.239, 246, 238, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
3409, d2bzhB_, 0.6068, 3.10, 0.243, 275, 239, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
3410, d2bikB_, 0.6068, 3.01, 0.245, 272, 237, HUMAN PIM1 PHOSPHORYLATED ON SER261
3411, d2b4sB_, 0.6068, 4.01, 0.215, 294, 256, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
3412, d1ywvA_, 0.6068, 3.04, 0.239, 274, 238, CRYSTAL STRUCTURES OF PROTO-ONCOGENE KINASE PIM1: A TARGET OF ABERRANT SOMATIC HYPERMUTATIONS IN DIFFUSE LARGE CELL LYMPHOMA
3413, d5eycA_, 0.6067, 3.58, 0.206, 288, 247, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH NAPHTHYRIDINONE INHIBITOR 5
3414, d5c8kA_, 0.6067, 3.29, 0.206, 300, 243, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 1
3415, d4u81A1, 0.6067, 3.46, 0.215, 288, 247, MEK1 KINASE BOUND TO SMALL MOLECULE INHIBITOR G659
3416, d2xyuA_, 0.6067, 2.85, 0.215, 260, 237, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH VUF 12058
3417, d2ituA_, 0.6067, 3.32, 0.205, 304, 244, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AFN941
3418, d2hogA_, 0.6067, 3.11, 0.264, 272, 239, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 20
3419, d5ct7B_, 0.6066, 2.86, 0.225, 254, 236, BRAF IN COMPLEX WITH RAF265
3420, d5ajqB_, 0.6066, 3.13, 0.238, 267, 239, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
3421, d4u80A_, 0.6066, 3.54, 0.217, 286, 249, MEK 1 KINASE BOUND TO G799
3422, d4twpA_, 0.6066, 3.30, 0.220, 266, 241, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
3423, d2qohB2, 0.6066, 3.26, 0.231, 280, 242, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
3424, d2oi4X_, 0.6066, 3.02, 0.239, 275, 238, CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH FLUORINATED RUTHENIUM PYRIDOCARBAZOLE
3425, d2ijmB_, 0.6066, 3.01, 0.212, 261, 240, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
3426, d6bqpA1, 0.6065, 3.20, 0.270, 262, 241, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CRENOLANIB
3427, d4ftiA_, 0.6065, 3.05, 0.265, 270, 238, CRYSTAL STRUCTURE OF THE CHK1
3428, d3v04A1, 0.6065, 3.45, 0.219, 288, 247, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
3429, d3c4eA_, 0.6065, 2.97, 0.236, 273, 237, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
3430, d2b4sD_, 0.6065, 3.98, 0.199, 294, 256, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
3431, d5e8sA1, 0.6064, 3.51, 0.209, 299, 244, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (WT)
3432, d5capA_, 0.6064, 3.43, 0.208, 303, 245, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 30
3433, d4k18A_, 0.6064, 3.09, 0.238, 277, 239, STRUCTURE OF PIM-1 KINASE BOUND TO 5-(4-CYANOBENZYL)-N-(4- FLUOROPHENYL)-7-HYDROXYPYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
3434, d4ccuA_, 0.6064, 3.28, 0.184, 292, 244, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPAN-2-OL
3435, d3h0yA_, 0.6064, 3.12, 0.245, 250, 241, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
3436, d2xk4A1, 0.6064, 2.69, 0.230, 244, 235, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 17
3437, d5ew3A_, 0.6063, 3.13, 0.229, 274, 240, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
3438, d4njdA1, 0.6063, 3.50, 0.242, 289, 244, STRUCTURE OF P21-ACTIVATED KINASE 4 WITH A NOVEL INHIBITOR KY-04031
3439, d4jq8A_, 0.6063, 3.53, 0.207, 303, 246, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4B
3440, d4hvdA_, 0.6063, 3.24, 0.216, 276, 241, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-122-TRIMETHYL-PROPYL)-AMIDE
3441, d4fszA_, 0.6063, 3.07, 0.269, 268, 238, CRYSTAL STRUCTURE OF THE CHK1
3442, d3lxkA_, 0.6063, 3.49, 0.215, 279, 246, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
3443, d2gsfA_, 0.6063, 3.02, 0.209, 281, 239, THE HUMAN EPHA3 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
3444, d5jfwA_, 0.6062, 2.87, 0.203, 277, 237, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05247452
3445, d5ghvA_, 0.6062, 3.10, 0.196, 265, 240, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3446, d4zk5B_, 0.6062, 3.32, 0.220, 294, 246, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
3447, d4xg5A_, 0.6062, 3.10, 0.196, 265, 240,  
3448, d3zfxI_, 0.6062, 3.14, 0.212, 263, 241, CRYSTAL STRUCTURE OF EPHB1
3449, d3kf4B_, 0.6062, 3.34, 0.223, 270, 242, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
3450, d3dtwA1, 0.6062, 3.13, 0.221, 281, 240, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
3451, d2qonA_, 0.6062, 3.14, 0.203, 281, 241, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:Y742A TRIPLE MUTANT
3452, d2qhnA_, 0.6062, 3.10, 0.273, 268, 238, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1A
3453, d2brmA_, 0.6062, 2.95, 0.271, 263, 236, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3454, d6bqlA1, 0.6061, 3.38, 0.250, 276, 244, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH TAE-226
3455, d4gk3A_, 0.6061, 3.07, 0.204, 275, 240, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 87
3456, d3ma6A_, 0.6061, 3.79, 0.291, 267, 254, CRYSTAL STRUCTURE OF KINASE DOMAIN OF TGCDPK1 IN PRESENCE OF 3BRB-PP1
3457, d2j2iB_, 0.6061, 3.06, 0.244, 273, 238, CRYSTAL STRUCTURE OF THE HUMAB PIM1 IN COMPLEX WITH LY333531
3458, d2c3lA_, 0.6061, 3.14, 0.264, 265, 239, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
3459, d5hieB_, 0.6060, 3.13, 0.233, 259, 240, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
3460, d4m0zA_, 0.6060, 3.50, 0.169, 264, 248, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 5 {4- (CARBAMOYLAMINO)-1-(7-METHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE}
3461, d4gt4A_, 0.6060, 3.43, 0.193, 274, 243, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
3462, d4g2fA_, 0.6060, 3.02, 0.205, 275, 239, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 7
3463, d4d4sB_, 0.6060, 3.22, 0.218, 260, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3464, d4bc6A_, 0.6060, 3.16, 0.223, 285, 238, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO NOVEL BOSUTINIB ISOFORM 1 PREVIOUSLY THOUGHT TO BE BOSUTINIB
3465, d1xqzA_, 0.6060, 3.11, 0.238, 277, 239, CRYSTAL STRUCTURE OF HPIM-1 KINASE AT 2.1 A RESOLUTION
3466, d1eh4B_, 0.6060, 3.22, 0.165, 293, 242, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
3467, d5opuA_, 0.6059, 2.96, 0.270, 261, 237, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
3468, d4aojA_, 0.6059, 3.04, 0.196, 260, 240, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
3469, d3oxzA1, 0.6059, 3.02, 0.223, 267, 238, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN BOUND WITH A DFG-OUT INHIBITOR AP24534
3470, d3c4cA1, 0.6059, 2.91, 0.219, 257, 237, B-RAF KINASE IN COMPLEX WITH PLX4720
3471, d3bz3A_, 0.6059, 3.25, 0.226, 259, 243, CRYSTAL STRUCTURE ANALYSIS OF FOCAL ADHESION KINASE WITH A METHANESULFONAMIDE DIAMINOPYRIMIDINE INHIBITOR
3472, d2ittA_, 0.6059, 3.43, 0.208, 302, 245, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AEE788
3473, d1ywnA_, 0.6059, 2.89, 0.225, 279, 236, VEGFR2 IN COMPLEX WITH A NOVEL 4-AMINO-FURO[23-D]PYRIMIDINE
3474, d1m17A_, 0.6059, 3.53, 0.211, 312, 246, EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE DOMAIN WITH 4-ANILINOQUINAZOLINE INHIBITOR ERLOTINIB
3475, d5aaaA_, 0.6058, 3.28, 0.180, 294, 244, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
3476, d4fodA_, 0.6058, 3.32, 0.171, 308, 245, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 36
3477, d4aotA1, 0.6058, 3.17, 0.237, 276, 241, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
3478, d3r7oA1, 0.6058, 3.53, 0.219, 295, 247, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG
3479, d3eqbA1, 0.6058, 3.46, 0.215, 288, 247, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
3480, d3b8qA1, 0.6058, 3.16, 0.221, 285, 240, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
3481, d2y6mA_, 0.6058, 2.90, 0.215, 262, 237, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN
3482, d2xnpA1, 0.6058, 2.70, 0.230, 245, 235, STRUCTURE OF NEK2 BOUND TO CCT244858
3483, d2hz0A_, 0.6058, 3.16, 0.212, 265, 241, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
3484, d1rjbA_, 0.6058, 3.36, 0.248, 298, 242, CRYSTAL STRUCTURE OF FLT3
3485, d6babC_, 0.6057, 3.46, 0.303, 284, 241, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
3486, d5fbnC_, 0.6057, 3.29, 0.189, 256, 244, BTK KINASE DOMAIN WITH INHIBITOR 1
3487, d5ew9A_, 0.6057, 3.50, 0.227, 257, 247, CRYSTAL STRUCTURE OF AURORA A KINASE DOMAIN BOUND TO MK-5108
3488, d5ar5A_, 0.6057, 3.28, 0.219, 284, 242, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
3489, d5a9uA_, 0.6057, 3.44, 0.179, 292, 246, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
3490, d4m14A_, 0.6057, 3.50, 0.169, 263, 248, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE]
3491, d3zewB_, 0.6057, 2.74, 0.213, 252, 235, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
3492, d1s9jA1, 0.6057, 3.45, 0.219, 288, 247, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
3493, d5canA_, 0.6056, 3.31, 0.206, 301, 243, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 27
3494, d4jr3A_, 0.6056, 3.54, 0.211, 303, 246, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 3G
3495, d4gfgA1, 0.6056, 3.43, 0.195, 273, 246, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R9021
3496, d4fnzA_, 0.6056, 3.10, 0.174, 287, 241, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PIPERIDINE-CARBOXAMIDE INHIBITOR 2
3497, d3zfyA_, 0.6056, 3.05, 0.201, 260, 239, CRYSTAL STRUCTURE OF EPHB3
3498, d3ppzA_, 0.6056, 3.19, 0.236, 264, 237, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
3499, d3eqcA_, 0.6056, 3.60, 0.221, 312, 249, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH COMPOUND 1 ATP-GS AND MG2P
3500, d2qobA_, 0.6056, 3.18, 0.194, 279, 242, HUMAN EPHA3 KINASE DOMAIN BASE STRUCTURE
3501, d5vo6A_, 0.6055, 3.14, 0.212, 271, 240, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE INHIBITOR
3502, d5knjA_, 0.6055, 2.99, 0.167, 252, 239, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 1.
3503, d5itaB_, 0.6055, 2.99, 0.224, 252, 237, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
3504, d4fk6A_, 0.6055, 3.70, 0.222, 285, 248, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
3505, d3a7gA_, 0.6055, 3.64, 0.211, 289, 247, HUMAN MST3 KINASE
3506, d6bp0C_, 0.6054, 3.76, 0.175, 315, 252, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3507, d5op2A_, 0.6054, 3.02, 0.269, 263, 238, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3508, d5caqA_, 0.6054, 3.23, 0.202, 301, 242, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 33
3509, d5bx0A_, 0.6054, 3.80, 0.222, 315, 252, AN AUTOMATED MICROSCALE THERMOPHORESIS SCREENING APPROACH FOR FRAGMENT-BASED LEAD DISCOVERY
3510, d4riwD_, 0.6054, 3.46, 0.233, 297, 245, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
3511, d4m12A_, 0.6054, 3.50, 0.165, 264, 248, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 7 [4- (CARBAMOYLAMINO)-1-(7-ETHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
3512, d4ft7A_, 0.6054, 3.02, 0.262, 270, 237, CRYSTAL STRUCTURE OF THE CHK1
3513, d4ctbA_, 0.6054, 3.29, 0.184, 292, 244, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (5R)-8-AMINO-3-FLUORO-519-DIMETHYL-20-OXO-5181920- TETRAHYDRO-711-(AZENO)PYRIDO(2 1 :23)IMIDAZO(45-H)(2511) BENZOXADIAZACYCLOTETRADECINE-14-CARBONITRILE
3514, d2z60A1, 0.6054, 3.35, 0.223, 280, 242, CRYSTAL STRUCTURE OF THE T315I MUTANT OF ABL KINASE BOUND WITH PPY-A
3515, d2gs6A2, 0.6054, 3.51, 0.211, 308, 246, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AN ATP ANALOG-PEPTIDE CONJUGATE
3516, d5e90A1, 0.6053, 3.55, 0.221, 300, 244, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249F S280T Y282FS287NA350CL352F) IN COMPLEX WITH 3-AMINO-6- [4-(2- HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2- CARBOXAMIDE
3517, d5ar2A_, 0.6053, 3.25, 0.217, 277, 240, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
3518, d4j96B_, 0.6053, 3.62, 0.252, 305, 246, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
3519, d4fg7A_, 0.6053, 2.92, 0.299, 250, 234, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-293 IN COMPLEX WITH ATP
3520, d4cmuA_, 0.6053, 3.30, 0.184, 294, 244, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (10R)-7-AMINO-12-FLUORO-1310 16-TETRAMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(43- H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
3521, d3cs9D_, 0.6053, 3.39, 0.218, 263, 243, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
3522, d1yxsA_, 0.6053, 3.08, 0.244, 274, 238, CRYSTAL STRUCTURE OF KINASE PIM1 WITH P123M MUTATION
3523, d1m14A_, 0.6053, 3.40, 0.212, 307, 245, TYROSINE KINASE DOMAIN FROM EPIDERMAL GROWTH FACTOR RECEPTOR
3524, d5xdlA_, 0.6052, 3.27, 0.207, 292, 242, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH CO-1686
3525, d5c8nA_, 0.6052, 3.28, 0.207, 300, 242, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 23
3526, d5aa9A_, 0.6052, 3.30, 0.180, 295, 244, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
3527, d4obqA_, 0.6052, 2.96, 0.242, 275, 236, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
3528, d4m13A_, 0.6052, 3.46, 0.166, 264, 247, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 8 [4- (CARBAMOYLAMINO)-1-(7-PROPOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
3529, d4j98B_, 0.6052, 3.55, 0.257, 304, 245, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
3530, d4fnwA_, 0.6052, 3.28, 0.184, 304, 244, CRYSTAL STRUCTURE OF THE APO F1174L ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
3531, d4cliA_, 0.6052, 3.30, 0.184, 294, 244, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-21016-TRIMETHYL-15 -OXO-10151617-TETRAHYDRO-2H-84-(METHENO)PYRAZOLO(43-H) (2511)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
3532, d3cp9A1, 0.6052, 3.04, 0.209, 281, 239, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
3533, d2xynA_, 0.6052, 3.30, 0.252, 264, 242, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
3534, d1xr1A_, 0.6052, 3.13, 0.243, 277, 239, CRYSTAL STRUCTURE OF HPIM-1 KINASE IN COMPLEX WITH AMP-PNP AT 2.1 A RESOLUTION
3535, d1py5A_, 0.6052, 3.64, 0.202, 301, 247, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH INHIBITOR
3536, d5kz0A_, 0.6051, 3.29, 0.184, 293, 244, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-[(1R)- 1-{[2-AMINO-5-(13-DIMETHYL-1H-PYRAZOL-4-YL)PYRIDIN-3-YL]OXY}ETHYL]- 4-FLUORO-NN-DIMETHYLBENZAMIDE
3537, d5hnvA1, 0.6051, 3.29, 0.186, 278, 242, CRYSTAL STRUCTURE OF PPKA
3538, d5edqA_, 0.6051, 3.26, 0.202, 298, 243, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 15: ~{N}-(7- CHLORANYL-1~{H}-INDAZOL-3-YL)-77-DIMETHYL-2-(1~{H}-PYRAZOL-4-YL)- 5~{H}-FURO[34-D]PYRIMIDIN-4-AMINE
3539, d5cf8B1, 0.6051, 3.49, 0.232, 287, 246, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3540, d4zjjC_, 0.6051, 3.29, 0.218, 276, 243, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
3541, d4knbA_, 0.6051, 3.44, 0.217, 273, 244, C-MET IN COMPLEX WITH OSI LIGAND
3542, d3ri1A_, 0.6051, 3.38, 0.256, 285, 242, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
3543, d3c4eB_, 0.6051, 3.00, 0.232, 273, 237, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
3544, d2yhvA_, 0.6051, 3.26, 0.164, 291, 244, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE
3545, d2hy0A_, 0.6051, 3.03, 0.270, 272, 237, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 22
3546, d5lohB_, 0.6050, 2.77, 0.261, 250, 234, KINASE DOMAIN OF HUMAN GREATWALL
3547, d5j9zA_, 0.6050, 3.36, 0.209, 291, 244, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1A
3548, d4z16A_, 0.6050, 3.20, 0.218, 271, 239, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
3549, d4yneA1, 0.6050, 3.07, 0.204, 276, 240, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
3550, d4xg3B_, 0.6050, 3.32, 0.197, 267, 244, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3551, d4x2nA1, 0.6050, 3.47, 0.210, 302, 243, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3552, d4u41B_, 0.6050, 3.51, 0.209, 297, 249, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
3553, d4k1bA_, 0.6050, 3.09, 0.239, 273, 238, STRUCTURE OF PIM-1 KINASE BOUND TO N-(5-(2-FLUOROPHENYL)-1H-PYRROLO[2 3-B]PYRIDIN-3-YL)-5-((((3R4R)-3-FLUOROPIPERIDIN-4-YL)METHYL)AMINO) PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
3554, d4ft3A_, 0.6050, 3.02, 0.270, 269, 237, CRYSTAL STRUCTURE OF THE CHK1
3555, d4ansA_, 0.6050, 3.30, 0.184, 293, 244, STRUCTURE OF L1196MG1269A DOUBLE MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
3556, d3v01A1, 0.6050, 3.48, 0.215, 288, 247, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
3557, d2itnA_, 0.6050, 3.52, 0.215, 304, 246, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AMP-PNP
3558, d5lmaA_, 0.6049, 3.25, 0.198, 267, 243, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
3559, d5ftqA1, 0.6049, 3.38, 0.176, 292, 245, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH CMPD 17
3560, d4m15A_, 0.6049, 3.47, 0.166, 263, 247, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE] AND ADP
3561, d4focA_, 0.6049, 3.34, 0.176, 296, 245, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 2
3562, d4fl1A_, 0.6049, 3.41, 0.197, 268, 244, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
3563, d3vvhA1, 0.6049, 3.36, 0.216, 286, 245, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
3564, d5dgzA_, 0.6048, 3.09, 0.231, 273, 238, DISCOVERY OF 35-SUBSTITUTED 6-AZAINDAZOLES AS POTENT PAN-PIM INHIBITORS
3565, d4wunA_, 0.6048, 3.11, 0.264, 282, 239, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
3566, d4riyD_, 0.6048, 3.54, 0.228, 297, 246, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
3567, d4nfnA_, 0.6048, 3.51, 0.222, 293, 248, HUMAN TAU TUBULIN KINASE 1 (TTBK1) COMPLEXED WITH 3-({5-[(4-AMINO-4- METHYLPIPERIDIN-1-YL)METHYL]PYRROLO[21-F][124]TRIAZIN-4-YL}AMINO)- 5-BROMOPHENOL
3568, d4m0yA_, 0.6048, 3.54, 0.165, 263, 248, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 1 [4- (CARBAMOYLAMINO)-1-(NAPHTHALEN-1-YL)-1H-PYRAZOLE-3-CARBOXAMIDE]
3569, d4dceB_, 0.6048, 3.23, 0.182, 284, 242, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
3570, d4cqeB_, 0.6048, 2.80, 0.226, 248, 234, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
3571, d4afeA1, 0.6048, 2.67, 0.231, 245, 234, NEK2 BOUND TO HYBRID COMPOUND 21
3572, d3p86A_, 0.6048, 2.85, 0.220, 250, 236, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
3573, d2j5fA_, 0.6048, 3.48, 0.207, 308, 246, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 34-JAB
3574, d2bzjA_, 0.6048, 3.08, 0.235, 273, 238, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU3
3575, d2bvaA_, 0.6048, 3.10, 0.232, 272, 237, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
3576, d4rpvA_, 0.6047, 3.07, 0.235, 273, 238, CO-CRYSTAL STRUCTURE OF PIM1 WITH COMPOUND 3
3577, d4oboB_, 0.6047, 3.51, 0.213, 297, 249, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
3578, d4n6yA_, 0.6047, 3.00, 0.241, 273, 237, PIM1 COMPLEXED WITH A PHENYLCARBOXAMIDE
3579, d4fsrA_, 0.6047, 3.10, 0.261, 269, 238, CRYSTAL STRUCTURE OF THE CHK1
3580, d4dceA_, 0.6047, 3.18, 0.174, 288, 242, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
3581, d4aojC_, 0.6047, 3.07, 0.192, 261, 240, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
3582, d3cp9B_, 0.6047, 3.06, 0.227, 269, 238, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
3583, d1mqbB_, 0.6047, 3.08, 0.196, 265, 240, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
3584, d5c26A1, 0.6046, 3.45, 0.200, 271, 245, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 1
3585, d4x2gA1, 0.6046, 3.39, 0.211, 302, 242, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3586, d4rvmA_, 0.6046, 3.01, 0.266, 264, 237, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 19
3587, d4rj4A_, 0.6046, 3.29, 0.202, 299, 242, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 6
3588, d4anqA_, 0.6046, 3.30, 0.184, 293, 244, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
3589, d3zlxA_, 0.6046, 3.83, 0.211, 312, 251, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 18
3590, d3ug2A_, 0.6046, 3.42, 0.201, 299, 244, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH GEFITINIB
3591, d5tq4A_, 0.6045, 3.62, 0.229, 290, 249, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3592, d5calA_, 0.6045, 3.33, 0.206, 300, 243, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 24
3593, d4xi2A2, 0.6045, 3.47, 0.171, 274, 246, CRYSTAL STRUCTURE OF AN AUTO-INHIBITED FORM OF BRUTON S TRYROSINE KINASE
3594, d4qqcA1, 0.6045, 2.91, 0.270, 271, 237, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
3595, d4p7eB_, 0.6045, 3.55, 0.231, 285, 247, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
3596, d4j97A_, 0.6045, 3.48, 0.254, 282, 244, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
3597, d4ft0A_, 0.6045, 3.04, 0.266, 266, 237, CRYSTAL STRUCTURE OF THE CHK1
3598, d3nsvA_, 0.6045, 3.32, 0.252, 264, 242,  
3599, d2yn8B_, 0.6045, 2.98, 0.207, 260, 237, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3600, d2xeyA_, 0.6045, 2.77, 0.270, 252, 233, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3601, d2pvfA_, 0.6045, 3.43, 0.250, 285, 244, CRYSTAL STRUCTURE OF TYROSINE PHOSPHORYLATED ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH ATP ANALOG AND SUBSTRATE PEPTIDE
3602, d5caoA_, 0.6044, 3.27, 0.207, 300, 242, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 29
3603, d4j97B_, 0.6044, 3.49, 0.254, 283, 244, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
3604, d3tjcB_, 0.6044, 3.56, 0.227, 287, 247, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
3605, d3nlbA_, 0.6044, 2.99, 0.267, 261, 236, NOVEL KINASE PROFILE HIGHLIGHTS THE TEMPORAL BASIS OF CONTEXT DEPENDENT CHECKPOINT PATHWAYS TO CELL DEATH
3606, d3dkgA_, 0.6044, 3.09, 0.225, 281, 240, STRUCTURE OF MUTANT(Y1248L) MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
3607, d2hakB_, 0.6044, 2.85, 0.248, 279, 234, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
3608, d1yi6B_, 0.6044, 3.41, 0.230, 274, 244, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
3609, d1xbcA1, 0.6044, 3.17, 0.196, 267, 240, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH STAUROSPORIN
3610, d5e8uA1, 0.6043, 3.64, 0.220, 303, 245, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F)
3611, d5aabA_, 0.6043, 3.31, 0.176, 293, 244, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
3612, d4x2fA1, 0.6043, 3.39, 0.211, 302, 242, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3613, d3tz8B_, 0.6043, 3.08, 0.252, 263, 238, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
3614, d5j7hA_, 0.6042, 3.24, 0.185, 291, 243, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) BOUND BY BRIGATINIB
3615, d4z16C_, 0.6042, 3.21, 0.218, 271, 239, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
3616, d4xmoA_, 0.6042, 3.62, 0.198, 289, 247, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (R)-5-(8-FLUORO-3-(1- FLUORO-1-(3-METHOXYQUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43- A]PYRIDIN-6-YL)-3-METHYLISOXAZOLE
3617, d4lqmA_, 0.6042, 3.38, 0.205, 305, 244, EGFR L858R IN COMPLEX WITH PD168393
3618, d4iwdA1, 0.6042, 3.57, 0.218, 295, 248, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-8033 ANALOG
3619, d3aoxA_, 0.6042, 3.26, 0.185, 298, 243, X-RAY CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CH5424802
3620, d2wtkC1, 0.6042, 3.00, 0.274, 261, 237, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
3621, d2c3jA_, 0.6042, 3.00, 0.262, 257, 237, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
3622, p5w5qB_, 0.6041, 3.40, 0.215, 297, 247, MAP4K4 IN COMPLEX WITH INHIBITOR COMPOUND 12 (N3-METHYL-10-(3-METHYL- 3-(5-METHYLOXAZOL-2-YL)BUT-1-YN-1-YL)-6;7-DIHYDRO-5H-5;7- METHANOBENZO[C]IMIDAZO[1;2-A]AZEPINE-2;3-DICARBOXAMIDE) 
3623, d5mjaA_, 0.6041, 3.13, 0.204, 271, 240, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
3624, d5fboA_, 0.6041, 3.17, 0.192, 255, 240, BTK-INHIBITOR CO-STRUCTURE
3625, d5eg3A_, 0.6041, 3.56, 0.248, 301, 246, CRYSTAL STRUCTURE OF THE ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH THE CSH2 DOMAIN OF PHOSPHOLIPASE C GAMMA (PLCGAMMA)
3626, d4r6vA1, 0.6041, 2.90, 0.274, 271, 237, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-3 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
3627, d4ll5A_, 0.6041, 3.07, 0.245, 268, 237, CRYSTAL STRUCTURE OF PIM-1 IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
3628, d4i6qA_, 0.6041, 3.37, 0.219, 277, 242, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-PHENOXY-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-1-CYCLOPROPYL-ETHYL)-AMIDE
3629, d3fupB_, 0.6041, 3.52, 0.228, 287, 246, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
3630, d1yxuA_, 0.6041, 3.11, 0.244, 273, 238, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
3631, d5ng3B_, 0.6040, 3.53, 0.190, 275, 247, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
3632, d4zimA_, 0.6040, 3.45, 0.224, 285, 246, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
3633, d4ji9A_, 0.6040, 3.29, 0.222, 284, 243, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
3634, d4aw5A_, 0.6040, 3.04, 0.197, 261, 239, COMPLEX OF THE EPHB4 KINASE DOMAIN WITH AN OXINDOLE INHIBITOR
3635, d4a7cA_, 0.6040, 3.12, 0.244, 273, 238, CRYSTAL STRUCTURE OF PIM1 KINASE WITH ETP46546
3636, d3jpvA_, 0.6040, 3.11, 0.239, 273, 238, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A PYRROLO[23- A]CARBAZOLE LIGAND
3637, d3dkcA1, 0.6040, 3.74, 0.206, 310, 252, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH ATP
3638, d2qo2A_, 0.6040, 2.83, 0.203, 282, 236, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION DEPHOSPHORYLATED APO STRUCTURE
3639, d2ijmA_, 0.6040, 3.14, 0.216, 260, 241, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
3640, d2brgA_, 0.6040, 2.89, 0.255, 257, 235, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3641, d1y57A3, 0.6040, 3.45, 0.235, 285, 243, STRUCTURE OF UNPHOSPHORYLATED C-SRC IN COMPLEX WITH AN INHIBITOR
3642, d5owrA_, 0.6039, 2.81, 0.223, 282, 233, HUMAN STK10 BOUND TO DASATINIB
3643, d5oq8A_, 0.6039, 3.01, 0.270, 261, 237, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3644, d5opsA_, 0.6039, 2.89, 0.272, 258, 235, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
3645, d4riyB_, 0.6039, 3.22, 0.216, 293, 241, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
3646, d4jq7A_, 0.6039, 3.40, 0.209, 303, 244, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 2A
3647, d4ftcA_, 0.6039, 3.02, 0.274, 266, 237, CRYSTAL STRUCTURE OF THE CHK1
3648, d4cqeA_, 0.6039, 3.01, 0.224, 250, 237, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
3649, d3we8A_, 0.6039, 3.11, 0.235, 273, 238, PIM-1 KINASE IN COMPLEX WITH RUTHENIUM-BASED INHIBITOR
3650, d2qoqA_, 0.6039, 2.94, 0.193, 284, 238, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION BASE AMP-PNP BOUND STRUCTURE
3651, d1yxuB_, 0.6039, 3.11, 0.239, 273, 238, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
3652, d5ttuA_, 0.6038, 3.37, 0.219, 271, 242, JAK3 WITH COVALENT INHIBITOR 7
3653, d5em6A_, 0.6038, 3.32, 0.207, 301, 242, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 19: 4-[(2- AZANYLPYRIMIDIN-4-YL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]- 2-OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
3654, d4x2kA1, 0.6038, 3.39, 0.211, 302, 242, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3655, d4x2jA1, 0.6038, 3.39, 0.211, 302, 242, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3656, d4u40B_, 0.6038, 3.38, 0.220, 299, 246, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
3657, d4kaoB_, 0.6038, 2.96, 0.210, 254, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
3658, d4j95A_, 0.6038, 3.52, 0.254, 279, 244, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
3659, d4bieB_, 0.6038, 2.97, 0.302, 257, 235, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3660, d3cpcA1, 0.6038, 3.10, 0.209, 277, 239, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
3661, d2yfxA_, 0.6038, 3.33, 0.189, 292, 244, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
3662, d2ityA1, 0.6038, 3.21, 0.211, 299, 242, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH IRESSA
3663, d2itvA_, 0.6038, 3.46, 0.208, 303, 245, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AMP-PNP
3664, d1oecA_, 0.6038, 3.48, 0.250, 280, 244, FGFR2 KINASE DOMAIN
3665, d5kgkA_, 0.6037, 3.10, 0.239, 273, 238, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 3-(4-METHOXYPHENYL)-1~{H}- PYRAZOL-5-AMINE
3666, d5fedA_, 0.6037, 3.47, 0.209, 288, 244, EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
3667, d5e8yA_, 0.6037, 3.57, 0.217, 298, 244, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH STAUROSPORINE
3668, d4qyhB_, 0.6037, 3.01, 0.267, 264, 236, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
3669, d3vvhC1, 0.6037, 3.52, 0.214, 282, 248, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
3670, d3tucA_, 0.6037, 3.08, 0.205, 257, 239, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-BENZYL-N-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
3671, d2reiA1, 0.6037, 2.88, 0.207, 274, 237, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7)
3672, d2p2iA2, 0.6037, 3.14, 0.238, 283, 239, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
3673, d4rixD_, 0.6036, 3.61, 0.215, 297, 247, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
3674, d3eflB_, 0.6036, 3.07, 0.223, 263, 238, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
3675, d3c1xA_, 0.6036, 2.96, 0.203, 290, 237, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOTRIAZINE BASED INHIBITOR
3676, d2r0uA_, 0.6036, 3.19, 0.264, 269, 239, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 54
3677, d2javA1, 0.6036, 2.56, 0.259, 245, 232, HUMAN KINASE WITH PYRROLE-INDOLINONE LIGAND
3678, d2helA_, 0.6036, 3.11, 0.208, 256, 240, CRYSTAL STRUCTURE OF A MUTANT EPHA4 KINASE DOMAIN (Y742A)
3679, d1gjoA_, 0.6036, 3.52, 0.250, 280, 244, THE FGFR2 TYROSINE KINASE DOMAIN
3680, d5edrA_, 0.6035, 3.06, 0.196, 299, 240, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 27: ~{N}-(1~{H}- INDAZOL-3-YL)-77-DIMETHYL-2-(2-METHYLPYRAZOL-3-YL)-5~{H}-FURO[34- D]PYRIMIDIN-4-AMINE
3681, d4mneE_, 0.6035, 3.48, 0.215, 286, 247, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3682, d4jx3A_, 0.6035, 3.09, 0.235, 274, 238, CRYSTAL STRUCTURE OF PIM1 KINASE
3683, d4ctcA_, 0.6035, 3.33, 0.189, 288, 244, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 7-AMINO-3-CYCLOPROPYL-12-FLUORO- 11016-TRIMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(4 3-H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
3684, d3nyxA1, 0.6035, 3.71, 0.209, 285, 249, NON-PHOSPHORYLATED TYK2 JH1 DOMAIN WITH QUINOLINE-THIADIAZOLE- THIOPHENE INHIBITOR
3685, d3dzqA_, 0.6035, 2.97, 0.206, 268, 238, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH INHIBITOR AWL-II- 38.3
3686, d2wouA1, 0.6035, 3.52, 0.210, 297, 243, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
3687, d2itzA_, 0.6035, 3.41, 0.205, 302, 244, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH IRESSA
3688, d5ui0B_, 0.6034, 3.56, 0.253, 304, 245, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
3689, d5friA1, 0.6034, 3.56, 0.209, 299, 244, ALK5 IN COMPLEX WITHA AN N-(4-ANILINO-2-PYRIDYL)ACETAMIDE INHIBITOR.
3690, d5cenA_, 0.6034, 3.22, 0.272, 281, 239, CRYSTAL STRUCTURE OF DLK (KINASE DOMAIN)
3691, d4j95C_, 0.6034, 3.53, 0.254, 281, 244, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
3692, d4fg8B_, 0.6034, 3.08, 0.286, 268, 238, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-315 IN COMPLEX WITH ATP
3693, d1u4dB_, 0.6034, 3.20, 0.209, 262, 239, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
3694, d5op4A_, 0.6033, 3.06, 0.274, 259, 237, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDINE LRRK2 INHIBITOR
3695, d5aacA_, 0.6033, 3.34, 0.180, 292, 244, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
3696, d4twoA_, 0.6033, 3.06, 0.209, 278, 239, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 164
3697, d4rvlA_, 0.6033, 2.99, 0.264, 258, 235, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 7: 3-(2- HYDROXYPHENYL)-9H-PYRROLO[23-B:54-C ]DIPYRIDINE-6-CARBONITRILE
3698, d4j95D_, 0.6033, 3.41, 0.267, 271, 243, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
3699, d4d58B_, 0.6033, 3.30, 0.214, 261, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
3700, d3zlyA_, 0.6033, 3.79, 0.216, 310, 250, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 8
3701, d5em7A_, 0.6032, 3.22, 0.199, 300, 241, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 13: 4-[(2- METHOXYPHENYL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
3702, d4mbiA_, 0.6032, 3.12, 0.239, 274, 238, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
3703, d4ftrA_, 0.6032, 3.02, 0.267, 258, 236, CRYSTAL STRUCTURE OF THE CHK1
3704, d4d0wA_, 0.6032, 3.92, 0.230, 289, 252, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
3705, d3a7hA_, 0.6032, 3.60, 0.211, 289, 246, HUMAN MST3 KINASE IN COMPLEX WITH ATP
3706, d5e8zA1, 0.6031, 3.68, 0.208, 300, 245, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 3- AMINO-6-[4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3- YL]PYRAZINE-2-CARBOXAMIDE
3707, d3zlwA_, 0.6031, 3.76, 0.220, 312, 250, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 3
3708, d3o50A_, 0.6031, 2.96, 0.249, 246, 237, CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA
3709, d3jxwA_, 0.6031, 3.12, 0.239, 274, 238, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
3710, d3bizA_, 0.6031, 3.02, 0.191, 250, 235, WEE1 KINASE COMPLEX WITH INHIBITOR PD331618
3711, d2x8eA_, 0.6031, 3.17, 0.270, 259, 237, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
3712, d2auhA1, 0.6031, 4.00, 0.208, 294, 255, CRYSTAL STRUCTURE OF THE GRB14 BPS REGION IN COMPLEX WITH THE INSULIN RECEPTOR TYROSINE KINASE
3713, d5feeA_, 0.6030, 3.55, 0.204, 287, 245, EGFR KINASE DOMAIN T790M MUTANT IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
3714, d5c1qB_, 0.6030, 3.12, 0.244, 273, 238, SERINE/THREONINE-PROTEIN KINASE PIM-1
3715, d4xeyB2, 0.6030, 3.14, 0.223, 264, 238, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
3716, d4wrsA_, 0.6030, 3.14, 0.244, 273, 238, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AZASPIRO PYRAZINYL-INDAZOLE INHIBITOR.
3717, d4qygB_, 0.6030, 3.03, 0.267, 264, 236, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
3718, d4obqB_, 0.6030, 3.33, 0.220, 293, 245, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
3719, d4jrvA_, 0.6030, 3.51, 0.213, 300, 244, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4C
3720, d4gk2A_, 0.6030, 2.98, 0.197, 265, 238, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 66
3721, d3zepB_, 0.6030, 3.51, 0.223, 268, 242, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3722, d3t9iA_, 0.6030, 3.06, 0.245, 273, 237, PIM1 COMPLEXED WITH A NOVEL 36-DISUBSTITUTED INDOLE AT 2.6 ANG RESOLUTION
3723, d3f3vA_, 0.6030, 3.18, 0.252, 261, 238, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
3724, d3dk6B_, 0.6030, 3.14, 0.219, 259, 237, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3725, d2jc6A_, 0.6030, 3.00, 0.280, 278, 236, CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE 1D
3726, d5kgeA_, 0.6029, 3.12, 0.239, 273, 238, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 5-(34-DICHLOROPHENYL)- 1~{H}-PYRAZOL-3-AMINE
3727, d4x0mA1, 0.6029, 3.41, 0.211, 302, 242, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3728, d5flfC_, 0.6028, 3.45, 0.251, 283, 243, DISEASE LINKED MUTATION IN FGFR
3729, d5aa8A_, 0.6028, 3.34, 0.176, 292, 244, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12- FLUORO-21016-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H- 84-(METHENO)PYRAZOLO(43-H)(2511) BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
3730, d4wsyA_, 0.6028, 3.13, 0.239, 273, 238, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIAZOLAMINE-INDAZOLE INHIBITOR.
3731, d4d5hB_, 0.6028, 3.27, 0.214, 260, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3732, d3e64A_, 0.6028, 4.00, 0.229, 291, 253, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
3733, d3dy7A_, 0.6028, 3.25, 0.218, 260, 243, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
3734, d3ctjA_, 0.6028, 3.13, 0.212, 289, 240, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
3735, d5kgdA_, 0.6027, 3.13, 0.239, 273, 238, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-PYRIDIN-3-YL-1~{H}- BENZIMIDAZOLE
3736, d5em5A_, 0.6027, 3.24, 0.203, 298, 241, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 2: 4-[2-(4- CHLOROPHENYL)ETHYLAMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
3737, d4ytfA_, 0.6027, 3.74, 0.226, 283, 248, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
3738, d4u3yB_, 0.6027, 3.50, 0.210, 300, 248, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
3739, d4rj8A_, 0.6027, 3.28, 0.207, 298, 241, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 8
3740, d4gfmA_, 0.6027, 3.95, 0.230, 289, 252, JAK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
3741, d3vvhB1, 0.6027, 3.60, 0.213, 289, 249, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
3742, d3u6iA_, 0.6027, 3.07, 0.227, 281, 238, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 58A
3743, d3gqiA_, 0.6027, 3.70, 0.247, 304, 247, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
3744, d3e62A_, 0.6027, 3.94, 0.226, 291, 252, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
3745, d2dq7X_, 0.6027, 3.46, 0.240, 262, 242, CRYSTAL STRUCTURE OF FYN KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
3746, d5cswA_, 0.6026, 2.93, 0.220, 254, 236, B-RAF IN COMPLEX WITH DABRAFENIB
3747, d4zjjB_, 0.6026, 3.13, 0.237, 277, 240, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
3748, d4wt6A_, 0.6026, 3.13, 0.244, 273, 238, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIADIAZOLAMINE-INDOLE INHIBITOR.
3749, d4j97C_, 0.6026, 3.42, 0.259, 283, 243, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
3750, d4fttA_, 0.6026, 3.03, 0.267, 266, 236, CRYSTAL STRUCTURE OF THE CHK1
3751, d3dqwB_, 0.6026, 3.51, 0.251, 278, 243, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
3752, d3c4eC_, 0.6026, 3.08, 0.236, 272, 237, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
3753, d2vz6B1, 0.6026, 3.64, 0.287, 288, 244, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
3754, d2o63A_, 0.6026, 3.13, 0.235, 274, 238, CRYSTAL STRUCTURE OF PIM1 WITH MYRICETIN
3755, d2jc6C_, 0.6026, 2.95, 0.281, 277, 235, CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE 1D
3756, d5tehA_, 0.6025, 3.06, 0.254, 261, 236, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
3757, d5eydA_, 0.6025, 3.51, 0.217, 289, 244, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH AMG 337
3758, d5cf4A_, 0.6025, 3.35, 0.230, 283, 244, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3759, d4xg7A1, 0.6025, 3.51, 0.200, 265, 245, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3760, d4medA_, 0.6025, 3.07, 0.236, 272, 237, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE DERIVATIVES
3761, d4fsyA_, 0.6025, 3.03, 0.271, 267, 236, CRYSTAL STRUCTURE OF THE CHK1
3762, d4dehA_, 0.6025, 3.48, 0.209, 286, 244, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 3
3763, d3tzmA_, 0.6025, 3.34, 0.212, 295, 241, TGF-BETA RECEPTOR TYPE 1 IN COMPLEX WITH SB431542
3764, d3rvgA_, 0.6025, 3.48, 0.224, 285, 245, CRYSTALS STRUCTURE OF JAK2 WITH A 1-AMINO-5H-PYRIDO[43-B]INDOL-4- CARBOXAMIDE INHIBITOR
3765, d3o50B_, 0.6025, 3.15, 0.246, 249, 240, CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA
3766, d3cpbB_, 0.6025, 3.07, 0.219, 263, 237, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
3767, d3cpbA1, 0.6025, 3.09, 0.214, 278, 238, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
3768, d3ckwA_, 0.6025, 2.65, 0.224, 255, 232, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24)
3769, d2jitB_, 0.6025, 3.62, 0.194, 312, 248, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
3770, d2b7aB_, 0.6025, 3.59, 0.227, 287, 247, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
3771, d6bu6D_, 0.6024, 4.00, 0.176, 318, 255, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
3772, d5t68B_, 0.6024, 3.14, 0.197, 264, 239, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
3773, d5hczA_, 0.6024, 3.43, 0.206, 300, 243, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-AZETIDINYL AZAINDAZOLE COMPOUND 21
3774, d4yc8A_, 0.6024, 3.29, 0.218, 259, 239, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
3775, d4xhkB_, 0.6024, 3.13, 0.244, 269, 238, PIM1 KINASE IN COMPLEX WITH COMPOUND 1S
3776, d4xg4A_, 0.6024, 3.13, 0.205, 264, 239, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3777, d4trlA_, 0.6024, 3.22, 0.200, 268, 240, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
3778, d4j99C_, 0.6024, 3.45, 0.247, 291, 243, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
3779, d3vapA_, 0.6024, 3.15, 0.246, 249, 240, SYNTHESIS AND SAR STUDIES OF IMIDAZO-[12-A]-PYRAZINE AURORA KINASE INHIBITORS WITH IMPROVED OFF TARGET KINASE SELECTIVITY
3780, d3oezA_, 0.6024, 3.17, 0.252, 261, 238, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
3781, d3b2tA_, 0.6024, 3.44, 0.255, 288, 243, STRUCTURE OF PHOSPHOTRANSFERASE
3782, d2w1iB_, 0.6024, 3.40, 0.217, 284, 244, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3783, d1k2pA_, 0.6024, 3.27, 0.183, 258, 241, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
3784, d5kgiA_, 0.6023, 3.13, 0.239, 273, 238, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR 2-[34-BIS(CHLORANYL) PHENOXY]ETHANAMINE
3785, d5iisA_, 0.6023, 3.24, 0.234, 273, 239, DESIGN SYNTHESIS AND STRUCTURE ACTIVITY RELATIONSHIP OF POTENT PAN- PIM KINASE INHIBITORS DERIVED FROM THE PYRIDYL-AMIDE SCAFFOLD
3786, d5hieA_, 0.6023, 3.16, 0.234, 258, 239, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
3787, d4a4xA1, 0.6023, 2.72, 0.231, 245, 234, NEK2-EDE BOUND TO CCT248662
3788, d3f3wB_, 0.6023, 2.97, 0.250, 260, 236, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
3789, d2x81A_, 0.6023, 2.95, 0.241, 242, 237, STRUCTURE OF AURORA A IN COMPLEX WITH MLN8054
3790, d2hyyB1, 0.6023, 3.04, 0.233, 252, 236, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
3791, d5oq6A_, 0.6022, 2.87, 0.269, 257, 234, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
3792, d5flfB_, 0.6022, 3.59, 0.253, 292, 245, DISEASE LINKED MUTATION IN FGFR
3793, d4u5jA_, 0.6022, 3.40, 0.260, 267, 242, C-SRC IN COMPLEX WITH RUXOLITINIB
3794, d3ri1B_, 0.6022, 3.60, 0.266, 283, 244, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
3795, d3r01A_, 0.6022, 3.14, 0.239, 274, 238, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
3796, d3b2tB_, 0.6022, 3.47, 0.251, 287, 243, STRUCTURE OF PHOSPHOTRANSFERASE
3797, d5t68A1, 0.6021, 3.18, 0.197, 264, 239, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
3798, d5dhjA_, 0.6021, 3.13, 0.244, 273, 238, PIM1 IN COMPLEX WITH CPD4 (3-METHYL-5-(PYRIDIN-3-YL)-1H-PYRAZOLO[34- C]PYRIDINE)
3799, d4qyhA_, 0.6021, 3.00, 0.272, 264, 235, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
3800, d4iaaA_, 0.6021, 3.07, 0.236, 272, 237, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE
3801, d4bhnB_, 0.6021, 2.97, 0.298, 257, 235, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3802, d3zzwB_, 0.6021, 3.45, 0.173, 265, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF ROR2
3803, d3lxpA_, 0.6021, 3.69, 0.227, 285, 247, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
3804, d2xj0A_, 0.6021, 3.15, 0.239, 274, 238, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-4 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
3805, d1s9iB_, 0.6021, 3.55, 0.235, 291, 247, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
3806, d5ttsA_, 0.6020, 3.39, 0.216, 274, 241, JAK3 WITH COVALENT INHIBITOR 4
3807, d5e8tA1, 0.6020, 3.61, 0.209, 300, 244, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D)
3808, d4usdB_, 0.6020, 3.09, 0.229, 267, 240, HUMAN STK10 (LOK) WITH SB-633825
3809, d4rblA_, 0.6020, 3.10, 0.245, 271, 237, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3810, d3tz9A_, 0.6020, 3.18, 0.252, 261, 238, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
3811, d3kf4A_, 0.6020, 3.24, 0.230, 281, 239, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
3812, d3f9nA_, 0.6020, 3.12, 0.275, 253, 236, CRYSTAL STRUCTURE OF CHK1 KINASE IN COMPLEX WITH INHIBITOR 38
3813, d2z7qA_, 0.6020, 2.68, 0.277, 255, 231, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK-1 BOUND TO AMP-PCP
3814, d2o65A_, 0.6020, 3.06, 0.236, 274, 237, CRYSTAL STRUCTURE OF PIM1 WITH PENTAHYDROXYFLAVONE
3815, d1yxvA_, 0.6020, 3.14, 0.239, 274, 238, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH 34-DIHYDROXY-1- METHYLQUINOLIN-2(1H)-ONE
3816, d6eimB_, 0.6019, 3.26, 0.213, 295, 239, HUMAN STK10 BOUND TO GW683134A
3817, d5flfA_, 0.6019, 3.60, 0.253, 296, 245, DISEASE LINKED MUTATION IN FGFR
3818, d5c27A1, 0.6019, 3.62, 0.194, 271, 247, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 2
3819, d4rj5A_, 0.6019, 3.20, 0.200, 296, 240, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 5
3820, d4rixB_, 0.6019, 3.31, 0.219, 293, 242, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
3821, d4g5jA_, 0.6019, 3.54, 0.213, 307, 244, CRYSTAL STRUCTURE OF EGFR KINASE IN COMPLEX WITH BIBW2992
3822, d4ft5A_, 0.6019, 3.05, 0.267, 265, 236, CRYSTAL STRUCTURE OF THE CHK1
3823, d3tz8A_, 0.6019, 3.18, 0.252, 261, 238, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
3824, d3fzsA_, 0.6019, 2.92, 0.152, 254, 237, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH BIRB796
3825, d3dqwA_, 0.6019, 3.52, 0.251, 278, 243, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
3826, d3bwfA_, 0.6019, 3.06, 0.232, 273, 237, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH AN OSMIUM COMPOUND
3827, d2xnoA1, 0.6019, 2.63, 0.224, 243, 232, STRUCTURE OF NEK2 BOUND TO CCT243779
3828, d1zycD1, 0.6019, 3.33, 0.234, 254, 244, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
3829, d5cauA_, 0.6018, 3.29, 0.203, 297, 241, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41B
3830, d4xh6A_, 0.6018, 3.05, 0.232, 273, 237, CRYSTAL STRUCTURE OF PROTO-ONCOGENE KINASE PIM1 BOUND TO HISPIDULIN
3831, d4d4yB_, 0.6018, 3.29, 0.210, 260, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3832, d3f3wA_, 0.6018, 3.06, 0.245, 261, 237, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
3833, d2o64A_, 0.6018, 3.23, 0.238, 274, 239, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETAGETIN
3834, d2bziB_, 0.6018, 3.09, 0.241, 272, 237, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU2
3835, d1s9iA_, 0.6018, 3.69, 0.225, 303, 249, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
3836, d5telA_, 0.6017, 3.16, 0.244, 273, 238, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
3837, d5ar4A_, 0.6017, 3.07, 0.224, 274, 237, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
3838, d4z16D_, 0.6017, 3.25, 0.218, 271, 239, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
3839, d4j99A_, 0.6017, 3.40, 0.248, 280, 242, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
3840, d4fsuA_, 0.6017, 2.97, 0.272, 260, 235, CRYSTAL STRUCTURE OF THE CHK1
3841, d3vc4A_, 0.6017, 3.16, 0.244, 274, 238, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3842, d2qu6B_, 0.6017, 3.24, 0.221, 260, 240, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
3843, d2psqA_, 0.6017, 3.49, 0.267, 287, 243, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
3844, d5cwzC_, 0.6016, 2.89, 0.230, 271, 235, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
3845, d4xg2A1, 0.6016, 3.02, 0.207, 258, 237, CRYSTAL STRUCTURE OF LIGAND-FREE SYK
3846, d4wkqA1, 0.6016, 3.56, 0.212, 294, 245, 1.85 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN WITH GEFITINIB
3847, d4mxxB_, 0.6016, 3.15, 0.252, 260, 238, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
3848, d4j98A_, 0.6016, 3.55, 0.254, 304, 244, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
3849, d4aojB_, 0.6016, 2.98, 0.203, 258, 237, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
3850, d3qgwA_, 0.6016, 2.90, 0.183, 244, 235, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
3851, d2zvaA1, 0.6016, 3.28, 0.231, 260, 242, LYN TYROSINE KINASE DOMAIN-DASATINIB COMPLEX
3852, d5w4wB_, 0.6015, 3.32, 0.203, 291, 241, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
3853, d5i8aA1, 0.6015, 3.33, 0.210, 265, 238, TRKA WITH (6~{R})-3-METHYLSULFANYL-6-PHENYL-1-(1~{H}-PYRAZOL-3-YL)-6 7-DIHYDRO-5~{H}-THIENO[34-C]PYRIDIN-4-ONE
3854, d4qo9A_, 0.6015, 3.46, 0.214, 280, 243, MST3 IN COMPLEX WITH DANUSERTIB
3855, d3jy0A_, 0.6015, 3.17, 0.244, 275, 238, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
3856, d3h4jA1, 0.6015, 3.94, 0.275, 313, 251, CRYSTAL STRUCTURE OF POMBE AMPK KDAID FRAGMENT
3857, d3g6gB_, 0.6015, 3.15, 0.248, 263, 238, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
3858, d1yxxA_, 0.6015, 3.14, 0.239, 274, 238, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH (3E)-3-[(4- HYDROXYPHENYL)IMINO]-1H-INDOL-2(3H)-ONE
3859, d5ui0A_, 0.6014, 3.56, 0.254, 301, 244, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
3860, d5texA_, 0.6014, 3.25, 0.234, 274, 239, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
3861, d5flfD_, 0.6014, 3.59, 0.253, 290, 245, DISEASE LINKED MUTATION IN FGFR
3862, p5cemA_, 0.6014, 3.19, 0.212, 252, 240, PSEUDOKINASE AND C-TERMINAL EXTENSION OF HUMAN TRIBBLES HOMOLOG 1
3863, d5casA_, 0.6014, 3.20, 0.200, 299, 240, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41A
3864, d4wnmA1, 0.6014, 3.38, 0.202, 269, 243, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT TRIAZOLOPYRIDINE INHIBITOR
3865, d4hnfA_, 0.6014, 3.06, 0.207, 289, 237, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
3866, d3q6uA1, 0.6014, 3.32, 0.214, 281, 243, STRUCTURE OF THE APO MET RECEPTOR KINASE IN THE DUALLY-PHOSPHORYLATED ACTIVATED STATE
3867, d3lpbA_, 0.6014, 3.39, 0.226, 278, 243, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
3868, d2pwlA_, 0.6014, 3.44, 0.252, 284, 242, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
3869, d1eh4A_, 0.6014, 3.32, 0.169, 293, 242, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
3870, d5oprA_, 0.6013, 2.94, 0.268, 258, 235, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIDINE LRRK2 INHIBITOR
3871, d4qygA_, 0.6013, 3.09, 0.280, 264, 236, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
3872, d3zfyB_, 0.6013, 2.93, 0.204, 255, 235, CRYSTAL STRUCTURE OF EPHB3
3873, d3jyaA_, 0.6013, 3.16, 0.239, 274, 238, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
3874, d3fqsA1, 0.6013, 3.08, 0.206, 264, 238, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R406
3875, d3c7qA_, 0.6013, 3.06, 0.227, 286, 238, STRUCTURE OF VEGFR2 KINASE DOMAIN IN COMPLEX WITH BIBF1120
3876, d3a99A_, 0.6013, 3.18, 0.244, 273, 238, STRUCTURE OF PIM-1 KINASE CRYSTALLIZED IN THE PRESENCE OF P27KIP1 CARBOXY-TERMINAL PEPTIDE
3877, d5hicA_, 0.6012, 3.40, 0.202, 302, 243, EGFR KINASE DOMAIN MUTANT TMLR WITH A IMIDAZOPYRIDINYL- AMINOPYRIMIDINE INHIBITOR
3878, d5hcxA_, 0.6012, 3.34, 0.202, 298, 242, EGFR KINASE DOMAIN MUTANT TMLR WITH AZABENZIMIDAZOLE COMPOUND 7
3879, d5cf8A1, 0.6012, 3.42, 0.230, 284, 244, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3880, d4riwB_, 0.6012, 3.10, 0.218, 293, 239, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
3881, d4mblA_, 0.6012, 3.23, 0.238, 274, 239, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
3882, d4j99D_, 0.6012, 3.34, 0.253, 281, 241, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
3883, d4j96A_, 0.6012, 3.57, 0.254, 302, 244, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
3884, d4i41A_, 0.6012, 3.11, 0.232, 272, 237, CRYSTAL STRUCTURE OF HUMAN SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE
3885, d4fk6B_, 0.6012, 3.71, 0.215, 284, 247, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
3886, d4d4rA_, 0.6012, 3.14, 0.206, 251, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3887, d4bieA_, 0.6012, 2.91, 0.297, 257, 232, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3888, d4bhnA_, 0.6012, 2.96, 0.296, 256, 233, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3889, d3kcfB_, 0.6012, 3.95, 0.205, 324, 249, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3890, d3f66B_, 0.6012, 3.17, 0.223, 269, 238, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
3891, d3eygA_, 0.6012, 3.59, 0.229, 280, 245, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
3892, d6bp0B_, 0.6011, 4.07, 0.164, 304, 256, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3893, d5t3qA1, 0.6011, 3.18, 0.213, 277, 239, CRYSTAL STRUCTURE OF THE C-MET KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
3894, d4rj7A_, 0.6011, 3.27, 0.204, 295, 240, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 1
3895, d4fnxA_, 0.6011, 3.39, 0.180, 292, 244, CRYSTAL STRUCTURE OF THE APO R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
3896, d3u6hA_, 0.6011, 3.09, 0.227, 280, 238, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 26
3897, d3r00A_, 0.6011, 3.17, 0.239, 274, 238, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
3898, d3f3vB_, 0.6011, 3.11, 0.253, 262, 237, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
3899, d5ipjA_, 0.6010, 3.17, 0.239, 273, 238, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A QUINAZOLINONE-PYRROLOPYRROLONE INHIBITOR.
3900, d5hcyA_, 0.6010, 3.47, 0.205, 302, 244, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-CARBOXAMIDE AZAINDOLE COMPOUND 13
3901, d4usdA_, 0.6010, 3.06, 0.222, 268, 239, HUMAN STK10 (LOK) WITH SB-633825
3902, d4rx7A1, 0.6010, 3.50, 0.201, 270, 244, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR
3903, d4equB_, 0.6010, 3.07, 0.222, 282, 234, HUMAN STK-10 (LOK) KINASE DOMAIN IN DFG-OUT CONFORMATION WITH INHIBITOR DSA-7
3904, d4ehzA_, 0.6010, 3.60, 0.215, 290, 246, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
3905, d3uzpA_, 0.6010, 3.30, 0.199, 292, 241, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
3906, d3qtiA_, 0.6010, 3.57, 0.221, 292, 244, C-MET KINASE IN COMPLEX WITH NVP-BVU972
3907, d2o3pA_, 0.6010, 3.08, 0.236, 274, 237, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETIN
3908, d5uhnA_, 0.6009, 3.51, 0.255, 282, 243, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
3909, d5t0pB_, 0.6009, 3.26, 0.261, 263, 238, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
3910, d4ztqA_, 0.6009, 3.01, 0.249, 247, 237, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK932
3911, d4rj6A_, 0.6009, 3.22, 0.200, 297, 240, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 4
3912, d4k8aA_, 0.6009, 3.01, 0.214, 251, 238, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
3913, d3q4uB1, 0.6009, 3.30, 0.240, 298, 242, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
3914, d3cs9B_, 0.6009, 2.86, 0.223, 247, 233, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
3915, d6eimA_, 0.6008, 3.17, 0.203, 286, 236, HUMAN STK10 BOUND TO GW683134A
3916, d5oq7B_, 0.6008, 3.01, 0.289, 256, 235, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3917, d5ar5B_, 0.6008, 3.15, 0.214, 279, 238, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
3918, d4mxzB_, 0.6008, 3.29, 0.255, 264, 239, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
3919, d4mxyB_, 0.6008, 3.29, 0.255, 264, 239, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
3920, d3lpbB1, 0.6008, 3.55, 0.234, 283, 244, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
3921, d3dcvA_, 0.6008, 3.24, 0.234, 273, 239, CRYSTAL STRUCTURE OF HUMAN PIM1 KINASE COMPLEXED WITH 4-(4- HYDROXY-3-METHYL-PHENYL)-6-PHENYLPYRIMIDIN-2(1H)-ONE
3922, d5mo4A3, 0.6007, 2.83, 0.211, 271, 232, ABL1 KINASE (T334I_D382N) IN COMPLEX WITH ASCIMINIB AND NILOTINIB
3923, d5k9iB_, 0.6007, 3.31, 0.259, 262, 239, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
3924, d4useA_, 0.6007, 3.19, 0.224, 286, 237, HUMAN STK10 (LOK) WITH SB-633825
3925, d4kbkB_, 0.6007, 3.27, 0.207, 289, 241, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
3926, d4hgsA1, 0.6007, 3.43, 0.164, 301, 244, CRYSTAL STRUCTURE OF CK1GS WITH COMPOUND 13
3927, d4dtkA_, 0.6007, 3.19, 0.235, 273, 238, NOVEL AND SELECTIVE PAN-PIM KINASE INHIBITOR
3928, d3f3tA_, 0.6007, 3.13, 0.249, 261, 237, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
3929, d5cxzA1, 0.6006, 3.27, 0.207, 267, 241, SYK CATALYTIC DOMAIN COMPLEXED WITH NAPHTHYRIDINE INHIBITOR
3930, d4hzrA_, 0.6006, 3.27, 0.208, 261, 240, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
3931, d3uqgA_, 0.6006, 3.25, 0.265, 263, 238, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
3932, d3qgyA1, 0.6006, 2.98, 0.183, 244, 235, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
3933, d5wfjA_, 0.6005, 3.14, 0.219, 265, 237, THE JAK3 KINASE DOMAIN IN COMPLEX WITH A COVALENT INHIBITOR
3934, d5uglA_, 0.6005, 3.51, 0.251, 285, 243, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
3935, d5tt7A1, 0.6005, 3.31, 0.207, 270, 241, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
3936, d4rssA_, 0.6005, 3.56, 0.196, 269, 245, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE SYK WITH AN INHIBITOR
3937, d4jx7A_, 0.6005, 3.17, 0.244, 274, 238, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR 2-[(TRANS- 4-AMINOCYCLOHEXYL)AMINO]-4-{[3-(TRIFLUOROMETHYL) PHENYL]AMINO}PYRIDO[43-D]PYRIMIDIN-5(6H)-ONE
3938, d4j97D_, 0.6005, 3.51, 0.255, 285, 243, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
3939, d4aluA_, 0.6005, 3.09, 0.236, 274, 237, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
3940, d3c4eD_, 0.6005, 3.18, 0.239, 273, 238, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
3941, d3bceC_, 0.6005, 3.49, 0.221, 286, 244, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
3942, d2pvyA_, 0.6005, 3.47, 0.248, 288, 242, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
3943, d5ugxB_, 0.6004, 3.50, 0.247, 282, 243, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
3944, d5fbnD_, 0.6004, 3.49, 0.193, 255, 243, BTK KINASE DOMAIN WITH INHIBITOR 1
3945, d4ty1A_, 0.6004, 3.16, 0.244, 273, 238, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AMINOOXADIAZOLE-INDOLE INHIBITOR.
3946, d4pdoB_, 0.6004, 2.98, 0.194, 261, 237, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
3947, d4pdoA_, 0.6004, 2.97, 0.190, 261, 237, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
3948, d3zm4A_, 0.6004, 3.83, 0.217, 309, 249, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 1
3949, d3w2rA_, 0.6004, 3.29, 0.212, 297, 241, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 4
3950, d3clyA_, 0.6004, 3.59, 0.249, 289, 245, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAINS TRAPPED IN TRANS-PHOSPHORYLATION REACTION
3951, d3bgzA_, 0.6004, 3.14, 0.245, 267, 237, HUMAN PIM-1 KINASE IN COMPLEX WITH DIPHENYL INDOLE INHIBITOR VX3
3952, d3bgpA_, 0.6004, 3.13, 0.241, 272, 237, HUMAN PIM-1 COMPLEXED WITH A BENZOISOXAZOLE INHIBITOR VX1
3953, d2qofA_, 0.6004, 2.85, 0.204, 280, 235, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F MUTANT
3954, d2pwlB_, 0.6004, 3.55, 0.251, 286, 243, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
3955, d1yxuD_, 0.6004, 3.18, 0.239, 273, 238, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
3956, d4p4cA_, 0.6003, 2.93, 0.203, 266, 236, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
3957, d4hokI_, 0.6003, 3.41, 0.193, 291, 243, CRYSTAL STRUCTURE OF APO CK1E
3958, d4hgeB_, 0.6003, 3.63, 0.227, 288, 247, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
3959, d4d4rB_, 0.6003, 3.47, 0.212, 270, 245, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3960, d3slsA1, 0.6003, 3.93, 0.212, 289, 250, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
3961, d3eflA1, 0.6003, 2.99, 0.220, 279, 236, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
3962, d2qodA_, 0.6003, 2.85, 0.209, 274, 235, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y602F MUTANT
3963, d2b7aA_, 0.6003, 3.40, 0.230, 284, 244, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
3964, d1yi4A_, 0.6003, 3.09, 0.233, 267, 236, STRUCTURE OF PIM-1 BOUND TO ADENOSINE
3965, d1jpaA_, 0.6003, 2.93, 0.208, 273, 236, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED EPHB2 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
3966, d1a06A_, 0.6003, 2.86, 0.293, 279, 232, CALMODULIN-DEPENDENT PROTEIN KINASE FROM RAT
3967, d5vd2A_, 0.6002, 3.32, 0.192, 258, 240, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PF- 03814735
3968, d5ugxA_, 0.6002, 3.61, 0.254, 297, 244, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
3969, d4u3zB_, 0.6002, 3.45, 0.215, 294, 246, APO MAP4K4 T181E PHOSPHOMIMETIC MUTANT
3970, d4e6dB_, 0.6002, 3.57, 0.229, 286, 245, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
3971, d3bymA_, 0.6002, 3.56, 0.239, 271, 243, X-RAY CO-CRYSTAL STRUCTURE AMINOBENZIMIDAZOLE TRIAZINE 1 BOUND TO LCK
3972, d2qo7A_, 0.6002, 2.90, 0.199, 278, 236, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION DEPHOSPHORYLATED AMP-PNP BOUND
3973, d2hyyC1, 0.6002, 3.09, 0.229, 249, 236, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
3974, d4yjtA_, 0.6001, 3.66, 0.198, 268, 247, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000233
3975, d4g16A1, 0.6001, 3.44, 0.164, 301, 244, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-{[3-(TRIFLUOROMETHYL)PYRIDIN2- YL]OXY}PHENYL)AMINO]-1H-BENZIMIDAZOLE-6-CARBONITRILE
3976, d3cpcB_, 0.6001, 3.10, 0.219, 262, 237, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
3977, d2yn8A_, 0.6001, 2.82, 0.209, 253, 234, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3978, d2qoiA_, 0.6001, 2.86, 0.209, 274, 235, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F DOUBLE MUTANT
3979, d2py3A_, 0.6001, 3.58, 0.251, 282, 243, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
3980, d1yxuC_, 0.6001, 3.05, 0.233, 272, 236, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
3981, d5x18A_, 0.6000, 3.27, 0.174, 294, 241, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
3982, d4twcB_, 0.6000, 3.30, 0.202, 292, 242, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
3983, d4k0yA_, 0.6000, 3.18, 0.239, 274, 238, STRUCTURE OF PIM-1 KINASE BOUND TO N-(4-FLUOROPHENYL)-7-HYDROXY-5- (PIPERIDIN-4-YL)PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
3984, d4hviA_, 0.6000, 3.31, 0.221, 274, 240, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-1-METHYL-2-OXO-2-PIPERIDIN-1-YL- ETHYL)-AMIDE
3985, d4dfnA1, 0.6000, 3.40, 0.198, 268, 243, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH AN ADAMANTYLPYRAZINE INHIBITOR
3986, d4degA_, 0.6000, 3.51, 0.218, 286, 243, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDAZINE INHIBITOR 2
3987, d3zepA_, 0.6000, 3.52, 0.218, 274, 243, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3988, d3q6wA1, 0.6000, 3.42, 0.226, 293, 243, STRUCTURE OF DUALLY-PHOSPHORYLATED MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG WITH SPECIFICITY FOR THE ACTIVATED RECEPTOR
3989, d3lvpD_, 0.6000, 3.65, 0.183, 282, 246, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
3990, d3dkoA1, 0.6000, 2.87, 0.196, 272, 235, COMPLEX BETWEEN THE KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7) AND INHIBITOR ALW-II-49-7
3991, d2x2mB1, 0.6000, 3.82, 0.222, 274, 248, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
3992, d5w4wA_, 0.5999, 3.15, 0.205, 291, 239, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
3993, d4yjrA_, 0.5999, 3.78, 0.202, 263, 248, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000225
3994, d4yjqA_, 0.5999, 3.78, 0.202, 264, 248, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000224
3995, d4rc4A_, 0.5999, 3.14, 0.232, 272, 237, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3996, d4p7eA_, 0.5999, 3.38, 0.222, 281, 243, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
3997, d4alvA_, 0.5999, 3.17, 0.239, 274, 238, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
3998, d3vw8A_, 0.5999, 3.63, 0.207, 303, 246, CRYSTAL STRUCTURE OF HUMAN C-MET KINASE DOMAIN WITH ITS INHIBITOR
3999, d3kmmA_, 0.5999, 3.52, 0.239, 270, 243, STRUCTURE OF HUMAN LCK KINASE WITH A SMALL MOLECULE INHIBITOR
4000, d3f6xB_, 0.5999, 3.30, 0.268, 267, 239, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4001, d2x2kA1, 0.5999, 3.79, 0.230, 284, 248, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
4002, d1b6cF_, 0.5999, 3.76, 0.202, 326, 248, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
4003, d5v19A_, 0.5998, 2.79, 0.294, 250, 231, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
4004, d5dlsA_, 0.5998, 2.92, 0.261, 257, 234, IDENTIFICATION OF NOVEL IN VIVO ACTIVE CHK1 INHIBITORS UTILIZING STRUCTURE GUIDED DRUG DESIGN
4005, d5diaA_, 0.5998, 3.19, 0.244, 273, 238, PIM1 IN COMPLEX WITH CPD36 ((1S3S)-N1-(6-(5-(PYRIDIN-3-YL)-1H- PYRAZOLO[34-C]PYRIDIN-3-YL)PYRIDIN-2-YL)CYCLOHEXANE-13-DIAMINE)
4006, d4rc3A_, 0.5998, 3.13, 0.236, 271, 237, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
4007, d3g6hB_, 0.5998, 3.05, 0.246, 259, 236, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
4008, d1vjyA_, 0.5998, 3.52, 0.210, 299, 243, CRYSTAL STRUCTURE OF A NAPHTHYRIDINE INHIBITOR OF HUMAN TGF- BETA TYPE I RECEPTOR
4009, d6bu6B_, 0.5997, 3.91, 0.169, 307, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
4010, d5opbA_, 0.5997, 3.10, 0.274, 262, 237, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH INDAZOLE LRRK2 INHIBITOR
4011, d5cy3A1, 0.5997, 3.58, 0.208, 274, 245, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT AND ORALLY BIOAVAILABLE BENZISOTHIAZOLE INHIBITOR
4012, d4xg3A_, 0.5997, 3.35, 0.202, 262, 242, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4013, d4tn6B_, 0.5997, 3.22, 0.205, 285, 239, CK1D IN COMPLEX WITH INHIBITOR
4014, d4p5zA_, 0.5997, 2.95, 0.208, 267, 236, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
4015, d4obpB_, 0.5997, 3.30, 0.214, 290, 243, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
4016, d4n70A_, 0.5997, 3.19, 0.239, 274, 238, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
4017, d4hglA1, 0.5997, 3.45, 0.164, 301, 244, CRYSTAL STRUCTURE OF CK1G3 WITH COMPOUND 1
4018, d3jvsA_, 0.5997, 2.94, 0.270, 256, 233, CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE
4019, d2qooA_, 0.5997, 2.86, 0.209, 273, 235, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:Y742F TRIPLE MUTANT
4020, d5turA_, 0.5996, 3.21, 0.235, 270, 238, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
4021, d4jjrB_, 0.5996, 3.33, 0.202, 283, 242, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
4022, d4e6dA_, 0.5996, 3.55, 0.229, 286, 245, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
4023, d3zepD_, 0.5996, 3.54, 0.218, 272, 243, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
4024, d2yjsA_, 0.5996, 3.40, 0.181, 286, 243, STRUCTURE OF C1156Y MUTANT ANAPLASTIC LYMPHOMA KINASE
4025, d2xk8A1, 0.5996, 2.65, 0.216, 238, 231, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 15
4026, d2wmvA_, 0.5996, 2.89, 0.276, 251, 232, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4027, d1u54B_, 0.5996, 3.30, 0.208, 261, 240, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
4028, d6b8uB_, 0.5995, 2.87, 0.220, 248, 232, CRYSTALS STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINYL BENZAMIDE INHIBITOR
4029, d5e1eA_, 0.5995, 3.45, 0.240, 279, 242, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
4030, d4mneA_, 0.5995, 3.50, 0.211, 286, 246, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4031, d4g17A1, 0.5995, 3.45, 0.164, 301, 244, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-TERT-BUTYLPHENYL)AMINO]-1H- BENZIMIDAZOLE-6-CARBONITRILE
4032, d3tkhA_, 0.5995, 3.10, 0.267, 269, 236, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S01
4033, d3pj2A_, 0.5995, 2.94, 0.188, 248, 234, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[4-(2- DIETHYLAMINO-ETHOXY)-PHENYLAMINO]-6-(4-FLUORO-PHENOXY)-8-METHYL-8H- PYRIDO[23-D]PYRIMIDIN-7-ONE
4034, d2py3B_, 0.5995, 3.56, 0.259, 284, 243, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
4035, d2og8B2, 0.5995, 3.02, 0.247, 247, 235, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
4036, d2ivtA1, 0.5995, 3.80, 0.230, 283, 248, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
4037, d2hw7A1, 0.5995, 2.78, 0.277, 269, 231, CRYSTAL STRUCTURE OF MNK2-D228G IN COMPLEX WITH STAUROSPORINE
4038, d5h2uB1, 0.5994, 3.46, 0.228, 261, 246, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
4039, d4tw9B_, 0.5994, 3.43, 0.202, 289, 243, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
4040, d4ebwA_, 0.5994, 3.22, 0.226, 259, 239, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
4041, d4e5wB_, 0.5994, 3.48, 0.226, 278, 243, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
4042, d3lq8A_, 0.5994, 3.41, 0.220, 278, 241, STRUCTURE OF THE KINASE DOMAIN OF C-MET BOUND TO XL880 (GSK1363089)
4043, d3f3uA_, 0.5994, 3.20, 0.248, 261, 238, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
4044, d2psqB_, 0.5994, 3.54, 0.267, 286, 243, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
4045, d2objA_, 0.5994, 3.16, 0.245, 272, 237, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH INHIBITOR
4046, d1zycB1, 0.5994, 3.29, 0.231, 252, 242, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
4047, d5x18B_, 0.5993, 3.38, 0.165, 294, 242, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
4048, d5itaA_, 0.5993, 3.04, 0.233, 250, 236, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
4049, d4fswA_, 0.5993, 3.06, 0.272, 265, 235, CRYSTAL STRUCTURE OF THE CHK1
4050, d3g6hA_, 0.5993, 3.37, 0.254, 266, 240, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
4051, d2ofuA_, 0.5993, 3.61, 0.238, 272, 244, X-RAY CRYSTAL STRUCTURE OF 2-AMINOPYRIMIDINE CARBAMATE 43 BOUND TO LCK
4052, d5vc3A_, 0.5992, 3.40, 0.187, 260, 241, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB
4053, d4rx9A1, 0.5992, 3.25, 0.212, 264, 240, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT PYRIMIDINE INHIBITOR
4054, d4c8bA_, 0.5992, 3.24, 0.206, 279, 238, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
4055, d3fupA_, 0.5992, 3.39, 0.226, 284, 243, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
4056, d1qpjA_, 0.5992, 3.54, 0.239, 265, 243, CRYSTAL STRUCTURE OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH STAUROSPORINE.
4057, d5e91A_, 0.5991, 3.55, 0.223, 297, 242, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH 3-AMINO-6-[4-(2- HYDROXYETHYL)PHENYL]-N-[4- (MORPHOLIN-4-YL)PYRIDIN-3-YL] PYRAZINE-2-CARBOXAMIDE
4058, d4byjA_, 0.5991, 3.08, 0.239, 246, 238, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
4059, d4btmB_, 0.5991, 3.62, 0.226, 293, 248, TTBK1 IN COMPLEX WITH INHIBITOR
4060, d3pp0B_, 0.5991, 3.41, 0.238, 296, 244, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
4061, d2xk3A1, 0.5991, 2.70, 0.228, 239, 232, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 35
4062, d2x8iA_, 0.5991, 3.30, 0.268, 261, 239, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
4063, d2pvyD_, 0.5991, 3.49, 0.248, 283, 242, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
4064, d2jkoA_, 0.5991, 3.00, 0.223, 256, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4065, d2brhA_, 0.5991, 2.85, 0.267, 257, 232, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4066, d5w86C_, 0.5990, 3.23, 0.218, 273, 238, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
4067, d5lmbB_, 0.5990, 3.27, 0.199, 261, 241, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
4068, d5kggA_, 0.5990, 3.19, 0.235, 273, 238, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-(5-CHLORANYL-1~{H}-INDOL- 3-YL)ETHANAMINE
4069, d4nt4A1, 0.5990, 3.36, 0.178, 299, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF GILGAMESH ISOFORM I FROM DROSOPHILA MELANOGASTER
4070, d4fstA_, 0.5990, 3.06, 0.277, 253, 235, CRYSTAL STRUCTURE OF THE CHK1
4071, d4dflA1, 0.5990, 3.27, 0.200, 262, 240, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A SULFONAMIDOPYRAZINE PIPERIDINE INHIBITOR
4072, d3u4wA_, 0.5990, 3.64, 0.247, 275, 247, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC4B
4073, d3tjcA_, 0.5990, 3.39, 0.226, 284, 243, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
4074, d3mdyC_, 0.5990, 3.85, 0.220, 320, 246, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
4075, d2xb7A_, 0.5990, 3.22, 0.175, 286, 240, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH NVP- TAE684
4076, d2izuA_, 0.5990, 3.36, 0.170, 297, 241, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
4077, d5e1eB_, 0.5989, 3.50, 0.226, 280, 243, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
4078, d4yjvA_, 0.5989, 3.73, 0.202, 263, 247, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000250
4079, d4usfB1, 0.5989, 3.48, 0.242, 283, 244, HUMAN SLK WITH SB-440719
4080, d4p2wB_, 0.5989, 3.14, 0.203, 253, 237,  
4081, d3vbyA_, 0.5989, 3.12, 0.237, 267, 236, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
4082, d3qlgA_, 0.5989, 3.10, 0.258, 259, 236, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
4083, d3q4uD_, 0.5989, 3.50, 0.234, 299, 244, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
4084, d3mdyA_, 0.5989, 4.07, 0.220, 320, 250, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
4085, d2hyyD1, 0.5989, 3.05, 0.230, 251, 235, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
4086, d1b6cD_, 0.5989, 3.69, 0.202, 326, 247, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
4087, d5tr6A1, 0.5988, 3.48, 0.202, 268, 242, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
4088, d5hzeA_, 0.5988, 3.79, 0.209, 305, 249, MEK1 ADOPTS DFG-OUT CONFORMATION WHEN BOUND TO AN ANALOG OF E6201.
4089, d5h2uD1, 0.5988, 3.47, 0.232, 261, 246, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
4090, d5eolA_, 0.5988, 3.12, 0.232, 273, 237, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A MACROCYCLIC QUINOXALINE-PYRROLODIHYDROPIPERIDINONE INHIBITOR
4091, d3zmmA_, 0.5988, 3.30, 0.229, 273, 240, INHIBITORS OF JAK2 KINASE DOMAIN
4092, d2vwvA_, 0.5988, 2.82, 0.197, 255, 234, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4093, d6bruD_, 0.5987, 4.06, 0.169, 311, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4094, d5uvfC_, 0.5987, 3.96, 0.165, 301, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4095, d5p9lA_, 0.5987, 3.45, 0.189, 252, 243, BTK1 IN COMPLEX WITH CC 292
4096, d4e1zA_, 0.5987, 3.73, 0.219, 288, 247, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
4097, d3el8A_, 0.5987, 3.33, 0.259, 263, 239, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
4098, d3bceA_, 0.5987, 3.39, 0.223, 285, 242, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
4099, d2xizA_, 0.5987, 3.07, 0.237, 273, 236, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-3 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
4100, d2ivsB1, 0.5987, 3.45, 0.243, 272, 243, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
4101, d4xg6A1, 0.5986, 3.47, 0.193, 270, 243, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4102, d4hokC_, 0.5986, 3.42, 0.198, 289, 242, CRYSTAL STRUCTURE OF APO CK1E
4103, d4ckiA1, 0.5986, 3.85, 0.234, 288, 248, CRYSTAL STRUCTURE OF ONCOGENIC RET TYROSINE KINASE M918T BOUND TO ADENOSINE
4104, d3byoA_, 0.5986, 3.55, 0.239, 270, 243, X-RAY CO-CRYSTAL STRUCTURE OF 2-AMINO-6-PHENYLPYRIMIDO[5  4 :56]PYRIMIDO[12-A]BENZIMIDAZOL-5(6H)-ONE 25 BOUND TO LCK
4105, d2ydkA_, 0.5986, 3.24, 0.269, 263, 238, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
4106, d2qu6A1, 0.5986, 3.06, 0.225, 276, 236, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
4107, d1zydB1, 0.5986, 3.28, 0.237, 251, 241, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE COMPLEXED WITH ATP.
4108, d1gzoA_, 0.5986, 2.84, 0.251, 271, 235, STRUCTURE OF PROTEIN KINASE B UNPHOSPHORYLATED
4109, d1gzkA_, 0.5986, 2.84, 0.251, 271, 235, MOLECULAR MECHANISM FOR THE REGULATION OF PROTEIN KINASE B/ AKT BY HYDROPHOBIC MOTIF PHOSPHORYLATION
4110, d5o1vA_, 0.5985, 4.03, 0.234, 278, 248, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE (A-LOOP SWAPPED)
4111, d4i4fA_, 0.5985, 3.19, 0.213, 255, 239, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH AN ALLOSTERIC BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
4112, d3tjdB_, 0.5985, 3.66, 0.227, 287, 247, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
4113, d3ac4A_, 0.5985, 3.52, 0.240, 270, 242, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4114, d2j7tA_, 0.5985, 2.90, 0.220, 285, 232, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO SU11274
4115, d5uhnB_, 0.5984, 3.40, 0.253, 269, 241, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
4116, d4ftmA_, 0.5984, 3.28, 0.275, 263, 236, CRYSTAL STRUCTURE OF THE CHK1
4117, d3vw6A_, 0.5984, 2.95, 0.302, 255, 232, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
4118, d3slsB1, 0.5984, 3.94, 0.208, 291, 250, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
4119, d2of4A_, 0.5984, 3.64, 0.238, 271, 244, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 1 BOUND TO LCK
4120, d1yhsA_, 0.5984, 3.04, 0.238, 267, 235, CRYSTAL STRUCTURE OF PIM-1 BOUND TO STAUROSPORINE
4121, d5v82A_, 0.5983, 3.19, 0.236, 273, 237, PIM1 KINASE IN COMPLEX WITH CPD17 (1-(6-(44-DIFLUOROPIPERIDIN-3-YL) PYRIDIN-2-YL)-6-(6-METHYLPYRAZIN-2-YL)-1H-PYRAZOLO[43-C]PYRIDINE)
4122, d5j79B_, 0.5983, 3.22, 0.207, 277, 237, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
4123, d4btjB_, 0.5983, 3.63, 0.218, 293, 248, TTBK1 IN COMPLEX WITH ATP
4124, d3p08A_, 0.5983, 3.30, 0.188, 252, 239, CRYSTAL STRUCTURE OF THE HUMAN BTK KINASE DOMAIN
4125, d3lckA_, 0.5983, 3.52, 0.236, 270, 242, THE KINASE DOMAIN OF HUMAN LYMPHOCYTE KINASE (LCK) ACTIVATED FORM (AUTO-PHOSPHORYLATED ON TYR394)
4126, d3kmwA_, 0.5983, 3.49, 0.192, 268, 245, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MGATP)
4127, d3f6xD_, 0.5983, 3.25, 0.265, 267, 238, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4128, d3ac1A_, 0.5983, 3.52, 0.240, 270, 242, CRYSTAL STRUCTURE OF PYRAZIN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4129, d2q0bA_, 0.5983, 3.44, 0.253, 280, 241, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
4130, d1yi3A_, 0.5983, 3.12, 0.246, 267, 236, CRYSTAL STRUCTURE OF PIM-1 BOUND TO LY294002
4131, d1u46B_, 0.5983, 3.23, 0.206, 257, 238, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
4132, d5ng3C_, 0.5982, 3.52, 0.193, 272, 244, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
4133, d5dwrA_, 0.5982, 3.16, 0.236, 273, 237, IDENTIFICATION OF N-(4-((1R3S5S)-3-AMINO-5-METHYLCYCLOHEXYL)PYRIDIN- 3-YL)-6-(26-DIFLUOROPHENYL)-5-FLUOROPICOLINAMIDE (PIM447) A POTENT AND SELECTIVE PROVIRAL INSERTION SITE OF MOLONEY MURINE LEUKEMIA (PIM) 12 AND 3 KINASE INHIBITOR IN CLINICAL TRIALS FOR HEMATOLOGICAL MALIGNANCIES
4134, d4mtaA_, 0.5982, 3.14, 0.236, 273, 237, CRYSTAL STRUCTURE OF PIM-1 KINASE DOMAIN IN COMPLEX WITH 2-METHYL-5- PHENYLFURAN-3-CARBOXYLIC ACID
4135, d4fynA1, 0.5982, 3.14, 0.197, 263, 238, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 3-(8-{4- [ETHYL-(2-HYDROXY-ETHYL)-AMINO]-PHENYLAMINO}-IMIDAZO[12-A]PYRAZIN-5- YL)-PHENOL
4136, d4ccbA_, 0.5982, 3.23, 0.187, 287, 240, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 3-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(5-METHYL-1H-PYRAZOL-4-YL)PYRIDIN-2-AMINE
4137, d2zv8A1, 0.5982, 3.29, 0.237, 256, 241, LYN TYROSINE KINASE DOMAIN-AMP-PNP COMPLEX
4138, d2x2mA1, 0.5982, 3.76, 0.227, 281, 247, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
4139, d2j0iA_, 0.5982, 3.68, 0.246, 289, 244, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
4140, d5wo4A_, 0.5981, 3.56, 0.225, 292, 244, JAK1 COMPLEXED WITH COMPOUND 28
4141, d4rc2A_, 0.5981, 3.08, 0.233, 272, 236, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
4142, d4p2kA_, 0.5981, 3.44, 0.173, 259, 243, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
4143, d4hgeA_, 0.5981, 3.40, 0.226, 284, 243, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
4144, d3pyyA1, 0.5981, 2.94, 0.224, 251, 232, DISCOVERY AND CHARACTERIZATION OF A CELL-PERMEABLE SMALL-MOLECULE C- ABL KINASE ACTIVATOR THAT BINDS TO THE MYRISTOYL BINDING SITE
4145, d3ggfA_, 0.5981, 3.58, 0.206, 275, 247, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
4146, d3fqhA_, 0.5981, 3.48, 0.202, 262, 242, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
4147, d3fpqA_, 0.5981, 3.29, 0.245, 262, 241, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF WNK1
4148, d5uglB_, 0.5980, 3.41, 0.249, 271, 241, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
4149, d4ebvA1, 0.5980, 3.25, 0.222, 261, 239, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
4150, d3vbtA_, 0.5980, 3.05, 0.234, 267, 235, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
4151, d3octA_, 0.5980, 3.10, 0.203, 244, 236, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE MUTANT V555R IN COMPLEX WITH DASATINIB
4152, d2xiyA_, 0.5980, 3.09, 0.233, 273, 236, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-2 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
4153, d4yjpA_, 0.5979, 3.27, 0.195, 263, 241, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000223
4154, d4pv0A1, 0.5979, 3.41, 0.202, 266, 242, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH AN IMIDAZOPYRAZINE INHIBITOR
4155, d4hokA_, 0.5979, 3.39, 0.190, 290, 242, CRYSTAL STRUCTURE OF APO CK1E
4156, d4cmtA_, 0.5979, 3.24, 0.183, 284, 240, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(3-(METHYLSULFONYL)PHENYL)PYRIDIN-2-AMINE
4157, d3vbxA_, 0.5979, 3.05, 0.234, 268, 235, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
4158, d3uysC_, 0.5979, 3.30, 0.204, 286, 240, CRYSTAL STRUCTURE OF APO HUMAN CK1D
4159, d3r04A_, 0.5979, 3.14, 0.242, 271, 236, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
4160, d1qpdA_, 0.5979, 3.56, 0.239, 270, 243, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
4161, d5hx8A_, 0.5978, 3.57, 0.225, 291, 244, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
4162, d5d7vB1, 0.5978, 3.52, 0.223, 262, 247, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
4163, d4mxoB_, 0.5978, 3.34, 0.255, 264, 239, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
4164, d4c62A_, 0.5978, 3.22, 0.230, 273, 239, INHIBITORS OF JAK2 KINASE DOMAIN
4165, d3vbwA_, 0.5978, 3.15, 0.246, 264, 236, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
4166, d2xneA_, 0.5978, 3.05, 0.246, 246, 236, STRUCTURE OF AURORA-A BOUND TO AN IMIDAZOPYRAZINE INHIBITOR
4167, d2xk7A1, 0.5978, 2.60, 0.230, 238, 230, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 23
4168, d2ivsA_, 0.5978, 3.59, 0.225, 284, 244, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
4169, d5f1zA1, 0.5977, 3.32, 0.225, 280, 240, STRUCTURE OF TYK2 WITH INHIBITOR 16: 3-AZANYL-5-[(2~{S})-3- METHYLBUTAN-2-YL]-7-[1-METHYL-5-(2-OXIDANYLPROPAN-2-YL)PYRAZOL-3-YL]- 1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
4170, d4gu9A_, 0.5977, 3.03, 0.211, 252, 237, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
4171, d3w2sA_, 0.5977, 3.57, 0.215, 307, 246, EGFR KINASE DOMAIN WITH COMPOUND4
4172, d3p08B_, 0.5977, 3.37, 0.192, 258, 240, CRYSTAL STRUCTURE OF THE HUMAN BTK KINASE DOMAIN
4173, d3dqwD_, 0.5977, 3.61, 0.235, 276, 243, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
4174, d3ac5A_, 0.5977, 3.54, 0.240, 270, 242, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4175, d2xf0A_, 0.5977, 2.94, 0.270, 251, 233, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4176, d2xa4A_, 0.5977, 3.28, 0.229, 276, 240, INHIBITORS OF JAK2 KINASE DOMAIN
4177, d2x2lA1, 0.5977, 3.85, 0.230, 282, 248, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
4178, d1iasE_, 0.5977, 4.04, 0.213, 330, 249, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
4179, d6bp0D_, 0.5976, 4.08, 0.169, 311, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4180, d5cswB_, 0.5976, 3.05, 0.234, 252, 235, B-RAF IN COMPLEX WITH DABRAFENIB
4181, d4mneH_, 0.5976, 3.45, 0.213, 275, 244, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4182, d4kabA_, 0.5976, 3.03, 0.207, 255, 237, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
4183, d4gh2A_, 0.5976, 3.01, 0.274, 266, 234, CRYSTAL STRUCTURE OF THE CHK1
4184, d4ftaA_, 0.5976, 3.08, 0.272, 264, 235, CRYSTAL STRUCTURE OF THE CHK1
4185, d2rfsA_, 0.5976, 3.52, 0.212, 264, 241, X-RAY STRUCTURE OF SU11274 BOUND TO C-MET
4186, d1qpcA_, 0.5976, 3.57, 0.239, 270, 243, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
4187, d1k2pB_, 0.5976, 3.31, 0.201, 258, 239, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
4188, d1gznA_, 0.5976, 2.86, 0.251, 271, 235, STRUCTURE OF PKB KINASE DOMAIN
4189, d5w86D_, 0.5975, 3.13, 0.219, 272, 237, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
4190, d5w4wC_, 0.5975, 3.23, 0.197, 284, 239, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
4191, d5h2uC1, 0.5975, 3.49, 0.232, 261, 246, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
4192, d4kaoA_, 0.5975, 2.97, 0.203, 252, 236, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
4193, d4i4eA_, 0.5975, 3.12, 0.214, 254, 238, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH HINGE BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
4194, d3repA_, 0.5975, 3.45, 0.184, 268, 244, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MNATP)
4195, d3of0A_, 0.5975, 3.23, 0.253, 260, 237, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN
4196, d3f2aA_, 0.5975, 3.16, 0.236, 276, 237, CRYSTAL STRUCTURE OF HUMAN PIM-1 IN COMPLEX WITH DAPPA
4197, d3ackA_, 0.5975, 3.59, 0.239, 270, 243, CRYSTAL STRUCTURE OF PYRROLO PYRAZINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4198, d2zm4A_, 0.5975, 3.54, 0.240, 270, 242, CRYSTAL STRUCTURE OF IMIDAZO QUINOXALINE 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK ACTIVATED FORM (AUTO- PHOSPHORYLATED ON TYR394)
4199, d5xgnB_, 0.5974, 3.65, 0.194, 308, 247, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
4200, d5kcxA_, 0.5974, 3.27, 0.235, 272, 238, PIM-1 KINASE IN COMPLEX WITH A SELECTIVE N-SUBSTITUTED 7-AZAINDOLE INHIBITOR
4201, d4e5wA1, 0.5974, 3.51, 0.218, 291, 243, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
4202, d4bf2B_, 0.5974, 2.84, 0.309, 252, 230, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4203, d3ad5A_, 0.5974, 3.46, 0.241, 270, 241, CRYSTAL STRUCTURE OF TRIAZOLONE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4204, d3acjA_, 0.5974, 3.51, 0.240, 270, 242, CRYSTAL STRUCTURE OF IMIDAZO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4205, d2pz5A_, 0.5974, 3.48, 0.249, 280, 241, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
4206, d2ivvA1, 0.5974, 3.74, 0.220, 277, 246, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR PP1
4207, d1u54A_, 0.5974, 3.43, 0.212, 262, 241, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
4208, d1iasC_, 0.5974, 3.76, 0.196, 330, 245, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
4209, d5lmbA_, 0.5973, 3.34, 0.199, 264, 241, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
4210, d3vw6B_, 0.5973, 2.91, 0.302, 253, 232, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
4211, d3bceB_, 0.5973, 3.39, 0.228, 286, 241, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
4212, d2q0bB_, 0.5973, 3.48, 0.253, 282, 241, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
4213, d2henA1, 0.5973, 3.02, 0.203, 258, 237, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
4214, d1yomA_, 0.5973, 3.10, 0.247, 260, 235, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
4215, d5uorA_, 0.5972, 2.86, 0.294, 249, 231, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4216, d4bzoA_, 0.5972, 3.20, 0.241, 272, 237, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO- PYRAZINONE INHIBITOR
4217, d3kcfE_, 0.5972, 3.82, 0.200, 330, 245, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
4218, d3kcfC_, 0.5972, 3.95, 0.214, 330, 248, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
4219, d3ad4A_, 0.5972, 3.51, 0.240, 270, 242, CRYSTAL STRUCTURE OF METHOXY BENZOFURAN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4220, d3ac3A_, 0.5972, 3.50, 0.240, 270, 242, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4221, d3ac2A_, 0.5972, 3.46, 0.241, 270, 241, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4222, d2zm1A_, 0.5972, 3.60, 0.239, 270, 243, CRYSTAL STRUCTURE OF IMIDAZO PYRAZIN 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4223, d2pvyB_, 0.5972, 3.29, 0.251, 286, 239, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
4224, d2henC1, 0.5972, 3.03, 0.198, 258, 237, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
4225, d4hokG_, 0.5971, 3.51, 0.193, 290, 243, CRYSTAL STRUCTURE OF APO CK1E
4226, d4bznA_, 0.5971, 3.12, 0.233, 272, 236, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO(12-A) PYRAZINONE INHIBITOR
4227, d3uqfA_, 0.5971, 3.20, 0.257, 260, 237, C-SRC KINASE DOMAIN IN COMPLEX WITH BKI RM-1-89
4228, d3pa3A_, 0.5971, 3.02, 0.265, 259, 234, X-RAY CRYSTAL STRUCTURE OF COMPOUND 70 BOUND TO HUMAN CHK1 KINASE DOMAIN
4229, d3en4B_, 0.5971, 3.36, 0.267, 266, 240, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
4230, d3dqxA_, 0.5971, 3.43, 0.261, 267, 241, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
4231, d3ad6A_, 0.5971, 3.51, 0.240, 272, 242, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4232, d2of2A_, 0.5971, 3.58, 0.235, 271, 243, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 8 BOUND TO LCK
4233, d1snuA_, 0.5971, 2.96, 0.184, 245, 234, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4234, d4hokO_, 0.5970, 3.43, 0.190, 290, 242, CRYSTAL STRUCTURE OF APO CK1E
4235, d4fsmA_, 0.5970, 3.08, 0.264, 265, 235, CRYSTAL STRUCTURE OF THE CHK1
4236, d3vbvA_, 0.5970, 3.07, 0.234, 268, 235, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
4237, d3pxkB_, 0.5970, 3.15, 0.209, 258, 239, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
4238, d2srcA3, 0.5970, 3.88, 0.235, 284, 251, CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC IN COMPLEX WITH AMP-PNP
4239, d1kswA3, 0.5970, 3.93, 0.230, 284, 252, STRUCTURE OF HUMAN C-SRC TYROSINE KINASE (THR338GLY MUTANT) IN COMPLEX WITH N6-BENZYL ADP
4240, d4mxxA_, 0.5969, 3.27, 0.256, 266, 238, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4241, d4hokU_, 0.5969, 3.50, 0.198, 289, 243, CRYSTAL STRUCTURE OF APO CK1E
4242, d3fqhB_, 0.5969, 3.27, 0.201, 258, 239, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
4243, d3bgqA_, 0.5969, 3.22, 0.245, 272, 237, HUMAN PIM-1 KINASE IN COMPLEX WITH AN TRIAZOLO PYRIDAZINE INHIBITOR VX2
4244, d2pzpA_, 0.5969, 3.52, 0.249, 280, 241, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
4245, d5h0gA3, 0.5968, 3.62, 0.203, 281, 246, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-N4-DIMETHYLPENTANAMIDE
4246, d4d4vB_, 0.5968, 3.11, 0.206, 255, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4247, d3vs3B3, 0.5968, 3.54, 0.230, 271, 243, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
4248, d3p9jA_, 0.5968, 3.21, 0.247, 249, 239, AURORA A KINASE DOMAIN WITH PHTHALAZINONE PYRAZOLE INHIBITOR
4249, d3mpmA_, 0.5968, 3.28, 0.224, 257, 241, LCK COMPLEXED WITH A PYRAZOLOPYRIMIDINE
4250, d2zybA_, 0.5968, 3.51, 0.240, 270, 242, CRYSTAL STRUCTURE OF PHENYLIMIDAZO PYRAZIN 2 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4251, d2pzpB_, 0.5968, 3.52, 0.253, 282, 241, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
4252, d2p2iB_, 0.5968, 3.10, 0.213, 263, 235, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
4253, d2og8A_, 0.5968, 3.06, 0.243, 246, 235, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
4254, d2a19B1, 0.5968, 3.15, 0.238, 261, 235, PKR KINASE DOMAIN- EIF2ALPHA- AMP-PNP COMPLEX.
4255, d1iasD_, 0.5968, 3.97, 0.214, 330, 248, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
4256, d5hx8B_, 0.5967, 3.54, 0.226, 279, 243, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
4257, d4pqnA_, 0.5967, 2.93, 0.180, 240, 233, ITK KINASE DOMAIN WITH COMPOUND GNE-9822
4258, d4ftnA_, 0.5967, 3.06, 0.270, 253, 233, CRYSTAL STRUCTURE OF THE CHK1
4259, d4ftkA_, 0.5967, 3.07, 0.266, 263, 233, CRYSTAL STRUCTURE OF THE CHK1
4260, d4dggA_, 0.5967, 3.05, 0.260, 261, 235, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
4261, d5vt1A1, 0.5966, 3.40, 0.260, 264, 242, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO A BENZAMIDE INHIBITOR
4262, d5h0eA3, 0.5966, 3.71, 0.211, 281, 247, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANAMIDE
4263, d5d7vD1, 0.5966, 3.50, 0.232, 262, 246, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
4264, d4mneD_, 0.5966, 3.46, 0.213, 285, 244, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4265, d3vf8A_, 0.5966, 3.38, 0.195, 265, 241, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH PYRAZOLYLBENZIMIDAZOLE INHIBITOR 416
4266, d3u9nA_, 0.5966, 2.91, 0.267, 257, 232, X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN
4267, d3oriB_, 0.5966, 3.33, 0.249, 267, 241, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4268, d3kcfA_, 0.5966, 3.94, 0.206, 328, 248, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
4269, d1xbbA1, 0.5966, 3.17, 0.202, 266, 238, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH GLEEVEC
4270, d5w86A_, 0.5965, 3.15, 0.219, 269, 237, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
4271, d5e92A_, 0.5965, 3.48, 0.212, 298, 240, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH AMPPNP
4272, d4rfmA1, 0.5965, 3.18, 0.176, 248, 238, ITK KINASE DOMAIN IN COMPLEX WITH COMPOUND 1 N-{1-[(11-DIOXO-1-THIAN- 2-YL)(PHENYL)METHYL]-1H- PYRAZOL-4-YL}-55-DIFLUORO-5A-METHYL-1H4H 4AH5H5AH6H-CYCLOPROPA[F]INDAZOLE-3-CARBOXAMIDE
4273, d4qpsC_, 0.5965, 3.43, 0.216, 276, 241, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
4274, d4kbkC_, 0.5965, 3.15, 0.206, 280, 238, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
4275, d4ivdB_, 0.5965, 3.54, 0.226, 280, 243, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
4276, d3ac8A_, 0.5965, 3.56, 0.231, 270, 242, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4277, d2pzrA_, 0.5965, 3.43, 0.246, 280, 240, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
4278, d2pz5B_, 0.5965, 3.49, 0.261, 280, 241, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
4279, d2ac3A1, 0.5965, 2.83, 0.273, 275, 231, STRUCTURE OF HUMAN MNK2 KINASE DOMAIN
4280, d1r1wA_, 0.5965, 3.09, 0.229, 287, 236, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET
4281, d5wo4B_, 0.5964, 3.55, 0.226, 280, 243, JAK1 COMPLEXED WITH COMPOUND 28
4282, d5fm3A_, 0.5964, 3.51, 0.236, 276, 242, CRYSTAL STRUCTURE OF HYPER-PHOSPHORYLATED RET KINASE DOMAIN WITH (PROXIMAL) JUXTAMEMBRANE SEGMENT
4283, d4i0sA1, 0.5964, 3.14, 0.203, 263, 237, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(6- CHLORO-1-METHYL-1H-INDAZOL-3-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID ISOPROPYLAMIDE
4284, d4equA_, 0.5964, 3.02, 0.225, 274, 231, HUMAN STK-10 (LOK) KINASE DOMAIN IN DFG-OUT CONFORMATION WITH INHIBITOR DSA-7
4285, d4c61A_, 0.5964, 3.29, 0.230, 272, 239, INHIBITORS OF JAK2 KINASE DOMAIN
4286, d3tz9B_, 0.5964, 3.08, 0.230, 259, 235, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
4287, d2pvyC_, 0.5964, 3.41, 0.261, 285, 241, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
4288, d2iztA_, 0.5964, 3.36, 0.162, 296, 241, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
4289, d2bmcF_, 0.5964, 3.18, 0.235, 257, 238, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4290, d1qpeA_, 0.5964, 3.67, 0.230, 270, 244, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
4291, d5w86B_, 0.5963, 3.04, 0.221, 267, 235, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
4292, d4kbcA_, 0.5963, 3.44, 0.190, 288, 242, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
4293, d3vf9A_, 0.5963, 3.33, 0.200, 265, 240, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 027
4294, d2wmrA_, 0.5963, 2.81, 0.255, 254, 231, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4295, d2henB1, 0.5963, 3.12, 0.202, 258, 238, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
4296, d5oxgC1, 0.5962, 3.48, 0.239, 299, 243, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
4297, d4zauA_, 0.5962, 3.23, 0.207, 283, 237, AZD9291 COMPLEX WITH WILD TYPE EGFR
4298, d4cnhA_, 0.5962, 3.25, 0.180, 285, 239, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
4299, d2ym6A_, 0.5962, 2.75, 0.261, 253, 230, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4300, d2xixA_, 0.5962, 3.08, 0.238, 272, 235, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-1 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
4301, d2bmcB_, 0.5962, 3.18, 0.244, 258, 238, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4302, d1xbaA1, 0.5962, 3.40, 0.195, 265, 241, CRYSTAL STRUCTURE OF APO SYK TYROSINE KINASE DOMAIN
4303, d1sm2A_, 0.5962, 2.96, 0.184, 245, 234, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4304, d1iasA_, 0.5962, 3.99, 0.205, 330, 249, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
4305, d5khxA_, 0.5961, 3.70, 0.212, 276, 245, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH PF-4950736
4306, d4rx8A1, 0.5961, 3.31, 0.208, 266, 240, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR2
4307, d3oezB_, 0.5961, 3.14, 0.250, 261, 236, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
4308, d2wmxA_, 0.5961, 2.74, 0.262, 248, 229, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4309, d2izrA_, 0.5961, 3.44, 0.161, 298, 242, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
4310, d2henD1, 0.5961, 3.12, 0.202, 258, 238, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
4311, d1b6cB_, 0.5961, 3.82, 0.202, 326, 248, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
4312, d5vuaB_, 0.5960, 3.12, 0.247, 270, 235, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
4313, d5ar8B_, 0.5960, 3.25, 0.214, 274, 238, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE
4314, d4wrgA1, 0.5960, 3.34, 0.213, 287, 239, 1.9 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN
4315, d4ckjA1, 0.5960, 3.67, 0.233, 287, 245, CRYSTAL STRUCTURE OF RET TYROSINE KINASE DOMAIN BOUND TO ADENOSINE
4316, d4bggB_, 0.5960, 3.37, 0.237, 293, 241, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
4317, d3g5dB_, 0.5960, 3.21, 0.267, 257, 236, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
4318, d3efwB_, 0.5960, 2.88, 0.245, 242, 233, STRUCTURE OF AURORAA WITH PYRIDYL-PYRIMIDINE UREA INHIBITOR
4319, d3efwA_, 0.5960, 2.85, 0.246, 240, 232, STRUCTURE OF AURORAA WITH PYRIDYL-PYRIMIDINE UREA INHIBITOR
4320, d6eixA_, 0.5959, 3.69, 0.237, 312, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE Q207E MUTANT OF ACVR1 (ALK2) IN COMPLEX WITH A 2-AMINOPYRIDINE INHIBITOR K02288
4321, d5kziA_, 0.5959, 3.25, 0.244, 273, 238, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN IMIDAZOPYRIDAZINE INHIBITOR.
4322, d5h2uA1, 0.5959, 3.52, 0.228, 261, 246, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
4323, d4xg9B_, 0.5959, 3.44, 0.195, 265, 241, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4324, d4wa9B1, 0.5959, 3.12, 0.230, 263, 235, THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB
4325, d4mxoA_, 0.5959, 3.30, 0.265, 266, 238, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
4326, d4ivbB_, 0.5959, 3.56, 0.230, 280, 243, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
4327, d4e4lD_, 0.5959, 3.66, 0.230, 281, 244, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
4328, d3zz2A_, 0.5959, 2.99, 0.220, 281, 232,  
4329, d3qlfB_, 0.5959, 3.07, 0.247, 258, 235, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE 5
4330, d5o11A_, 0.5958, 3.05, 0.244, 268, 234, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
4331, d4p2wA_, 0.5958, 3.09, 0.200, 250, 235,  
4332, d4c3fA_, 0.5958, 3.31, 0.224, 257, 241, STRUCTURE OF LCK IN COMPLEX WITH A COMPOUND DISCOVERED BY VIRTUAL FRAGMENT LINKING
4333, d4bibA_, 0.5958, 2.97, 0.299, 254, 231, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4334, d3tjdA_, 0.5958, 3.46, 0.222, 284, 243, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
4335, d3srvB_, 0.5958, 3.30, 0.200, 263, 240, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
4336, d3dqwC_, 0.5958, 3.56, 0.231, 275, 242, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
4337, d2xj2A_, 0.5958, 3.13, 0.237, 273, 236, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4338, d5tq7A_, 0.5957, 3.49, 0.228, 275, 241, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4339, d5hieD_, 0.5957, 3.09, 0.231, 253, 234, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
4340, d5h09A3, 0.5957, 3.72, 0.211, 281, 247, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-ETHYL2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOATE
4341, d5d7vC1, 0.5957, 3.51, 0.232, 262, 246, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
4342, d5amnA1, 0.5957, 3.80, 0.220, 282, 246, THE DISCOVERY OF 2-SUBSTITUTED PHENOL QUINAZOLINES AS POTENT AND SELECTIVE RET KINASE INHIBITORS
4343, d4px6A1, 0.5957, 3.18, 0.210, 261, 238, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT PYRIDOPYRIMIDINONE INHIBITOR
4344, d4n6zA_, 0.5957, 3.32, 0.231, 272, 238, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
4345, d4hzrB_, 0.5957, 3.27, 0.202, 258, 238, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
4346, d4ftqA_, 0.5957, 3.06, 0.269, 254, 234, CRYSTAL STRUCTURE OF THE CHK1
4347, d4ftlA_, 0.5957, 3.11, 0.261, 263, 234, CRYSTAL STRUCTURE OF THE CHK1
4348, d3oriA_, 0.5957, 3.35, 0.249, 267, 241, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4349, d3hmmA_, 0.5957, 3.18, 0.208, 293, 236, STRUCTURE OF ALK5 + GW855857
4350, d3efkA_, 0.5957, 3.09, 0.219, 276, 237, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
4351, d3cjfA_, 0.5957, 3.16, 0.216, 276, 236, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
4352, d3byuA_, 0.5957, 3.19, 0.227, 256, 238, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE REVERSE AMIDE 23
4353, d2xj1A_, 0.5957, 3.13, 0.237, 273, 236, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INIBITOR
4354, d5hidB1, 0.5956, 3.01, 0.228, 252, 232, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH AZ628
4355, d4yjuA_, 0.5956, 3.42, 0.198, 262, 243, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000249
4356, d4bidA_, 0.5956, 2.94, 0.303, 254, 231, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4357, d3qrjB1, 0.5956, 3.20, 0.220, 252, 236, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN T315I MUTANT IN COMPLEX WITH DCC-2036
4358, d3pa4A_, 0.5956, 2.99, 0.270, 257, 233, X-RAY CRYSTAL STRUCTURE OF COMPOUND 2A BOUND TO HUMAN CHK1 KINASE DOMAIN
4359, d2zv2A_, 0.5956, 3.19, 0.266, 256, 237, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2 BETA CAMKK2 KINASE DOMAIN IN COMPLEX WITH STO-609
4360, d2hakH_, 0.5956, 2.76, 0.249, 277, 229, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4361, d6bruB_, 0.5955, 4.06, 0.169, 301, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4362, d5toeA_, 0.5955, 3.21, 0.232, 272, 237, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
4363, d2xp2A_, 0.5955, 3.28, 0.187, 285, 240, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB (PF-02341066)
4364, d2oiqB_, 0.5955, 3.39, 0.255, 265, 239, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
4365, d2bmcC_, 0.5955, 3.24, 0.239, 257, 238, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4366, d5hieC_, 0.5954, 3.16, 0.229, 253, 236, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
4367, d4bggA_, 0.5954, 3.41, 0.237, 296, 241, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
4368, d3srvA_, 0.5954, 3.37, 0.203, 262, 241, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
4369, d3i5nA_, 0.5954, 3.36, 0.222, 280, 239, CRYSTAL STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR 13
4370, d2wqbA_, 0.5954, 3.13, 0.209, 289, 235, STRUCTURE OF THE TIE2 KINASE DOMAIN IN COMPLEX WITH A THIAZOLOPYRIMIDINE INHIBITOR
4371, d2izsA_, 0.5954, 3.45, 0.161, 298, 242, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
4372, d5to8A_, 0.5953, 2.83, 0.195, 250, 231, SELECTIVITY SWITCH BETWEEN FAK AND PYK2: MACROCYCLIZATION OF FAK INHIBITORS IMPROVES PYK2 POTENCY
4373, d5t0pA_, 0.5953, 3.32, 0.249, 264, 237, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
4374, d4kioC1, 0.5953, 3.23, 0.176, 249, 238, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
4375, d4k33A_, 0.5953, 3.66, 0.261, 293, 245, CRYSTAL STRUCTURE OF FGF RECEPTOR 3 (FGFR3) KINASE DOMAIN HARBORING THE K650E MUTATION A GAIN-OF-FUNCTION MUTATION RESPONSIBLE FOR THANATOPHORIC DYSPLASIA TYPE II AND SPERMATOCYTIC SEMINOMA
4376, d3w16A_, 0.5953, 3.15, 0.248, 249, 238, STRUCTURE OF AURORA KINASE A COMPLEXED TO PYRAZOLE-AMINOQUINOLINE INHIBITOR III
4377, d2ym5A_, 0.5953, 2.70, 0.268, 248, 228, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4378, d2ivuA1, 0.5953, 3.80, 0.236, 283, 246, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR ZD6474
4379, d1b6cH_, 0.5953, 3.59, 0.193, 326, 244, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
4380, d5tobA_, 0.5952, 2.63, 0.180, 245, 228, SELECTIVITY SWITCH BETWEEN FAK AND PYK2: MACROCYCLIZATION OF FAK INHIBITORS IMPROVES PYK2 POTENCY
4381, d4v0gA_, 0.5952, 3.27, 0.224, 267, 237, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
4382, d3r02A_, 0.5952, 3.19, 0.242, 271, 236, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
4383, d2xezA_, 0.5952, 2.75, 0.271, 249, 229, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4384, d2vwwA_, 0.5952, 2.93, 0.201, 253, 234, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4385, d4ivcB_, 0.5951, 3.56, 0.226, 280, 243, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
4386, d4d5kB_, 0.5951, 3.18, 0.206, 256, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4387, d3d7uC1, 0.5951, 3.15, 0.228, 255, 237, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
4388, d3d7uA1, 0.5951, 3.15, 0.228, 255, 237, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
4389, d6btwB_, 0.5950, 4.05, 0.169, 301, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4390, d5sysB_, 0.5950, 3.06, 0.248, 258, 234, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
4391, d4asxA1, 0.5950, 3.67, 0.223, 295, 242, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
4392, d3g51A_, 0.5950, 3.30, 0.234, 280, 239, STRUCTURAL DIVERSITY OF THE ACTIVE CONFORMATION OF THE N- TERMINAL KINASE DOMAIN OF P90 RIBOSOMAL S6 KINASE 2
4393, d2qolA_, 0.5950, 3.00, 0.209, 271, 235, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596:Y602:S768G TRIPLE MUTANT
4394, d5uoxB_, 0.5949, 2.97, 0.303, 252, 231, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4395, d4lmuA_, 0.5949, 3.14, 0.247, 265, 235, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH THE INHIBITOR QUERCETIN (RESULTING FROM DISPLACEMENT OF SKF86002)
4396, d4i5cA_, 0.5949, 3.58, 0.230, 279, 243, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
4397, d3kcfD_, 0.5949, 3.89, 0.195, 330, 246, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
4398, d5swhA_, 0.5948, 3.07, 0.252, 258, 234, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
4399, d5o12A_, 0.5948, 3.09, 0.239, 264, 234, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
4400, d5hezB_, 0.5948, 3.56, 0.231, 289, 242, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
4401, d5h0bA3, 0.5948, 3.74, 0.206, 281, 247, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOIC ACID
4402, d4ftjA_, 0.5948, 3.08, 0.265, 266, 234, CRYSTAL STRUCTURE OF THE CHK1
4403, d4e4nB_, 0.5948, 3.57, 0.226, 280, 243, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
4404, d3zfxF_, 0.5948, 3.11, 0.220, 254, 236, CRYSTAL STRUCTURE OF EPHB1
4405, d3zfxB_, 0.5948, 3.14, 0.220, 254, 236, CRYSTAL STRUCTURE OF EPHB1
4406, d2bmcD_, 0.5948, 3.15, 0.232, 256, 237, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4407, d4k77A_, 0.5947, 3.65, 0.217, 282, 244, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
4408, d4fz6A1, 0.5947, 3.22, 0.202, 262, 238, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH [6-((S)-2- METHYL-PYRROLIDIN-1-YL)-PYRIDIN-2-YL]-(6-PHENYL-IMIDAZO[12- B]PYRIDAZIN-8-YL)-AMINE
4409, d4fsqA_, 0.5947, 3.09, 0.269, 263, 234, CRYSTAL STRUCTURE OF THE CHK1
4410, d2pzrB_, 0.5947, 3.48, 0.246, 282, 240, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
4411, d1zydA1, 0.5947, 3.47, 0.239, 268, 243, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE COMPLEXED WITH ATP.
4412, d1u46A_, 0.5947, 3.08, 0.217, 255, 235, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
4413, d1ad5A3, 0.5947, 3.49, 0.230, 271, 243, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
4414, d4i0rA1, 0.5946, 3.31, 0.201, 260, 239, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(345- TRIMETHOXY-PHENYL)-5H-PYRROLO[23-B]PYRAZINE-7-CARBOXYLIC ACID ISOPROPYLAMIDE
4415, d1yxtA_, 0.5946, 3.36, 0.238, 274, 239, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMPPNP
4416, d1k9aB3, 0.5946, 3.17, 0.236, 267, 237, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4417, d5xy1A1, 0.5945, 3.44, 0.246, 252, 240, CRYSTAL STRUCTURE OF LYN KINASE DOMAIN IN COMPLEX WITH N-(1H-INDAZOL- 6-YL)-8-(PIPERIDIN-4-YLOXY)-6-PROPYLQUINAZOLIN-2-AMINE
4418, d4hnfB_, 0.5945, 3.28, 0.196, 290, 240, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
4419, d3zfmA_, 0.5945, 2.93, 0.210, 248, 233, CRYSTAL STRUCTURE OF EPHB2
4420, d3uytA_, 0.5945, 3.11, 0.209, 287, 235, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
4421, d3pa5A_, 0.5945, 3.21, 0.254, 255, 236, X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN
4422, d2bdjA_, 0.5945, 3.42, 0.251, 254, 239, SRC KINASE IN COMPLEX WITH INHIBITOR AP23464
4423, d5h0hA3, 0.5944, 3.76, 0.219, 281, 247, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-NN4-TRIMETHYLPENTANAMIDE
4424, d5bpyB1, 0.5944, 3.14, 0.182, 246, 236, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
4425, d4puzA_, 0.5944, 3.28, 0.201, 263, 239, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
4426, d4fyoA1, 0.5944, 3.17, 0.203, 263, 237, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH N-{(S)-1- [7-(34-DIMETHOXY-PHENYLAMINO)-THIAZOLO[54-D]PYRIMIDIN-5-YL]- PYRROLIDIN-3-YL}-TEREPHTHALAMIC ACID
4427, d3h9rA_, 0.5944, 3.57, 0.244, 312, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TYPE I ACTIVIN RECEPTOR (ACVR1) IN COMPLEX WITH FKBP12 AND DORSOMORPHIN
4428, d2zv9A1, 0.5944, 3.38, 0.232, 255, 241, LYN TYROSINE KINASE DOMAIN-PP2 COMPLEX
4429, d2jiuB_, 0.5944, 3.65, 0.191, 309, 246, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
4430, d5ih5A_, 0.5943, 3.41, 0.202, 286, 242, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A
4431, d3oroA_, 0.5943, 3.53, 0.239, 272, 243, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 4)
4432, d2zv7A1, 0.5943, 3.38, 0.232, 256, 241, LYN TYROSINE KINASE DOMAIN APO FORM
4433, d2csnA_, 0.5943, 3.39, 0.167, 293, 240, BINARY COMPLEX OF CASEIN KINASE-1 WITH CKI7
4434, d5tiuA1, 0.5942, 3.41, 0.204, 262, 240, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH INHIBITOR
4435, d5oq7A_, 0.5942, 3.06, 0.282, 259, 234, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
4436, d4jikA_, 0.5942, 2.88, 0.268, 256, 231, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22A (R)-2-(4-CHLOROPHENYL)-8- (PIPERIDIN-3-YLAMINO)IMIDAZO[12-C]PYRIMIDINE-5-CARBOXAMIDE BOUND TO HUMAN CHK1 KINASE DOMAIN
4437, d3vs7A3, 0.5942, 3.42, 0.233, 267, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
4438, d3svvA_, 0.5942, 3.18, 0.254, 261, 236, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
4439, d3pp0A_, 0.5942, 3.47, 0.239, 286, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
4440, d3is5E1, 0.5942, 2.74, 0.313, 243, 230, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4441, d3dqxB_, 0.5942, 3.45, 0.253, 268, 241, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
4442, d2c47D1, 0.5942, 3.19, 0.177, 289, 237, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
4443, d2bmcE_, 0.5942, 3.18, 0.241, 256, 237, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4444, d2bmcA_, 0.5942, 3.08, 0.242, 256, 236, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4445, d1u4dA_, 0.5942, 3.17, 0.216, 258, 236, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
4446, d4o2pB_, 0.5941, 3.33, 0.248, 265, 238, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
4447, d4lm5A_, 0.5941, 3.08, 0.231, 264, 234, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH 2-{4-[(3-AMINOPROPYL) AMINO]QUINAZOLIN-2-YL}PHENOL (RESULTING FROM DISPLACEMENT OF SKF86002)
4448, d4k77B_, 0.5941, 3.59, 0.226, 280, 243, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
4449, d3qtiB_, 0.5941, 3.32, 0.231, 280, 238, C-MET KINASE IN COMPLEX WITH NVP-BVU972
4450, d3comA_, 0.5941, 3.22, 0.246, 264, 236, CRYSTAL STRUCTURE OF MST1 KINASE
4451, d1k9aA3, 0.5941, 3.22, 0.232, 267, 237, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4452, d3qlgB_, 0.5940, 3.10, 0.266, 260, 233, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
4453, d3ot8A_, 0.5940, 3.03, 0.253, 251, 233, X-RAY CRYSTAL STRUCTURE OF COMPOUND 17R BOUND TO HUMAN CHK1 KINASE DOMAIN
4454, d3og7A_, 0.5940, 3.06, 0.222, 247, 234, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
4455, d2hk5A2, 0.5940, 3.35, 0.227, 268, 238, HCK KINASE IN COMPLEX WITH LCK TARGETTED INHIBITOR PG-1009247
4456, d5hx6A_, 0.5939, 3.52, 0.199, 259, 241, CRYSTAL STRUCTURE OF RIP1 KINASE WITH A BENZO[B][14]OXAZEPIN-4-ONE
4457, d4d4vA_, 0.5939, 3.15, 0.201, 256, 239, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4458, d3cs9C_, 0.5939, 2.74, 0.236, 243, 229, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
4459, d2vwuA_, 0.5939, 2.95, 0.201, 253, 234, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4460, d1yomB_, 0.5939, 3.05, 0.248, 261, 234, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
4461, d1ad5B3, 0.5939, 3.51, 0.230, 271, 243, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
4462, d5ih6A_, 0.5938, 3.40, 0.203, 286, 241, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A DERIVATIVE
4463, d4v0gB_, 0.5938, 3.17, 0.220, 272, 236, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
4464, d4hokQ_, 0.5938, 3.48, 0.194, 290, 242, CRYSTAL STRUCTURE OF APO CK1E
4465, d4ei4B_, 0.5938, 3.59, 0.230, 280, 243, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
4466, d3socB1, 0.5938, 3.65, 0.224, 294, 241, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
4467, d2xbaA_, 0.5938, 3.27, 0.180, 283, 239, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PHA-E429
4468, d5imeA1, 0.5937, 2.90, 0.231, 279, 229, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
4469, d2h8hA3, 0.5937, 3.80, 0.238, 280, 248, SRC KINASE IN COMPLEX WITH A QUINAZOLINE INHIBITOR
4470, d5v24A_, 0.5936, 2.72, 0.298, 249, 228, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
4471, d5da3A1, 0.5936, 3.52, 0.229, 261, 245, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN WITH INHIBITOR
4472, d3en4A_, 0.5936, 3.05, 0.248, 257, 234, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
4473, d2wmwA_, 0.5936, 2.73, 0.268, 247, 228, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4474, d2chlA_, 0.5936, 3.37, 0.162, 298, 240, STRUCTURE OF CASEIN KINASE 1 GAMMA 3
4475, d5tq6A_, 0.5935, 3.47, 0.228, 274, 241, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4476, d2w1iA_, 0.5935, 3.88, 0.223, 284, 247, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
4477, d1ckiA_, 0.5935, 3.42, 0.194, 292, 242, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
4478, d5xp7A_, 0.5934, 3.16, 0.263, 265, 236, C-SRC IN COMPLEX WITH ATP-CHCL
4479, d5oxgB_, 0.5934, 3.35, 0.237, 296, 240, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
4480, d5ih4A_, 0.5934, 3.41, 0.203, 286, 241, HUMAN CASEIN KINASE 1 ISOFORM DELTA APO (KINASE DOMAIN)
4481, d3emgA_, 0.5934, 3.10, 0.200, 255, 235, DISCOVERY AND SAR OF NOVEL 4-THIAZOLYL-2- PHENYLAMINOPYRIMIDINES AS POTENT INHIBITORS OF SPLEEN TYROSINE KINASE (SYK)
4482, d5o13A_, 0.5933, 3.09, 0.235, 270, 234, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
4483, d4ivbA1, 0.5933, 3.56, 0.223, 290, 242, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
4484, d3q4uC_, 0.5933, 3.45, 0.237, 296, 241, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
4485, d1k9aE3, 0.5933, 2.99, 0.235, 268, 234, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4486, d5oy6D_, 0.5932, 3.35, 0.238, 292, 239, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
4487, d4alwA_, 0.5932, 3.22, 0.237, 273, 236, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
4488, d3pxkA_, 0.5931, 3.13, 0.210, 256, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
4489, d2c0tB3, 0.5931, 3.50, 0.232, 268, 241, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
4490, d6btwD_, 0.5930, 3.95, 0.168, 307, 250, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4491, d5jsmA1, 0.5930, 3.43, 0.207, 262, 241, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
4492, d4g5pB_, 0.5930, 3.64, 0.201, 303, 244, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
4493, d3umwA_, 0.5930, 3.14, 0.248, 264, 234, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDAZOL-3-YL)METHYLENE]-6-METHOXY-7-(PIPERAZIN-1-YLMETHYL)BENZOFURAN- 3(2H)-ONE
4494, d3d7tB_, 0.5930, 3.33, 0.248, 265, 238, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
4495, d1qcfA3, 0.5930, 3.75, 0.219, 281, 247, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH A SRC FAMILY- SELECTIVE TYROSINE KINASE INHIBITOR
4496, d1ckiB_, 0.5930, 3.50, 0.198, 286, 243, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
4497, d5vubB_, 0.5929, 3.06, 0.245, 269, 233, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
4498, d5jsmB1, 0.5929, 3.65, 0.210, 259, 243, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
4499, d5d7vA1, 0.5929, 3.57, 0.232, 262, 246, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
4500, d4knbC_, 0.5929, 3.37, 0.231, 271, 238, C-MET IN COMPLEX WITH OSI LIGAND
4501, d4i0tA1, 0.5929, 3.16, 0.203, 262, 236, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(5678- TETRAHYDRO-IMIDAZO[15-A]PYRIDIN-1-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID TERT-BUTYLAMIDE
4502, d4c02A_, 0.5929, 3.89, 0.244, 313, 246, CRYSTAL STRUCTURE OF HUMAN ACVR1 (ALK2) IN COMPLEX WITH FKBP12.6 AND DORSOMORPHIN
4503, d4asxB1, 0.5929, 3.78, 0.226, 296, 243, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
4504, d3vs3A3, 0.5929, 3.51, 0.232, 269, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
4505, d3uytD_, 0.5929, 3.16, 0.211, 268, 237, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
4506, d3pizA_, 0.5929, 2.90, 0.199, 245, 231, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH (5-AMINO-1-O- TOLYL-1H-PYRAZOL-4-YL)-[3-(1-METHANESULFONYL-PIPERIDIN-4-YL)-PHENYL]- METHANONE
4507, d4kb8A_, 0.5928, 3.17, 0.211, 265, 237, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
4508, d3socA1, 0.5928, 3.63, 0.224, 296, 241, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
4509, d3d2kA_, 0.5928, 3.15, 0.255, 245, 235, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH [7-(2-{2-[3-(3-CHLORO- PHENYL)-UREIDO]-THIAZOL-5-YL}-ETHYLAMINO)-PYRAZOLO[43- D]PYRIMIDIN-1-YL]-ACETIC ACID
4510, d1snxB_, 0.5928, 3.03, 0.175, 245, 234, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4511, d1snxA_, 0.5928, 3.04, 0.175, 245, 234, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4512, d4ivcA1, 0.5927, 3.57, 0.219, 290, 242, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
4513, d3vrzB3, 0.5927, 3.53, 0.241, 269, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
4514, d3my0M1, 0.5927, 3.42, 0.220, 297, 241, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4515, d3f3uB_, 0.5927, 3.05, 0.252, 259, 234, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
4516, d2hckA3, 0.5927, 3.56, 0.230, 271, 243, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
4517, d1ckjB_, 0.5927, 3.49, 0.193, 293, 243, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
4518, d4l7sA1, 0.5926, 3.22, 0.173, 248, 237, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
4519, d4k11A3, 0.5926, 3.80, 0.223, 282, 247, THE STRUCTURE OF 1NA IN COMPLEX WITH SRC T338G
4520, d3vbqA_, 0.5926, 3.16, 0.238, 271, 235, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
4521, d3d7tA_, 0.5926, 2.94, 0.223, 249, 233, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
4522, d2ym3A_, 0.5926, 2.70, 0.269, 247, 227, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4523, d1mryA_, 0.5926, 2.92, 0.248, 270, 234, CRYSTAL STRUCTURE OF AN INACTIVE AKT2 KINASE DOMAIN
4524, d5w4wD_, 0.5925, 3.28, 0.203, 287, 237, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
4525, d5tf9B_, 0.5925, 3.44, 0.241, 266, 237, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH MN2+AMPPNP AND WNK476
4526, d4yjsA_, 0.5925, 3.36, 0.205, 257, 239, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000226
4527, d4d4sA_, 0.5925, 3.13, 0.202, 255, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4528, d4bf2A_, 0.5925, 2.99, 0.306, 253, 229, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4529, d3vs4A3, 0.5925, 3.57, 0.231, 270, 242, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
4530, d3vs1A3, 0.5925, 3.51, 0.232, 268, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
4531, d2nryB_, 0.5925, 3.90, 0.232, 286, 246, CRYSTAL STRUCTURE OF IRAK-4
4532, d5d11A_, 0.5924, 2.93, 0.264, 254, 231, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
4533, d5a6nB1, 0.5924, 3.07, 0.302, 265, 232, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH COMPOUND 2
4534, d4tw9A_, 0.5924, 3.38, 0.195, 290, 241, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
4535, d4mxzA_, 0.5924, 3.37, 0.256, 266, 238, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4536, d4mxyA_, 0.5924, 3.37, 0.256, 266, 238, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4537, d4hokW_, 0.5924, 3.47, 0.191, 289, 241, CRYSTAL STRUCTURE OF APO CK1E
4538, d4hokE_, 0.5924, 3.60, 0.193, 291, 243, CRYSTAL STRUCTURE OF APO CK1E
4539, d3fqeA1, 0.5924, 3.38, 0.197, 265, 239, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH YM193306
4540, d3dbdA_, 0.5924, 2.86, 0.261, 261, 230, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 094
4541, d2xk6A1, 0.5924, 2.49, 0.229, 235, 227, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 36
4542, d4mcvB_, 0.5923, 3.42, 0.251, 265, 239, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
4543, d3ma3A_, 0.5923, 3.10, 0.249, 266, 233, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A NAPHTHO-DIFURAN LIGAND
4544, d3kxzA_, 0.5923, 3.60, 0.227, 263, 242, THE COMPLEX CRYSTAL STRUCTURE OF LCK WITH A PROBE MOLECULE W259
4545, d3geqB1, 0.5923, 3.34, 0.266, 270, 237, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
4546, d3bysA_, 0.5923, 3.15, 0.237, 255, 236, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE AMIDE 10B
4547, d2c0tA3, 0.5923, 3.54, 0.232, 268, 241, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
4548, d5xp7B_, 0.5922, 3.49, 0.264, 267, 239, C-SRC IN COMPLEX WITH ATP-CHCL
4549, d5vucB_, 0.5922, 3.16, 0.248, 269, 234, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
4550, d5e8vA_, 0.5922, 3.40, 0.223, 296, 238, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A)
4551, d3zfxG_, 0.5922, 3.14, 0.217, 253, 235, CRYSTAL STRUCTURE OF EPHB1
4552, d3cd8A_, 0.5922, 3.40, 0.223, 278, 238, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
4553, d2xkeA1, 0.5922, 2.58, 0.229, 235, 227, STRUCTURE OF NEK2 BOUND TO AMINIPYRAZINE COMPOUND 5
4554, d2bdfB_, 0.5922, 3.49, 0.250, 265, 240, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
4555, d1k9aD3, 0.5922, 3.23, 0.238, 268, 235, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4556, d1jpaB_, 0.5922, 2.92, 0.215, 269, 233, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED EPHB2 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
4557, d5hezD_, 0.5921, 3.53, 0.228, 289, 241, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
4558, d4e4nA1, 0.5921, 3.57, 0.219, 290, 242, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
4559, d3vs0A3, 0.5921, 3.51, 0.232, 268, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
4560, d3q4tB1, 0.5921, 3.69, 0.224, 293, 241, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
4561, d3my0L1, 0.5921, 3.42, 0.221, 295, 240, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4562, d5jrqA1, 0.5920, 3.31, 0.210, 257, 238, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-6-VEM
4563, d4mcvA_, 0.5920, 3.46, 0.218, 267, 239, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
4564, d5a6oB1, 0.5919, 3.02, 0.303, 264, 231, CRYSTAL STRUCTURE OF THE APO FORM OF THE UNPHOSPHORYLATED HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3)
4565, d3ormA_, 0.5919, 3.25, 0.248, 266, 238, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN D76A MUTANT
4566, d3my0B_, 0.5919, 3.37, 0.221, 295, 240, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4567, d2hz4B1, 0.5919, 3.10, 0.227, 248, 233, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
4568, d3vs2A3, 0.5918, 3.47, 0.233, 268, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
4569, d3op5D_, 0.5918, 3.91, 0.175, 302, 251, HUMAN VACCINIA-RELATED KINASE 1
4570, d1mp8A_, 0.5918, 3.09, 0.213, 252, 235, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE (FAK)
4571, d5oy6B_, 0.5917, 3.41, 0.237, 292, 240, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
4572, d4q9sA_, 0.5917, 3.20, 0.215, 252, 237, CRYSTAL STRUCTURE OF HUMAN FOCAL ADHESION KINASE (FAK) BOUND TO COMPOUND1 (35-DIHYDRO[124]TRIAZINO[34-C][14]BENZOXAZIN-2(1H)- ONE)
4573, d4ivdA1, 0.5917, 3.54, 0.224, 289, 241, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
4574, d3v5lC1, 0.5917, 3.22, 0.177, 242, 237, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
4575, d1ckjA_, 0.5917, 3.46, 0.190, 296, 242, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
4576, d5u6bA_, 0.5916, 3.21, 0.206, 270, 238, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
4577, d5j79A_, 0.5916, 3.38, 0.212, 283, 236, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
4578, d4p90A_, 0.5916, 3.09, 0.212, 272, 231, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
4579, d3zfxC_, 0.5916, 3.04, 0.218, 248, 234, CRYSTAL STRUCTURE OF EPHB1
4580, d4fz7A1, 0.5915, 3.23, 0.198, 261, 237, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 6-((1R2S)- 2-AMINO-CYCLOHEXYLAMINO)-4-(6-ETHYL-PYRIDIN-2-YLAMINO)-PYRIDAZINE-3- CARBOXYLIC ACID AMIDE
4581, d4fg9B_, 0.5915, 3.09, 0.286, 279, 234, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-320 IN COMPLEX WITH ATP
4582, d4ehzB_, 0.5915, 3.63, 0.222, 280, 243, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
4583, d3geqA1, 0.5915, 3.33, 0.258, 269, 236, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
4584, d4btmA_, 0.5914, 3.60, 0.229, 292, 245, TTBK1 IN COMPLEX WITH INHIBITOR
4585, d3vs2B3, 0.5914, 3.46, 0.233, 268, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
4586, d3uysD_, 0.5914, 3.29, 0.198, 284, 237, CRYSTAL STRUCTURE OF APO HUMAN CK1D
4587, d3ikaB_, 0.5914, 3.75, 0.191, 310, 246, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
4588, d2xkcA1, 0.5914, 2.49, 0.221, 236, 226, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 14
4589, d2c47B_, 0.5914, 3.19, 0.178, 289, 236, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
4590, d4enyA_, 0.5913, 3.16, 0.244, 261, 234, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH (2E5Z)-2-(2- CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-METHOXYBENZYLIDENE)THIAZOLIDIN-4- ONE
4591, d4enxA_, 0.5913, 3.16, 0.244, 266, 234, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH INHIBITOR (2E5Z)-2- (2-CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-NITROBENZYLIDENE)THIAZOLIDIN-4- ONE
4592, d3vs7B3, 0.5913, 3.37, 0.234, 266, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
4593, d2rfeD_, 0.5913, 3.50, 0.227, 278, 242, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
4594, d2c0oB3, 0.5913, 3.53, 0.232, 268, 241, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
4595, d2c0iA3, 0.5913, 3.47, 0.233, 268, 240, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
4596, d5tehB_, 0.5912, 3.30, 0.257, 262, 237, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
4597, d5jsmD1, 0.5912, 3.48, 0.208, 255, 240, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
4598, d5j5sA_, 0.5912, 3.11, 0.231, 258, 234, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
4599, d5a6oA_, 0.5912, 2.98, 0.303, 265, 231, CRYSTAL STRUCTURE OF THE APO FORM OF THE UNPHOSPHORYLATED HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3)
4600, d4m69B_, 0.5912, 3.61, 0.154, 264, 247, CRYSTAL STRUCTURE OF THE MOUSE RIP3-MLKL COMPLEX
4601, d3vrzA3, 0.5912, 3.54, 0.232, 268, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
4602, d5tf9A_, 0.5911, 3.55, 0.244, 262, 238, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH MN2+AMPPNP AND WNK476
4603, d5j5sB_, 0.5911, 3.20, 0.247, 258, 235, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
4604, d4puzB_, 0.5911, 3.39, 0.197, 265, 239, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
4605, d3vs1B3, 0.5911, 3.52, 0.232, 268, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
4606, d1csnA_, 0.5911, 3.46, 0.167, 293, 240, BINARY COMPLEX OF CASEIN KINASE-1 WITH MGATP
4607, d4xg9A_, 0.5910, 3.18, 0.203, 259, 236, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4608, d4twcA_, 0.5910, 3.51, 0.194, 293, 242, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
4609, d4i5cB1, 0.5910, 3.60, 0.223, 290, 242, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
4610, d3uytC_, 0.5910, 3.32, 0.209, 286, 239, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
4611, d2wmtA_, 0.5910, 2.78, 0.268, 248, 228, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4612, d2c0oA3, 0.5910, 3.50, 0.237, 268, 240, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
4613, d5sysA_, 0.5909, 3.22, 0.247, 258, 235, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
4614, d5oxgD_, 0.5909, 3.26, 0.239, 293, 238, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
4615, d5fqdC_, 0.5909, 3.57, 0.194, 294, 242, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
4616, d3qgyB1, 0.5909, 3.04, 0.179, 244, 234, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
4617, d3q4tA1, 0.5909, 3.60, 0.225, 294, 240, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
4618, d3h0zB_, 0.5909, 3.15, 0.247, 240, 235, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
4619, d3db8A_, 0.5909, 2.78, 0.262, 261, 229, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 041
4620, d2ydjA_, 0.5909, 2.92, 0.274, 252, 230, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
4621, d5wdyA_, 0.5908, 3.45, 0.245, 260, 237, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH 1-CYCLOHEXYL-N-({6-FLUORO-1- [2-(3-METHOXYPHENYL)PYRIDIN-4-YL]-1H-INDOL-3-YL}METHYL)METHANAMINE (COMPOUND 6)
4622, d5fqdF_, 0.5908, 3.57, 0.190, 294, 242, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
4623, d3sv0A_, 0.5908, 3.48, 0.174, 294, 241, CRYSTAL STRUCTURE OF CASEIN KINASE-1 LIKE PROTEIN IN PLANT
4624, d3fmeA1, 0.5908, 3.22, 0.234, 267, 235, CRYSTAL STRUCTURE OF HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (MEK6) ACTIVATED MUTANT (S207D T211D)
4625, d2c0iB3, 0.5908, 3.56, 0.232, 268, 241, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
4626, d1k9aC3, 0.5908, 3.19, 0.238, 266, 235, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4627, d5uafA_, 0.5907, 3.23, 0.213, 291, 235, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
4628, d5uadA_, 0.5907, 3.23, 0.213, 291, 235, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
4629, d5tq6B_, 0.5907, 3.50, 0.221, 271, 240, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4630, d5swhB_, 0.5907, 3.26, 0.243, 261, 235, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
4631, d5f20A_, 0.5907, 3.47, 0.230, 274, 239, STRUCTURE OF TYK2 WITH INHIBITOR 4: 3-AZANYL-5-(2-METHYLPHENYL)-7-(1- METHYLPYRAZOL-3-YL)-1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
4632, d4u3zA_, 0.5907, 3.54, 0.213, 282, 239, APO MAP4K4 T181E PHOSPHOMIMETIC MUTANT
4633, d4ftoA_, 0.5907, 3.04, 0.272, 252, 232, CRYSTAL STRUCTURE OF THE CHK1
4634, d3vs4B3, 0.5907, 3.53, 0.232, 269, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
4635, d3vs0B3, 0.5907, 3.45, 0.233, 268, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
4636, d5we8A_, 0.5906, 3.59, 0.238, 270, 239, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH N-{(3R)-1-[(4-CHLOROPHENYL) METHYL]PYRROLIDIN-3-YL}-2-(3-METHOXYPHENYL)-N-METHYLQUINOLINE-4- CARBOXAMIDE (COMPOUND 8)
4637, d4d5hA_, 0.5905, 3.16, 0.202, 255, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4638, d3my0A1, 0.5905, 3.36, 0.222, 295, 239, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4639, d3g5dA_, 0.5905, 3.22, 0.274, 256, 234, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
4640, d1yolB_, 0.5905, 3.09, 0.236, 253, 233, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
4641, d4u42B_, 0.5904, 3.10, 0.245, 265, 233, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
4642, d4mf1B1, 0.5904, 3.20, 0.182, 244, 236, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
4643, d4ithB_, 0.5904, 3.71, 0.176, 270, 244, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-1 ANALOG
4644, d4btjA_, 0.5904, 3.60, 0.225, 292, 244, TTBK1 IN COMPLEX WITH ATP
4645, d3vs6A3, 0.5904, 3.51, 0.232, 269, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
4646, d3f82A_, 0.5904, 3.04, 0.202, 278, 233, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH N- (4-(2-AMINO-3-CHLOROPYRIDIN-4-YLOXY)-3-FLUOROPHENYL)-4- ETHOXY-1-(4-FLUOROPHENYL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
4647, d3vs6B3, 0.5903, 3.51, 0.232, 269, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
4648, d3op5C_, 0.5903, 3.97, 0.179, 308, 252, HUMAN VACCINIA-RELATED KINASE 1
4649, d3gxlA_, 0.5903, 3.22, 0.209, 285, 235, ALK-5 KINASE COMPLEX WITH GW857175
4650, d5u6bC_, 0.5902, 3.24, 0.206, 270, 238, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
4651, d5tx5A_, 0.5902, 3.65, 0.195, 259, 241, RIP1 KINASE ( FLAG 1-294 C34A C127A C233A C240A) WITH GSK772
4652, d5khwA_, 0.5902, 3.59, 0.212, 276, 241, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
4653, d4l7sB1, 0.5902, 3.21, 0.174, 248, 236, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
4654, d4kb8D_, 0.5902, 3.23, 0.204, 278, 235, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
4655, d4e4lE_, 0.5902, 3.72, 0.214, 280, 243, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
4656, d3ggfB_, 0.5902, 3.57, 0.209, 270, 244, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
4657, d2ym4A_, 0.5902, 3.02, 0.260, 251, 231, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4658, d5uvfD_, 0.5901, 3.88, 0.173, 296, 249, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4659, d5gnkA_, 0.5901, 3.68, 0.221, 277, 244, CRYSTAL STRUCTURE OF EGFR 696-988 T790M IN COMPLEX WITH LXX-6-34
4660, d4tn6A_, 0.5901, 3.42, 0.192, 292, 240, CK1D IN COMPLEX WITH INHIBITOR
4661, d3w18B_, 0.5901, 2.84, 0.252, 236, 230, STRUCTURE OF AURORA KINASE A COMPLEXED TO BENZOIMIDAZOLE-INDAZOLE INHIBITOR XIII
4662, d3my0N1, 0.5901, 3.43, 0.221, 299, 240, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4663, d2hckB3, 0.5901, 3.48, 0.228, 271, 241, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
4664, d5oxgA_, 0.5900, 3.28, 0.239, 293, 238, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
4665, d4kbaD_, 0.5900, 3.23, 0.204, 274, 235, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4666, d4ehzD_, 0.5900, 3.68, 0.218, 280, 243, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
4667, d4agwB_, 0.5900, 2.96, 0.254, 257, 232, DISCOVERY OF A SMALL MOLECULE TYPE II INHIBITOR OF WILD- TYPE AND GATEKEEPER MUTANTS OF BCR-ABL PDGFRALPHA KIT AND SRC KINASES
4668, d3vryA3, 0.5900, 3.53, 0.232, 269, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
4669, d2rioA_, 0.5900, 3.15, 0.262, 396, 233, STRUCTURE OF THE DUAL ENZYME IRE1 REVEALS THE BASIS FOR CATALYSIS AND REGULATION OF NON-CONVENTIONAL SPLICING
4670, d5hezC_, 0.5899, 3.60, 0.224, 289, 241, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
4671, d4ybjA_, 0.5899, 3.14, 0.252, 255, 234, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
4672, d4kbkD_, 0.5899, 3.24, 0.204, 281, 235, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
4673, d4hokK_, 0.5898, 3.51, 0.191, 290, 241, CRYSTAL STRUCTURE OF APO CK1E
4674, d4d5kA_, 0.5898, 3.19, 0.197, 255, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4675, d3my0W1, 0.5898, 3.32, 0.223, 280, 238, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4676, d3ccnA_, 0.5898, 3.35, 0.225, 275, 236, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
4677, d5w5oM_, 0.5897, 3.22, 0.209, 276, 235, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4678, d4d4yA_, 0.5897, 3.19, 0.197, 255, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4679, d2ym7A_, 0.5897, 2.76, 0.264, 248, 227, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4680, d1k9aF3, 0.5897, 3.28, 0.229, 264, 236, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4681, d5w5oA_, 0.5896, 3.29, 0.217, 275, 235, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4682, d5d12B_, 0.5896, 2.94, 0.252, 253, 230, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
4683, d3my0U1, 0.5896, 3.38, 0.222, 284, 239, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4684, d5w5oE_, 0.5895, 3.29, 0.217, 275, 235, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4685, d5up3B_, 0.5895, 2.63, 0.302, 243, 225, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4686, d5a6nA1, 0.5895, 2.96, 0.300, 270, 230, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH COMPOUND 2
4687, d3pj1A_, 0.5895, 2.85, 0.201, 241, 229, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 3-(26-DICHLORO- PHENYL)-7-[4-(2-DIETHYLAMINO-ETHOXY)-PHENYLAMINO]-1-METHYL-34- DIHYDRO-1H-PYRIMIDO[45-D]PYRIMIDIN-2-ONE
4688, d3my0C1, 0.5895, 3.39, 0.222, 298, 239, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4689, d5we8B_, 0.5894, 3.50, 0.241, 272, 237, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH N-{(3R)-1-[(4-CHLOROPHENYL) METHYL]PYRROLIDIN-3-YL}-2-(3-METHOXYPHENYL)-N-METHYLQUINOLINE-4- CARBOXAMIDE (COMPOUND 8)
4690, d3uixA_, 0.5894, 3.21, 0.244, 266, 234, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4691, d3my0V1, 0.5894, 3.39, 0.222, 281, 239, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4692, d3a60A_, 0.5894, 2.86, 0.276, 263, 228, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED P70S6K1 (FORM I)
4693, d2ym8A_, 0.5894, 2.75, 0.260, 246, 227, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4694, d4kbkA_, 0.5893, 3.25, 0.209, 283, 235, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
4695, d4hjoA_, 0.5893, 3.62, 0.209, 278, 244, CRYSTAL STRUCTURE OF THE INACTIVE EGFR TYROSINE KINASE DOMAIN WITH ERLOTINIB
4696, d1pkgA_, 0.5893, 3.68, 0.251, 290, 243, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
4697, d5jrsB1, 0.5892, 2.98, 0.185, 239, 232, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
4698, d3q4uA_, 0.5892, 3.51, 0.237, 298, 241, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
4699, d3bqrA1, 0.5892, 3.19, 0.306, 273, 232, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH AN IMIDAZO-PYRIDAZINE LIGAND
4700, d5x17A_, 0.5891, 3.52, 0.195, 290, 241, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
4701, d4c3pD_, 0.5891, 3.41, 0.219, 260, 237, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO TPX2 AND AMPPCP
4702, d3umxA_, 0.5891, 3.11, 0.241, 261, 232, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDOL-3-YL)METHYLENE]-7-(AZEPAN-1-YLMETHYL)-6-HYDROXYBENZOFURAN- 3(2H)-ONE
4703, d3q4zA1, 0.5891, 3.16, 0.203, 281, 232, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
4704, d5k9iA_, 0.5890, 3.21, 0.255, 258, 235, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
4705, d5dbxA_, 0.5890, 3.58, 0.241, 284, 237, CRYSTAL STRUCTURE OF MURINE SPAK(T243D) IN COMPLEX WITH AMPPNP
4706, d5cepA_, 0.5890, 3.06, 0.273, 269, 231, DLK IN COMPLEX WITH INHIBITOR N-(1-ISOPROPYL-5-(PIPERIDIN-4-YL)-1H- PYRAZOL-3-YL)-4-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE
4707, d4usfA1, 0.5889, 3.66, 0.239, 275, 243, HUMAN SLK WITH SB-440719
4708, d4jjrA_, 0.5889, 3.16, 0.200, 284, 235, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
4709, d3mtfB_, 0.5889, 3.46, 0.242, 298, 240, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
4710, d3f3tB_, 0.5889, 3.07, 0.270, 259, 233, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
4711, d2c47A_, 0.5889, 3.19, 0.174, 288, 235, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
4712, d1sm2B_, 0.5889, 3.08, 0.176, 241, 233, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4713, d5w5oO_, 0.5888, 3.32, 0.212, 276, 236, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4714, d5khwB_, 0.5888, 3.56, 0.212, 276, 240, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
4715, d4kb8B_, 0.5888, 3.25, 0.209, 285, 235, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
4716, d4bdiA1, 0.5888, 3.26, 0.306, 289, 232, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4717, d3oriD_, 0.5888, 3.34, 0.251, 267, 239, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4718, d3dj6A_, 0.5888, 3.01, 0.251, 252, 231, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 823.
4719, d4k6zA_, 0.5886, 3.64, 0.219, 279, 242, THE JAK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 37
4720, d4bggC_, 0.5886, 3.23, 0.242, 279, 236, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
4721, d3u51A_, 0.5886, 3.15, 0.235, 256, 234, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
4722, d3gxjA_, 0.5886, 3.33, 0.207, 288, 237,  
4723, d2wqoA1, 0.5886, 2.58, 0.217, 234, 226, STRUCTURE OF NEK2 BOUND TO THE AMINOPYRIDINE CCT241950
4724, d5imxA_, 0.5885, 3.06, 0.193, 266, 233, ANAPLASTIC LYMPHOMA KINASE (ALK) CATALYTIC DOMAIN COMPLEXED WITH NOVEL INHIBITOR 3-SULFONYLPYRAZOL-4-AMINO PYRIMIDINE
4725, d4r1yA_, 0.5885, 3.26, 0.209, 265, 234, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITOR
4726, d4kbaB_, 0.5885, 3.25, 0.209, 285, 235, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4727, d3uysA_, 0.5885, 3.13, 0.209, 281, 234, CRYSTAL STRUCTURE OF APO HUMAN CK1D
4728, d5i4nA1, 0.5884, 3.60, 0.139, 273, 245, CRYSTAL STRUCTURE OF THE E596A V617F MUTANT JAK2 PSEUDOKINASE DOMAIN BOUND TO MG-ATP
4729, d4pp9B1, 0.5884, 3.25, 0.182, 246, 236, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
4730, d4oa2A_, 0.5884, 3.70, 0.259, 280, 243,  
4731, d3my0G1, 0.5884, 3.34, 0.223, 293, 238, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4732, d2x7fE_, 0.5884, 2.65, 0.230, 251, 226, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
4733, d2rioB_, 0.5884, 3.10, 0.272, 395, 232, STRUCTURE OF THE DUAL ENZYME IRE1 REVEALS THE BASIS FOR CATALYSIS AND REGULATION OF NON-CONVENTIONAL SPLICING
4734, d2gs7B_, 0.5883, 3.77, 0.202, 288, 247, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
4735, d5cnnB_, 0.5882, 3.94, 0.222, 304, 248, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
4736, d4ybjB_, 0.5882, 2.94, 0.257, 253, 230, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
4737, d4c3pA_, 0.5882, 3.38, 0.247, 264, 235, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO TPX2 AND AMPPCP
4738, d3kexA_, 0.5882, 3.73, 0.167, 292, 246, CRYSTAL STRUCTURE OF THE CATALYTICALLY INACTIVE KINASE DOMAIN OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
4739, d2wqeA_, 0.5882, 3.01, 0.228, 241, 232, STRUCTURE OF S155R AURORA-A SOMATIC MUTANT
4740, d3oriC_, 0.5881, 3.36, 0.251, 267, 239, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4741, d2bdfA_, 0.5881, 3.36, 0.236, 261, 237, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
4742, d1zy4A1, 0.5881, 3.64, 0.234, 269, 244, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: R794G HYPERACTIVATING MUTANT IN APO FORM.
4743, d1snuB_, 0.5881, 3.06, 0.177, 241, 232, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4744, d5tq7B_, 0.5880, 3.36, 0.228, 269, 237, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4745, d4xg8C_, 0.5880, 3.14, 0.201, 254, 234, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4746, d4itiB_, 0.5880, 3.78, 0.181, 270, 243, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-3 ANALOG
4747, d3dj5A_, 0.5880, 3.02, 0.251, 252, 231, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 290.
4748, d5ceoA_, 0.5879, 3.07, 0.273, 269, 231, DLK IN COMPLEX WITH INHIBITOR 2-((6-(33-DIFLUOROPYRROLIDIN-1-YL)-4- (1-(OXETAN-3-YL)PIPERIDIN-4-YL)PYRIDIN-2-YL)AMINO)ISONICOTINONITRILE
4749, d4qpsA_, 0.5879, 3.19, 0.223, 270, 233, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
4750, d4kb8C_, 0.5879, 3.18, 0.204, 277, 235, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
4751, d4itjB_, 0.5879, 3.79, 0.198, 276, 243, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
4752, d4d58A_, 0.5879, 3.28, 0.202, 255, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4753, d3my0S1, 0.5879, 3.37, 0.223, 293, 238, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4754, d3my0F1, 0.5879, 3.36, 0.223, 293, 238, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4755, d3my0E1, 0.5879, 3.36, 0.223, 293, 238, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4756, d3f6xA_, 0.5879, 3.21, 0.253, 264, 233, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4757, d1zycC1, 0.5879, 3.78, 0.236, 269, 246, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
4758, d5w5oJ_, 0.5877, 3.29, 0.209, 275, 235, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4759, d4m7iA1, 0.5877, 3.21, 0.230, 246, 235, CRYSTAL STRUCTURE OF GSK6157 BOUND TO PERK (R587-R1092 DELETE A660- T867) AT 2.34A RESOLUTION
4760, d4hokM_, 0.5877, 3.46, 0.192, 291, 239, CRYSTAL STRUCTURE OF APO CK1E
4761, d3vs5B3, 0.5877, 3.51, 0.233, 268, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
4762, d3my0R1, 0.5877, 3.36, 0.223, 293, 238, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4763, d5hx6B_, 0.5876, 3.61, 0.186, 264, 237, CRYSTAL STRUCTURE OF RIP1 KINASE WITH A BENZO[B][14]OXAZEPIN-4-ONE
4764, d5hezA_, 0.5876, 3.68, 0.225, 287, 240, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
4765, d4xg8A_, 0.5876, 3.36, 0.198, 258, 237, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4766, d4knbB_, 0.5876, 3.25, 0.222, 256, 234, C-MET IN COMPLEX WITH OSI LIGAND
4767, d4dggB_, 0.5876, 2.94, 0.277, 259, 231, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
4768, d4bggD_, 0.5876, 3.09, 0.244, 286, 234, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
4769, d3vs5A3, 0.5876, 3.53, 0.233, 268, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
4770, d2qluA1, 0.5876, 3.67, 0.222, 295, 239, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE II KINASE DOMAIN FROM HUMAN
4771, d5lpzA_, 0.5875, 3.74, 0.252, 283, 242, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1196) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
4772, d3wzuA_, 0.5875, 3.06, 0.235, 270, 234, THE STRUCTURE OF MAP2K7 IN COMPLEX WITH 5Z-7-OXOZEAENOL
4773, d3w18A_, 0.5875, 2.86, 0.236, 234, 229, STRUCTURE OF AURORA KINASE A COMPLEXED TO BENZOIMIDAZOLE-INDAZOLE INHIBITOR XIII
4774, d3oomA_, 0.5875, 3.35, 0.239, 297, 238, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00507
4775, d3my0H1, 0.5875, 3.39, 0.223, 293, 238, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4776, d3my0D1, 0.5875, 3.39, 0.223, 297, 238, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4777, d3efjA_, 0.5875, 3.28, 0.215, 276, 237, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
4778, d2r4bA_, 0.5875, 3.47, 0.225, 292, 240, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
4779, d1zy5A1, 0.5875, 3.67, 0.234, 269, 244, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: R794G HYPERACTIVATING MUTANT COMPLEXED WITH AMPPNP.
4780, d5vo1A_, 0.5874, 3.10, 0.273, 269, 231, DLK IN COMPLEX WITH COMPOUND 10 (5-(1-ISOPROPYL-5-(3-(OXETAN-3-YL)-3- AZABICYCLO[3.1.0]HEXAN-6-YL)-1H-PYRAZOL-3-YL)-3-(TRIFLUOROMETHYL) PYRIDIN-2-AMINE)
4781, d5lpvA_, 0.5874, 3.82, 0.253, 282, 245, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH AMPPNP AND MN FROM ARABIDOPSIS THALIANA
4782, d4zseB_, 0.5874, 3.84, 0.219, 313, 247, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
4783, d3my0Q1, 0.5874, 3.38, 0.223, 293, 238, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4784, d1pkgB_, 0.5874, 3.66, 0.264, 277, 242, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
4785, d4kbaA_, 0.5873, 3.17, 0.204, 263, 235, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4786, d3uqgB_, 0.5873, 3.30, 0.274, 257, 234, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
4787, d3efkB_, 0.5873, 3.09, 0.215, 272, 233, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
4788, d2rfnB_, 0.5873, 3.21, 0.209, 269, 235, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
4789, d5ceqA_, 0.5872, 3.10, 0.273, 269, 231, DLK IN COMPLEX WITH INHIBITOR 2-((1-CYCLOPENTYL-5-(1-(OXETAN-3-YL) PIPERIDIN-4-YL)-1H-PYRAZOL-3-YL)AMINO)ISONICOTINONITRILE
4790, d4g31A1, 0.5872, 3.30, 0.229, 247, 236, CRYSTAL STRUCTURE OF GSK6414 BOUND TO PERK (R587-R1092 DELETE A660- T867) AT 2.28 A RESOLUTION
4791, d4ei4A1, 0.5872, 3.57, 0.225, 288, 240, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
4792, d3vryB3, 0.5872, 3.56, 0.232, 269, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
4793, d3my0P_, 0.5872, 3.32, 0.224, 290, 237, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4794, d3k54A_, 0.5872, 2.97, 0.191, 243, 230, STRUCTURES OF HUMAN BRUTON S TYROSINE KINASE IN ACTIVE AND INACTIVE CONFORMATIONS SUGGESTS A MECHANISM OF ACTIVATION FOR TEC FAMILY KINASES.
4795, d2gs7A_, 0.5872, 3.81, 0.207, 281, 246, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
4796, d5d12A_, 0.5871, 2.98, 0.261, 260, 230, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
4797, d4yo6C_, 0.5871, 3.95, 0.224, 286, 246, IRAK4-INHIBITOR CO-STRUCTURE
4798, d3my0I1, 0.5871, 3.33, 0.224, 292, 237, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4799, d2qi8B_, 0.5871, 2.85, 0.259, 249, 228, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN
4800, d1yi6A_, 0.5870, 3.71, 0.237, 274, 241, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
4801, d4zseA_, 0.5869, 3.79, 0.205, 297, 244, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
4802, d4hokS_, 0.5869, 3.40, 0.197, 286, 238, CRYSTAL STRUCTURE OF APO CK1E
4803, d2wtdA_, 0.5869, 3.38, 0.309, 285, 233, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4804, d5mqvC_, 0.5868, 3.43, 0.193, 288, 238, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4805, d3mtfA_, 0.5868, 3.37, 0.239, 296, 238, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
4806, d3efjB_, 0.5868, 3.22, 0.204, 275, 235, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
4807, d2oibB_, 0.5868, 3.84, 0.230, 278, 243, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4808, d5w5oH_, 0.5867, 3.35, 0.217, 275, 235, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4809, d5w5oG_, 0.5867, 3.34, 0.217, 275, 235, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4810, d5w5oD_, 0.5867, 3.33, 0.221, 275, 235, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4811, d5o1vB_, 0.5867, 3.75, 0.237, 270, 240, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE (A-LOOP SWAPPED)
4812, d4kbaC_, 0.5867, 3.19, 0.200, 277, 235, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4813, d3my0T1, 0.5867, 3.28, 0.225, 291, 236, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4814, d2wtiA_, 0.5867, 3.38, 0.309, 286, 233, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4815, d4kbcB_, 0.5866, 3.34, 0.208, 277, 236, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
4816, d5x17B_, 0.5865, 3.52, 0.196, 289, 240, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
4817, d5oy6C_, 0.5865, 3.48, 0.238, 291, 239, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
4818, d5jsmC1, 0.5865, 3.54, 0.230, 259, 239, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
4819, d4pmtA1, 0.5865, 3.59, 0.193, 269, 238, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N~4~-(4-MORPHOLIN- 4-YLPHENYL)-N~6~-(PYRIDIN-3-YLMETHYL)PYRIDO[32-D]PYRIMIDINE-46- DIAMINE
4820, d4a9uA1, 0.5865, 3.32, 0.309, 286, 233, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4821, d2rfnA_, 0.5865, 3.23, 0.204, 268, 235, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
4822, d5w5oK_, 0.5863, 3.33, 0.221, 275, 235, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4823, d4e4lB_, 0.5863, 3.73, 0.219, 279, 242, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
4824, d3u51B_, 0.5862, 3.15, 0.236, 255, 233, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
4825, d3svvB_, 0.5862, 3.16, 0.240, 257, 233, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
4826, d3p86B_, 0.5862, 2.67, 0.232, 239, 224, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
4827, d2xm9A_, 0.5862, 3.26, 0.310, 287, 232, STRUCTURE OF A SMALL MOLECULE INHIBITOR WITH THE KINASE DOMAIN OF CHK2
4828, d5w5oI_, 0.5861, 3.37, 0.217, 275, 235, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4829, d5d41B_, 0.5861, 3.88, 0.219, 302, 247, EGFR KINASE DOMAIN IN COMPLEX WITH MUTANT SELECTIVE ALLOSTERIC INHIBITOR
4830, d4pp9A1, 0.5861, 3.14, 0.184, 245, 234, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
4831, d4a9tA1, 0.5861, 3.24, 0.306, 288, 232, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4832, p3c4wB3, 0.5861, 3.28, 0.226, 287, 234, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.7A
4833, d2ydjB_, 0.5861, 2.98, 0.275, 251, 229, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
4834, d2xa4B_, 0.5861, 3.41, 0.236, 275, 237, INHIBITORS OF JAK2 KINASE DOMAIN
4835, d5vo2A_, 0.5860, 3.14, 0.273, 269, 231, DLK IN COMPLEX WITH INHIBITOR 5-(1-ISOPROPYL-5-(1-(OXETAN-3-YL) PIPERIDIN-4-YL)-1H-PYRAZOL-3-YL)-3-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE (COMPOUND 7)
4836, d4xs2A_, 0.5860, 3.84, 0.222, 283, 243, IRAK4-INHIBITOR CO-STRUCTURE
4837, d3uytB_, 0.5860, 3.21, 0.213, 286, 235, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
4838, d3uysB_, 0.5860, 3.07, 0.208, 279, 231, CRYSTAL STRUCTURE OF APO HUMAN CK1D
4839, d5t1sC_, 0.5859, 3.94, 0.229, 284, 245, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4840, d4ztlD_, 0.5859, 3.92, 0.225, 285, 244, IRAK4-INHIBITOR CO-STRUCTURE
4841, d3orpA_, 0.5859, 3.65, 0.230, 274, 244, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 5)
4842, d5y8uA_, 0.5858, 2.97, 0.238, 267, 231, CRYSTAL STRUCTURE OF THE C276S MUTANT OF MAP2K7
4843, d5uabA_, 0.5858, 3.19, 0.216, 288, 232, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
4844, d4ludB3, 0.5858, 3.45, 0.227, 264, 238, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
4845, d3f6xC_, 0.5858, 3.19, 0.275, 265, 233, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4846, d5w5oP_, 0.5857, 3.27, 0.218, 275, 234, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4847, d5lpwA_, 0.5857, 3.70, 0.253, 280, 241, CRYSTAL STRUCTURE OF THE APO-BRI1 KINASE DOMAIN (865-1160)
4848, d4fgbA_, 0.5857, 3.71, 0.259, 282, 243, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I APO FORM
4849, d4agwA_, 0.5857, 2.96, 0.251, 258, 231, DISCOVERY OF A SMALL MOLECULE TYPE II INHIBITOR OF WILD- TYPE AND GATEKEEPER MUTANTS OF BCR-ABL PDGFRALPHA KIT AND SRC KINASES
4850, d2wmuA_, 0.5857, 2.79, 0.270, 246, 226, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4851, d5w5oL_, 0.5856, 3.29, 0.209, 275, 234, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4852, d5t1tC_, 0.5856, 4.01, 0.232, 286, 246, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4853, d5dbxB_, 0.5856, 3.67, 0.242, 282, 236, CRYSTAL STRUCTURE OF MURINE SPAK(T243D) IN COMPLEX WITH AMPPNP
4854, d4ztlA_, 0.5856, 3.85, 0.222, 280, 243, IRAK4-INHIBITOR CO-STRUCTURE
4855, d2r4bB_, 0.5856, 3.46, 0.226, 291, 239, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
4856, d5oy6A_, 0.5855, 3.51, 0.238, 291, 239, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
4857, d4ztnC_, 0.5855, 3.95, 0.229, 284, 245, IRAK4-INHIBITOR CO-STRUCTURE
4858, d4c62B_, 0.5854, 3.31, 0.230, 271, 235, INHIBITORS OF JAK2 KINASE DOMAIN
4859, d4c61B_, 0.5854, 3.31, 0.230, 274, 235, INHIBITORS OF JAK2 KINASE DOMAIN
4860, d3w32A_, 0.5854, 4.01, 0.205, 317, 249, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 20A
4861, d3el8B_, 0.5854, 3.17, 0.267, 259, 232, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
4862, d5hidA1, 0.5853, 2.74, 0.227, 240, 225, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH AZ628
4863, d4oa6A_, 0.5853, 3.65, 0.257, 279, 241,  
4864, d4fvrA_, 0.5853, 3.58, 0.132, 274, 243, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN MUTANT V617F (MG- ATP-BOUND FORM)
4865, d3en5B_, 0.5853, 3.03, 0.220, 261, 232, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP494 A MULTITARGETED KINASE INHIBITOR
4866, d2y4pC_, 0.5853, 3.15, 0.294, 264, 231, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN
4867, d2hz0B_, 0.5853, 2.98, 0.226, 243, 230, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
4868, d2c47C_, 0.5853, 3.17, 0.172, 282, 233, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
4869, d3my0O1, 0.5852, 3.39, 0.224, 296, 237, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4870, d1bygA_, 0.5852, 3.12, 0.228, 246, 232, KINASE DOMAIN OF HUMAN C-TERMINAL SRC KINASE (CSK) IN COMPLEX WITH INHIBITOR STAUROSPORINE
4871, d4zseC_, 0.5851, 3.66, 0.213, 301, 244, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
4872, d3qrjA1, 0.5851, 3.09, 0.226, 246, 230, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN T315I MUTANT IN COMPLEX WITH DCC-2036
4873, d5w5oB_, 0.5850, 3.18, 0.215, 275, 233, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4874, d1xkkA_, 0.5850, 3.61, 0.216, 289, 241, EGFR KINASE DOMAIN COMPLEXED WITH A QUINAZOLINE INHIBITOR- GW572016
4875, d4ehzC_, 0.5848, 3.73, 0.215, 278, 242, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
4876, d2wtcA_, 0.5848, 3.32, 0.306, 284, 232, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4877, d5d10A_, 0.5847, 3.01, 0.240, 248, 229, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL236
4878, d4f4pA1, 0.5847, 3.41, 0.203, 260, 237, SYK IN COMPLEX WITH LIGAND LASW836
4879, d4rixC_, 0.5846, 3.62, 0.169, 275, 242, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
4880, d2xbjA_, 0.5844, 3.26, 0.312, 286, 231, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4881, d2cn5A1, 0.5843, 3.31, 0.307, 281, 231, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH ADP
4882, d4af3A_, 0.5842, 2.97, 0.249, 253, 229, HUMAN AURORA B KINASE IN COMPLEX WITH INCENP AND VX-680
4883, d4oa9A_, 0.5841, 3.78, 0.255, 280, 243,  
4884, d4e4lA_, 0.5841, 3.66, 0.221, 277, 240, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
4885, d3zmmB_, 0.5841, 3.34, 0.230, 274, 235, INHIBITORS OF JAK2 KINASE DOMAIN
4886, d5w5oF_, 0.5840, 3.19, 0.215, 275, 233, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4887, d3qgwB_, 0.5840, 3.00, 0.177, 240, 231, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
4888, d3kexB_, 0.5840, 3.73, 0.172, 283, 244, CRYSTAL STRUCTURE OF THE CATALYTICALLY INACTIVE KINASE DOMAIN OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
4889, d4itjA_, 0.5839, 3.59, 0.197, 261, 239, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
4890, d4lghB_, 0.5838, 2.87, 0.265, 247, 226, CRYSTAL STRUCTURE OF 1NM-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
4891, d4i24B_, 0.5838, 3.96, 0.215, 304, 246, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
4892, d3el7A_, 0.5837, 3.19, 0.254, 254, 232, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 3
4893, d4riyC_, 0.5836, 3.63, 0.169, 275, 242, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
4894, d5tx5B_, 0.5835, 3.46, 0.184, 263, 234, RIP1 KINASE ( FLAG 1-294 C34A C127A C233A C240A) WITH GSK772
4895, d4mf1A1, 0.5835, 3.16, 0.189, 241, 233, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
4896, d3orkA1, 0.5835, 3.66, 0.230, 272, 243, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 2)
4897, d3miyB1, 0.5835, 2.98, 0.191, 238, 230, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH SUNITINIB
4898, d2iwiB_, 0.5835, 3.04, 0.231, 249, 229, CRYSTAL STRUCTURE OF THE HUMAN PIM2 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
4899, d4useB_, 0.5832, 2.88, 0.230, 278, 226, HUMAN STK10 (LOK) WITH SB-633825
4900, d4pwnA_, 0.5832, 3.31, 0.253, 245, 233, CRYSTAL STRUCTURE OF ACTIVE WNK1 KINASE
4901, d3l8pA_, 0.5832, 3.47, 0.212, 292, 236, CRYSTAL STRUCTURE OF CYTOPLASMIC KINASE DOMAIN OF TIE2 COMPLEXED WITH INHIBITOR CEP11207
4902, d5b2kA_, 0.5831, 3.06, 0.237, 264, 232, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
4903, d4riwC_, 0.5831, 3.64, 0.169, 275, 242, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
4904, d4a9rA_, 0.5831, 3.24, 0.309, 285, 230, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4905, d3v5lD1, 0.5831, 3.31, 0.179, 244, 235, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
4906, d5kx8C_, 0.5830, 4.10, 0.227, 287, 247, IRAK4-INHIBITOR CO-STRUCTURE
4907, d4u3yA_, 0.5830, 3.85, 0.216, 295, 241, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
4908, d4g34A1, 0.5830, 3.29, 0.231, 247, 234, CRYSTAL STRUCTURE OF GSK6924 BOUND TO PERK (R587-R1092 DELETE A660- T867) AT 2.70 A RESOLUTION
4909, d5jrqB1, 0.5829, 3.43, 0.230, 245, 235, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-6-VEM
4910, d2j90A1, 0.5829, 3.10, 0.297, 259, 229, CRYSTAL STRUCTURE OF HUMAN ZIP KINASE IN COMPLEX WITH A TETRACYCLIC PYRIDONE INHIBITOR (PYRIDONE 6)
4911, d5w5oC_, 0.5828, 3.33, 0.218, 275, 234, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4912, d3w33A_, 0.5828, 3.55, 0.225, 297, 240, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 19B
4913, d3dakB_, 0.5828, 3.92, 0.223, 278, 242, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
4914, d1yolA_, 0.5828, 3.02, 0.243, 256, 230, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
4915, d3pj3A_, 0.5827, 2.86, 0.190, 240, 226, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-METHYL-5-[(E)- (3-PHENYL-ACRYLOYL)AMINO]-N-(2-PHENYL-3H-IMIDAZO[45-B]PYRIDIN-6-YL)- BENZAMIDE
4916, d1mrvA_, 0.5827, 2.72, 0.251, 261, 227, CRYSTAL STRUCTURE OF AN INACTIVE AKT2 KINASE DOMAIN
4917, d5m55A1, 0.5826, 2.59, 0.224, 230, 223, NEK2 BOUND TO ARYLAMINOPURINE 71
4918, d4a9sA_, 0.5826, 3.35, 0.312, 282, 231, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4919, d5mqvF_, 0.5825, 3.49, 0.203, 286, 237, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4920, d5jt2A1, 0.5825, 3.46, 0.216, 253, 236, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
4921, d4ztmD_, 0.5823, 3.98, 0.221, 282, 244, IRAK4-INHIBITOR CO-STRUCTURE
4922, d2wtjA1, 0.5822, 3.37, 0.310, 286, 232, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4923, d5hesB_, 0.5821, 3.06, 0.245, 278, 229, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
4924, d3d5vA_, 0.5821, 2.99, 0.281, 260, 228, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
4925, d3v8tB1, 0.5820, 3.27, 0.175, 242, 234, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 477
4926, d3zxtA_, 0.5819, 3.04, 0.313, 249, 227, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN IN COMPLEX WITH AMPPCP-MG
4927, d1zxeD1, 0.5818, 3.43, 0.239, 246, 238, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: D835N INACTIVATING MUTANT IN APO FORM
4928, d5lpyA_, 0.5817, 3.81, 0.257, 282, 241, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH ATP FROM ARABIDOPSIS THALIANA
4929, d4fg8A_, 0.5817, 3.28, 0.293, 263, 232, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-315 IN COMPLEX WITH ATP
4930, d5gtyH_, 0.5815, 3.74, 0.207, 300, 241, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
4931, d4oacA_, 0.5815, 3.75, 0.256, 280, 242,  
4932, d3v8wB1, 0.5814, 3.08, 0.177, 240, 231, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
4933, d5hesA_, 0.5813, 3.06, 0.262, 287, 229, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
4934, d2nruA_, 0.5813, 4.15, 0.223, 293, 247, CRYSTAL STRUCTURE OF IRAK-4
4935, d4y73C_, 0.5812, 4.08, 0.228, 290, 246, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4936, d2jboA_, 0.5812, 3.26, 0.230, 295, 230, PROTEIN KINASE MK2 IN COMPLEX WITH AN INHIBITOR (CRYSTAL FORM-1 SOAKING)
4937, d5uiqC_, 0.5810, 3.92, 0.239, 280, 243, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4938, d4bdfA1, 0.5810, 3.23, 0.310, 284, 229, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4939, d4bdeA1, 0.5810, 3.24, 0.306, 282, 229, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4940, d3gt8D_, 0.5810, 3.90, 0.229, 295, 245, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
4941, d1zycA1, 0.5810, 3.71, 0.240, 259, 242, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
4942, d5kx7B_, 0.5809, 3.98, 0.225, 286, 244, IRAK4-INHIBITOR CO-STRUCTURE
4943, d4ztmC_, 0.5809, 3.84, 0.241, 282, 241, IRAK4-INHIBITOR CO-STRUCTURE
4944, d4oabA_, 0.5809, 3.72, 0.261, 279, 241,  
4945, d4ludA3, 0.5809, 3.38, 0.231, 261, 234, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
4946, d4d9uA_, 0.5809, 3.08, 0.288, 307, 229, RSK2 C-TERMINAL KINASE DOMAIN (E)-TERT-BUTYL 3-(4-AMINO-7-(3- HYDROXYPROPYL)-5-P-TOLYL-7H-PYRROLO[23-D]PYRIMIDIN-6-YL)-2- CYANOACRYLATE
4947, d2wmsA_, 0.5809, 2.76, 0.268, 243, 224, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4948, d2wmqA_, 0.5809, 2.75, 0.263, 246, 224, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4949, d2rgpA_, 0.5809, 3.71, 0.216, 284, 241, STRUCTURE OF EGFR IN COMPLEX WITH HYDRAZONE A POTENT DUAL INHIBITOR
4950, d4ztnA_, 0.5808, 3.99, 0.221, 286, 244, IRAK4-INHIBITOR CO-STRUCTURE
4951, d4fvqA_, 0.5808, 3.65, 0.132, 274, 243, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN (MG-ATP-BOUND FORM)
4952, d5t1tA_, 0.5806, 4.11, 0.224, 283, 246, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4953, d4ztlC_, 0.5806, 3.88, 0.241, 282, 241, IRAK4-INHIBITOR CO-STRUCTURE
4954, d4l00A_, 0.5806, 3.67, 0.148, 277, 244, CRYSTAL STRUCTURE OF THE APO JAK1 PSEUDOKINASE DOMAIN
4955, d4jg8A_, 0.5805, 2.96, 0.282, 300, 227, STRUCTURE OF RSK2 T493M CTD MUTANT BOUND TO 2-CYANO-N-(1-HYDROXY-2- METHYLPROPAN-2-YL)-3-(3-(345-TRIMETHOXYPHENYL)-1H-INDAZOL-5-YL) ACRYLAMIDE
4956, d3v8wA1, 0.5805, 3.23, 0.172, 241, 233, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
4957, d5mqvA_, 0.5804, 3.45, 0.199, 286, 236, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4958, d4zseD_, 0.5804, 3.79, 0.215, 297, 242, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
4959, d2uv2A1, 0.5804, 3.18, 0.236, 286, 229, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 4-(4-( 5-CYCLOPROPYL-1H-PYRAZOL-3-YLAMINO)-QUINAZOLIN-2-YLAMINO)- PHENYL)-ACETONITRILE
4960, d2jflA_, 0.5804, 3.35, 0.237, 286, 232, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE ( DIPHOSPHORYLATED FORM) BOUND TO 5- AMINO-3-((4-( AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-12 4-TRIAZOLE-1-CARBOTHIOAMIDE
4961, d4d9tA_, 0.5803, 3.02, 0.289, 299, 228, RSK2 C-TERMINAL KINASE DOMAIN WITH INHIBITOR (E)-METHYL 3-(4-AMINO-7- (3-HYDROXYPROPYL)-5-P-TOLYL-7H-PYRROLO[23-D]PYRIMIDIN-6-YL)-2- CYANOACRYLATE
4962, d3v5lB1, 0.5803, 3.28, 0.176, 239, 233, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
4963, d3tl8D_, 0.5803, 4.19, 0.213, 306, 249, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
4964, d1zxeC1, 0.5803, 3.73, 0.236, 265, 242, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: D835N INACTIVATING MUTANT IN APO FORM
4965, d5lpbA_, 0.5802, 3.81, 0.249, 280, 241, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
4966, d5gtyG_, 0.5802, 3.81, 0.207, 299, 242, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
4967, d5d11B_, 0.5802, 3.23, 0.257, 255, 230, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
4968, d4ztmA_, 0.5802, 4.06, 0.224, 287, 245, IRAK4-INHIBITOR CO-STRUCTURE
4969, d4yp8C_, 0.5802, 4.15, 0.227, 287, 247, IRAK4-INHIBITOR CO-STRUCTURE
4970, d4jvgD1, 0.5802, 2.82, 0.240, 245, 225, B-RAF KINASE IN COMPLEX WITH BIRB796
4971, d4bdcA_, 0.5802, 3.28, 0.310, 283, 229, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4972, d3zxtC_, 0.5802, 3.29, 0.307, 259, 231, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN IN COMPLEX WITH AMPPCP-MG
4973, d5w5oN_, 0.5801, 3.34, 0.216, 272, 232, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4974, d4ztnD_, 0.5801, 4.00, 0.225, 285, 244, IRAK4-INHIBITOR CO-STRUCTURE
4975, d4dymA_, 0.5801, 3.40, 0.238, 293, 235, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00135
4976, d2jfmA_, 0.5801, 3.30, 0.234, 287, 231, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE (UNLIGANDED FORM)
4977, d5k76B_, 0.5800, 4.06, 0.225, 281, 244, IRAK4 IN COMPLEX WITH COMPOUND 28
4978, d5jt2B1, 0.5799, 3.49, 0.229, 250, 236, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
4979, d4jvgA1, 0.5799, 2.83, 0.236, 245, 225, B-RAF KINASE IN COMPLEX WITH BIRB796
4980, d4l00B_, 0.5798, 3.70, 0.144, 278, 243, CRYSTAL STRUCTURE OF THE APO JAK1 PSEUDOKINASE DOMAIN
4981, d3belA_, 0.5798, 3.66, 0.212, 280, 240, X-RAY STRUCTURE OF EGFR IN COMPLEX WITH OXIME INHIBITOR
4982, d5t1tD_, 0.5797, 4.07, 0.224, 283, 245, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4983, d4ybkA_, 0.5797, 3.48, 0.253, 266, 237, C-HELIX-OUT DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
4984, d4kioD1, 0.5797, 3.13, 0.182, 240, 231, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
4985, d5mqvB_, 0.5796, 3.48, 0.195, 287, 236, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4986, d4x7oA_, 0.5796, 3.39, 0.226, 246, 234, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 1-[5-(4-AMINO-27-DIMETHYL-7H- PYRROLO[23-D]PYRIMIDIN-5-YL)-23-DIHYDRO-1H-INDOL-1-YL]-2-[3-FLUORO- 5-(TRIFLUOROMETHYL)PHENYL]ETHANONE INHIBITOR
4987, d4nifD_, 0.5796, 2.97, 0.305, 313, 226, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
4988, d4bdbA1, 0.5796, 3.21, 0.307, 282, 228, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4989, d3pozA_, 0.5796, 3.74, 0.208, 293, 240, EGFR KINASE DOMAIN COMPLEXED WITH TAK-285
4990, d2oibC_, 0.5796, 3.76, 0.230, 278, 239, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4991, d4bdhA_, 0.5795, 3.17, 0.304, 282, 227, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4992, d5k7gC_, 0.5794, 4.12, 0.235, 283, 247, IRAK4 IN COMPLEX WITH AZ3862
4993, d5eymB_, 0.5794, 3.70, 0.225, 292, 240, MEK1 IN COMPLEX WITH BI 847325
4994, d3pyyB1, 0.5794, 2.69, 0.229, 244, 223, DISCOVERY AND CHARACTERIZATION OF A CELL-PERMEABLE SMALL-MOLECULE C- ABL KINASE ACTIVATOR THAT BINDS TO THE MYRISTOYL BINDING SITE
4995, d2ja0A_, 0.5794, 3.32, 0.234, 285, 231,  
4996, p6c3eA_, 0.5793, 3.60, 0.181, 258, 237, CRYSTAL STRUCTURE OF RIP1 KINASE BOUND TO INHIBITOR
4997, d5c03B_, 0.5793, 3.16, 0.170, 260, 235, CRYSTAL STRUCTURE OF KINASE
4998, d4xv9A1, 0.5793, 2.95, 0.226, 244, 226, B-RAF KINASE DOMAIN IN COMPLEX WITH PLX5568
4999, d3ortA_, 0.5793, 3.72, 0.236, 271, 242, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 6)
5000, d3gt8B_, 0.5792, 3.73, 0.224, 292, 241, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
